

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2019250507 B2**

(54) Title
Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase

(51) International Patent Classification(s)
C07D 487/04 (2006.01) **A61P 35/00** (2006.01)
A61P 29/00 (2006.01) **A61P 37/00** (2006.01)
A61P 31/00 (2006.01) **C07D 519/00** (2006.01)

(21) Application No: **2019250507** (22) Date of Filing: **2019.04.11**

(87) WIPO No: **WO19/197549**

(30) Priority Data

(31)	Number	(32)	Date	(33)	Country
	62/656,070		2018.04.11		US

(43) Publication Date: **2019.10.17**

(44) Accepted Journal Date: **2023.09.28**

(71) Applicant(s)
Qurient Co., Ltd.;Lead Discovery Center GmbH

(72) Inventor(s)
NAM, Kiyeon;KIM, Jaeseung;JEON, Yeejin;YU, Donghoon;SEO, Mooyoung;PARK, Dongsik;EICKHOFF, Jan;ZISCHINSKY, Gunther

(74) Agent / Attorney
Pizzey's Patent and Trade Mark Attorneys Pty Ltd, GPO Box 1374, Brisbane, QLD, 4001, AU

(56) Related Art
WO 2013/128029 A1
WO 2013/128028 A1



(51) International Patent Classification:

C07D 487/04 (2006.01) A61P 29/00 (2006.01)

C07D 519/00 (2006.01) A61P 35/00 (2006.01)

A61P 31/00 (2006.01) A61P 37/00 (2006.01)

(21) International Application Number:

PCT/EP2019/059302

(22) International Filing Date:

11 April 2019 (11.04.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/656,070 11 April 2018 (11.04.2018) US

(71) Applicants: **QURIENT CO., LTD.** [KR/KR]; C-801, 242, Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13487 (KR). **LEAD DISCOVERY CENTER GMBH** [DE/DE]; Otto-Hahn-Straße 15, 44227 Dortmund (DE).

(72) Inventors: **NAM, Kiyeon**; 605-2402, 248, Jeongjail-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13554 (KR). **KIM, Jaeseung**; 209-1903, 8, Samseong-ro 111-gil, Gangnam-gu, Seoul 06095 (KR). **JEON, Yeejin**; 112-901, 58, Mokgam-ro, Gwangmyeong-si, Gyeonggi-do 14295 (KR). **YU, Donghoon**; 108-608, 59 Munin-ro, Suji-gu, Yongin-si, Gyeonggi-do 16830 (KR). **SEO, Mooyoung**; 107-1403, 55, Munjeong-ro, Suji-gu, Yongin-si, Gyeonggi-do 16838 (KR). **PARK, Dongsik**; 107-1701, 91, Pungdeokcheon-ro, Suji-gu, Yongin-si, Gyeonggi-do 16836 (KR). **EICK-HOFF, Jan**; Zickenkamp 6, 58131 Herdecke (DE). **ZISCHINSKY, Gunther**; Herdecker Weg 16, 44229 Dortmund (DE).

(74) Agent: **BOEHMERT & BOEHMERT ANWALTS-PARTNERSCHAFT MBB**; Markus ENGELHARD, Pettenkoferstraße 22, 80336 München (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITOR OF CYCLIN DEPENDENT KINASE

(57) Abstract: The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.

Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase

The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.

Background of the invention

Cyclin-dependent kinase (CDK) family members that trigger passage through the cell cycle are being considered as attractive therapeutic targets, especially for cancer. CDK family members that control other processes such as transcription and RNA processing have caught less attention so far, although experimental evidence for their involvement in different pathological processes is emerging. Together with cell cycle control, CDK/cyclin complexes also have been identified as conserved components of the RNA polymerase II (Pol II) transcriptional machinery (*Bregman et al.*, 2000, *Front Biosci.* 5:244–257). There are currently 20 known mammalian CDKs. While CDK7 – 13 have been linked to transcription, only CDK 1, 2, 4, and 6 show demonstrable association with cell cycle. Unique among the mammalian CDKs, CDK7 has consolidated kinase activities, regulating both the cell cycle progression and transcription (*Desai et al.*, 1995, *Mol. Cell Biol.* 15, 345-350).

The general transcription factor TFIIF purified from mammalian cells consists of ten subunits, seven of which (p62, p52, p44, p34, XPD, XPB, and TTDA) form the core complex. Three subunits (cyclin H, MAT1, and CDK7) form the CDK-activating kinase (CAK), which is linked to TFIIF's core via the XPD (ATP-dependent helicase) subunit of complex. During the process of transcription initiation, the helicase activity of TFIIF opens the core promoter DNA, while CDK7 phosphorylates the C-terminal domain (CTD) of Pol II at serine 5 and 7 (*Akhtar et al.*, 2009, *Mol. Cell* 34, 387-393) as well as other transcription factors controlling the initiation-to-elongation transition (*Larochelle et al.*, 2012, *Nat. Struct. Mol. Biol.* 19, 1108-1115). Therefore CDK7 is an essential factor for the transcription process, which suggests that CDK7 is a target for cancer therapy, especially transcription addicted cancer.

CDK7 has long been asserted as having an essential role in cellular metabolism and viability. Transcriptional CDK inhibitors down-regulate a large number of short-lived anti-apoptotic proteins, such as the anti-apoptotic proteins myeloid cell leukemia-1 (Mcl-1), B-cell lymphoma extra-long (Bcl-xL) and XIAP (X-linked IAP), D-cyclins, c-Myc, Mdm-2 (leading to p53 stabilization), p21^{waf1} proteins whose transcription is mediated by nuclear factor-kappa B (NF-kB) and hypoxia-induced VEGF (*Shapiro GI. 2006, J Clin Oncol; 24(11):1770-83*). The transcriptional non-selective cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. These findings supported previous postulates that CDK7 might be a valuable target for drugs directed toward the treatment of malignancies and cell cycle-associated diseases (*Lolli G and Johnson LN. 2005. Cell Cycle 4:572-577*).

The function of CDK7 as regulator of general transcription and CDK7 is a therapeutic target for treatment of many diseases and syndromes are associated with mutations in regulatory regions and in transcription factors, cofactors, chromatin regulators and noncoding RNAs. These mutations can contribute to cancer, autoimmunity, neurological disorders, developmental syndromes, diabetes, cardiovascular disease, and obesity, among others. Some transcription factors control RNA polymerase II pause release and elongation and, when their expression or function is altered, can produce aggressive tumor cells (c-Myc) or some forms of autoimmunity (AIRE) (*Tong Ihn Lee and Richard A. Young, Cell, 2013, 152:1237-1251*). Therefore, inhibition of human CDK7 kinase activity is likely to result in anti-proliferative activity through the function in cell cycle progression and transcriptional regulation by inhibition of some transcription factor related to oncogene through inhibition of general transcription process. More important thing is that CDK7 has been shown to regulate exponential expression of oncogenic transcription factors more dramatically than it does to other housekeeping genes in cancer cells. Thus Inhibition of CDK7 can differentially affect transcription of certain oncogenes and housekeeping gene, therefore therapeutic window can be secured. For this reason, transcriptional regulation and pharmacological inhibition through appropriate general transcription inhibition by CDK7 could be applied to treat proliferative disorder, including cancer. As a general regulator of transcription, CDK7 is a therapeutic target for treatment of disease like inflammation, virus replication such as HIV, EBV, cancer and cardiac hypertrophy.

HIV-1 gene expression is regulatory by a viral transactivator protein (Tat) which induces


transcriptional elongation of HIV-1 long tandem repeat. This induction requires hyperphosphorylation of the C-terminal domain repeat of RNA polymerase II. To achieve said hyperphosphorylation, Tat stimulates CTD kinases associated with general transcription factors of the promoter complex, specifically TFIIF-associated CDK7 (Nekhai et al.; *Biochem J.* (2002) 364, 649-657). The inventors of US 615968 also described that Tat binds to CDK7 and that this interaction increases the ability of CAK to phosphorylate CTD. The authors of US 615968 further disclose that the transcriptional activation by Tat is dependent upon the kinase activity of CDK7. Additionally, Young Kyeung Kim and colleagues conclude that the recruitment and activation of TFIIF represents a rate-limiting step for the emergence of HIV from latency (Young Kyeung Kim, *EMBO* (2006) 25, 3596-3604).

Levels of CDK7 and CDK9, as well as other components of the kinase complexes, MAT-1/cyclin H are upregulated during Human cytomegalovirus infection. In addition, there is an increase in the kinase activities of CDK7 and CDK9 (Tamrakar et al., *Journal of Virology*, 2005, 79; 15477-15493).

Many antiviral drugs target viral proteins. These have the disadvantage that viruses often develop resistance against these drugs. Antiviral drugs targeting cellular proteins essential for viral process, like CDK7, could bypass this disadvantage. These drugs may further be effective in treating several unrelated viruses and their effects should be additive to traditional antiviral agents. Inhibitors of CDK7, which has its dual function of CDK-activating kinase and transcription regulation is very effective in the treatment of several viruses.

It is an object of the present invention to provide compounds and/or pharmaceutically acceptable salts thereof which can be used as pharmaceutically active agents, especially for prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases, as well as compositions comprising at least one of those compounds and/or pharmaceutically acceptable salts thereof as pharmaceutically active ingredients.

In one aspect, the present invention relates to pyrazolo-triazine or pyrazolo-pyrimidine compounds which are defined by general formula I



Formula I

wherein

X is, independently at each occurrence, selected from CH and N;

L¹ is either absent or independently, at each occurrence, selected from the group consisting of -NH-, -NH(CH₂)-, -NH(C=O)-, -NHSO₂-, -O-, -O(CH₂)-, -(C=O)-, -(C=O)NH- and -(C=O)(CH₂)-;

Q is, independently at each occurrence, selected from the group consisting of C3-C8 cycloalkyl, aryl, heteroaryl, heterocyclyl, and C1-C6 alkyl, wherein C1-C6 alkyl is substituted with one or two of -OR⁵, -N(R⁵)R⁵, aryl, heteroaryl and heterocyclyl,

C3-C8 cycloalkyl can be substituted with one or two of R³ and R⁴ and -(C=O)R⁵,

heterocyclyl can be substituted with one or two of R³ and R⁴ and -(C=O)R⁵

aryl or heteroaryl substituted with one or two of C1-C6 alkyl, -OR⁵, -N(R⁵)R⁵, -(C=O)R⁵, halogen, heteroaryl and heterocyclyl;

R¹ is, at each occurrence, independently selected from the group consisting of hydrogen and methyl;

R² is, at each occurrence, independently selected from the group consisting of halogen, C1-C6 alkyl, C3-C10 cycloalkyl, -CN, -(C=O)CH₃, -NR⁹R¹² and C1-C3 haloalkyl, any of which is optionally substituted;


R³ is independently, at each occurrence, selected from the group consisting of hydrogen, -OR⁵, halogen, -N(R⁵)R⁵, -NR⁹R¹², -NH(C=O)R⁵, -(C=O)NH₂, aryl, heteroaryl, heterocyclyl, C1-C6 alkyl and C1-C6 alkyl substituted with -OH or -NH₂;

R⁴ is, independently, at each occurrence, selected from the group consisting of hydrogen,

halogen, $-OR^5$, $-N(R^5)R^5$, $(=O)$, aryl, heteroaryl, heterocyclyl, C1-C6 alkyl and C1-C6 alkyl substituted with $-OH$ or $-NH_2$;

R^5 is, at each occurrence, independently selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C3 haloalkyl, heteroaryl, heterocyclyl, heteroaryl substituted with one or two of halogen, $-OR^{11}$, $-N(R^{11})R^{11}$, C1-C6 alkyl and C1-C6 alkyl substituted with $-OH$ or $-NH_2$, heterocyclyl substituted with one or two of halogen, $-OR^{11}$, $-N(R^{11})R^{11}$, C1-C6 alkyl and C1-C6 alkyl substituted with $-OH$ or $-NH_2$;

Z is any structure of the following group A;




Group A

Wherein

X^1 is, independently at each occurrence, selected from CR^{24} and N;


X^2 is, independently at each occurrence, selected from CR^{25} and N;

R^6 is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkyl substituted with $-OH$, C3-C10 cycloalkyl, C3-C10 heterocyclyl, $-(C=O)NHR^{11}$, $-NHR^9$, $-NH(C=O)NHR^{11}$, $-N(CH_3)(C=O)CH_3$, $-NH(C=O)R^{12}$, $-NR^9R^{12}$, $-OR^{12}$, and any structure of the following group B;



Group B

R⁷ is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, -NH(C=O)R¹², -NR⁹R¹², -OR¹² and any structure of the following group C;



Group C

R^8 and R^{10} are, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C3 haloalkyl, $-NH_2$, $-OH$, $-OR^5$, $-CN$, $-(C=O)R^5$, $-(C=O)OR^5$, $-(C=O)NH_2$, $-(C=O)NHR^{21}$, $-CH_2(C=O)NHR^{21}$, $-NH(C=O)R^{13}$, $-NHS(=O)_2R^5$, $-S(=O)_2NH_2$, $-S(=O)_2NHR^{21}$, and C1-C6 alkyl substituted with $-OH$, $-OR^5$ or $-NHR^9$;

R^9 is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C3 haloalkyl, $-OR^5$, $-CN$, C3-C10 cycloalkyl, C3-C10 heterocyclyl and C1-C6 alkyl substituted with $-OH$ or $-OR^5$;

R^{11} is, at each occurrence, independently selected from the group consisting of hydrogen, C1-C6 alkyl and C3-C10 cycloalkyl;

R^{12} is, at each occurrence, absent or independently selected from the group consisting of C1-

C6 alkyl, C1-C6 alkyl substituted with $-OR^5$ or $-N(R^5)R^5$, C6-C10 aryl, phenyl, benzyl, C3-C9 heteroaryl, C3-C6 heterocyclyl, benzyl substituted with one to four halogens or C1-C3 alkyls, C3-C9 heteroaryl substituted with one to four halogens or C1-C3 alkyls, C3-C6 heterocyclyl substituted with C1-C3 alkyl, and C6-C10 aryl substituted with one to four halogens and/or one to four $-NH(C=O)R^{13}$;

R^{13} is, at each occurrence, independently selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkyl substituted with $-CN$, $-OH$, $-OR^5$, $-NH_2$, $-NHR^5$ or $-N(R^5)R^5$ and C3-C10 cycloalkyl;

R^{14} and R^{15} are, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkyl substituted with $-OH$ or $-NH_2$, C3-C10 cycloalkyl, $-(C=O)R^5$, $-(C=O)NHR^{21}$, $-C(R^9)(R^{11})OR^{21}$, $-NH(C=O)R^{21}$, $-NR^9R^{21}$, $-OR^{21}$, $-OC(R^9)(R^{11})(R^{21})$, C3-C10 heterocyclyl, C3-C10 heterocyclyl substituted with R^4 , C3-C10 heteroaryl substituted with one to four halogens or C1-C3 alkyl, C6-C10 aryl, e.g. phenyl and aryl substituted with $-(C=O)R^5$, $-(C=O)OR^5$, $-(C=O)NH_2$, $-(C=O)NHR^{21}$, $-CH_2(C=O)NHR^{21}$, $-NH(C=O)R^{13}$, $-NHS(=O)_2R^5$, $-S(=O)_2NH_2$ or $-S(=O)_2NHR^{21}$;

R^{16} is, at each occurrence, independently selected from the group consisting of hydrogen, C1-C6 alkyl, $-(C=O)R^{13}$ and C1-C6 alkyl substituted with $-OR^5$;


R^{17} , R^{18} , R^{19} and R^{20} are, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C3 haloalkyl, C6-C10 aryl, e.g. phenyl, $-CN$, $-CHCF_3NR^9R^{11}$, $-OH$, $-OR^{21}$, $-NO_2$, $-(C=O)R^5$, $-(C=O)OR^5$, $-(C=O)NH_2$, $-(C=O)NHR^{21}$, $-NH(C=O)R^{13}$, $-NHR^5$, $-NHS(=O)_2R^5$, $-S(=O)_2NH_2$, $-S(=O)_2NHR^{21}$ and C1-C6 alkyl substituted with $-CN$, $-OH$, $-OR^5$, $-(C=O)NHR^5$, $-NH_2$, $-NH(C=O)R^5$, $-NHR^5$ or $-N(R^5)R^5$;


R^{21} is, at each occurrence, independently selected from the group consisting of C1-C6 alkyl, C3-C10 cycloalkyl, C3-C10 heterocyclyl, C1-C3 haloalkyl, aryl, phenyl, benzyl, C1-C6 alkyl substituted with $-CN$, $-OH$, $-OR^5$, $-NH_2$, $-NHR^5$ or $-N(R^5)R^5$, aryl substituted with halogen or

C1-C3 haloalkyl, C3-C10 heteroaryl substituted with one to four halogens or C1-C3 alkyl and C3-C10 heterocyclyl substituted with R^4 ;

R^{22} and R^{23} are, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C3 haloalkyl, -OH, -OR⁵, -CN and C1-C6 alkyl substituted with -OH, -OR⁵ or -NHR⁹;

R^{24} and R^{25} are, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C3 haloalkyl, -NH₂, -OH, -OR⁵, -CN, -(C=O)R⁵, -(C=O)OR⁵, -(C=O)NH₂, -(C=O)NHR²¹, -CH₂(C=O)NHR²¹, -NH(C=O)R¹³, -NHS(=O)₂R⁵, -S(=O)₂NH₂ or -S(=O)₂NHR²¹ and C1-C6 alkyl substituted with -OH, -OR⁵ or -NHR⁹;



With the proviso that when Z is , then one of R⁶ and R⁷ is not H;

Wherein, if R¹ is H, R² is CH(CH₃)₂, L¹ is absent, Q is heterocyclyl substituted with R³ and R⁴, R³ is N(R⁵)R⁵, R⁴ is H, R⁵ is H, X is N, Z is phenyl, R⁷ is H, R⁸ is H, R⁹ is H and R¹⁰ is H, then R⁶ is not 1H-pyrazole;

Wherein, if R¹ is H, R² is CH(CH₃)₂, L¹ is O, Q is heterocyclyl substituted with R³ and R⁴, R³ is CH₃, R⁴ is H, X is N, Z is phenyl, R⁷ is H, R⁸ is H, R⁹ is H and R¹⁰ is H, then R⁶ is not CH₃, Cl or 1H-pyrazole;

Wherein, if R¹ is H, R² is CH(CH₃)₂, L¹ is O, Q is heterocyclyl substituted with R³ and R⁴, R³ is CH₃, R⁴ is H, X is N, Z is phenyl, R⁶ is OR¹², R⁷ is H, R⁸ is H, R⁹ is H and R¹⁰ is H, then R¹² is not phenyl, CH(CH₃)₂, CH₂CH₃ or CH₃;

Wherein, if R¹ is H, R² is CH(CH₃)₂, L¹ is O, Q is heterocyclyl substituted with R³ and R⁴, R³ is CH₃, R⁴ is H, X is N, Z is phenyl, R⁶ is Cl, R⁷ is H, R⁸ is H and R⁹ is H, then R¹⁰ is not Cl;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q is heterocyclyl substituted with R^3 and R^4 , R^3 is CH_3 , R^4 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is Cl, then R^6 is not Cl;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q is heterocyclyl substituted with R^3 and R^4 , R^3 is CH_3 , R^4 is H, X is N, Z is phenyl, R^6 is Cl, R^7 is H, R^8 is H and R^9 is H, then R^{10} is not CH_3 ;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q is heterocyclyl substituted with R^3 and R^4 , R^3 is CH_3 , R^4 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is Cl, then R^6 is not CH_3 ;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q is heterocyclyl substituted with R^3 and R^4 , R^3 is CH_3 , R^4 is H, X is N, Z is phenyl, R^6 is F, R^7 is H, R^8 is H and R^9 is H, then R^{10} is not F;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q is heterocyclyl substituted with R^3 and R^4 , R^3 is CH_3 , R^4 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is F, then R^6 is not F;

Wherein, if R^1 is CH_3 , R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q is heterocyclyl substituted with R^3 and R^4 , R^3 is CH_3 , R^4 is H, X is N, Z is phenyl, R^6 is OR^{12} , R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is $-(\text{C}=\text{O})-$, Q is heterocyclyl substituted with R^3 and R^4 , R^4 is H, X is N, Z is phenyl, R^6 is 1H-pyrazole, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^3 is not H;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is $-(\text{C}=\text{O})-$, Q is heterocyclyl substituted with R^3 and R^4 , R^3 is $\text{N}(\text{R}^5)\text{R}^5$, R^4 is H, R^5 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole,

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q is heterocyclyl substituted with R^3 and R^4 , R^3 is H, R^4 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q is heterocyclyl substituted with R^3 and R^4 , R^3 is H, R^4 is H, X is N, Z is phenyl, R^6 is OR^{12} , R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not $\text{CH}(\text{CH}_3)_2$;

Wherein, if R^1 is CH_3 , R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q is heterocyclyl substituted with R^3 and R^4 , R^3 is H, R^4 is H, X is N, Z is phenyl, R^6 is OR^{12} , R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q is C3-C8 cycloalkyl substituted with R^3 and R^4 , R^3 is $\text{N}(\text{R}^5)\text{R}^5$, R^4 is H, R^5 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is NH, Q is heterocyclyl substituted with R^3 and R^4 , R^3 is H, R^4 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is NH, Q is C3-C8 cycloalkyl substituted with R^3 and R^4 , R^3 is $\text{N}(\text{R}^5)\text{R}^5$, R^4 is H, R^5 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q is heterocyclyl substituted with R^3 and R^4 , R^3 is H, R^4 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is F, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is CH_3 , R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q is heterocyclyl substituted with R^3 and R^4 , R^3 is H, R^4 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q is heterocyclyl substituted with R^3 and R^4 , R^3 is CH_3 , R^4 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, L^1 is O, Q is heterocyclyl substituted with R^3 and R^4 , R^3 is H, R^4 is H, X is N, Z is phenyl, R^6 is H, R^7 is OR^{12} , R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, L^1 is O, Q is heterocyclyl substituted with R^3 and R^4 , R^3 is CH_3 , R^4 is H, X is N, Z is phenyl, R^6 is H, R^8 is H, R^9 is H and R^{10} is H, then R^7 is not Cl;

Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, L^1 is O, Q is heterocyclyl substituted with R^3 and R^4 , R^3 is CH_3 , R^4 is H, X is N, Z is phenyl, R^6 is H, R^7 is OR^{12} , R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, L^1 is O, Q is C3-C8 cycloalkyl substituted with R^3 and R^4 , R^3 is $N(R^5)R^5$, R^4 is H, R^5 is H, X is N, Z is phenyl, R^6 is H, R^7 is OR^{12} , R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, L^1 is NH, Q is heterocyclyl substituted with R^3 and R^4 , R^3 is H, R^4 is H, X is N, Z is phenyl, R^6 is H, R^7 is OR^{12} , R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, L^1 is absent, Q is heterocyclyl substituted with R^3 and R^4 , R^3 is $N(R^5)R^5$, R^4 is H, R^5 is H, X is N, Z is phenyl, R^6 is H, R^7 is OR^{12} , R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, L^1 is absent, Q is heterocyclyl substituted with R^3 and R^4 , R^3 is $N(R^5)R^5$, R^4 is H, R^5 is H, X is N, Z is phenyl, R^6 is OR^{12} , R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;


Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, L^1 is NH, Q is C3-C8 cycloalkyl substituted with R^3 and R^4 , R^3 is $N(R^5)R^5$, R^4 is H, R^5 is H, X is N, Z is phenyl, R^6 is H, R^7 is OR^{12} , R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, L^1 is $-(C=O)-$, Q is heterocyclyl substituted with R^3 and R^4 , R^3 is H, R^4 is H, X is N, Z is phenyl, R^6 is H, R^7 is OR^{12} , R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, L^1 is $-(C=O)-$, Q is heterocyclyl substituted with R^3 and R^4 , R^3 is $N(R^5)R^5$, R^4 is H, R^5 is H, X is N, Z is phenyl, R^6 is H, R^7 is OR^{12} , R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

or an enantiomer, stereoisomeric form, mixture of enantiomers, diastereomer, mixture of diastereomers, racemate of the above mentioned compounds, or a pharmaceutically acceptable salt thereof.


In one embodiment, R^1 is hydrogen and the compound has the general formula II



Formula II

Wherein X, Q, L^1 , R^2 and Z are as defined above for general formula II.

In one embodiment, the present invention relates to compounds having the general formula III



Formula III

wherein X, L¹, R¹, R² and Z are as defined above for general formula I, and

Q¹ is either absent or independently, at each occurrence, selected from the group consisting of aryl, heteroaryl, heterocyclyl, aryl substituted with one or two of C1-C6 alkyl, -OR⁵, -N(R⁵)R⁵, and halogen; heteroaryl substituted with one or two of C1-C6 alkyl, -OR⁵, -N(R⁵)R⁵ and halogen; and heterocyclyl substituted with one or two of R²⁹ and R³⁰;

R²⁹ is either absent or independently, at each occurrence, selected from the group consisting of hydrogen, -OR⁵, halogen, -N(R⁵)R⁵, -NR⁹R¹², -NH(C=O)R⁵, -(C=O)NH₂, aryl, heteroaryl, heterocyclyl, C1-C6 alkyl and C1-C6 alkyl substituted with -OH or -NH₂;

R³⁰ is, independently, at each occurrence, selected from the group consisting of hydrogen, halogen, -OR⁵, -N(R⁵)R⁵, (=O), aryl, heteroaryl, heterocyclyl, C1-C6 alkyl and C1-C6 alkyl substituted with -OH or -NH₂;

Wherein R⁵, R⁹ and R¹² are as defined in claim 1;

L² is either absent or independently, at each occurrence, selected from the group consisting of -O-, -NH-, -(C=O)- and -(C=O)NH-;

Y¹ is, independently at each occurrence, selected from CH, C(OH) and N;

Y² is, independently at each occurrence, selected from CH, CR³⁰, O and N;

m is, independently at each occurrence, selected from 0, 1 and 2;

n is, independently at each occurrence, selected from 0 and 1;

Wherein, if R^1 is H, R^2 is $CH(CH_3)_2$, L^1 is absent, Q^1 is absent, L^2 is absent, Y^1 is N, Y^2 is CH, m is 1, n is 1, R^{29} is $N(R^5)R^5$, R^{30} is H, R^5 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is H, R^2 is $CH(CH_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 1, n is 1, R^{29} is CH_3 , R^{30} is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not CH_3 , Cl or 1H-pyrazole;

Wherein, if R^1 is H, R^2 is $CH(CH_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 1, n is 1, R^{29} is CH_3 , R^{30} is H, X is N, Z is phenyl, R^6 is OR^{12} , R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not phenyl, $CH(CH_3)_2$, CH_2CH_3 or CH_3 ;

Wherein, if R^1 is H, R^2 is $CH(CH_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 1, n is 1, R^{29} is CH_3 , R^{30} is H, X is N, Z is phenyl, R^6 is Cl, R^7 is H, R^8 is H and R^9 is H, then R^{10} is not Cl;

Wherein, if R^1 is H, R^2 is $CH(CH_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 1, n is 1, R^{29} is CH_3 , R^{30} is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is Cl, then R^6 is not Cl;

Wherein, if R^1 is H, R^2 is $CH(CH_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 1, n is 1, R^{29} is CH_3 , R^{30} is H, X is N, Z is phenyl, R^6 is Cl, R^7 is H, R^8 is H and R^9 is H, then R^{10} is not CH_3 ;

Wherein, if R^1 is H, R^2 is $CH(CH_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 1, n is 1, R^{29} is CH_3 , R^{30} is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is Cl, then R^6 is not CH_3 ;

Wherein, if R^1 is H, R^2 is $CH(CH_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 1, n is 1, R^{29} is CH_3 , R^{30} is H, X is N, Z is phenyl, R^6 is F, R^7 is H, R^8 is H and R^9 is H, then R^{10} is not F;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 1, n is 1, R^{29} is CH_3 , R^{30} is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is F, then R^6 is not F;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is $-(\text{C}=\text{O})-$, Q^1 is absent, L^2 is absent, Y^1 is N, Y^2 is N, m is 1, n is 1, R^{30} is H, X is N, Z is phenyl, R^6 is 1H-pyrazole, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^{29} is not H;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is $-(\text{C}=\text{O})-$, Q^1 is absent, L^2 is absent, Y^1 is N, Y^2 is CH, m is 1, n is 1, R^{29} is $\text{N}(\text{R}^5)\text{R}^5$, R^{30} is H, R^5 is H, R^{30} is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 1, n is 1, R^{29} is H, R^{30} is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 1, n is 1, R^{29} is H, R^{30} is H, X is N, Z is phenyl, R^6 is OR^{12} , R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not $\text{CH}(\text{CH}_3)_2$;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 1, n is 0, R^{29} is H, R^{30} is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 1, n is 0, R^{29} is H, R^{30} is H, X is N, Z is phenyl, R^6 is OR^{12} , R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not $\text{CH}(\text{CH}_3)_2$;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is CH, m is 1, n is 1, R^{29} is $\text{N}(\text{R}^5)\text{R}^5$, R^{30} is H, R^5 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is NH, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 1, n is 0, R^{29} is H, R^{30} is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is absent, Q^1 is absent, L^2 is absent, Y^1 is N, Y^2 is CH, m is 1, n is 0, R^{29} is $\text{N}(\text{R}^5)\text{R}^5$, R^{30} is H, R^5 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is NH, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is CH, m is 1, n is 1, R^{29} is $\text{N}(\text{R}^5)\text{R}^5$, R^{30} is H, R^5 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is absent, Q^1 is absent, L^2 is absent, Y^1 is N, Y^2 is CH, m is 2, n is 0, R^{29} is $\text{N}(\text{R}^5)\text{R}^5$, R^{30} is H, R^5 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 2, n is 0, R^{29} is H, R^{30} is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is F, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 1, n is 1, R^{29} is CH_3 , R^{30} is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is CH_3 , R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 1, n is 1, R^{29} is CH_3 , R^{30} is H, X is N, Z is phenyl, R^6 is OR^{12} , R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 1, n is 0, R^{29} is H, R^{30} is H, X is N, Z is phenyl, R^6 is OR^{12} , R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 1, n is 1, R^{29} is H, R^{30} is H, X is N, Z is phenyl, R^6 is OR^{12} , R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 2, n is 0, R^{29} is H, R^{30} is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 1, n is 1, R^{29} is H, R^{30} is H, X is N, Z is phenyl, R^6 is H, R^7 is OR^{12} , R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 1, n is 1, R^{29} is CH_3 , R^{30} is H, X is N, Z is phenyl, R^6 is H, R^8 is H, R^9 is H and R^{10} is H, then R^7 is not Cl;

Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 1, n is 0, R^{29} is H, R^{30} is H, X is N, Z is phenyl, R^6 is H, R^7 is OR^{12} , R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 1, n is 1, R^{29} is CH_3 , R^{30} is H, X is N, Z is phenyl, R^6 is H, R^7 is OR^{12} , R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is CH, m is 1, n is 1, R^{29} is $N(R^5)R^5$, R^{30} is H, R^5 is H, X is N, Z is phenyl, R^6 is H, R^7 is OR^{12} , R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, L^1 is NH, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 1, n is 0, R^{29} is H, R^{30} is H, X is N, Z is phenyl, R^6 is H, R^7 is OR^{12} , R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, L^1 is absent, Q^1 is absent, L^2 is absent, Y^1 is N, Y^2 is CH, m is 1, n is 0, R^{29} is $N(R^5)R^5$, R^{30} is H, R^5 is H, X is N, Z is phenyl, R^6 is H, R^7 is OR^{12} , R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, L^1 is absent, Q^1 is absent, L^2 is absent, Y^1 is N, Y^2 is CH, m is 1, n is 1, R^{29} is $N(R^5)R^5$, R^{30} is H, R^5 is H, X is N, Z is phenyl, R^6 is OR^{12} , R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, L^1 is absent, Q^1 is absent, L^2 is absent, Y^1 is N, Y^2 is CH, m is 1, n is 1, R^{29} is $N(R^5)R^5$, R^{30} is H, R^5 is H, X is N, Z is phenyl, R^6 is H, R^7 is OR^{12} , R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, L^1 is NH, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is CH, m is 1, n is 1, R^{29} is $N(R^5)R^5$, R^{30} is H, R^5 is H, X is N, Z is phenyl, R^6 is H, R^7 is OR^{12} , R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;


Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, L^1 is $-(C=O)-$, Q^1 is absent, L^2 is absent, Y^1 is N, Y^2 is N, m is 1, n is 1, R^{29} is H, R^{30} is H, X is N, Z is phenyl, R^6 is H, R^7 is OR^{12} , R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, L^1 is $-(C=O)-$, Q^1 is absent, L^2 is absent, Y^1 is N, Y^2 is CH, m is 1, n is 1, R^{29} is $N(R^5)R^5$, R^{30} is H, R^5 is H, X is N, Z is phenyl, R^6 is H, R^7 is OR^{12} , R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, L^1 is absent, Q^1 is absent, L^2 is absent, Y^1 is N, Y^2 is CH, m is 2, n is 0, R^{29} is $N(R^5)R^5$, R^{30} is H, R^5 is H, X is N, Z is phenyl, R^6 is H, R^7 is OR^{12} , R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

or an enantiomer, stereoisomeric form, mixture of enantiomers, diastereomer, mixture of diastereomers, racemate of the above mentioned compounds, or a pharmaceutically acceptable salt thereof.

In one embodiment, the present invention relates to compounds having the general formula Ia



Formula Ia

Wherein

X is, independently at each occurrence, selected from CH and N;

Y^1 is, independently at each occurrence, selected from CH, C(OH) and N;

Y^2 is, independently at each occurrence, selected from CH, CR⁴, O and N;

m is, independently at each occurrence, selected from 0, 1 and 2;

n is, independently at each occurrence, selected from 0 and 1;

L¹ is either absent or independently, at each occurrence, selected from the group consisting of -NH-, -NH(CH₂)-, -NH(C=O)-, -NHSO₂-, -O-, -O(CH₂)-, -(C=O)-, -(C=O)NH- and -(C=O)(CH₂)-;

Q is either absent or independently, at each occurrence, selected from the group consisting of heterocyclyl, C3-C6 heteroaryl, aryl, e.g. phenyl, aryl substituted with halogen;

L² is either absent or independently, at each occurrence, selected from the group consisting of -O-, -NH-, -(C=O)- and -(C=O)NH-;

R¹ is, at each occurrence, independently selected from the group consisting of hydrogen and methyl;


R² is, at each occurrence, independently selected from the group consisting of halogen, C1-C6 alkyl, C3-C10 cycloalkyl, -CN, -(C=O)CH₃, -NR⁹R¹² and C1-C3 haloalkyl, any of which is optionally substituted;

R^3 is, at each occurrence, absent or independently selected from the group consisting of hydrogen, -OH, halogen, -NH₂, -NR⁹R¹², -NH(C=O)R⁵, -(C=O)NH₂, heterocyclyl, C1-C6 alkyl and C1-C6 alkyl substituted with -OH or -NH₂;

R^4 is, at each occurrence, absent or independently selected from the group consisting of hydrogen, halogen, -OH, -OR⁵, -NH₂, (=O), C1-C6 alkyl and C1-C6 alkyl substituted with -OH or -NH₂;

R^5 is, at each occurrence, independently selected from the group consisting of C1-C6 alkyl, C3-C6 cycloalkyl, C3-C10 heterocyclyl, C1-C3 haloalkyl and C3-C10 heterocyclyl substituted with halogen, -OH, -NH₂, C1-C6 alkyl and C1-C6 alkyl substituted with -OH or -NH₂;

Z is any structure of the following group A;



Group A


Wherein

X^1 is, independently at each occurrence, selected from CR²⁴ and N;

X^2 is, independently at each occurrence, selected from CR²⁵ and N;


R^6 is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C3-C10 cycloalkyl, C3-C10 heterocyclyl, -(C=O)NHR¹¹, -NHR⁹, -

$\text{NH}(\text{C}=\text{O})\text{NHR}^{11}$, $-\text{N}(\text{CH}_3)(\text{C}=\text{O})\text{CH}_3$, $-\text{NH}(\text{C}=\text{O})\text{R}^{12}$, $-\text{NR}^9\text{R}^{12}$, $-\text{OR}^{12}$, and any structure of the following group **B**;



Group B

R^7 is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, $-\text{NH}(\text{C}=\text{O})\text{R}^{12}$, $-\text{NR}^9\text{R}^{12}$, $-\text{OR}^{12}$ and any structure of the following group **C**;



R^8 and R^{10} are, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C3 haloalkyl, $-NH_2$, $-OH$, $-OR^5$, $-CN$, $-(C=O)R^5$, $-(C=O)OR^5$, $-(C=O)NH_2$, $-(C=O)NHR^{21}$, $-CH_2(C=O)NHR^{21}$, $-NH(C=O)R^{13}$, $-NHS(=O)_2R^5$, $-S(=O)_2NH_2$, $-S(=O)_2NHR^{21}$, and C1-C6 alkyl substituted with OH , $-OR^5$ or $-NHR^9$;

R^9 is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C3 haloalkyl, $-OR^5$, $-CN$, C3-C10 cycloalkyl, C3-C10 heterocyclyl and C1-C6 alkyl substituted with $-OH$ or $-OR^5$;

R^{11} is, at each occurrence, independently selected from the group consisting of hydrogen, C1-C6 alkyl and C3-C10 cycloalkyl;

R^{12} is, at each occurrence, absent or independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkyl substituted with $-OR^5$ or $-N(R^5)R^5$, C6-C10 aryl, phenyl, benzyl, C3-C9 heteroaryl, C3-C6 heterocyclyl, benzyl substituted with one to four halogens or C1-C3 alkyls, C3-C9 heteroaryl substituted with one to four halogens or C1-C3 alkyls, C3-C6 heterocyclyl substituted with C1-C3 alkyl, and C6-C10 aryl substituted with one to four halogens and/or one to four $-NH(C=O)R^{13}$;

R^{13} is, at each occurrence, independently selected from the group consisting of hydrogen, C1-

C6 alkyl, C1-C6 alkyl substituted with $-\text{CN}$, $-\text{OH}$, $-\text{OR}^5$, $-\text{NH}_2$, $-\text{NHR}^5$ or $-\text{N(R}^5\text{)R}^5$ and C3-C10 cycloalkyl;

R^{14} and R^{15} are, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkyl substituted with $-\text{OH}$ or $-\text{NH}_2$, C3-C10 cycloalkyl, $-(\text{C}=\text{O})\text{R}^5$, $-(\text{C}=\text{O})\text{NHR}^{21}$, $-\text{C(R}^9\text{)(R}^{11}\text{)OR}^{21}$, $-\text{NH(C}=\text{O)R}^{21}$, $-\text{NR}^9\text{R}^{21}$, $-\text{OR}^{21}$, $-\text{OC(R}^9\text{)(R}^{11}\text{)(R}^{21}\text{)}$, C3-C10 heterocyclyl, C3-C10 heterocyclyl substituted with R^4 , C3-C10 heteroaryl substituted with one to four halogens or C1-C3 alkyl, C6-C10 aryl, e.g. phenyl and aryl substituted with $-(\text{C}=\text{O})\text{R}^5$, $-(\text{C}=\text{O})\text{OR}^5$, $-(\text{C}=\text{O})\text{NH}_2$, $-(\text{C}=\text{O})\text{NHR}^{21}$, $-\text{CH}_2(\text{C}=\text{O})\text{NHR}^{21}$, $-\text{NH(C}=\text{O)R}^{13}$, $-\text{NHS(=O)}_2\text{R}^5$, $-\text{S(=O)}_2\text{NH}_2$ or $-\text{S(=O)}_2\text{NHR}^{21}$;


R^{16} is, at each occurrence, independently selected from the group consisting of hydrogen, C1-C6 alkyl, $-(\text{C}=\text{O})\text{R}^{13}$ and C1-C6 alkyl substituted with $-\text{OR}^5$;

R^{17} , R^{18} , R^{19} and R^{20} are, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C3 haloalkyl, C6-C10 aryl, e.g. phenyl, $-\text{CN}$, $-\text{CHCF}_3\text{NR}^9\text{R}^{11}$, $-\text{OH}$, $-\text{OR}^{21}$, $-\text{NO}_2$, $-(\text{C}=\text{O})\text{R}^5$, $-(\text{C}=\text{O})\text{OR}^5$, $-(\text{C}=\text{O})\text{NH}_2$, $-(\text{C}=\text{O})\text{NHR}^{21}$, $-\text{NH(C}=\text{O)R}^{13}$, $-\text{NHR}^5$, $-\text{NHS(=O)}_2\text{R}^5$, $-\text{S(=O)}_2\text{NH}_2$, $-\text{S(=O)}_2\text{NHR}^{21}$ and C1-C6 alkyl substituted with $-\text{CN}$, $-\text{OH}$, $-\text{OR}^5$, $-(\text{C}=\text{O})\text{NHR}^5$, $-\text{NH}_2$, $-\text{NH(C}=\text{O)R}^5$, $-\text{NHR}^5$ or $-\text{N(R}^5\text{)R}^5$;

R^{21} is, at each occurrence, independently selected from the group consisting of C1-C6 alkyl, C3-C10 cycloalkyl, C3-C10 heterocyclyl, C1-C3 haloalkyl, aryl, phenyl, benzyl, C1-C6 alkyl substituted with $-\text{CN}$, $-\text{OH}$, $-\text{OR}^5$, $-\text{NH}_2$, $-\text{NHR}^5$ or $-\text{N(R}^5\text{)R}^5$, aryl substituted with halogen or C1-C3 haloalkyl, C3-C10 heteroaryl substituted with one to four halogens or C1-C3 alkyl and C3-C10 heterocyclyl substituted with R^4 ;

R^{22} and R^{23} are, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C3 haloalkyl, $-\text{OH}$, $-\text{OR}^5$, $-\text{CN}$ and C1-C6 alkyl substituted with $-\text{OH}$, $-\text{OR}^5$ or $-\text{NHR}^9$;

R^{24} and R^{25} are, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C3 haloalkyl, $-\text{NH}_2$, $-\text{OH}$, $-\text{OR}^5$, $-\text{CN}$, $-(\text{C}=\text{O})\text{R}^5$, $-(\text{C}=\text{O})\text{OR}^5$, $-(\text{C}=\text{O})\text{NH}_2$, $-(\text{C}=\text{O})\text{NHR}^{21}$, $-\text{CH}_2(\text{C}=\text{O})\text{NHR}^{21}$, $-\text{NH(C}=\text{O)R}^{13}$, $-\text{NHS(=O)}_2\text{R}^5$, $-\text{S(=O)}_2\text{NH}_2$ or $-\text{S(=O)}_2\text{NHR}^{21}$ and C1-C6 alkyl substituted with $-\text{OH}$, $-\text{OR}^5$ or $-\text{NHR}^9$;



With the proviso that when Z is , then one of R^6 and R^7 is not H.

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, R^3 is NH_2 , R^4 is H, L^1 is absent, Q is absent, L^2 is absent, X is N, n is 1, Y^1 is N, Y^2 is CH, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, R^3 is CH_3 , R^4 is H, L^1 is O, Q is absent, L^2 is absent, X is N, n is 1, Y^1 is CH, Y^2 is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not CH_3 , Cl or 1H-pyrazole;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, R^3 is CH_3 , R^4 is H, L^1 is O, Q is absent, L^2 is absent, X is N, n is 1, Y^1 is CH, Y^2 is N, Z is phenyl, R^6 is OR^{12} , R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not phenyl, $\text{CH}(\text{CH}_3)_2$, CH_2CH_3 or CH_3 ;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, R^3 is CH_3 , R^4 is H, L^1 is O, Q is absent, L^2 is absent, X is N, n is 1, Y^1 is CH, Y^2 is N, Z is phenyl, R^6 is Cl, R^7 is H, R^8 is H and R^9 is H, then R^{10} is not Cl;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, R^3 is CH_3 , R^4 is H, L^1 is O, Q is absent, L^2 is absent, X is N, n is 1, Y^1 is CH, Y^2 is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is Cl, then R^6 is not Cl;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, R^3 is CH_3 , R^4 is H, L^1 is O, Q is absent, L^2 is absent, X is N, n is 1, Y^1 is CH, Y^2 is N, Z is phenyl, R^6 is Cl, R^7 is H, R^8 is H and R^9 is H, then R^{10} is not CH_3 ;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, R^3 is CH_3 , R^4 is H, L^1 is O, Q is absent, L^2 is absent, X is N, n is 1, Y^1 is CH, Y^2 is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is Cl, then R^6 is not CH_3 ;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, R^3 is CH_3 , R^4 is H, L^1 is O, Q is absent, L^2 is absent, X is N, n is 1, Y^1 is CH, Y^2 is N, Z is phenyl, R^6 is F, R^7 is H, R^8 is H and R^9 is H, then R^{10} is not F;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, R^3 is CH_3 , R^4 is H, L^1 is O, Q is absent, L^2 is absent, X is N, n is 1, Y^1 is CH, Y^2 is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is F, then R^6 is not F;

Wherein, if R^1 is CH_3 , R^2 is $\text{CH}(\text{CH}_3)_2$, X is N, L^1 is O, Q is absent, L^2 is absent, Y^1 is CH, Y^2 is N, n is 1, R^3 is CH_3 , R^4 is H, Z is phenyl, R^6 is OR^{12} , R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, X is N, L^1 is $-(\text{C}=\text{O})-$, Q is absent, L^2 is absent, Y^1 is N, Y^2 is N, n is 1, R^3 is H, R^4 is H, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, X is N, L^1 is $-(\text{C}=\text{O})-$, Q is absent, L^2 is absent, Y^1 is N, Y^2 is CH, n is 1, R^3 is NH_2 , R^4 is H, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, X is N, L^1 is O, Q is absent, L^2 is absent, Y^1 is CH, Y^2 is N, n is 1, R^3 is H, R^4 is H, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, X is N, L^1 is O, Q is absent, L^2 is absent, Y^1 is CH, Y^2 is N, n is 1, R^3 is H, R^4 is H, Z is phenyl, R^6 is OR^{12} , R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not $\text{CH}(\text{CH}_3)_2$;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, X is N, L^1 is O, Q is absent, L^2 is absent, Y^1 is CH, Y^2 is N, n is 0, R^3 is H, R^4 is H, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, X is N, L^1 is O, Q is absent, L^2 is absent, Y^1 is CH, Y^2 is N, n is 0, R^3 is H, R^4 is H, Z is phenyl, R^6 is OR^{12} , R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not $\text{CH}(\text{CH}_3)_2$;

Wherein, if R^1 is CH_3 , R^2 is $\text{CH}(\text{CH}_3)_2$, X is N, L^1 is O, Q is absent, L^2 is absent, Y^1 is CH, Y^2 is N, n is 0, R^3 is H, R^4 is H, Z is phenyl, R^6 is OR^{12} , R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $\text{CH}(\text{CH}_3)_2$, X is N, L^1 is O, Q is absent, L^2 is absent, Y^1 is CH, Y^2 is N, n is 1, R^3 is H, R^4 is H, Z is phenyl, R^6 is OR^{12} , R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, R^3 is NH_2 , R^4 is H, L^1 is O, Q is absent, L^2 is absent, X is N, n is 1, Y^1 is CH, Y^2 is CH, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, R^3 is H, R^4 is H, L^1 is NH, Q is absent, L^2 is absent, X is N, n is 0, Y^1 is CH, Y^2 is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, R^3 is NH_2 , R^4 is H, L^1 is absent, Q is absent, L^2 is absent, X is N, n is 0, Y^1 is N, Y^2 is CH, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, R^3 is NH_2 , R^4 is H, L^1 is NH, Q is absent, L^2 is absent, X is N, n is 1, Y^1 is CH, Y^2 is CH, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, R^3 is H, R^4 is NH_2 , L^1 is absent, Q is absent, L^2 is absent, X is N, n is 1, Y^1 is N, Y^2 is CH, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

Wherein, if R^1 is CH_3 , R^2 is $\text{CH}(\text{CH}_3)_2$, X is N, L^1 is O, Q is absent, L^2 is absent, Y^1 is CH, Y^2 is N, n is 1, R^3 is H, R^4 is H, Z is phenyl, R^6 is H, R^7 is OR^{12} , R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $\text{CH}(\text{CH}_3)_2$, X is N, L^1 is O, Q is absent, L^2 is absent, Y^1 is CH, Y^2 is N, n is 1, R^3 is CH_3 , R^4 is H, Z is phenyl, R^6 is H, R^8 is H, R^9 is H and R^{10} is H, then R^7 is not Cl;

Wherein, if R^1 is CH_3 , R^2 is $\text{CH}(\text{CH}_3)_2$, X is N, L^1 is O, Q is absent, L^2 is absent, Y^1 is CH, Y^2 is N, n is 1, R^3 is H, R^4 is H, Z is phenyl, R^6 is H, R^7 is OR^{12} , R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $\text{CH}(\text{CH}_3)_2$, X is N, L^1 is O, Q is absent, L^2 is absent, Y^1 is CH, Y^2 is N, n is 1, R^3 is NH_2 , R^4 is H, Z is phenyl, R^6 is H, R^7 is OR^{12} , R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $\text{CH}(\text{CH}_3)_2$, X is N, L^1 is O, Q is absent, L^2 is absent, Y^1 is CH, Y^2 is CH, n is 1, R^3 is NH_2 , R^4 is H, Z is phenyl, R^6 is H, R^7 is OR^{12} , R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $\text{CH}(\text{CH}_3)_2$, X is N, L^1 is absent, Q is absent, L^2 is absent, Y^1 is N, Y^2 is CH, n is 1, R^3 is NH_2 , R^4 is H, Z is phenyl, R^6 is H, R^7 is OR^{12} , R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $\text{CH}(\text{CH}_3)_2$, X is N, L^1 is NH, Q is absent, L^2 is absent, Y^1 is CH, Y^2 is N, n is 0, R^3 is H, R^4 is H, Z is phenyl, R^6 is H, R^7 is OR^{12} , R^8 is H, R^9 is H and R^{10} is H, then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, X is N , L^1 is absent, Q is absent, L^2 is absent, Y^1 is N , Y^2 is CH , n is 0, R^3 is NH_2 , R^4 is H , Z is phenyl, R^6 is H , R^7 is OR^{12} , R^8 is H , R^9 is H and R^{10} is H , then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, X is N , L^1 is NH , Q is absent, L^2 is absent, Y^1 is CH , Y^2 is CH , n is 1, R^3 is NH_2 , R^4 is H , Z is phenyl, R^6 is H , R^7 is OR^{12} , R^8 is H , R^9 is H and R^{10} is H , then R^{12} is not CH_3 ;


Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, X is N , L^1 is $-(C=O)-$, Q is absent, L^2 is absent, Y^1 is N , Y^2 is N , n is 1, R^3 is H , R^4 is H , Z is phenyl, R^6 is H , R^7 is OR^{12} , R^8 is H , R^9 is H and R^{10} is H , then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, X is N , L^1 is $-(C=O)-$, Q is absent, L^2 is absent, Y^1 is N , Y^2 is CH , n is 1, R^3 is NH_2 , R^4 is H , Z is phenyl, R^6 is H , R^7 is OR^{12} , R^8 is H , R^9 is H and R^{10} is H , then R^{12} is not CH_3 ;

Wherein, if R^1 is CH_3 , R^2 is $CH(CH_3)_2$, X is N , L^1 is absent, Q is absent, L^2 is absent, Y^1 is N , Y^2 is CH , n is 1, R^3 is NH , R^4 is NH_2 , Z is phenyl, R^6 is H , R^7 is OR^{12} , R^8 is H , R^9 is H and R^{10} is H , then R^{12} is not CH_3 ;

Or an enantiomer, stereoisomeric form, mixture of enantiomers, diastereomer, mixture of diastereomers, racemate of the above mentioned compounds, or a pharmaceutically acceptable salt thereof.

In one embodiment, the present invention relates to compounds having the general formula IV




Formula IV

wherein X, L¹ and R² are as defined above for general formula I;

wherein m, n, Y¹, Y², L², R²⁹, R³⁰ and Q¹ are as defined above for general formula III;


wherein Z¹ is any structure of the following group **D**;



Group D

wherein R⁶, R⁷, R⁸, R⁹ and R¹⁰ are as defined above for general formula I.

In one embodiment, the present invention relates to compounds having the general formula V




Formula V

wherein X, X¹, X², L¹, R², R⁶, R²² and R²³ are as defined above for general formula I;

wherein m, n, Y¹, Y², L², R²⁹, R³⁰ and Q¹ are as defined above for general formula III.

In one embodiment, the present invention relates to compounds having the general formula VI



Formula VI

wherein X, L¹ and R² are as defined above for general formula I;

wherein m, n, Y¹, Y², L², R²⁹, R³⁰ and Q¹ are as defined above for general formula III;


X³ is, independently at each occurrence, selected from CR¹⁰ and N;

R²⁶, R²⁷ and R²⁸ are, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C3 haloalkyl, -OR⁵, -CN and C1-C6 alkyl substituted

with -OH, -OR⁵ or -NHR⁹;

R⁵, R⁹ and R¹⁰ are as defined above for general formula I;


R⁷ is any structure of the following group E;



Group E

wherein R⁸ and R¹⁴ – R²⁰ are as defined above for general formula I.

In one embodiment, the present invention relates to compounds having the general formula VII




.Formula VII

wherein X, L¹, R², R⁶, R²², R²³, R²⁴ and R²⁵ are as defined above for general formula I;

m, n, Y¹, Y², L², R²⁹, R³⁰ and Q¹ are as defined above for general formula III.


In one embodiment, the present invention relates to compounds having the general formula VIII



Formula VIII

wherein X, L¹, R², R⁶ and R¹⁰ are as defined above for general formula I.


In one embodiment, the present invention relates to compounds having the general formula IX



Formula IX

wherein L^1 , R^2 , R^6 , R^{22} , R^{23} , R^{24} and R^{25} are as defined above for general formula I, and X^3 is as defined above for general formula VI;

wherein Q^2 is any structure of the following group F;



Group F

R^{31} and R^{32} are either absent or independently, at each occurrence, selected from the group consisting of hydrogen, $-OR^5$, halogen, $-N(R^5)R^5$, $-NR^9R^{12}$, $-NH(C=O)R^5$, $-(C=O)NH_2$, aryl, heteroaryl, heterocyclyl, C1-C6 alkyl and C1-C6 alkyl substituted with $-OH$ or $-NH_2$;

wherein R^5 , R^9 and R^{12} are as defined above for general formula I.

In one embodiment, the present invention also relates to pharmaceutically acceptable salts of the compounds according to the present invention, as defined herein.

In one embodiment, the compound according to the present invention is a compound selected from structures 1 – 279, as listed further below in table 11.

In a further aspect, the present invention relates to a pharmaceutical composition comprising a compound according to the present invention as defined herein, as an active ingredient, together with at least one pharmaceutically acceptable carrier, excipient and/or diluent.

In one aspect, the present invention also relates to a compound according to the present invention as defined herein, for use as a pharmaceutical or pharmaceutically active agent, wherein said pharmaceutical or pharmaceutically active agent preferably has an inhibitory activity on cyclin-dependent kinase 7 (CDK7).

In one aspect, the present invention also relates to a compound according to the present invention, as defined herein, for use in a method of prevention and/or treatment of a disease which is associated with inhibition of apoptosis, abnormal transcriptional activity and/or cell cycle arrest by aberrant activity and/or overexpression of one or several cyclin-dependent kinases (CDKs), in particular cyclin-dependent kinase 7 (CDK7), wherein the disease is selected from proliferative diseases, infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, and inflammatory diseases.

In one embodiment, the disease associated with inhibition of apoptosis, abnormal transcriptional activity and/or cell cycle arrest by aberrant activity and/or overexpression of one or several cyclin-dependent kinases (CDKs), in particular cyclin-dependent kinase 7 (CDK7), is a disease associated with, accompanied by, caused by and/or induced by CDK7 dysfunction and/or hyperfunction. In one embodiment, the disease associated with inhibition of apoptosis, abnormal transcriptional activity and/or cell cycle arrest by aberrant activity and/or overexpression of one or several cyclin-dependent kinases (CDKs), in particular cyclin-dependent kinase 7 (CDK7), is a proliferative disease. In one embodiment said proliferative disease is a cancer.

In one embodiment said cancer is selected from adenocarcinoma, choroidal melanoma, acute leukemia, acoustic neurinoma, ampullary carcinoma, anal carcinoma, astrocytoma, basal cell

carcinoma, pancreatic cancer, Desmoid tumor, bladder cancer, bronchial carcinoma, estrogen dependent and independent breast cancer, Burkitt's lymphoma, corpus cancer, Carcinoma unknown primary tumor (CUP-syndrome), colorectal cancer, small intestine cancer, small intestinal tumors, ovarian cancer, endometrial carcinoma, ependymoma, epithelial cancer types, Ewing's tumors, gastrointestinal tumors, gastric cancer, gallbladder cancer, gall bladder carcinomas, uterine cancer, cervical cancer, cervix, glioblastomas, gynecologic tumors, ear, nose and throat tumors, hematologic tumor, hairy cell leukemia, urethral cancer, skin cancer, skin testis cancer, brain tumors (gliomas), brain metastases, testicle cancer, hypophysis tumor, carcinoids, Kaposi's sarcoma, laryngeal cancer, germ cell tumor, bone cancer, colorectal carcinoma, head and neck tumors (tumors of the ear, nose and throat area), colon carcinoma, craniopharyngiomas, oral cancer (cancer in the mouth area and on lips), cancer of the central nervous system, liver cancer, liver metastases, leukemia, eyelid tumor, lung cancer, lymphomas, stomach cancer, malignant melanoma, malignant neoplasia, malignant tumors gastrointestinal tract, breast carcinoma, rectal cancer, medulloblastomas, melanoma, meningiomas, Hodgkin's / Non-Hodgkin's lymphoma, mycosis fungoides, nasal cancer, neurinoma, neuroblastoma, kidney cancer, renal cell carcinomas, oligodendroglioma, esophageal carcinoma, osteolytic carcinomas and osteoplastic carcinomas, osteosarcomas, ovarian carcinoma, pancreatic carcinoma, penile cancer, plasmacytoma, prostate cancer, pharyngeal cancer, rectal carcinoma, retinoblastoma, vaginal cancer, thyroid carcinoma, esophageal cancer, T-cell lymphoma, thymoma, tube carcinoma, eye tumors, urethral cancer, urologic tumors, urothelial carcinoma, vulva cancer, wart appearance, soft tissue tumors, soft tissue sarcoma, Nephroblastoma, cervical carcinoma, tongue cancer, invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, lobular carcinoma in situ, small-cell lung carcinoma, non-small-cell lung carcinoma, bronchial adenoma, pleuropulmonary blastoma, mesothelioma, brain stem glioma, hypothalamic glioma, cerebellar astrocytoma, cerebral astrocytoma, neuroectodermal tumor, pineal tumors, sarcoma of the uterus, salivary gland cancers, anal gland adenocarcinomas, mast cell tumors, pelvis tumor, ureter tumor, hereditary papillary renal cancers, sporadic papillary renal cancers, intraocular melanoma, hepatocellular carcinoma, cholangiocarcinoma, mixed hepatocellular cholangiocarcinoma, squamous cell carcinoma, malignant melanoma, Merkel cell skin cancer, non-melanoma skin cancer, hypopharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer, oral cavity cancer, squamous cell cancer, oral melanoma, AIDS-related lymphoma, cutaneous T-cell lymphoma, lymphoma of the central nervous system, malignant fibrous

histiocytoma, lymph sarcoma, rhabdomyosarcoma, malignant histiocytosis, fibroblastic sarcoma, hemangiosarcoma, hemangiopericytoma, leiomyosarcoma (LMS), canine mammary carcinoma, and feline mammary carcinoma.

In one embodiment, said infectious disease, including opportunistic diseases, is selected from AIDS, Adenovirus Infection, Alveolar Hydatid Disease (AHD), Amoebiasis, Angiostrongyliasis, Anisakiasis, Anthrax, Babesiosis, Balantidiasis, Baylisascaris Infection, Bilharzia (Schistosomiasis), Blastocystis hominis Infection, Lyme Borreliosis, Botulism, Brainerd Diarrhea, Brucellosis, Bovine Spongiform Encephalopathy (BSE), Candidiasis, Capillariasis, Chronic Fatigue Syndrome (CFS), Chagas Disease, Chickenpox, Chlamydia pneumoniae Infection, Cholera, Chronic Fatigue Syndrome, Creutzfeldt-Jakob Disease (CJD), Clonorchiasis, Cutaneous Larva migrans (CLM), Coccidioidomycosis, Conjunctivitis, Coxsackievirus A16 (Cox A16), Cryptococcal disease, Cryptosporidiosis, West Nile fever, Cyclosporiasis, Neurocysticercosis, Cytomegalovirus Infection, Dengue Fever, Dipylidium caninum Infection, Ebola Hemorrhagic Fever (EHF), Alveolar Echinococcosis (AE), Encephalitis, Entamoeba coli Infection, Entamoeba dispar Infection, Entamoeba hartmanni Infection, Entamoeba polecki Infection, Pinworm Infection, Enterovirus Infection (Polio / Non-Polio), Epstein Barr Virus Infection, Escherichia coli Infection, Foodborne Infection, Aphthae epizooticae, Fungal Dermatitis, Fungal Infections, Gastroenteritis, Group A streptococcal Disease, Group B streptococcal Disease, Hansen's Disease (Leprosy), Hantavirus Pulmonary Syndrome, Head Lice Infestation (Pediculosis), Helicobacter pylori Infection, Hematologic Disease, Hendra Virus Infection, Hepatitis (HCV, HBV), Herpes Zoster (Shingles), HIV Infection, Human Ehrlichiosis, Human Parainfluenza Virus Infection, Influenza, Isosporiasis, Lassa Fever, Leishmaniasis, Visceral leishmaniasis (VL), Malaria, Marburg Hemorrhagic Fever, Measles, Meningitis, Mycobacterium avium Complex (MAC) Infection, Naegleria Infection, Nosocomial Infections, Nonpathogenic Intestinal Amebae Infection, Onchocerciasis, Opisthorchiasis, Papilloma virus Infection, Parvovirus Infection, Plague, Pneumocystis Pneumonia (PCP), Polyomavirus Infection, Q Fever, Rabies, Respiratory Syncytial Virus (RSV) Infection, Rheumatic Fever, Rift Valley Fever, Rotavirus Infection, Roundworms Infection, Salmonellosis, Scabies, Shigellosis, Shingles, Sleeping Sickness, Smallpox, Streptococcal Infection, Tapeworm Infection, Tetanus, Toxic Shock Syndrome, Tuberculosis, duodenum, Vibrio parahaemolyticus Infection, Vibrio septicemia, Viral Hemorrhagic Fever, Warts, Waterborne infectious Diseases, Varicella-Zoster Virus

infection, Pertussis and Yellow Fever.

In one embodiment, the immunological disease and/or autoimmune disease is selected from asthma, diabetes, rheumatic diseases, rejection of transplanted organs and tissues, rhinitis, chronic obstructive pulmonary diseases, osteoporosis, ulcerative colitis, sinusitis, lupus erythematosus, recurrent infections, atopic dermatitis / eczema and occupational allergies, food allergies, drug allergies, severe anaphylactic reactions, anaphylaxis, manifestations of allergic diseases, primary immunodeficiencies, antibody deficiency states, cell mediated immunodeficiencies, severe combined immunodeficiency, DiGeorge syndrome, Hyper IgE syndrome (HIES), Wiskott-Aldrich syndrome (WAS), ataxia-telangiectasia, immune mediated cancers, white cell defects, autoimmune diseases, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), immune-mediated or Type 1 Diabetes Mellitus, immune mediated glomerulonephritis, scleroderma, pernicious anemia, alopecia, pemphigus, pemphigus vulgaris, myasthenia gravis, inflammatory bowel diseases, Crohn's disease, psoriasis, autoimmune thyroid diseases, Hashimoto's disease, dermatomyositis, Goodpasture syndrome (GPS), myasthenia gravis (MG), Sympathetic ophthalmia, Phakogene Uveitis, chronic aggressive hepatitis, primary biliary cirrhosis, autoimmune hemolytic anemia, and Werlhof's disease.

In one embodiment, the inflammatory disease is caused, induced, initiated and/or enhanced by bacteria, viruses, prions, parasites, fungi, and/or caused by irritative, traumatic, metabolic, allergic, autoimmune, or idiopathic agents.

In one embodiment, the inflammatory disease is selected from the group comprising or consisting of inflammatory diseases of the central nervous system (CNS), inflammatory rheumatic diseases, inflammatory diseases of blood vessels, inflammatory diseases of the middle ear, inflammatory bowel diseases, inflammatory diseases of the skin, inflammatory disease uveitis, and inflammatory diseases of the larynx.

In one embodiment, the inflammatory disease is selected from inflammatory diseases of the central nervous system (CNS), inflammatory rheumatic diseases, inflammatory diseases of blood vessels, inflammatory diseases of the middle ear, inflammatory bowel diseases, inflammatory diseases of the skin, inflammatory disease uveitis, inflammatory diseases of the larynx, wherein preferably said inflammatory diseases are selected from the group comprising abscessation, acanthamoeba infection, acne vulgaris, actinomycosis, acute

inflammatory dermatoses, acute laryngeal infections of adults, acute multifocal placoid pigment epitheliopathy, acute (thermal) injury, acute retinal necrosis, acute suppurative otitis media, algal disorders, allergic contact dermatitis, amyloidosis angioedema, ankylosing spondylitis, aspergillosis, atopic dermatitis, pseudorabies, autoantibodies in vasculitis, bacterial disorders, bacterial laryngitis, bacterial meningitis, Behçet's disease (BD), birdshot choroidopathy, Gilchrist's disease, Borna disease, brucellosis, bullous myringitis, bursitis, candidiasis, canine distemper encephalomyelitis, canine distemper encephalomyelitis in immature animals, canine hemorrhagic fever, canine herpes virus encephalomyelitis, cholesteatoma, chronic granulomatous diseases (CGD), chronic inflammatory dermatoses, chronic relapsing encephalomyelitis, chronic suppurative otitis media, Ocular Cicatricial pemphigoid (OCP), common upper respiratory infection, granuloma, Crohn's disease, cryptococcal disease, dermatomyositis, diphtheria, discoid lupus erythematosus (DLE), drug-induced vasculitis, drug or hypersensitivity reaction, encephalitozoonosis, eosinophilic meningoencephalitis, Erythema multiforme (EM), feline leukemia virus, feline immunodeficiency virus, feline infectious peritonitis, feline Polioencephalitis, feline spongiform encephalopathy, fibromyalgia, Fuchs Heterochromic Uveitis, gastroesophageal (laryngopharyngeal) reflux disease, giant cell arteritis, glanders, glaucomatocyclitic crisis, gonorrhea granular myringitis, Granulomatous meningoencephalitis (GME), herpes simplex, histoplasmosis, idiopathic diseases, idiopathic inflammatory disorders, immune and idiopathic disorders, infections of the immunocompromised host, infectious canine hepatitis, inhalation laryngitis, interstitial nephritis, irritant contact dermatitis, juvenile rheumatoid arthritis, Kawasaki's disease, La Crosse virus encephalitis, laryngeal abscess, laryngotracheobronchitis, leishmaniasis, lens-induced uveitis, leprosy, leptospirosis, leukemia, lichen planus, lupus, lymphoma, meningitis, meningoencephalitis in greyhounds, miscellaneous meningitis / meningoencephalitis, microscopic polyangiitis, multifocal choroiditis, multifocal distemper encephalomyelitis in mature animals, multiple sclerosis, Muscle Tension Dysphonia (MTD), mycotic (fungal) diseases, mycotic diseases of the CNS, necrotizing encephalitis, neosporosis, old dog encephalitis, onchocerciasis, parasitic encephalomyelitis, parasitic infections, Pars planitis, parvovirus encephalitis, pediatric laryngitis, pollution and inhalant allergy, polymyositis, post-vaccinal canine distemper encephalitis, prion protein induced diseases, protothecosis, protozoal encephalitis-encephalomyelitis, psoriasis, psoriatic arthritis, pug dog encephalitis, radiation injury, radiation laryngitis, radionecrosis, relapsing polychondritis, Reiter's syndrome, retinitis

pigmentosa, retinoblastoma, rheumatoid arthritis, Rickettsial disorders, rocky mountain spotted fever, salmon poisoning disease (SPD), Sarcocystosis, sarcoidosis, schistosomiasis, scleroderma, Rhinoscleroma, serpiginous choroiditis, shaker dog disease, Sjogren's syndrome, spasmodic croup, spirochetal (syphilis) diseases, spongiotic dermatitis, sporotrichosis, steroid responsive meningitis-arteritis, Stevens-Johnson syndrome (SJS, EM major), epiglottitis, sympathetic ophthalmia, Syngamiasis, syphilis, systemic vasculitis in sarcoidosis, Takayasu's arteritis, tendinitis (tendonitis), Thromboangiitis obliterans (Buerger Disease), tick-borne encephalitis in dogs, toxic epidermal necrolysis (TEN), toxocariasis, toxoplasmosis, trauma, traumatic laryngitis, trichinosis, trypanosomiasis, tuberculosis, tularemia, ulcerative colitis, urticaria (hives), vasculitis, vasculitis and malignancy, vasculitis and rheumatoid arthritis, vasculitis in the idiopathic inflammatory myopathies, vasculitis of the central nervous system, vasculitis secondary to bacterial, fungal, and parasitic infection, viral disorders, viral laryngitis, vitiligo, vocal abuse, vocal-cord hemorrhage, Vogt-Koyanagi-Harada syndrome (VKH), Wegener's granulomatosis, and Whipple's disease.

The present invention also relates to a method of treatment and/or prevention of a disease which is associated with inhibition of apoptosis, abnormal transcriptional activity and/or cell cycle arrest by aberrant activity and/or overexpression of one or several cyclin-dependent kinases (CDKs), in particular cyclin-dependent kinase 7 (CDK7), wherein the disease is selected from proliferative diseases, infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, and inflammatory diseases, wherein said method of treatment and/or prevention comprises administering a compound according to the present invention as defined herein, to a patient in need thereof.

In one embodiment, the patient in need thereof is a mammal. In one embodiment, the patient in need thereof is a human being. In another embodiment, the patient in need thereof is a non-human animal.

In one embodiment, the disease which is prevented or treated in said method is as defined herein.

The present invention also relates to the use of a compound according to the present invention as defined herein in the manufacture of a medicament for the prevention and/or treatment of a disease which is associated with inhibition of apoptosis, abnormal

transcriptional activity and/or cell cycle arrest by aberrant activity and/or overexpression of one or several cyclin-dependent kinases (CDKs), in particular cyclin-dependent kinase 7 (CDK7), wherein the disease is selected from proliferative diseases, infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, and inflammatory diseases, as defined herein.

Further advantageous features, aspects and details of the invention are evident from the dependent claims, the description, the examples and the drawings.

The compounds of the present invention are highly efficient inhibitors of CDK7 threonine/serine kinase and/or its complex, CDK7/MAT1/CycH. The inventive compounds are suitable for the use as a pharmaceutically active agent. The inventive compounds are suitable for the treatment of disorders associated with, accompanied by, caused by and/or induced by CDK7 and its complex, in particular a hyperfunction or dysfunction thereof. The inventive compounds are thus suitable for the treatment of CDK7-associated diseases or disorders and CDK7 complex induced disorders.

The inventive compounds are also useful in the manufacture of a medicament or of a pharmaceutical composition for the treatment of disorders associated with, accompanied by, caused by and/or induced by CDK7 and its complex, in particular a hyperfunction or dysfunction thereof. The inventive compounds are further used in the manufacture of a medicament or of a pharmaceutical composition for the treatment and/or prevention of CDK7 and its complex induced disorders.

The term “optionally substituted” as used herein is meant to indicate that a hydrogen atom where present and attached to a member atom within a group, or several such hydrogen atoms, may be replaced by a suitable group, such as halogen including fluorine, C₁-C₃ alkyl, C₁-C₃ haloalkyl, methylhydroxyl, COOMe, C(O)H, COOH, OMe, or OCF₃;

The term “alkyl” refers to a monovalent straight, branched or cyclic chain, saturated aliphatic hydrocarbon radical having a number of carbon atoms in the specified range. Thus, for example, “C₁-C₆ alkyl” refers to any of the hexyl alkyl and pentyl alkyl isomers as well as n-, iso-, sec-, and t-butyl, n- and isopropyl, cyclic propyl, ethyl and methyl.

The term “alkenyl” refers to a monovalent straight or branched chain aliphatic hydrocarbon radical containing one carbon-carbon double bond and having a number of carbon atoms in the specified range. Thus, for example, “C₂-C₆ alkenyl” refers to all of the hexenyl and pentenyl isomers as well as 1-butenyl, 2-butenyl, 3-butenyl, isobutenyl, 1-propenyl, 2-propenyl, and ethenyl (or vinyl).

The term “cycloalkyl”, alone or in combination with any other term, refers to a group, such as optionally substituted or non-substituted cyclic hydrocarbon, having from three to eight carbon atoms, unless otherwise defined. Thus, for example, “C₃-C₈ cycloalkyl” refers to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.

The term “haloalkyl” refers to an alkyl group, as defined herein that is substituted with at least one halogen. Examples of straight or branched chained “haloalkyl” groups useful in the present invention include, but are not limited to, methyl, ethyl, propyl, isopropyl, *n*-butyl, and *t*-butyl substituted independently with one or more halogens. The term “haloalkyl” should be interpreted to include such substituents such as -CHF₂, -CF₃, -CH₂-CH₂-F, -CH₂-CF₃, and the like.

The term “heteroalkyl” refers to an alkyl group where one or more carbon atoms have been replaced with a heteroatom, such as, O, N, or S. For example, if the carbon atom of alkyl group which is attached to the parent molecule is replaced with a heteroatom (*e.g.*, O, N, or S) the resulting heteroalkyl groups are, respectively, an alkoxy group (*e.g.*, -OCH₃, etc.), an amine (*e.g.*, -NHCH₃, -N(CH₃)₂, etc.), or thioalkyl group (*e.g.*, -SCH₃, etc.). If a non-terminal carbon atom of the alkyl group which is not attached to the parent molecule is replaced with a heteroatom (*e.g.*, O, N, or S) and the resulting heteroalkyl groups are, respectively, an alkyl ether (*e.g.*, -CH₂CH₂-O-CH₃, etc.), alkyl amine (*e.g.*, -CH₂NHCH₃, -CH₂N(CH₃)₂, etc.), or thioalkyl ether (*e.g.*, -CH₂-S-CH₃).

The term “halogen” refers to fluorine, chlorine, bromine, or iodine.

The term “phenyl” as used herein is meant to indicate that optionally substituted or non-substituted phenyl group.

The term “benzyl” as used herein is meant to indicate that optionally substituted or non-substituted benzyl group.

The term “heteroaryl” refers to (i) optionally substituted 5- and 6-membered heteroaromatic rings and (ii) optionally substituted 9- and 10-membered bicyclic, fused ring systems in which at least one ring is aromatic, wherein the heteroaromatic ring or the bicyclic, fused ring system contains from 1 to 4 heteroatoms independently selected from N, O, and S, where each N is optionally in the form of an oxide and each S in a ring which is not aromatic is optionally S(O) or S(O)₂. Suitable 5- and 6-membered heteroaromatic rings include, for example, pyridyl, pyrrolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thienyl, furanyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isooxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, and thiadiazolyl. Suitable 9- and 10-membered heterobicyclic, fused ring systems include, for example, benzofuranyl, indolyl, indazolyl, naphthyridinyl, isobenzofuranyl, benzopiperidinyl, benzisoxazolyl, benzoxazolyl, chromenyl, quinolinyl, isoquinolinyl, cinnolinyl, quinazolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, isoindolyl, benzodioxolyl, benzofuranyl, imidazo[1,2-a]pyridinyl, benzotriazolyl, dihydroindolyl, dihydroisoindolyl, indazolyl, indolyl, isoindolyl, quinoxalyl, quinazolinyl, 2,3-dihydrobenzofuranyl, and 2,3-dihydrobenzo-1,4-dioxinyl.

The term “heterocyclyl” refers to (i) optionally substituted 4- to 8-membered, saturated and unsaturated but non-aromatic monocyclic rings containing at least one carbon atom and from 1 to 4 heteroatoms, (ii) optionally substituted bicyclic ring systems containing from 1 to 6 heteroatoms, and (iii) optionally substituted tricyclic ring systems, wherein each ring in (ii) or (iii) is independent of fused to, or bridged with the other ring or rings and each ring is saturated or unsaturated but nonaromatic, and wherein each heteroatom in (i), (ii), and (iii) is independently selected from N, O, and S, wherein each N is optionally in the form of an oxide and each S is optionally oxidized to S(O) or S(O)₂. Suitable 4- to 8-membered saturated heterocyclyls include, for example, azetidyl, piperidinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, isothiazolidinyl, oxazolidinyl, isoxazolidinyl, pyrrolidinyl, imidazolidinyl, piperazinyl, tetrahydrofuranyl, tetrahydrothienyl, pyrazolidinyl, hexahydropyrimidinyl, thiazinanyl, thiazepanyl, azepanyl, diazepanyl, tetrahydropyranyl, tetrahydrothiopyranyl, dioxanyl, and azacyclooctyl. Suitable unsaturated heterocyclic rings include those corresponding to the saturated heterocyclic rings listed in the above sentence in which a single bond is replaced with a double bond. It is understood that the specific rings and ring

systems suitable for use in the present invention are not limited to those listed in this and the preceding paragraphs. These rings and ring systems are merely representative.

Pharmaceutically acceptable salts

Examples of pharmaceutically acceptable addition salts include, without limitation, the non-toxic inorganic and organic acid addition salts such as the acetate derived from acetic acid, the aconate derived from aconitic acid, the ascorbate derived from ascorbic acid, the benzenesulfonate derived from benzenesulfonic acid, the benzoate derived from benzoic acid, the cinnamate derived from cinnamic acid, the citrate derived from citric acid, the embonate derived from embonic acid, the enantate derived from enanthic acid, the formate derived from formic acid, the fumarate derived from fumaric acid, the glutamate derived from glutamic acid, the glycolate derived from glycolic acid, the hydrochloride derived from hydrochloric acid, the hydrobromide derived from hydrobromic acid, the lactate derived from lactic acid, the maleate derived from maleic acid, the malonate derived from malonic acid, the mandelate derived from mandelic acid, the methanesulfonate derived from methane sulphonic acid, the naphthalene-2-sulphonate derived from naphthalene-2-sulphonic acid, the nitrate derived from nitric acid, the perchlorate derived from perchloric acid, the phosphate derived from phosphoric acid, the phthalate derived from phthalic acid, the salicylate derived from salicylic acid, the sorbate derived from sorbic acid, the stearate derived from stearic acid, the succinate derived from succinic acid, the sulphate derived from sulphuric acid, the tartrate derived from tartaric acid, the toluene-p-sulphonate derived from p-toluene sulphonic acid, and the like. Such salts may be formed by procedures well known and described in the art.

Other acids such as oxalic acid, which may not be considered pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining a chemical compound of the invention and its pharmaceutically acceptable acid addition salt.

In another embodiment, the compounds of the invention are used in their respective free base form according to the present invention.

Metal salts of a chemical compound of the invention include alkali metal salts, such as the sodium salt of a chemical compound of the invention containing a carboxy group.

The chemical compounds of the invention may be provided in unsolvated or solvated forms together with a pharmaceutically acceptable solvent(s) such as water, ethanol, and the like. Solvated forms may also include hydrated forms such as the monohydrate, the dihydrate, the hemihydrate, the trihydrate, the tetrahydrate, and the like. In general, solvated forms are considered equivalent to unsolvated forms for the purposes of this invention.

Further aspects of the present invention are illustrated and exemplified by the following schemes, examples, tables and procedural descriptions which are given merely to illustrate, not to limit the present invention. The scope of protection for the present invention is merely limited by the appended claims.

Tables and figure

Reference is now made to tables, wherein

Table 1 shows activity data in CDK1, CDK2, CDK5 and CDK7 enzymatic assay for selected compounds of the invention. Inhibition is indicated as IC_{50} with the following key: A = IC_{50} less than 100 nM; B = IC_{50} greater than 100 nM, but less than 1,000 nM; C = IC_{50} greater than 1,000 nM. Also table 1 shows selectivity data in CDK1/CDK7, CDK2/CDK7 and CDK5/CDK7 for selected compounds of the invention. Selectivity is indicated as CDK1/CDK7*, CDK2/CDK7** and CDK5/CDK7*** with the following key: A = greater than 200 fold; B = less than 200 fold, but greater than 20 fold; C = less than 20 fold.

Table 2 shows activity data of cellular HCT116 viability assay for selected compounds of the invention. Inhibition is indicated as IC_{50} with the following key: A = IC_{50} less than 1 μ M; B = IC_{50} greater than 1 μ M, but less than 10 μ M; C = IC_{50} greater than 10 μ M.

Table 3 shows activity data cellular H460 viability assay for selected compounds of the invention. Inhibition is indicated as IC_{50} with the following key: A = IC_{50} less than 1 μ M; B = IC_{50} greater than 1 μ M, but less than 10 μ M; C = IC_{50} greater than 10 μ M.

Table 4 shows activity data of cellular MM.1S viability assay for selected compounds of the invention. Inhibition is indicated as IC_{50} with the following key: A = IC_{50} less than 1 μ M; B = IC_{50} greater than 1 μ M, but less than 10 μ M; C = IC_{50} greater than 10 μ M.

Table 5 shows activity data of cellular MV4-11 viability assay for selected compounds of the

invention. Inhibition is indicated as IC_{50} with the following key: A = IC_{50} less than 1 μ M; B = IC_{50} greater than 1 μ M, but less than 10 μ M; C = IC_{50} greater than 10 μ M.

Table 6 shows activity data of cellular MOLT-4 viability assay for selected compounds of the invention. Inhibition is indicated as IC_{50} with the following key: A = IC_{50} less than 1 μ M; B = IC_{50} greater than 1 μ M, but less than 10 μ M; C = IC_{50} greater than 10 μ M.

Table 7 shows activity data of cellular RPMI-8226 viability assay for selected compounds of the invention. Inhibition is indicated as IC_{50} with the following key: A = IC_{50} less than 1 μ M; B = IC_{50} greater than 1 μ M, but less than 10 μ M; C = IC_{50} greater than 10 μ M.

Table 8 shows activity data of cellular A2780 viability assay for selected compounds of the invention. Inhibition is indicated as IC_{50} with the following key: A = IC_{50} less than 1 μ M; B = IC_{50} greater than 1 μ M, but less than 10 μ M; C = IC_{50} greater than 10 μ M.

Table 9 shows activity data of cellular OVCAR-3 viability assay for selected compounds of the invention. Inhibition is indicated as IC_{50} with the following key: A = IC_{50} less than 1 μ M; B = IC_{50} greater than 1 μ M, but less than 10 μ M; C = IC_{50} greater than 10 μ M.

Table 10 shows comparative data of a panel assay showing the CDK7 selectivity profile in CDKs family for compound 210 of the invention.

Table 11 summarizes compounds 1-279 in terms of their structures and corresponding characteristics.

Figure 1 show *in vivo* antitumor activity of CDK7 inhibitor in OVCAR-3 xenograft model.

Examples

The invention is now further described by reference to the following examples which are intended to illustrate, not to limit the scope of the invention.

Example 1: Enzymatic assay for CDK1, CDK2, CDK5 and CDK7

Enzymatic binding assay protocol for CDK1, CDK2, CDK5 and CDK7

Inhibition activity of the respective compound on CDK kinase under K_m value of ATP was tested in FRET based The LANCE® Ultra kinase assay (Perkin Elmer), which uses a ULIGHT™-labeled peptide substrate and an appropriate Europium-labeled anti-phospho-

antibody. Test compounds were made with DMSO solutions, and then 4-fold serial dilutions for 8 doses were prepared using automated liquid handler (POD810, LABCYTE) and 80nL/well of diluted compound solutions were added into the 384-well plates (Greiner, Cat# 784075). And then 68nM of ULight-MBP peptide (Perkin Elmer, Cat # TRF0109-M) and 5ul/well of ATP (Sigma, Cat #A7699) were added to the plate. After 1min centrifugation at 1000 rpm, Purified CDKs/Cyclin complex were added following concentrations respectively. 24 uM for CDK1/Cyclin B (Invitrogen, Cat# PR4768C), 22 uM for CDK2/Cyclin A (Invitrogen, Cat# PV6290), 10 uM for CDK5/p25 (Invitrogen, Cat# PR8543B) and 400 uM for CDK7/Cyclin H/MNAT1 (Invitrogen, Cat# PR6749B) were added to the each corresponding plate for CDK1, CDK2, CDK5 and CDK7. Incubate at 23 °C for 60 min and then Eu-labeled anti-phospho-Myelin Basic Protein (PE, Cat # TRF0201-M) and EDTA (Invitrogen, Cat #15575038) mixture in Lance Detection Buffer (Perkin Elmer, Cat #CR97100) was added in each well. After additional incubation at 23 °C for 60 min, test articles were measured the fluorescence using Envision leader (Perkin Elmer, USA) [Laser as excitation light; APC 615 nm and Europium 665 as the first and the second emission filter]. Data was analyzed using XL Fit software.

Example 2: Cellular HCT116, H460, MV4-11, MM.1S, MOLT-4, RPMI-8226, A2780 and OVCAR-3 viability assay

Cell culture

Human T-cell acute lymphoblastic leukemia cell line, MOLT-4 (ATCC, Cat# CRL-1582), Human multiple myeloma cell line, RPMI-8226(Invitrogen, Cat# 22400-089) and MM.1S (ATCC, Cat# CRL-2974), NSCLC (Non-small cell lung cancer) cell line H460 (ATCC, Cat# HTB-177), Human colon colorectal carcinoma cell line HCT116 (ATCC, Cat #CCL-247), Human acute monocytic leukemia cell line MV4-11 (ATCC, Cat# CRL-9591), OVCAR-3(ATCC, Cat# HTB-161) and A2780(ECACC, Cat#93112519) were obtained from ATCC. Cells were grown in RPMI-1640 media (Invitrogen, Cat#22400-089) supplemented with 10% FBS (Invitrogen, Cat# 10099141) and 1% penicillin/streptomycin (Invitrogen, Cat# 15070063) and cultured at 37°C, 5%CO₂ in a humidified chamber. All cell lines were routinely tested for mycoplasma.

Cell HCT116, H460, MV4-11, MM.1S, MOLT-4, RPMI-8226, A2780 and OVCAR-3 viability assay protocol

The effect of the CDK7 inhibitor to inhibit the growth of target cancer cells was evaluated through the 72 hours time period of viability assay. Briefly, the candidate cell line were plated in 96 well plate at the following density of cells respectively. 1×10^4 cells/well for MOLT-4, RPMI-8226, MV4-11 and MM.1S, 5×10^3 for H460, HCT116 and OVCAR-3 and 1×10^3 for A2780. After 24 hours, the cells were treated with various concentrations of the compound (ranging from 0.0015uM to 10uM). DMSO solvent without compound served as a control and final DMSO concentration less than 0.1%. After 72 hours of incubation at 37°C, 5% CO₂ incubator, cells were analyzed for the viability using the CellTiter-Glo Luminescent Cell Viability Assay (Promega, Cat# G7570). All viability assays were performed in duplicate and Luminescence was read using an Envision (Perkin Elmer, USA). Data was analyzed using XLfit software.

Example 3: *in vitro* IC₅₀ profile for CDKs family kinase

In vitro IC₅₀ profile for CDK7 inhibitor among 28 CDKs family kinases.

The IC₅₀ profile of compounds were determined using 28 CDKs family protein kinases through ProQinase GmbH (Freiburg, Germany). All the protocol and materials had been provided by ProQinase GmbH. Briefly, in the process, 90 µl H₂O were added to each well of a compound dilution plate. To minimize potential precipitation, the H₂O was added to the plate only a few minutes before the transfer of the compound solutions into the assay plates. The plate was shaken thoroughly, resulting in a "compound dilution plate/ 10 % DMSO". The compound dilution plate(s) were discarded at the end of the working day. For the assays (see below), 5 µl solution from each well of the compound dilution plate were transferred into the assay plates. The final volume of the assay was 50 µl. All compounds were tested at 10 final assay concentrations in the range from 1×10^{-05} M to 3×10^{-10} M. The final DMSO concentration in the reaction cocktails was 1 % in all cases. All protein kinases provided by ProQinase were expressed in Sf9 insect cells or in E.coli as recombinant GST-fusion proteins or His-tagged proteins, either as full-length or enzymatically active fragments. All kinases were produced from human cDNAs and purified by either GSH affinity chromatography or immobilized metal affinity chromatography. The purity of the protein kinases was examined by SDS-PAGE/Coomassie staining, the identity was checked by mass spectroscopy. Kinases from external vendors, Carma Biosciences Inc.; Invitrogen Corp.; and Millipore Corp., were expressed, purified and quality-controlled by virtue of the vendors readings. A radiometric

protein kinase assay (³³PanQinase[®] Activity Assay) was used for measuring the kinase activity of the 28 protein kinases. All kinase assays were performed in 96-well FlashPlates[™] from PerkinElmer (Boston, MA, USA) in a 50 µl reaction volume. The reaction cocktails were incubated at 30 °C for 60 minutes. The reaction was stopped with 50 µl of 2 % (v/v) H₃PO₄, plates were aspirated and washed two times with 200 µl 0.9 % (w/v) NaCl. Incorporation of ³³Pi was determined with a microplate scintillation counter (Microbeta, Wallac). All assays were performed with a BeckmanCoulter/SAGIAN[™] Core System. As part of the data evaluation the low control value from a particular plate was subtracted from the high control value as well as from all 80 "compound values" of the corresponding plate. The residual activity (in %) for each well of a particular plate was calculated by using the following formula: Res. Activity (%) = 100 X [(cpm of compound – low control) / (high control – low control)]. Results are represented in table (table 10).

Example 4: *in vivo* efficacy study for OVCAR-3 model

In vivo efficacy of CDK7 inhibitor in the OVCAR-3 human epithelial ovarian cancer xenograft model.


To evaluate inhibitory activity to the growth of OVCAR-3(ATCC, HTB-161) xenograft tumors, *in vivo* efficacy study was conducted. OVCAR-3 cells were grown in RPMI-1640 medium (Gibco, C2400500BT) supplemented with 20 % fetal bovine serum(Hyclone, SV30087.03), 0.01 mg/ml bovine insulin (Yuanyue, S12033) and 1 % anti anti(Gibco, 15240-062) at 37 °C in an atmosphere of 5 % CO₂ in air. To establish tumors, 10 X 10⁶ OVCAR-3 cells were injected subcutaneously in 200 µl of PBS (Corning, 21-031-CVR) mixed with 50% of Matrigel (Corning, 354234) into the upper right flank of the female Balb/c nude mouse (Vital River Laboratory Animal Co., LTD., Beijing). Tumor volume was measured twice a week and body weight was monitored daily. Mice were measured for tumor size in two dimensions using a caliper, and the tumor volume (mm³) was calculated using formula, "V = 0.5 a X b²" where a and b are the long and short diameters of the tumor in mm. respectively. The animals were randomized based on tumor volumes into three groups of eight animals each. To evaluate efficacy, compound-210 was administered orally using 70% PEG400 (Sigma-Aldrich, P3265) in distilled water as vehicle. Once the average tumor size had reached approximately 160 mm³, the animals were treated with vehicle, 20 mg/kg or 40 mg/kg of co

mpound-210 daily (q24h/ qd schedule) for 25days post randomization. Statistical analysis of difference in tumor volume among the groups was conducted on the data obtained on PG-D25. All data was analyzed using Graphpad Prism (GraphPad, Prism 6.00). $p < 0.05$ is considered to be statistically significant. Results are shown in graph (Figure 1).

Example 5: Derivatization of the pyrazolo-triazine and pyrazolo-pyrimidine general scaffold

Presented compounds underwent derivation according to the methods outlined below (**Scheme 1-56**). Resulting derivatives were examined for enzymatic binding cellular activity (HCT116, H460, MV4-11, MM.1S, MOLT-4, RPMI-8226, A2780 and OVCAR-3), CDK7 selectivity in CDKs family and in vivo efficacy study (OVCAR-3) using the assays described above (Example 1, 2, 3 and 4) and the results are summarized in **Table 1-10** and **Figure 1**. The synthesized compounds 1-279 are shown in **Table 11**.

Scheme 1-a: General Synthetic route



The method to prepare compounds of **I-3** and **I-4** is shown in Scheme 1-a.


Route I: Compound C7 can be synthesized by treating in presence of POCl_3 . Compound C7 can be further treated with group B in presence of DIPEA to give compounds I-1. Compounds I-1 can be further treated with m-CPBA to provide the compounds of formula I-2. The compounds of formula I-3 can be synthesized by treating compounds I-2 with group A.

Route II: Route II having the similar reaction condition with Route I and different order.

Compound C13 can be synthesized by treating in presence of m-CPBA. The compounds of formula II-1 can be synthesized by treating compounds C13 with appropriated group A. Compounds II-2 can be synthesized by treating in presence of POCl_3 . The compounds of formula I-3 can be synthesized by treating compounds II-2 with DIPEA and group B.

De-protection step: The compounds of formula I-4 can be prepared by using compounds of formula I-3 in presence of acid such as TFA, HBr and AcOH, or base such as hydrazine.

Scheme 1-b: General Synthetic route



The method to prepare compounds of **III-2** and **III-3** is shown in Scheme 1-b.

Route III: Compound E1 can be synthesized by treating in presence of NaOEt. Compound E2 can be synthesized by treating in presence of POCl_3 . Compound E2 can be further treated with group B in presence of K_2CO_3 to give compounds III-1. Compounds III-1 can be further treated with group A to provide the compounds of formula III-2. The compounds of formula III-3 can be prepared by using compounds of formula III-2 in presence of acid such as TFA, HBr and AcOH, or base such as hydrazine.

Procedure for synthesis of E1


Na (859 mg, 37.4 mmol) was added into anhydrous EtOH (100 mL) at 10°C, the resulting mixture was stirred for 1 hour at 10°C under N₂ atmosphere, then compound C3 (3.90 g, 31.1 mmol) and diethyl propanedioate (5.99 g, 37.4 mmol) was added to the mixture. The mixture was heated at 80°C and stirred for another 15 hours under N₂ atmosphere to give yellow solution. TLC showed the reaction was completed. The reaction mixture was cooled to room temperature and concentrated to obtain residue. The residue was dissolved in water (60 mL) and acidified to pH= 3 with 3M HCl, filtered to give compound E1 (3.60 g) as an off-white solid.

Procedure for synthesis of E2

To a solution of compound E1 (3.60 g, 18.6 mmol) in POCl₃ (57.1 g, 373 mmol) was added N, N-diethylaniline (2.78 g, 18.6 mmol). The resulting mixture was heated at 100°C and stirred for 2 hours under N₂ atmosphere to give red solution. TLC showed the reaction was completed, one major spot was formed. The reaction mixture was concentrated most of solvent and poured into H₂O (40 mL), extracted with DCM (50 mL x 3). The organic layer was washed with brine (50 mL x 2), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give crude product. The crude product was purified by silica column to obtain compound E2 (2.85 g) as yellowish solid.

General schemes of group A

Scheme 2: Synthetic route for A1




Procedure for synthesis of A1

A mixture of 4-aminophenol (1.00 g, 9.16 mmol) and 1,4-dibromobutane (9.89 g, 45.8 mmol)

in DMF (100 mL) was stirred at 65°C for 18 hours. Saturated NaHCO₃ (150 mL) was added dropwise into the reaction mixture carefully to quench the reaction. The mixture was diluted with EtOAc (100 mL). The organic phase were separated and the aqueous phase was extracted with EtOAc (100 mL x 2), the combined organic phase was washed with water (70 mL x 4), brine (100 mL), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give crude product, The crude compound was purified by Combi-Flash to give compound **A1** (110mg) as a brown powder.

Scheme 3: Synthetic route for A5




Procedure for synthesis of A4

To a solution of compound **A2** (1.00 g, 5.76 mmol), compound **A3** (2.16 g, 11.5 mmol) and PPh₃ (3.02 g, 11.5 mmol) in anhydrous THF (15 mL) was added DEAD (2.01 g, 11.5 mmol), the mixture was stirred at 20°C for 17 hours. TLC showed the reaction was completed. The reaction was quenched with water (50 mL), extracted with EtOAc (50 mL x 3), the combined extracts was washed with brine (100 mL), dried over anhydrous Na₂SO₄, filtered, the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by Combi flash to give 1.60 g of compound **A4** as a white powder.

Procedure for synthesis of A5


To a suspension of compound **A4** (800 mg, 2.33 mmol) and NH₄Cl (1.25 g, 23.3 mmol) in EtOH (15 mL) was added Zn (1.53 g, 23.3 mmol), the mixture was stirred at 50°C for 17 hours. TLC and LCMS showed the reaction was completed. The mixture was filtered, the filter cake was washed with DCM (50 mL x 2), the combined organic phase was concentrated under reduced pressure to give a residue, the residue was dissolved in DCM (100 mL), washed with water (50 mL x 3), dried over anhydrous Na₂SO₄, filtered, the filtrate was concentrated under reduced pressure to give 650 mg of compound **A5** as a yellow gum.

Scheme 4: Synthetic route for A9**Procedure for synthesis of A8**

To a solution of compound **A6** (1.00 g, 5.78 mmol) in H₂O (5 mL) and dioxane (10 mL) was added compound **A7** (2.14 g, 6.94 mmol), K₂CO₃ (2.00 g, 14.5 mmol) and Pd(dppf)Cl₂ (422 mg, 0.578 mmol). The reaction mixture was stirred at 90 °C for 16 hour under N₂ atmosphere. LCMS showed 50.4% desired MS. The mixture was partitioned between DCM (50 mL) and H₂O (50 mL). The aqueous was extracted with DCM (50 mL). The combined organic extract was washed with water (50 mL x 2), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Combi flash to give compound **A8** (1.30 g) as a white powder.

Procedure for synthesis of A9

To a suspension of compound **A8** (1.30 g, 4.72 mmol) in MeOH (2 mL) was added Pd/C (0.13 g, 50% wet, 10% Pd), the mixture was stirred under H₂ balloon (15 psi) at 25 °C for 2 hours to give a black suspension. LCMS showed compound **A8** was consumed, and desired MS was observed. The mixture was filtered and concentrated under reduced pressure to give compound **A9** (1.20 g) as yellow powder.

Scheme 5: Synthetic route for A13**Procedure for synthesis of A11**

To a mixture of Et₃N (21 mL) in MeNO₂ (50 mL) was added compound **A10** (5 g, 25.1

mmol). The mixture was stirred at 10-15°C for 48 hours to give a yellow suspension. The suspension was diluted with EtOAc (100 mL) and washed with water (100 mL), saturated NH_4Cl (100 mL), brine (100 mL), dried over Na_2SO_4 , filtered, concentrated under reduced pressure to give compound **A11** (7.6 g) as a yellow solid.


Procedure for synthesis of A12

To a mixture of compound **A11** (2 g, 7.68 mmol), imidazole (2.62 g, 38.4 mmol) in DMF (5 mL) was added chloro(triethyl)silane (10 mL). The mixture was stirred at 70-80°C for 12 hours to give a yellow mixture. The mixture was cooled to room temperature and diluted with water (50 mL). The aqueous phase was extracted with EtOAc (50 mL x 3). The combined extracted phase was washed with brine (50 mL), dried over Na_2SO_4 , filtered, concentrated under reduced pressure to give compound **A12** (5 g) as yellow oil.

Procedure for synthesis of A13

To a mixture of Pd/C (1 g, 10%) in MeOH (100 mL) was added compound **A12** (4.9 g, 13.08 mmol). The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred at 25°C under H_2 (50 psi) for 30 hours to give a black mixture. Crude HNMR showed the reaction was completed. The mixture was filtered, the filtrate was concentrated under reduced pressure to give a yellow gum, which was purified by Combi flash to give compound **A13** (2.3 g) as yellow oil.

Scheme 6: Synthetic route for A16



Procedure for synthesis of A15


The mixture of **A14** (1.5 g, 9.54 mmol), N-benzylhydroxylamine (2.28 g, 14.3 mmol), $(\text{HCHO})_n$ (2.15 g, 23.8 mmol) and TEA (1.45 g, 14.3 mmol, 2.0 mL) in toluene (100 mL)

was refluxed for 20 hours. Much white solid was observed. LCMS showed the reaction was completed. Most of the solvent was removed under reduced pressure. The residue was partitioned between EtOAc (50 mL) and H₂O (50 mL). The aqueous phase was extracted with EtOAc (50 mL x 2). The organic extract was washed with brine (100 mL x 3), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give the crude product, which was purified by combi flash to give compound **A15** (2.05 g) as a pale-yellow solid.

Procedure for synthesis of A16

To a solution of **A15** (1.5 g, 5.13 mmol) in EtOH (10 mL) was added Pd(OH)₂/C (0.5 g, 20% purity). The reaction suspension was purged with H₂ (balloon, 15 psi) for several times and stirred at 15°C for 16 hours to give a black mixture. TLC (PE/EA=1/1) showed new spot. The reaction was diluted with MeOH (200 mL) and filtered over celite pad. The filtrate was concentrated under reduced pressure to give **A16** (1.15 g, crude) as white solid.


Scheme 7: Synthetic route for A18



Procedure for synthesis of A18

To a mixture of **A17** (500 mg, 5.61 mmol) in DCM (10 mL) was added Boc₂O (1.35 g, 6.17 mmol), the mixture was stirred at 25°C for 16 hours to give a colorless oil. TLC showed the reaction was completed. The mixture was concentrated under reduced pressure to give compound **A18** (1.2 g, crude) as a colorless oil.

Scheme 8: Synthetic route for A21




Procedure for synthesis of A20

To the solution of compound **A19** (500 mg, 2.46 mmol) in DMF (5 mL) was added NaN_3 (319 mg, 4.92 mmol) and NH_4Cl (158 mg, 2.95 mmol). The mixture was stirred at 80°C for 3 hours to give a yellow mixture. LCMS showed the reaction was completed. The mixture was partitioned between EtOAc (30 mL) and H_2O (20 mL). The aqueous phase was extracted with EtOAc (30 mL x 2). The combined organic extract was dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure to give compound **A20** (820 mg, crude) as a yellow oil.

Procedure for synthesis of A21

To a mixture of compound **A20** (820 mg, 3.33 mmol) in MeOH (10 mL) was added Pd/C (100 mg). The mixture was stirred at 25°C for 16 hours to give a black mixture. TLC and LCMS showed the reaction was completed. The mixture was filtered. The filtrate was concentrated under reduced pressure to afford compound **A21** (680 mg, crude) as a yellow oil.

Scheme 9: Synthetic route for A26



Procedure for synthesis of A24

To a mixture of **A23** (3.34 g, 18.0 mmol) and TMBAC (335 mg, 1.80 mmol) in IPA (50 mL) was added **A22** (5.00 g, 54.1 mmol), the mixture was stirred at 20°C for 72 hours to form a white mixture. TLC (eluent: PE/EtOAc = 2/1) showed new spots. The mixture was

partitioned between EtOAc (80 mL) and H₂O (80 mL). The aqueous phase was extracted with EtOAc (80 mL x 2). The combined organic extract was washed with brine (80 mL x 3), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give a residue, which was purified by combi flash to give **A24** (1.1 g) as a white solid.


Procedure for synthesis of A25

To a mixture of compound **A24** (1 g, 4.92 mmol) in THF (10 mL) was added TEA (597 mg, 5.91 mmol, 822 uL) and 2-hydroxy-2-methyl-propanenitrile (502 mg, 5.91 mmol), the mixture was stirred at 75°C for 12 hours to give a yellow mixture. LCMS showed the reactant was remained. The mixture was stirred for another 16 hours to give a brown mixture. TLC showed the reaction was completed. The mixture was partitioned between EtOAc (30 mL) and H₂O (20 mL). The aqueous phase was extracted with EtOAc (30 mL x 2). The combined organic extract was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give a crude product. The crude product was purified by combi flash to afford compound **A25** (450 mg) as an off-white solid.

Procedure for synthesis of A26

To a mixture of compound **A25** (40 mg, 0.17 mmol) in EtOH (10 mL) was added PtO₂ (4.0 mg, 0.017 mmol, 0.1 eq) and HCl (0.05 mL), the mixture was stirred at 25°C for 1 hour to give a black mixture. TLC showed the reaction was completed. The mixture was filtered and concentrated under pressure to give compound **A26** (40 mg, crude) as an off-white gum.

Scheme 10: Synthetic route for A29



Procedure for synthesis of A29

To a solution of compound **A27** (200 mg, 0.979 mmol), TEA (409 uL) in DCM (5 mL) was added CbzOSu (217 mg, 0.870 mmol) at 0-10°C and the mixture was stirred at


20 °C for 1 hour to give yellow mixture. TLC showed the reaction was completed. The mixture was quenched with water (100 mL) and extracted with EtOAc (100 mL x 3). The combined organic extract was washed with water (100 mL), dried over Na₂SO₄, filtered, concentrated under reduced pressure to give a yellow oil, which was washed with PE (10 mL) to give compound **A29** (310 mg) as yellow oil.

Procedure for synthesis of A30

The compound **A29** (290mg) was followed the same procedure of **B14** to obtain 270 mg of compound **A30** as a yellow gum.

Commercial available reagent were used for group A such as tert-butyl piperidin-3-ylcarbamate, tert-butyl 4-aminopiperidine-1-carboxylate, piperidine-4-carboxamide, tert-butyl (4-methylpiperidin-4-yl)carbamate, tert-butyl piperidin-4-ylcarbamate, benzyl piperidin-4-ylcarbamate, piperidin-4-ol, piperazine, piperazin-2-one, tetrahydro-2H-pyran-4-amine, tert-butyl 3-methylpiperazine-1-carboxylate, N-(piperidin-4-yl)acetamide, 1-methylpiperidin-4-ol, tert-butyl ((4-hydroxypiperidin-4-yl)methyl)carbamate, tert-butyl (morpholin-2-ylmethyl)carbamate, tert-butyl 4-(aminomethyl)piperidine-1-carboxylate, tert-butyl (R)-3-hydroxypiperidine-1-carboxylate, tert-butyl 4-(piperidin-4-yl)piperazine-1-carboxylate, tert-butyl (piperidin-4-ylmethyl)carbamate, 1,2,3,4-tetrahydro-2,6-naphthyridine, tert-butyl (4-methylpiperidin-4-yl)carbamate, tert-butyl ((4-fluoropiperidin-4-yl)methyl)carbamate, (S)-2-(piperidin-2-yl)ethan-1-ol, (S)-piperidin-2-ylmethanol, (1s,4s)-4-aminocyclohexan-1-ol, (1r,4r)-4-aminocyclohexan-1-ol, 4-methoxycyclohexan-1-amine, (tetrahydro-2H-pyran-4-yl)methanamine, morpholine, cyclohexane-1,4-diol, tert-butyl (S)-3-(hydroxymethyl)piperazine-1-carboxylate, tert-butyl 2-(aminomethyl)morpholine-4-carboxylate, 1H-indol-4-amine, 4-(trifluoromethoxy)piperidine, 4-ethoxypiperidine, 4-isopropoxypiperidine, 4-methoxycyclohexan-1-amine, 4-isopropoxycyclohexan-1-amine, 1H-pyrrol-3-amine and tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate.


General schemes of group B

Scheme 11: Synthetic route for B3**Procedure for synthesis of B2**

To a solution of compound **B1** (5.00 g, 41.3 mmol) and phenol (5.80 g, 61.9 mmol) in DMA (50 mL) was added 18-crown-6 (1.10 g, 4.13 mmol) and K_2CO_3 (11.4 g, 82.6 mmol), the reaction mixture was stirred at $110^\circ C$ for 16 hours to give a brown mixture. LCMS showed the reaction was complete. To the reaction mixture was added H_2O (50 mL), the reaction mixture was extracted with EtOAc (50 mL x 3), the combined organic phase was washed with H_2O (40 mL x 2) and brine (100 mL), dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure to give a brown oil, which was purified by Combi Flash to give compound **B2** (9.80 g) as a yellow oil.

Procedure for synthesis of B3

To a solution of compound **B2** (1.00 g, 5.12 mmol) in MeOH (30 mL) was added Raney-Ni (43.9 mg, 0.512 mmol) and $NH_3 \cdot H_2O$ (3 mL), the reaction mixture was stirred under H_2 balloon (15 psi) at $15^\circ C$ for 16 hours to give a black suspension. TLC showed the reaction was complete. The reaction mixture was filtered, the filtrate was concentrated under reduced pressure to remove MeOH. The residue was diluted with DCM (20 mL), dried over anhydrous Na_2SO_4 , filtered and concentrated under reduce pressure to give compound **B3** (820 mg) as a yellow oil.


Scheme 12: Synthetic route for B7**Procedure for synthesis of B6**

To a solution of 2-hydroxybenzonitrile **B4** (200 mg, 1.68 mmol) and 2-chloroquinoline **B5** (261 mg, 1.60 mmol) in DMA (3.0 mL) was added Cs_2CO_3 (1.04 g, 3.20 mmol). The reaction mixture was stirred at 100 °C for 5 hours. TLC showed the reaction was completed. The residue was partitioned between water (20 mL) and EtOAc (20 mL). The organic layer was washed with water (10 mL x 2), brine (10 mL), dried over anhydrous Na_2SO_4 , and concentrated under reduced pressure to give a residue. The residue was purified by Combi flash to give compound **B6** (80 mg) as a yellow powder.

Procedure for synthesis of **B7**

The compound **B6** (80mg) was followed the same procedure of **B3** to obtain 64 mg of compound **B7** as a yellow powder.

Scheme 13: Synthetic route for **B10**




Procedure for synthesis of **B9**

To a mixture of NaH (198 mg, 4.96 mmol, 60% in mineral oil) in THF (3 mL) was added a solution of compound **B8** (571 mg, 4.96 mmol) in THF (3 mL) dropwise. After the reaction mixture was stirred for 5 minutes, to the mixture was added 2-fluorobenzonitrile (500 mg, 4.13 mmol). The reaction mixture was stirred at 40 °C for 2 hours. LCMS showed the reaction was completed. The reaction mixture was quenched by water (10 mL), extracted with DCM (10 mL x 2). The organic layer was washed with water (10 mL), dried over anhydrous Na_2SO_4 , filtered, concentrated under reduced pressure. The residue was purified by Combi flash to give compound **B9** (432 mg) as a light brown oil.

Procedure for synthesis of **B10**

The compound **B9** (430mg) was followed the same procedure of **B102** to obtain 410 mg of compound **B10** as a white powder.

Scheme 14: Synthetic route for B14




Procedure for synthesis of B13

To a solution of compound **B11** (150 mg, 0.675 mmol) and compound **B12** (114 mg, 0.81 mmol) in DCM (10 mL) was added DIPEA (174 mg, 1.35 mmol). The resulting mixture was stirred at 20°C for 12 hours to give yellowish solution. TLC showed the reaction was completed, one major spot was formed. The reaction mixture was quenched by addition H₂O (30 mL) and extracted with DCM (30 mL x 2). The combined organic layers were washed with brine (10 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Combi flash to obtain compound **B13** (200 mg) as a white solid.

Procedure for synthesis of B14

To a solution of compound **B13** (200 mg, 0.613 mmol) in DCM (7 mL) was added TFA (3 mL). The resulting mixture was stirred at 20°C for 1 hour to give yellow solution. TLC showed the reaction was completed. The reaction mixture was concentrated under reduced pressure to give compound **B14** (130 mg) as a yellow oil.

Scheme 15: Synthetic route for B18




Procedure for synthesis of B17

To a solution of compound **B15** (1.00 g, 3.49 mmol) and compound **B16** (536 mg, 4.19 mmol) in DME (10 mL) was added Pd(dppf)Cl₂ (128 mg, 0.174 mmol) and Na₂CO₃ (370 mg, 3.49 mmol) in H₂O (2.5 mL), the reaction mixture was stirred at 90 °C for 3 hours to give a black suspension. TLC showed the reaction was complete. To the reaction solution was added H₂O (10 mL), extracted with EtOAc (10 mL x 2), the organic layer was washed with brine (10 mL), dried over anhydrous Na₂SO₄, filtered, concentrated under reduced pressure to give a brown oil, which was purified by Combi Flash to give compound **B17** (705 mg) as a yellow oil.

Procedure for synthesis of B18

The compound **B17** (350mg) was followed the same procedure of **B14** to obtain 220 mg of compound **B18** as a yellow powder.

Scheme 16: Synthetic route for B21



Procedure for synthesis of B20


A mixture of compound **B19** (2.00 g, 16.5 mmol), pyrrolidine (1.29 g, 18.1 mmol), K₂CO₃ (4.56 g, 33.0 mmol) in DMF (10 mL) was stirred at 60 °C for 16 hours. TLC showed that the reaction was completed. The mixture was poured into water (100 mL). The mixture was extracted with EtOAc (30 mL x 3), the combined mixture were washed with water (50 mL x 2), brine (50 mL x 2), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give compound **B20** (2.78 g) as a colorless oil.

Procedure for synthesis of B21

The compound **B20** (1.5g) was followed the same procedure of **B3** to obtain 1.5 g of

compound **B21** as a colorless oil.

Scheme 17: Synthetic route for B24




Procedure for synthesis of B23

To a solution of compound **B22** (5 g, 35.7 mmol) and Cs_2CO_3 (29.1 g, 89.2 mmol) in DMF (50 mL) was added 2-fluorobenzonitrile (6.48 g, 53.5 mmol, 5.69 mL). The reaction mixture was stirred at 25°C for 16 hours to give yellow mixture. TLC showed the reaction was completed. The reaction mixture was quenched by addition H_2O (200 mL) and extracted with EtOAc (150 mL x2). The combined organic layers was dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give crude product. The crude product was purified by silica gel column to give compound **B23** (5 g) as a white powder.

Procedure for synthesis of B24

To a solution of compound **B23** (200 mg, 0.829 mmol) in THF (2 mL) was added LiAlH_4 (126 mg, 3.32 mmol) at 0°C under N_2 atmosphere. The reaction mixture was stirred at 25°C for 2 hours to give yellow solution. LCMS showed the reaction mixture was completed. The reaction was quenched by water (1 mL) and NaOH aqueous (1 mL, 2.0 M) slowly at 5°C. The mixture was stirred at 5°C for 10 minutes. The mixture was filtered, the filtrate was extracted with EtOAc (5 mL x 2). The combined organic phase was washed with brine (5 mL), dried over anhydrous Na_2SO_4 , filtered and concentrated to give crude compound **B24** (180 mg) as a light yellow gum.

Scheme 18: Synthetic route for B28



Procedure for synthesis of **B26**

To a solution of compound **B25** (5 g, 35.7 mmol) in THF (50 mL) was added MeMgBr (3 M, 47.6 mL) dropwise at 0-5 °C under N₂ atmosphere. The resulting mixture was stirred at 10 °C for 15 hours to form a white suspension. TLC showed the reaction was completed. The mixture was poured into saturated aqueous NH₄Cl (50 mL). The mixture was extracted with EtOAc (50 mL x 3). The combined organic extract was washed with brine (80 mL x 2), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give compound **B26** (2.6 g) as a white solid.

Procedure for synthesis of **B27**


To a mixture of compound **B26** (2.6 g, 20.6 mmol) and 2-fluorobenzonitrile (3.00 g, 24.7 mmol) in DMF (50 mL) was added Cs₂CO₃ (13.4 g, 41.2 mmol). The mixture was stirred at 15 °C for 15 hours to form a white suspension. TLC showed the reaction was completed. The mixture was partitioned between EtOAc (150 mL) and H₂O (150 mL). The aqueous phase was extracted with EtOAc (150 mL x 2). The combined organic extracts were washed with brine (100 mL x 3), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give the crude product, which was purified by combi flash to give compound **B27** (3.6 g) as a white solid.

Procedure for synthesis of **B28**

To a solution of compound **B27** (3.6 g, 15.84 mmol) in MeOH (100 mL) was added Raney-Ni (1 g, in water) under N₂ atmosphere. The suspension was degassed under vacuum and purged with H₂ several times. The mixture was stirred under H₂ (15psi) at 20 °C for 15 hours to form a black suspension. TLC showed the reaction was completed. The reaction mixture was filtered over a pad of celite. The filter cake was washed with MeOH (80 mL).

The filtrate was concentrated under reduced pressure to give compound **B28** (3.5 g) as a colorless gum.

Scheme 19: Synthetic route for B31




Procedure for synthesis of B30

To a mixture of morpholine (2.63 g, 30.2 mmol) and compound **B29** (500 mg, 2.02 mmol) in toluene (5 mL) was added XPhos (192 mg, 0.403 mmol), CS_2CO_3 (1.64 g, 5.04 mmol) and $Pd_2(dba)_3$ (185 mg, 0.202 mmol), the reaction mixture was stirred at 110 °C for 16 hours under N_2 atmosphere to give a black suspension. LCMS (R_t = 0.908 min) shows the reaction was completed. The reaction mixture was partitioned between EtOAc (80 mL) and water (80 mL). The aqueous phase was extracted with EtOAc (70 mL x 2). The combined organic layer was washed with water (100 mL x2), brine (100 mL x 2) and dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure to give residue. The reaction mixture was purified by Combi flash to give compound **B30** (190 mg) as brown gum.

Procedure for synthesis of B31

The compound **B30** (190mg) was followed the same procedure of **B3** to obtain 170 mg of compound **B31** as a colorless gum.

Scheme 20: Synthetic route for B38



Procedure for synthesis of B33

To a mixture of compound **B31** (10 g, 37.7 mmol) in DMF (5 mL) was added compound **B32** (9.13 g, 75.3 mmol). The mixture was stirred at 50 °C for 12 hours to give a yellow suspension. LCMS showed the reaction was completed. The mixture was added with water (30mL x 2), which was filtered and concentrated under reduced pressure to give a yellow powder, which was washed with PE (50 mL) to give compound **B32** (7 g) as a brown powder.

Procedure for synthesis of B34

To a mixture of compound **B33** (4 g, 18.7 mmol) in MeOH (30 mL) was added NH_4Cl (9.99 g, 186 mmol) and Zn (12.2 g, 186 mmol). The mixture was stirred at 25°C for 15 hours to give an off-white suspension. LCMS showed the reaction was completed. After filtration, the filter cake was washed with MeOH (50 mL), the filtrate was partitioned between DCM (50 mL) and water (50 mL). The aqueous phase was extracted with DCM (50 mL x 2), the combined extracted phase was washed with water (50 mL x 2), dried over anhydrous Na_2SO_4 , concentrated under reduced pressure to give compound **B34** (2 g) as a yellow powder.

Procedure for synthesis of B36

To a mixture of compound **B34** (2 g, 10.8 mmol) in n-BuOH (20 mL) was added compound **B35** (1.94 g, 10.8 mmol). The reaction was refluxed at 117°C for 48 hours to give a yellow suspension. LCMS showed the reaction was completed. The mixture was added with NaOH (868 mg, 21.7 mmol) and H_2O (10 mL), dioxane (10 mL), tert-butoxycarbonyl tert-butyl carbonate (3.56 g, 16.2 mmol). The mixture was stirred at 25 °C for 2 hours to give a yellow suspension. LCMS ($R_t = 1.268$ min) showed the reaction was completed. The mixture was

partitioned between DCM (50 mL) and water (50 mL). The aqueous phase was extracted with DCM (50 mL x 2), the combined extracted phase was washed with water (50 mL x 2), dried over anhydrous Na_2SO_4 , concentrated under reduced pressure to give a yellow gum, which was purified by Combi flash to give compound **B36** (400 mg) as a yellow oil.


Procedure for synthesis of B37

The compound **B36** (1.0 g) was followed the same procedure of **B72** to obtain 400 mg of compound **B37** as a yellow solid.

Procedure for synthesis of B38

The compound **B37** (200mg) was followed the same procedure of **B3** to obtain 200 mg of compound **B38** as a yellow powder.

Scheme 21: Synthetic route for B42




Procedure for synthesis of B41

To a mixture of compound **B39** (423 mg, 2.88 mmol), compound **B40** (500 mg, 2.40 mmol), K_2CO_3 (663 mg, 4.80 mmol) in dioxane (5 mL) / H_2O (1 mL) was added Pd(dppf)Cl_2 (175 mg, 0.24 mmol). The mixture was stirred at 110 °C for 16 hours. TLC showed a new spot. The mixture was poured into water (20 mL). The mixture was extracted with DCM (30 mL x3). The combined mixture was washed with water (50 mL x2), dried over anhydrous Na_2SO_4 , then filtered and concentrated under reduced pressure to give a residue (brown gum). The residue was purified by Combi Flash to give compound **B41** (200 mg) as a red powder.

Procedure for synthesis of B42

The compound **B41** (200mg) was followed the same procedure of **B3** to obtain 200 mg of compound **B42** as a brown oil.

Scheme 22: Synthetic route for B46




Procedure for synthesis of B45

To a solution of compound **B43** (300 mg, 1.37 mmol) and compound **B44** (335 mg, 1.51 mmol) in i-PrOH (10 mL) was heated at 80°C and stirred for 4 hours, then tributylphosphane (1.39 g, 6.85 mmol) was added to the mixture and stirred for another 12 hours to give yellow solution. LCMS and TLC showed the reaction was completed. The reaction mixture was quenched by addition H₂O (50 mL) and extracted with EtOAc (50 mL x 2). The combined organic layers were washed with brine (20 mL x 2), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Combi flash to obtain compound **B45** (524 mg) as a yellow solid.

Procedure for synthesis of B46

The compound **B45** (524mg) was followed the same procedure of **B14** to obtain 430 mg of compound **B46** as a yellow solid.

Scheme 23: Synthetic route for B50




Procedure for synthesis of **B49**

To a solution of compound **B47** (500 mg, 3.70 mmol) in AcOH (10 mL) was added compound **B48** (1.11 g, 4.44 mmol), Pd(OAc)₂ (415 mg, 1.85 mmol), then the reaction mixture was stirred at 25 °C under O₂ (15 psi) for 16 hours to give a black suspension. LCMS and TLC showed the reaction was completed. The reaction was poured into water (50 mL) and partitioned between EtOAc (100 mL) and water (100 mL). The aqueous phase were extracted with EtOAc (100 mL x 2), The combined organic layers were washed with water (100 mL x 2), brine (100 mL), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Combi flash to give compound **B49** (240 mg, 0.705 mmol) as a yellow gum.

Procedure for synthesis of **B50**

The compound **B49** (240mg) was followed the same procedure of **B14** to obtain 170 mg of compound **B50** as a yellow gum.

Scheme 24: Synthetic route for **B56**



Procedure for synthesis of **B53**

To a solution of compound **B51** (600 mg, 3.35 mmol) in i-PrOH (10 mL) was added compound **B52** (744 mg, 3.35 mmol). The reaction solution was heated to 80°C and stirred for 3 hours to give a yellow solution. The reaction was cooled to 30-40°C and tributylphosphane (2.03 g, 2.48 mL) was added and stirred for another 16 hours at 80°C to

give a black solution. TLC showed the reaction was completed. The reaction mixture was quenched by addition H₂O (100 mL) and extracted with EtOAc (100 mL x 2). The combined organic layers were washed with saturated NH₄Cl (50 mL) and brine (10 mL x 2), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by Combi flash to give compound **B53** (784 mg) as a yellow solid.

Procedure for synthesis of B54

To a solution of compound **B53** (784 mg, 2.06 mmol) in MeOH (5 mL) and H₂O (1 mL) was added LiOH.H₂O (431 mg, 10.3 mmol). The resulting mixture was stirred at 20°C for 12 hrs to give yellow suspension. TLC showed the reaction was completed. The reaction mixture was concentrated most of MeOH under reduced pressure, then acidified with 1M HCl to pH ~4 and lots of white solid was precipitated, the mixture was filter under reduced pressure to give filter cake compound **B54** (724 mg) as a white solid.


Procedure for synthesis of B55

To a solution of compound **B54** (625 mg, 1.70 mmol) and methanamine (230 mg, 3.40 mmol) in DMF (10 mL) was added Et₃N (516mg, 5.10 mmol) and HATU (647 mg, 1.70 mmol, 1 eq). The resulting mixture was stirred at 20°C for 2 hr to give yellow solution. TLC showed the reaction was completed, one main new spot was formed. The reaction mixture was quenched with H₂O (20 mL) and lots of white solid was precipitated, then filtered under reduced pressure to give filter cake compound **B55** (693 mg) as a white solid.

Procedure for synthesis of B56

The compound **B55** (200mg) was followed the same procedure of **B14** to obtain 130 mg of compound **B56** as a yellow oil.

Scheme 25: Synthetic route for 61



Procedure for synthesis of **B59**

The compound **B57** (500mg) was followed the same procedure of **B41** to obtain 840 mg of compound **B59** as a yellow solid.


Procedure for synthesis of **B60**

To a solution of compound **B59** (350 mg, 1.08 mmol) in MeOH (10 mL) was added Pd/C (20 mg, 10% purity, wet) under N_2 atmosphere. The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (50 psi) at 20°C for 12 hours to give black suspension, LCMS showed the reaction didn't work, the reaction was added acetic acid (0.1 mL), The suspension was degassed under vacuum and purged with H_2 several times. The mixture was stirred under H_2 (50 psi) at 20°C for 12 hours to give black suspension. LCMS showed the reaction was completed. The reaction mixture was filtered by pad celite and concentrated under reduced pressure to give compound **B60** (450 mg, crude) as yellowish oil, the crude product was used in the next step without purification.

Procedure for synthesis of **B61**

The compound **B60** (450mg) was followed the same procedure of **B14** to obtain 330 mg of compound **B61** as a yellow oil.

Scheme 26: Synthetic route for **B66**



Procedure for synthesis of B63

A solution of compound **B62** (1.00 g, 8.84 mmol) in DMF/DMA (20 mL) was heated at 110°C and stirred for 2 hours to give red solution. The reaction mixture was concentrated under reduced pressure to give crude product compound **B63** (1.20 g) as a red solid.

Procedure for synthesis of B64

To a solution of compound **B63** (700 mg, 4.16 mmol) in EtOH (10 mL) was added NH₂NH₂.H₂O (208 mg, 4.16 mmol). The resulting mixture was heated at 100°C and stirred for 16 hrs to give yellow solution. The reaction mixture was concentrated under reduced pressure to give compound **B64** (550 mg) as a yellow solid.


Procedure for synthesis of B65

The compound **B64** (400mg) was followed the same procedure of **B33** to obtain 445 mg of compound **B65** as a yellow solid.

Procedure for synthesis of B66

The compound **B65** (100mg) was followed the same procedure of **B3** to obtain 91 mg of compound **B66** as a white powder.

Scheme 27: Synthetic route for B70




Procedure for synthesis of **B69**

To a mixture of compound **B67** (300 mg, 1.41 mmol), compound **B68** (710 mg, 2.83 mmol), Cs_2CO_3 (1.15 g, 3.54 mmol) in dioxane (3 mL), H_2O (0.9 mL) was added $\text{Pd}(\text{dppf})\text{Cl}_2$ (104 mg, 0.141 mmol). The mixture was stirred at 100°C under N_2 atmosphere for 12 hours to give a brown suspension. LCMS showed the reaction was completed. The mixture was cooled to room temperature, partitioned between DCM (50 mL) and water (50 mL). The aqueous phase was extracted with DCM (30 mL x 2). The combined extracted phase was washed with water (30 mL x 2), dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure to crude product as red oil, which was purified by Combi flash to give compound **B69** (108 mg) as brown oil.

Procedure for synthesis of **B70**

To a mixture of compound **B69** (100 mg, 0.296 mmol) in DCM (4 mL) was added TFA (1 mL). The mixture was stirred at 15°C for 20 minutes to give a yellow mixture. LCMS showed the reaction was completed. The mixture was concentrated under reduced pressure to give compound **B70** (90 mg) as yellow oil.

Scheme 28: Synthetic route for **B75**



Procedure for synthesis of **B72**

To a mixture of compound **B71** (1 g, 5.68 mmol) in DCM (5 mL) was added Boc_2O (1.49 g, 6.82 mmol). The mixture was stirred at 25°C for 2 hours to give a yellow mixture. LCMS showed the reaction was completed. The mixture was partitioned between DCM (50 mL) and

water (50 mL). The aqueous phase was extracted with DCM (30 mL x 2), the combined extracts were washed with water (50 mL x 2), dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure to give compound **B72** (950 mg) as a white powder.


Procedure for synthesis of B74

To a mixture of compound **B72** (850 mg, 3.08 mmol), compound **B73** (804 mg, 3.08 mmol) and Cs_2CO_3 (2.51 g, 7.69 mmol) in dioxane (5 mL) and H_2O (1.5 mL) was added $\text{Pd}(\text{dppf})\text{Cl}_2$ (225 mg, 0.308 mmol), the mixture was stirred at 100°C under N_2 atmosphere for 12 hours to give a red mixture. LCMS showed the reaction was completed. The mixture was cooled to room temperature and partitioned between DCM (50 mL) and water (50 mL). The aqueous phase was extracted with DCM (50 mL x 2). The combined extracted phase was washed with water (50 mL x 2), dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure to give crude product, which was purified by Combi flash to give compound **B74** (420 mg) as a white powder.

Procedure for synthesis of B75

The compound **B74** (230 mg) was followed the same procedure of **B14** to obtain 170 mg of compound **B75** as a yellow oil.

Scheme 29: Synthetic route for B81



Procedure for synthesis of B77

To a mixture of compound **B76** (8.00 g, 56.3 mmol) in MeOH (60 mL) was added TEA (11.4 g, 113 mmol) and methylhydrazine (8.11 g, 56.3 mmol). The mixture was stirred at 60 °C for 15 hours to form a brown mixture. Desired MS value was detected by LC-MS. The mixture was cooled to 5 °C, allowed to stand for 2 hours, until the white crystals precipitated, filtered, washed with ethanol, and dried to obtain compound **B77** (3.5 g) as a white solid.

Procedure for synthesis of **B78**

A mixture of compound **B77** (750 mg, 4.80 mmol) and TEA (1.34 mL) in DCM (5 mL) was cooled to 0 °C in a salt water/ice bath. Then TiF_2O (2.71 g, 9.61 mmol) was added dropwise keeping the temperature at 0° C. After the addition was complete, the reaction mixture was warmed to 20 °C and stirred for 1 hour to form a colorless mixture. LCMS showed the starting material was consumed completely. The reaction mixture was quenched with water (30 mL) and the layers were separated. The aqueous phase was extracted with DCM (50 mL x 2). The combined organic extract was washed with brine (80 mL x 3), dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure to give a residue, which was purified by Combi flash to give compound **B78** (530 mg) as a yellow oil.


Procedure for synthesis of **B80**

To a mixture of compound **B78** (430 mg, 1.49 mmol) and compound **B79** (544 mg, 2.24 mmol) in dioxane (4 mL) and H_2O (1 mL) was added Cs_2CO_3 (1.22 g, 3.73 mmol) and $\text{Pd}(\text{dppf})\text{Cl}_2$ (109 mg, 0.15 mmol), the mixture was stirred at 80 °C for 12 hours under N_2 atmosphere to form a brown mixture. LCMS showed the reaction was completed. The mixture was filtered over a pad of celite. The filtrate was partitioned between EtOAc (30 mL) and H_2O (30 mL). The aqueous phase was extracted with EtOAc (30 mL x 2). The combined organic extract was washed with brine (80mL x 3), dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure to give a residue, which was purified by Combi flash to give compound **B80** (200 mg) as a white solid.

Procedure for synthesis of **B81**

To a mixture of methyl compound **B80** (150 mg, 0.58 mmol) in THF (4 mL) was added LiAlH_4 (111 mg, 2.94 mmol) at 0 °C, the mixture was stirred at 10 °C for 12 hours to form a white mixture. LCMS showed the reaction was completed. The mixture was quenched with saturated NH_4Cl (10 mL). The mixture was filtered over a pad of celite and washed with EtOAc (10 mL). The filtrate was partitioned between EtOAc (30 mL) and H_2O (30 mL). The aqueous phase was extracted with EtOAc (30 mL x 2). The combined organic extract was washed with brine (50 mL x 3), dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure to give compound **B81** (100 mg) as a white solid, which was used for next step without further purification.

Scheme 30: Synthetic route for B88



Procedure for synthesis of B84

To a mixture of compound **B82** (1 g, 7.14 mmol), Cs_2CO_3 (5.81 g, 17.8 mmol) in DMF (15 mL) was added compound **B83** (6.14 g, 35.68 mmol). The mixture was stirred at 20 °C for 12 hours to give a yellow suspension. TLC showed the reaction was completed. The mixture was partitioned between EtOAc (100 mL) and water (100 mL), the aqueous phase was extracted with EtOAc (80 mL x 2), the combined extracted phase was washed with water (80 mL), dried over Na_2SO_4 , filtered, concentrated under reduced pressure to give a yellow oil, which was purified by Combi flash to give compound **B84** (1.9 g) as a white solid.

Procedure for synthesis of B85

To a mixture of compound **B84** (300 mg, 1.09 mmol) in THF (2 mL), MeOH (2 mL), H_2O (1 mL) was added LiOH (130 mg, 5.44 mmol). The mixture was stirred at 15 °C for 12 hours to

give a yellow mixture. LCMS showed the reaction was completed. The mixture was concentrated under reduced pressure to remove MeOH. The aqueous phase was diluted with water (30 mL), acidized with HCl (3 M) to pH =4-5 and lyophilized to give compound **B85** (201 mg) as a white solid


Procedure for synthesis of B87

To a mixture of compound **B85** (200 mg, 0.808 mmol), HOBt (131 mg, 0.969 mmol), EDCI (186 mg, 0.969 mmol) in DMF (3 mL) was added DIEA (313 mg, 2.42 mmol), compound **B86** (324 mg, 1.62 mmol). The mixture was stirred at 20°C for 12 hours to give a yellow mixture. LCMS showed the reaction was completed. The reaction mixture was quenched with H₂O (20 mL) and lots of white solid was precipitated, then filtered under reduced pressure to give compound **B87** (205 mg) as a white powder.

Procedure for synthesis of B88

The compound **B87** (200mg) was followed the same procedure of **B3** to obtain 254 mg of compound **B88** as a yellow solid.

Scheme 31: Synthetic route for B95



Procedure for synthesis of B90

To a solution of compound **B89** (5 g, 41.3 mmol), Pyridine (8.33 mL) in DCM (50 mL) was added TFAA (7.17 mL) at 0°C. The mixture was stirred at 20°C for 12 hours to give yellow

mixture. LCMS showed the reaction was completed. The reaction mixture was poured into 0.5 N HCl (30 mL) and vigorously stirred for 5 min. The layers were separated, and the aqueous layer was extracted with CH₂Cl₂ (3 x 10 mL). The combined organic layers were washed with 0.5 N HCl (20 mL), H₂O (2 x 20 mL), and saturated NaHCO₃ (20 mL) and dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give compound **B90** (9.3 g, crude) as a yellow gum.

Procedure for synthesis of **B91**

To a solution of CF₃SO₃H (2.44 mL) in DCM (50 mL) was added HNO₃ (622 uL) at 0 °C and stirred at 0°C for 30 mins. The mixture was cooled to -70 °C and added the solution of compound **B90** (3.00 g, 13.8 mmol) in DCM (20 mL) for 1 hour. The mixture was stirred at -70°C for 30 minutes then. The mixture was stirred at -40°C for 12 hour to give a yellow mixture. LCMS showed the reaction was completed. The yellow-orange reaction mixture was poured into ice (50 g) and stirred vigorously for 10 minutes. The layers were separated, and the aqueous layer was extracted with CH₂Cl₂ (3 x 25 mL). The organic layers were combined, washed with H₂O (3 x 50 mL), saturated NaHCO₃ (50 mL), and H₂O (50 mL), and dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give Compound **B91** (3.12 g) as a yellow solid.

Procedure for synthesis of **B92**

To a mixture of compound **B91** (500 mg, 1.91 mmol) in EtOH (10 mL) was added Pd/C (0.1 g, 10% purity, 50% water). The suspension was degassed under vacuum and purged with H₂ atmosphere several times. The mixture was stirred at 15 °C under H₂ atmosphere (15 psi) for 12 hours to give a black suspension. LCMS showed the reaction was completed. The combined batches mixture was filtrated, the filtrate was concentrated under reduced pressure to give compound **B92** (480 mg) as yellow oil.

Procedure for synthesis of **B94**

To a solution of compound **B92** (390 mg, 2.58 mmol) in *i*-PrOH (15 mL) was added

compound **B93** (600 mg, 2.58 mmol). The reaction solution was heated to 80°C and stirred for 3 hours to give a yellow solution. The reaction was cooled to 30-40°C, P(n-Bu)₃ (1.57 g, 7.74 mmol) was added and stirred for another 12 hours at 80°C to give a black brown solution. LCMS showed the reaction was completed. The reaction mixture was quenched by addition H₂O (100 mL) and extracted with EtOAc (100 mL x 2). The combined organic layers were washed with saturated NH₄Cl (50 mL) and brine (10 mL x 2), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give a residue, which was purified by Combi flash to give compound **B94** (200 mg) as yellow gum.

Procedure for synthesis of B95

To a solution of compound **B94** (200 mg, 0.600 mmol) in MeOH (8 mL) was added K₂CO₃ (415 mg, 3.00 mmol). The resulting mixture was stirred at 60-70°C for 2 hours to give yellow solution. TLC showed the starting material was consumed. The reaction mixture was concentrated under reduced pressure to give compound **B95** (141 mg) as yellow gum.

Scheme 32: Synthetic route for B98




Procedure for synthesis of B97

To a solution of compound **B96** (4.00 g, 32.8 mmol) in DMA (50 mL) was added 1H-pyrazole (2.68 g, 39.3 mmol) and Cs₂CO₃ (10.7 g, 32.8 mmol). The reaction mixture was stirred at 80 °C for 5 hours. TLC showed the reaction was complete. The reaction mixture was partitioned between water (250 mL) and EtOAc (250 mL). The organic layer was washed with water (100 mL x 2), brine (10 mL), dried over anhydrous Na₂SO₄, and concentrated under reduced pressure to give a residue. The residue was purified by Combi Flash to give compound **B97** (4.76 g) as a white powder.

Procedure for synthesis of B98

To a solution of compound **B97** (1.3 g, 7.64 mmol) in MeOH (30 mL) was added Raney-Ni (497 mg, 5.81 mmol). The reaction mixture was stirred at 20 °C for 3 hours under H₂ atmosphere (15 psi). TLC showed the reaction was complete. The reaction mixture was filtered through a pad of Celite. The filtrate was concentrated under reduced pressure to give 560 mg of dark brown gum as the crude product. The crude product was purified by Combi Flash to give compound **B98** (350 mg) as a light purple oil.

Scheme 33: Synthetic route for B102Procedure for synthesis of B100

To a solution of compound **B99** (1.00 g, 8.05 mmol) and CuBr₂ (2.16 g, 9.66 mmol) in CH₃CN (10 mL) was added *tert*-butylnitrite (1.25 g, 12.1 mmol) at 0°C, the reaction mixture was stirred at 15°C for 3 hours to give a brown solution. TLC showed the reaction was complete. To the reaction mixture was added 2M HCl (50 mL), extracted with EtOAc (30 mL x 3), the organic phase was washed with brine (50 mL), dried over anhydrous Na₂SO₄, filtered and concentrated under reduce pressure to give a brown oil. The product was purified by Combi Flash to give compound **B100** (380 mg) as a yellow oil.

Procedure for synthesis of B101


To a solution of compound **B100** (380 mg, 2.02 mmol) in dioxane (6 mL) was added CuI (115 mg, 0.606 mmol) and K₂CO₃ (559 mg, 4.04 mmol) and *trans*-N₁,N₂-dimethylcyclohexane-1,2-diamine (86.2 mg, 0.606 mmol) and 1H pyrazole (165 mg, 2.42 mmol), the reaction was stirred at 80°C for 16 hours to give a brown suspension. TLC showed a new spot. To the reaction solution was added 1H pyrazole (500 mg), the solution was stirred at 110°C for 8 hours. TLC showed the reaction wasn't complete. The mixture was filtered. The filtrate was partitioned between EtOAc (20 mL) and water (20 mL). The organic

layer was washed with 28% $\text{NH}_3 \cdot \text{H}_2\text{O}$ (30 mL x 2), brine (20 mL x 2), dried over anhydrous Na_2SO_4 , then filtered and concentrated under reduced pressure to give a yellow oil. The product was purified by Combi Flash to give compound **B101** (180 mg) as a white solid.

Procedure for synthesis of B102

The compound **B102** (180mg) was followed the same procedure of **B3** to obtain 143 mg of compound **B101** as a yellow oil.

Scheme 34: Synthetic route for B105




Procedure for synthesis of B104

To a mixture of compound **B103** (1.00 g, 4.81 mmol) and $\text{Pd(PPh}_3)_4$ (556 mg, 0.481 mmol) in anhydrous DMF (10 mL) was added Zn(CN)_2 (678 mg, 5.77 mmol). The reaction mixture was heated at 80 °C under N_2 atmosphere for 16 hours. LCMS showed the reaction was complete. The reaction mixture was cooled to room temperature, then the mixture was poured into water (50 mL) and the crude product was extracted with EtOAc (100 mL), the organic layer was washed with water (50 mL x 2), brine (50 mL), dried over anhydrous Na_2SO_4 , filtered, concentrated under reduced pressure to provide the crude product as a brown oil. The crude product was purified by Combi Flash to give compound **B104** (700 mg) as a white powder.

Procedure for synthesis of B105

The compound **B104** (700mg) was followed the same procedure of **B102** to obtain 660 mg of compound **B105** as a brown oil.

Scheme 35: Synthetic route for B111**Procedure for synthesis of B107**

To a mixture of compound **B106** (10.0 g, 45.4 mmol) in DMF (5 mL) was added MeNH₂ (2M in THF, 68.2 mL), then K₂CO₃ (9.42 g, 68.2 mmol) was added, the resulting mixture was stirred at 25 °C for 12 hours to give a yellow suspension. TLC showed the reaction was completed. The mixture was diluted with EtOAc (300 mL), washed with water (200 mL x 3) and brine (200 mL), dried with anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give compound **B107** (13.0 g) as a yellow oil, which was used directly for next step without further purification.

Procedure for synthesis of B108

To a mixture of compound **B107** (6.00 g) in MeOH (60 mL) was added AcOH (15.6 g, 259 mmol), then Fe powder (7.25 g, 129.9 mmol) was added, the resulting mixture was stirred at 25 °C for 12 hours. Crude LCMS showed the reaction worked well. The suspension was filtered and washed with MeOH (80 mL). The filtrate was concentrated under reduced pressure. The residue was basified by saturated NaHCO₃ to pH = 9-10, extracted with EtOAc (200 mL x 2), the combined organic phase was dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give compound **B108** (4.60 g) as a brown oil. The crude product was directly used for next step.

Procedure for synthesis of B109

To compound **B108** (4.60 g, crude) was added HCOOH (20 mL), the resulting mixture was stirred at 90°C for 12 hours. LCMS showed the reaction worked well. 50 mL water was

added to quench the reaction, neutralized with saturated NaHCO_3 to adjusted to pH = 8-9, the resulting mixture was extracted with EtOAc (200 mL x 3), the combined organic phase was washed with brine (150 mL), dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure to give compound **B109** (3.70 g, 3-step yield: 83.6%) as a brown solid.


Procedure for synthesis of B110

The compound **B109** (2.0 g) was followed the same procedure of **B104** to obtain 900 mg of compound **B110** as a purple powder.

Procedure for synthesis of B111

The compound **B110** (1.2 g) was followed the same procedure of **B3** to obtain 1.0 g of compound **B111** as a white powder.

Scheme 36: Synthetic route for B115



Procedure for synthesis of B113

A mixture of compound **B112** (1.00 g, 5.32 mmol) in 1,1,1-triethoxyethane (4.40 g, 27.1 mmol) was stirred at 120°C under N_2 for 2 hours to form a black red solution. LCMS showed 91.7% of desired MS. Most of MeC(OEt)_3 was removed under reduced pressure to give compound **B113** (950 mg) as a red powder.


Procedure for synthesis of B114

The compound **B113** (950mg) was followed the same procedure of **B104** to obtain 230 mg of compound **B114** as a pink powder.

Procedure for synthesis of B115

The compound **B114** (257mg) was followed the same procedure of **B3** to obtain 250 mg of compound **B115** as a yellow gum.

Scheme 37: Synthetic route for B122



Procedure for synthesis of B118

To a stirred solution of compound **B116** (6.80 g, 53.5 mmol) in DCM (50 mL) was added dropwise compound **B117** (8.38 g, 48.6 mmol) dissolved in DCM (50 mL) at $-5-0^\circ\text{C}$. Then the mixture was stirred at $1-11^\circ\text{C}$ for 64 hours. TLC showed compound **B116** was completely consumed. The mixture was washed with water (100 mL) and brine (100 mL), dried over anhydrous sodium sulfate and concentrated to afford compound **B118** (10.0 g) as a brown solid.

Procedure for synthesis of B119

Compound **B118** (10.0 g, 38.0 mmol) and AlCl_3 (12.7 g, 95.2 mmol) was stirred at 120°C for 4 hours under N_2 atmosphere. TLC showed compound **B118** was completely consumed. The mixture was dissolved in DCM (30 mL), poured into ice water (50 mL) and separated. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to afford the crude product as a brown oil. The crude product was purified by Combi flash to afford compound **B119** (1.10 g) as yellow solid.

Procedure for synthesis of B120

To a stirred solution of compound **B119** (1.10 g, 4.87 mmol) in DMSO (30 mL) was added KOH (1.09 g, 19.4 mmol) and MeI (2.07 g, 14.5 mmol). Then the mixture was stirred at 10°C for 64 hours. LCMS showed compound **B119** was completely consumed. The mixture was poured into water (100 mL), extracted with EtOAc (50 mL x 3). The combined organic layers were washed with brine (50 mL x 2), dried over anhydrous sodium sulfate and concentrated to afford the crude product as a brown oil. The crude product was purified by Combi flash to afford compound **B120** (840 mg) as a yellow oil.


Procedure for synthesis of B121

The compound **B120** (600mg) was followed the same procedure of **B104** to obtain 450 mg of compound **B121** as a yellow solid.

Procedure for synthesis of B122

The compound **B121** (400mg) was followed the same procedure of **B3** to obtain 180 mg of compound **B122** as a red oil.

Scheme 38: Synthetic route for B125



Procedure for synthesis of B124


To a solution of 2,2,6,6-tetramethylpiperidine (1.23 g, 8.72 mmol) in THF (18 mL) was added n-BuLi (2.5 M, 2.91 mL) at -10°C under N₂ atmosphere for 10 min. Then a solution of **B123** (1 g, 7.27 mmol) in THF (10 mL) was added to the mixture and the reaction mixture

was stirred at -78°C for 10 min. Then acetone (844 mg, 14.5 mmol, 1.07 mL) was added to the reaction mixture. The reaction mixture was stirred at 15°C for 16 hr to give a brown mixture. TLC showed new spot. The reaction mixture was quenched with NH_4Cl (200 mL) and extracted with EA (150 mL x 2). The organic layer was dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure to give crude product. The residue was purified by column chromatography to give compound **B124** (1.3 g) as light yellow oil.

Procedure for synthesis of B125

To a solution of **B124** (1.3 g, 6.64 mmol) in THF (15 mL) was added $\text{BH}_3\cdot\text{THF}$ (1 M, 33.2 mL) at 0°C under N_2 atmosphere and stirred for 30 min. Then the reaction mixture was stirred at 60°C for 16 hours to give colorless mixture. LCMS showed the desired MS and the R1 was consumed up. The reaction mixture was quenched with MeOH (20 mL) and adjust pH=2 by 0.5M HCl aq. Then the mixture was extracted with DCM (100 mL *2). The water phase was basified to pH = 8 with 2M NaOH and extracted with DCM (100 mL*2). The organic layer was dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure to **B125** (800 mg, crude) as white solid.

Scheme 39: Synthetic route for B129



Procedure for synthesis of B127

To a solution of **B126** (1 g, 6.60 mmol) in CCl_4 (10 mL) was added NBS (1.29 g, 7.25 mmol) and BPO (16 mg, 66 μmol). The reaction mixture was stirred at 85°C for 16 hr to give a light yellow mixture. TLC showed new spot. The reaction mixture was filtered and the filter cake was washed with CCl_4 (100 mL). The filtrate was concentrated to give a residue. The residue was purified by column chromatography to give **B127** (1.5 g) as a light yellow solid.


Procedure for synthesis of B128

To a solution of **B127** (1.5 g, 6.51 mmol) in DMF (15 mL) was added NaN_3 (570 mg, 8.77 mmol). Then the reaction mixture was stirred at 60°C under N_2 atmosphere for 16 hours to give light yellow mixture. TLC showed new spot. The reaction mixture was quenched with brine (150 mL) and extracted with MTBE (150 mL). The organic layer was washed with brine (100 mL), dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure to give **B128** (1.1 g, crude) as a light yellow oil.

Procedure for synthesis of B129

To a solution of **B128** (1.1 g, 5.71 mmol) in THF (9 mL)/ H_2O (1 mL) was added PPh_3 (2.25 g, 8.57 mmol). The reaction mixture was stirred at 80°C for 16 hr to give a brown mixture. LCMS showed the desired MS value. The reaction mixture was diluted with water (100 mL) and adjusted to pH = 3 with HCl (0.5 M), then extracted with EtOAc (100 mL x 2). The water phase was adjusted to pH = 8 with aqueous NaHCO_3 and extracted with EtOAc (100 mL). No product was observed by TLC in organic extract. The water phase was concentrated to give **B129** (2.3 g, crude) as a brown solid

Scheme 40: Synthetic route for B136



Procedure for synthesis of B131

The compound **B130** (100mg) was followed the same procedure of **B41** to obtain 87 mg of compound **B131** as a brown solid.


Procedure for synthesis of B132

The compound **B131** (87mg) was followed the same procedure of **B26** to obtain 90 mg of compound **B132** as a brown gum.

Procedure for synthesis of B133

The compound **B132** (90mg) was followed the same procedure of **B28** to obtain 80 mg of compound **B133** as a brown solid.

Scheme 41: Synthetic route for B138



Procedure for synthesis of B135

To a solution of SOCl_2 (2.07 g, 17.4 mmol, 1.26 mL) in MeOH (20 mL) at 0°C was added **B134** (1 g, 8.69 mmol). The reaction mixture was stirred at 20°C for 3 hours to give colorless mixture. TLC showed new spot. The reaction mixture was concentrated under reduced pressure to give **B135** (1.3 g) as colorless oil.

Procedure for synthesis of B136

The compound **B135** (1.3 g) was followed the same procedure of **B21** to obtain 1.8 g of compound **B136** as a white solid.


Procedure for synthesis of B137

The compound **B136** (1.8 g) was followed the same procedure of **B26** to obtain 1.81 g of compound **B137** as a yellow gum.

Procedure for synthesis of B138

The compound **B137** (1 g) was followed the same procedure of **B125** to obtain 600 mg of compound **B138** as a yellow gum.

Scheme 42: Synthetic route for B143



Procedure for synthesis of **B140**

To a solution of compound **B139** (3 g, 11.9 mmol) in MeOH (20 mL) was added H_2SO_4 (2.38 g, 23.8 mmol, 1.29 mL). The mixture was refluxed for 17 hours to form a brown solution. TLC showed the reaction was completed. The mixture was partitioned between EtOAc (30 mL) and H_2O (30 mL). The aqueous phase was extracted with EtOAc (30 mL x 2). The combined organic extracts were washed with brine (50 mL x 3), dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure to give compound **B140** (2.8 g) as a yellow solid.

Procedure for synthesis of **B141**

The compound **B140** (500 mg) was followed the same procedure of **B26** to obtain 910 mg of compound **B141** as a yellow powder.


Procedure for synthesis of **B142**

The compound **B141** (910 mg) was followed the same procedure of **B104** to obtain 560 mg of compound **B142** as a pale-yellow powder.

Procedure for synthesis of **B143**

The compound **B142** (100 mg) was followed the same procedure of **B28** to obtain 100 mg of compound **B143** as a pale-yellow powder.

Scheme 43: Synthetic route for **B147**




Procedure for synthesis of **B146**

To a solution of compound **B144** (792.88 mg, 3.06 mmol) and compound **B145** (500 mg, 3.06 mmol) in dioxane (10 mL) and H_2O (2 mL) were added Pd(dppf)Cl_2 (111.95 mg, 153.00 μmol) and Cs_2CO_3 (1.99 g, 6.12 mmol) under N_2 . The resulting mixture was heated at 100°C and stirred for 3 hours to give gray suspension. LCMS showed the reaction was not completed. Then the reaction mixture was stirred at 100°C for 18 hours, and LCMS showed the reaction have 32% of desired product and 36% of material. The mixture was partitioned between EtOAc (50 mL) and water (30 mL). The aqueous layer was extracted with EtOAc (30 mL * 3). The combined organic layer was washed with saturated brine (30 mL), dried over anhydrous Na_2SO_4 , filtered, and concentrated under reduced pressure to give the crude product as a yellow oil. It was purified by column chromatography to obtain compound **B146** (236 mg) as yellow oil.

Procedure for synthesis of **B147**

The compound **B146** (236 mg) was followed the same procedure of **A30** to obtain 200 mg of compound **B147** as yellow oil

Scheme 44: Synthetic route for compound 209 through Route I



Procedure for synthesis of **C2**

To a mixture of diisopropylamine (6.69 g, 66.2 mmol) in anhydrous THF (20 mL) was added $n\text{-BuLi}$ (2.5 M, 27.7 mL) at 0°C and stirred at 0°C for 0.5 hour, then the mixture was cooled to -70°C and **C1** (5.00 g, 60.2 mmol) in THF (20 mL) was added into the mixture at -70°C and stirred at -70°C for 0.5 hour, then the mixture was poured into a mixture of ethyl formate (4.90 g, 66.2 mmol) in THF (20 mL) at -70°C under N_2 atmosphere and the resulting mixture was stirred at -70°C for 0.5 hours, then warmed to 15°C and stirred at 15°C for 17 hours. TLC (silica gel, $\text{PE}/\text{EtOAc} = 2/1$) showed the reaction was completed. The reaction mixture was poured into aqueous HCl (150 mL, 1M) at 0°C and stirred at 0°C for 0.5 hours, then the mixture was extracted with EtOAc (150 mL x 3). The organic layer was washed with brine (250 mL), dried over anhydrous Na_2SO_4 , filtered, the filtrate was concentrated under reduced pressure to give compound **C2** (5.0 g) as a yellow oil. The crude product was used directly in next step without further purification.

Procedure for synthesis of **C3**

To a solution of compound **C2** (8.82 g, 67.5 mmol) and AcOH (7.09 g, 118 mmol) in EtOH (5 mL) was added $\text{NH}_2\text{-NH}_2 \cdot \text{H}_2\text{O}$ (4.39 g, 87.7 mmol), the resulting mixture was stirred at 78°C for 17 hours to give a pale yellow solution. TLC showed the reaction was completed. The reaction mixture was concentrated under reduced pressure to give a residue, then the pH

value of the residue was adjusted to 9 with aqueous NaOH (1M), diluted with water (50 mL) and extracted with EtOAc (100 mL x 3). The organic layer was washed with brine (150 mL), dried over anhydrous Na₂SO₄, filtered and the filtrate was concentrated under reduced pressure to give compound **C3** (10.0 g, crude) as a yellow gum. The crude product was used directly in next step without further purification.

Procedure for synthesis of C4

To a mixture of compound **C3** (5.00 g, 40.0 mmol) in anhydrous DCM (25 mL) was added a mixture of ethoxycarbonyl isothiocyanate (4.72 g, 36.0 mmol) in anhydrous DCM (25 mL) at -70°C and stirred at -70°C for 1 hour, a lot of white solid appeared. TLC showed the reaction was completed. Then the mixture was allowed to warm to -10°C and filtered, and the filter cake was washed with DCM (15 mL) to give 4.50 g of desired compound as a white solid, the structure was confirmed by HNMR. The filtrate was purified by silica gel column to give compound **C4** (1.80 g) as a white solid.

Procedure for synthesis of C5

To a mixture of compound **C4** (6.30 g, 24.6 mmol) in MeCN (50 mL) was added K₂CO₃ (6.79 g, 49.2 mmol), the mixture was stirred at 80°C for 8 hours. Crude LCMS showed the reaction was completed. The mixture was cooled to room temperature, then AcOH (15 mL) was added into the mixture and stirred at 15°C for 20 minutes, then the resulting mixture was concentrated under reduced pressure to give a residue, which was washed with water (50 mL x 3) to give compound **C5** (4.20 g) as a white solid.

Procedure for synthesis of C6

To a mixture of compound **C5** (4.20 g, 20.0 mmol) in EtOH (40 mL) was added NaOH (2.00 g, 50.0 mmol) in H₂O (20 mL) at 15°C, then MeI (2.84 g, 20.0 mmol) was added into above mixture and the resulting mixture was stirred at 15 °C for 2 hours. Crude LCMS showed the reaction was completed. The mixture was concentrated under reduced to give a residue, which was treated with ice cold water (50 mL) and aqueous HCl (20 mL, 6M) for 30 minutes,

a lot of white solid appeared, filtered to give the crude product. The crude product was poured into MeCN (50 mL) to give a suspension, then the suspension was concentrated under reduced pressure to give compound **C6** (3.60 g) as a white solid.

Procedure for synthesis of **C7**

To a solution of Compound **C6** (500 mg, 2.23 mmol) in POCl₃ (5 mL) was added N,N-diethylaniline (998 mg, 6.69 mmol) dropwise. The reaction mixture was stirred at 90 °C for 2 hours. The reaction solution was concentrated under reduced pressure to give crude compound **C7** (710 mg) as a dark oil, which was used directly in the next step without further purification.

Procedure for synthesis of **C8**

To a mixture of compound **B42** (700 mg, 2.99 mmol) in CH₃CN (20 mL) was added DIEA (772 mg, 5.98 mmol) and compound **C7** (652 mg, 2.69 mmol), the mixture was stirred at 15°C for 2 hours to give a yellow mixture. LCMS showed the reaction was completed. The reaction was concentrated under reduced pressure to give crude product. The crude product was purified by Combi flash to give compound **C8** (650 mg) as yellow gum.

Procedure for synthesis of **C9**

To a mixture of compound **C8** (650 mg, 1.48 mmol) in DCM (10 mL) was added *m*-CPBA (659 mg, 3.25 mmol) in portions at 15°C. The reaction mixture was stirred at 15°C for 2 hours under N₂ atmosphere to give yellow mixture. LCMS showed the reaction was completed. The reaction mixture was filtered, combined filtrate and concentrated under reduced pressure to give crude product. The crude product was purified by Combi flash to give compound **C9** (350 mg) as yellow gum.

Procedure for synthesis of **C11**


A mixture of compound **C9** (350 mg, 0.740 mmol) and compound **C10** (317 mg, 1.48 mmol)

in NMP (10 mL) was stirred at 140°C for 16 hours to give brown mixture. LCMS showed the reaction was completed. The reaction was quenched by water (50 mL), and extracted by EtOAc (100 mLx2). The combined organic phase was washed with brine (100mL x 2), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give crude product, which was purified by Combi flash to afford compound **C11** (220 mg) as yellow gum.

Procedure for synthesis of compound 209

A solution of compound **C11** (220 mg, 0.362 mmol) in HCl/MeOH (3 mL, 4M) was stirred at 15°C for 16 hours to give yellow solution. LCMS showed the reaction was completed. The solution was concentrated under reduced pressure to give crude product. The crude product was purified by prep-HPLC (0.1% TFA), the fraction was basified to pH = 8 with saturated NaHCO₃, extracted with DCM (20 mL x 2), the separated organic layer was washed with brine (20 mL x 2), dried over anhydrous Na₂SO₄, filtered and lyophilized to afford compound **209** (62 mg) as a white powder.

Scheme 45: Synthetic route for compound 245 through Route I




Procedure for synthesis of C12

The compound **C9** (1.46 g) and compound **A30** (680 mg) were followed the same procedure of **C11** to obtain 110 mg of compound **C12** as a yellow solid.

Procedure for synthesis of compound 245

To a mixture of compound **C12** (110 mg, 0.179 mmol) in EtOH (5 mL) was added $\text{N}_2\text{H}_4\cdot\text{H}_2\text{O}$ (12.7 mg, 12.3 μL , 85% purity). The mixture was stirred at 25°C for 2 hours to give a colorless mixture. LCMS showed the reaction was completed. The reaction mixture was concentrated under reduced pressure to remove **EtOH**, residue was diluted with H_2O extracted with **EtOAc** (10 mL x 3). The combined organic layers were washed with **brine** (20 mL), dried over Na_2SO_4 , **filtered and concentrated under reduced pressure to give the crude product, which** was purified by prep-TLC to afford compound **245** (17.6 mg) as a white powder.

Scheme 46: Synthetic route for compound 48 through Route II



Procedure for synthesis of **C13**

To a mixture of compound **C6** (5.00 g, 22.3 mmol) in DCM (100 mL) was added *m*-CPBA (10.1 g, 46.8 mmol) in portions at 25 °C. The mixture was stirred at 25 °C for 2 hours under N_2 atmosphere. Much white solid appeared. TLC showed the reaction was completed. The reaction mixture was filtered. Most of DCM was moved under reduce pressure, then the mixture was filtered. The filter cake was washed with cold DCM (15 mL x 2). This process was repeated twice. The filtrate was dried over anhydrous Na_2SO_4 , then filtered and concentrated under reduce pressure to give compound **C13** (5.7 g) as a white powder. The crude product was used for next step directly without further purification.

Procedure for synthesis of **C15**

To a solution of compound **C13** (6.62 g, 25.83 mmol) in NMP (100 mL) was added compound **C14** (18.15 g, 77.5 mmol). The reaction mixture was stirred at 140 °C for 16 hours. TLC showed the reaction was complete. The reaction mixture was partitioned between brine (500 mL) and EtOAc (400 mL). The organic layer was washed with water (100 mL x 2), brine (100 mL), dried over anhydrous Na₂SO₄, and concentrated under reduced pressure to give a residue. The residue was purified by Combi Flash to give a brown gum, which was triturated with CH₃CN (50 mL) to give compound **C15** (2.06 g) as an off-white powder.

Procedure for synthesis of C16

To a mixture of compound **C15** (89 mg, 0.22 mmol) in POCl₃ (4.41 g, 28.7 mmol) was added N,N-diethylaniline (97 mg, 0.65 mmol) at 20 °C. The reaction mixture was stirred at 80 °C for 2 hours. The reaction mixture was concentrated under reduced pressure to give compound **C16** (93 mg) as a brown gum as the crude product. The crude product was used directly in next step without further purification.

Procedure for synthesis of C17


To a mixture of compound **C16** (100 mg, 0.233 mmol), DIPEA (60.3 mg, 0.466 mmol) in MeCN (3 mL) was added compound **B42** (109 mg, 0.466 mmol). The mixture was stirred at 15 °C for 2 hours. TLC showed that the reaction was completed. The mixture was filtered. The filter cake was washed with MeCN (1 mL x2), PE (1 mL x2) to give compound **C17** (100 mg) as a yellow powder.

Procedure for synthesis of compound 48

A mixture of compound **C17** (90 mg, 0.143 mmol) in HBr/HOAc (2.5 mL, 35% purity) was stirred at 15 °C for 20 minutes. TLC showed a new spot. The mixture was concentrated under reduced pressure to give a residue. The residue was added sat. NaHCO₃ solution to pH= 8. The mixture was extracted with DCM (30 mL x2). The combined extracts were washed with water (40 mL x 2), dried over anhydrous Na₂SO₄, then filtered and concentrated under reduced pressure to give a residue (as a yellow gum). The residue was purified by prep-HPLC

and remaining solvent was removed by lyophilization to afford compound **48** (24.3 mg) as a white powder.

Scheme 47: Synthetic route for compound 73 through Route III



Procedure for synthesis of C18

To a solution of compound **E2** (300 mg, 1.30 mmol) in CH_3CN (20 mL) was added compound **B42** (305 mg, 1.30 mmol) and K_2CO_3 (180 mg, 1.30 mmol). The resulting mixture was heated at $80^\circ C$ and stirred for 3 hours to give yellow suspension. TLC showed the reaction was completed. The reaction mixture was quenched by addition H_2O (50 mL) and extracted with EtOAc (50 mL x 2). The combined organic layers were washed with brine (20 mL), dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give a residue. The crude product was purified by silica column, the fraction was concentrated to obtain compound **C18** (420 mg) as a yellow solid.

Procedure for synthesis of C20


To a solution of compound **C18** (200 mg, 0.467 mmol) in NMP (20 mL) was added compound **C19** (468 mg, 2.34 mmol). The resulting mixture was heated at $140^\circ C$ and stirred for 12 hrs to give yellow solution. TLC showed most of compound **5** was consumed, one major spot was formed. The reaction mixture was quenched by addition H_2O (100 mL) and extracted with EtOAc (50 mL x 2). The combined organic layers were washed with brine (10 mL), dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give a residue. The residue was purified by silica column to obtain compound **C20** (168 mg) as an off-white solid.

Procedure for synthesis of compound **73**

To a solution of compound **C20** (168 mg, 0.284 mmol) in DCM (14 mL) was added TFA (6 mL). The resulting mixture was stirred for 1.5 hours at 20°C to give yellow solution. LCMS and HPLC showed the reaction was completed. The reaction mixture was concentrated to remove most of TFA, then basified with saturated aqueous NaHCO₃ to pH~9 and extracted with EtOAc (50 mL x 5). The combined organic layers were washed with brine (5 mL x 5), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The residue was purified by triturated with MTBE (20 mL), filtered under reduced pressure to obtain compound **73** (122.3 mg) as an off-white solid.

Exceptional synthetic route

Scheme 48: Synthetic route for compound **178**



Procedure for synthesis of **D2**

To a mixture of (2-bromophenyl)methanamine (5.14 g, 27.7 mmol) in CH₃CN (50 mL) was added compound **D1** (4.00 g, 25.1 mmol). The mixture was stirred at 85°C for 12 hours to give a yellow mixture. LCMS showed the reaction was completed. The mixture was concentrated under reduced pressure to give a yellow residue, which was purified by Combi flash to give compound **D2** (3.2 g) as a yellow powder.

Procedure for synthesis of **D3**

To a solution of compound **D2** (1 g, 3.23 mmol) in DMA (8 mL) was added Pd₂(dba)₃ (296 mg, 0.323 mmol), DPPF (359 mg, 0.647 mmol), Zn(CN)₂ (228 mg, 1.94 mmol), Zn (21.2 mg,

0.323 mmol). The reaction was stirred at 150°C under microwave condition for 0.5 hour under N₂ atmosphere to give a red brown suspension. TLC showed the reaction was completed. The mixture was partitioned between with water (50 mL) and EtOAc (50 mL). The aqueous phase was extracted with EtOAc (50 mL). The combined extracts were washed with brine (30 mL x 3), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give crude product as a brown oil, which was purified by Combi flash to give compound **D3** (530 mg) as a yellow gum.

Procedure for synthesis of **D4**

To a mixture of Raney-Ni (100 mg in water) in MeOH (30 mL) was added compound **D3** (500 mg, 1.96 mmol), NH₃.H₂O (2 mL). The suspension was degassed under vacuum and purged with H₂ several times. The mixture was stirred at 15 °C under H₂ (15 psi) for 2 hours to give a black suspension. TLC showed the reaction was completed. The mixture was filtered, the filtrate was concentrated under reduced pressure to give compound **D4** (500 mg) as a yellow powder.

Procedure for synthesis of **D5**

To a mixture of compound **D4** (500 mg, 1.93 mmol) in MeCN (5 mL) was added DIEA (1 mL) compound **C16** (827 mg, 1.93 mmol). The mixture was stirred at 15 °C for 12 hours to give a yellow mixture. TLC showed the reaction was completed. The mixture was partitioned between EtOAc (50 mL) and water (50 mL). The aqueous was extracted with EtOAc (50 mL x 2). The combined extracted was washed with brine (50 mL), dried over Na₂SO₄, filtered, concentrated under reduced pressure to give a yellow oil, which was purified by Combi flash to give compound **D5** (830 mg) as yellow powder.

Procedure for synthesis of **D6**


To a mixture of tetrahydro-2H-pyran-4-amine (111 mg, 1.10 mmol) in DCM (2 mL) was added Al(CH₃)₃ (2 M, 405 uL) at -60°C under N₂ atmosphere. The mixture was stirred at 20°C for 1 hour. Then a solution of compound **D5** (100 mg, 0.162 mmol) in dry DCM (1 mL)

was added dropwise. The mixture was stirred at 20°C for 12 hours to give a yellow suspension. LCMS showed the reaction was completed. The reaction mixture was filtered through Celite, and concentrated under reduced pressure to give a yellow residue, which was purified by prep-TLC to give compound **D6** (53 mg) as a yellow gum.

Procedure for synthesis of compound **178**

To a mixture of compound **D6** (53.0 mg, 0.0750 mmol) in HBr/HOAc (1 mL, 35% HBr in HOAc) was stirred at 0-10 °C for 0.5 hour to give a yellow mixture. TLC (PE/EA = 1/1) showed the reaction was completed. To the reaction mixture was added MTBE (10 mL) to precipitate red powder. The red was collected by filtration and washed with MTBE (5 mL x 2). The red solid was purified by cation exchange resin eluting with 5% NH₃.H₂O, then lyophilized to give a white powder, which was purified by prep-TLC and lyophilized to give compound **178** (20.5 mg) as a white powder.

Scheme 49: Synthetic route for compound **24**



Procedure for synthesis of D8

A mixture of compound **D7** (50.0 g, 430 mmol) in SOCl_2 (328 g, 2.76 mol) was stirred at 78 °C for 2 hours to give a light yellow solution. The solution was concentrated under reduced pressure to give acyl chloride (65.0 g, crude) as a light yellow oil. The crude product was used in next step directly. To a solution of $\text{NH}_3 \cdot \text{H}_2\text{O}$ (109 g, 22%) in DCM (300 mL) was added acyl chloride (65.0 g, crude) dropwise. The reaction mixture was stirred at 15 °C for 0.5 hour. The mixture was extracted with DCM (150 mL x 3), the combined organic layers was washed with brine (250 mL), dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure to give compound **D8** (20.5 g) as a white powder.

Procedure for synthesis of D9

To a solution of compound **D8** (10.0 g, 86.8 mmol) in DCM (150 mL) was added TEA (43.9 g, 434 mmol) and TFAA (45.6 g, 217 mmol) dropwise in turn under N_2 atmosphere. The reaction mixture was stirred at 15 °C for 16 hours. The reaction was quenched with saturated NH_4Cl (200 mL), then extracted with DCM (100 mL x 2), the combined organic layers was washed with brine (150 mL), dried over anhydrous Na_2SO_4 , filtered, concentrated under vacuum to give compound **D9** (16.2 g, crude) as a yellow oil.

Procedure for synthesis of D10

To a solution of n-BuLi (2.5 M, 56.8 mL) in anhydrous THF (200 mL) was added N-isopropylpropan-2-amine (13.7 g, 135 mmol) dropwise at -70 °C under N_2 atmosphere. The mixture was stirred at 15 °C for 1 hour under N_2 atmosphere. Then compound **D9** (12.0 g, 123 mmol) in anhydrous THF (20 mL) was added into the mixture at -70 °C under N_2 atmosphere and the resulting mixture was stirred at -70 °C under N_2 atmosphere for 2 hours. HCO_2Et (12.8 g, 173 mmol) in anhydrous THF (20 mL) was added dropwise at -70 °C under N_2 atmosphere, the reaction mixture was stirred at 15 °C for 16 hours. TLC showed a new spot. The reaction was quenched with aqueous HCl (10%), adjusted pH = 3~4, extracted with EtOAc (120 mL x 2), the combined organic layers was washed with brine (150 mL), dried over anhydrous Na_2SO_4 , filtered and concentrated under vacuum to give compound **D10** (13.0 g, crude) as a brown oil. The crude product was used in next step without any

purification.

Procedure for synthesis of D11

To a solution of compound **D10** (900 mg, 7.19 mmol) in EtOH (15 mL) was added $\text{NH}_2\text{NH}_2 \cdot \text{H}_2\text{O}$ (478 mg, 9.35 mmol) and AcOH (734 mg, 12.2 mmol) dropwise in turn. The solution was stirred at 78 °C for 16 hours. TLC showed a new spot. The solution was concentrated under reduced pressure to give yellow oil. EtOAc (20 mL) and H_2O (50 mL) was added to the residue, the aqueous phase was neutralized by 1M NaOH and adjusted pH to 9, extracted by EtOAc (20 mL x 2). The combined organic layers and washed with brine (30 mL), dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure to give compound **D11** (550 mg, crude) as a yellow oil, which was used in next step without any purification.

Procedure for synthesis of D12

To a solution of compound **D11** (550 mg, 3.95 mmol) in DCM (10 mL) at -78 °C was added $\text{EtO}_2\text{C-NCS}$ (518 mg, 3.95 mmol) dropwise under N_2 atmosphere. The reaction solution was stirred at -78 °C for 10 minutes. TLC showed the starting material was consumed and some new spots were formed. The reaction solution was concentrated under reduced pressure to give a yellow crude oil, which was purified by Combi Flash to give an intermediate (230 mg) as a yellow solid. To a solution of an intermediate (230 mg, 0.850 mmol) in MeCN (4 mL) was added K_2CO_3 (235 mg, 1.70 mmol) in one portion. The suspension was stirred at 80 °C for 1 hour. LCMS showed the reaction was completed. This suspension was neutralized by AcOH and adjusted pH to 4, concentrated under reduced pressure to give a yellow oil. DCM (20 mL) was added to dissolve the product, washed with H_2O (2 x 20 mL) and brine (20 mL). The organic layers was dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure to give compound **D12** (300 mg) as a yellow solid.

Procedure for synthesis of D13

To a solution of compound **D12** (300 mg, 1.34 mmol) in EtOH (7 mL) and NaOH (2 M, 1.34

mL) was added MeI (190 mg, 1.34 mmol) dropwise. The mixture was stirred at 15 °C for 0.5 hour. LCMS showed the reaction was completed. The mixture was concentrated under vacuum to give the residue, DCM (15 mL) was added, 6M HCl (2 mL) was added and the resulting mixture was stirred for 10 minutes. The mixture was extracted with DCM (20 mL x 2), the combined organic layers were washed by water (20 mL x 2) and brine (30 mL), dried over anhydrous Na₂SO₄, filtered and concentrated under vacuum to give compound **D13** (160 mg) as a yellow solid, which was used in next step without any purification.

Procedure for synthesis of **D14**

To a solution of compound **D13** (500 mg, 2.10 mmol) in N, N-diethylaniline (1.57 g, 10.5 mmol) was added POCl₃ (16.5 g, 107 mmol), the reaction mixture was stirred at 90 °C for 2 hours to give a brown solution. The mixture was concentrated under reduced pressure to remove POCl₃. The product was used for next without further purification.

Procedure for synthesis of **D16**

To a solution of compound **D14** (500 mg, 1.95 mmol) in MeCN (2.00 mL) was added DIEA (1.26 g, 9.75 mmol), then compound **D15** (675 mg, 3.90 mmol) was added into above mixture, the resulting mixture was stirred at 20°C for 2 hours. LCMS show desired MS value. The mixture was poured into water (50 mL), extracted with EtOAc (50 mL x 3), the combined extracts was washed with brine (100 mL), dried over anhydrous Na₂SO₄, filtered, the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by Combi flash to give compound **D16** (524 mg) as a white powder.

Procedure for synthesis of **D17**

To a solution of compound **D16** (524 mg, 1.33 mmol) in CH₂Cl₂ (5.00 mL) was added *m*-CPBA (573 mg, 2.66 mmol) the mixture was stirred at 20°C for 1 hour. LCMS showed compound **D16** was consumed, and desired MS has been got. The reaction was quenched with saturated aqueous Na₂S₂O₃ (20 mL), the mixture was extracted with DCM (30 mL x 3), the combined extracts was washed with saturated aqueous NaHCO₃ (30 mL) and water (30

mL x 2), the organic phase was dried over anhydrous Na₂SO₄, filtered, the filtrate was concentrated under reduced pressure to give compound **D17** (450 mg) as yellow oil.


Procedure for synthesis of **D18**

To a mixture of compound **D17** (450 mg, 1.06 mmol) in NMP (5.00 mL) was added compound **D5** (423 mg, 2.12 mmol) in one portion at 120°C under N₂. The mixture was stirred at 120 °C for 3 hours to give a yellow solution. TLC showed compound **D17** was consumed, and a new spot was formed. The mixture was poured into water (10 mL), a lot of white solid appeared, the mixture was filtered, the filter cake was washed with water (10 mL) and dried over high vacuum to give compound **D18** (390 mg) as white powder.

Procedure for synthesis of compound **24**

To a mixture of compound **D18** (390 mg, 0.714 mmol) in CH₂Cl₂ (10.0 mL) was added TFA (4.84 g, 42.4 mmol) in one portion. The mixture was stirred at 25 °C for 2 hours to give a yellow solution. LCMS showed the reaction was complete. To the reaction solution was added aqueous saturated NaHCO₃ solution to give pH = 7 ~ 8, extracted with DCM (10 mL x 2), the combined organic phase was concentrated under reduced pressure to give brown oil. The crude product was purified by prep-HPLC (0.01% TFA). Most of MeCN was removed under reduced pressure. The remaining solvent was removed by lyophilization to give compound **24** (161.1 mg) as a white powder.

Scheme 50: Synthetic route for compound 18



Procedure for synthesis of **D20**

To a mixture of compound **D19** (5.00 g, 30.9 mmol) in anhydrous DMF (30 mL) was added a mixture of ethyl ethoxycarbonyl isothiocyanate (3.64 g, 27.8 mmol) at 0°C and stirred at 0°C for 1 hour, then the a lot of white solid appeared. Crude LCMS showed the reaction was completed. Then the mixture was poured into water (200 mL), a lot of white solid appeared, the mixture was filtered to give the crude product. The crude product was washed with EtOH (30 mL) to give compound **D20** (4.50 g) as a white powder.

Procedure for synthesis of **D21**

To absolute EtOH (40 mL) was added Na (686 mg, 30.0 mmol), the mixture was stirred at 20 °C for 0.5 hour, then compound **D20** (3.50 g, 11.9 mmol) was added into above mixture, the resulting mixture was stirred at 80°C for 3 hours. Crude LCMS showed the reaction was completed. The mixture was concentrated under reduced pressure to give a residue, then the pH value of the residue was adjusted to 5 with aqueous HCl (1 M) to give a suspension, then the mixture was filtered to give compound **D21** (2.10 g) as a white powder.

Procedure for synthesis of **D22**

To a mixture of compound **D21** (900 mg, 3.64 mmol) in EtOH (20 mL) was added NaOH (364 mg, 9.11 mmol) in H₂O (10 mL), then MeI (517 mg, 3.64 mmol) was added into above mixture, the resulting mixture was stirred at 20°C for 17 hours. Two batches reaction was combined and crude LCMS showed the reaction was completed. The mixture was concentrated under reduced pressure to give a residue. The pH value of the residue was adjusted to 5 with aqueous HCl (1M), a lot of white solid appeared, filtered to give compound **D22** (1.80 g) as a white powder.

Procedure for synthesis of **D23**

To a mixture of compound **D22** (800 mg, 3.06 mmol) in POCl₃ (6 mL) was added N, N-diethylaniline (2.74 g, 18.4 mmol), the mixture was stirred at 90°C for 2 hours. The mixture was concentrated under reduced pressure to give 4.20 g (crude) of compound **D23** as a yellow gum.

Procedure for synthesis of **D24**

To a solution of compound **D23** (4.20 g, crude) and DIPEA (11.7 g, 90.1 mmol) in MeCN (10 mL) was added compound **D15** (1.20 g, 6.91 mmol), the mixture was stirred at 20°C for 17 hours. Crude LCMS showed the reaction worked not well, then DIPEA (11.7 g, 90.1 mmol) was added into above mixture, the mixture was stirred at 20°C for 17 hours. Crude LCMS showed the reaction completed. The mixture was poured into water (50 mL), extracted with EtOAc (50 mL x 3), the combined extracts was washed with brine (100 mL), dried over anhydrous Na₂SO₄, filtered, the filtrate was concentrated under reduced pressure to give a residue, which was purified by Combi flash to give 300 mg of compound **D24** as a yellow gum.

Procedure for synthesis of **D25**

To a solution of compound **D24** (300 mg, 0.721 mmol) in DCM (10 mL) was added *m*-CPBA (326 mg, 1.51 mmol, 80% purity), the mixture was stirred at 20°C for 1 hour. A lot of white solid appeared. Crude LCMS showed the reaction was completed. The reaction was quenched with saturated aqueous Na₂S₂O₃ (3 mL), then the mixture was poured into DCM (100 mL),

washed with saturated aqueous NaHCO_3 (100 mL x 3) and brine (100 mL x 2), the organic phase was dried over anhydrous Na_2SO_4 , filtered, the filtrate was concentrated under reduced pressure to give 250 mg of compound **D25** as a white powder.


Procedure for synthesis of D26

To a solution of compound **D25** (250 mg, 0.558 mmol) in NMP (3 mL) was added compound **D5** (223 mg, 1.12 mmol), the mixture was stirred at 120°C under N_2 atmosphere for 1 hour. Crude LCMS showed the reaction was completed. After cooling to room temperature, the mixture was poured into water (30 mL), a lot of white solid appeared, the mixture was filtered, the filter cake was washed with water (50 mL) to give 153 mg of compound **D26** as a yellow powder.

Procedure for synthesis of compound 18

To a solution of compound **D26** (150 mg, 0.264 mmol) in DCM (3 mL) was added TFA (4.62 g, 40.5 mmol), the mixture was stirred at 20°C for 20 minutes. Crude LCMS showed the reaction was completed. The mixture was concentrated under reduced pressure to give a residue, the pH value of the residue was adjusted to 8 with saturated aqueous NaHCO_3 , diluted with water (20 mL), the mixture was extracted with DCM (30 mL x 3), the combined extracts was washed with brine (50 mL), dried over anhydrous Na_2SO_4 , filtered, the filtrate was concentrated under reduced pressure to give a residue, which was purified by prep-HPLC (0.05%, HCl salt). Most of CH_3CN was removed by evaporation under reduced pressure, and the remaining solvent was removed by lyophilization to give 78.6 mg of compound **18** as a white powder.

Scheme 51: Synthetic route for compound 35




Procedure for synthesis of D28

To a mixture of compound **D26** (500 mg, 0.879 mmol) in dioxane (5 mL) was added compound **D27** (952 mg, 2.64 mmol) and Pd(PPh₃)₄ (101 mg, 0.0879 mmol) in one portion at 120°C under N₂ atmosphere. The mixture was stirred at 120 °C for 16 h to give a yellow solution. LCMS showed 10.4% of desired MS. The mixture was poured into NH₄Cl aqueous (50 mL) and stirred for 10 minutes. The mixture was partitioned between EtOAc (50 mL) and water (50 mL). The aqueous was extracted with EtOAc (50 mL). The combined organic extract was washed with water (50 mL x 2), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure to give a residue. The crude product was purified by Combi Flash to give compound **D28** (91.6 mg) as a white powder.

Procedure for synthesis of compound 35

To a mixture of compound **D28** (110 mg, 0.206 mmol) in CH₂Cl₂ (2 mL) was added TFA (1.40 g, 12.3 mmol) in one portion. The mixture was stirred at 25 °C for 1 hour to give a yellow solution. LCMS showed the reaction was complete and 52.8% desired MS was showed. To the reaction solution was added aqueous saturated NaHCO₃ solution to adjust pH = 7 ~ 8, extracted with DCM (10 mL x 2), the combined organic phase was concentrated under reduced pressure to give brown oil, which was purified by prep-HPLC (0.01% TFA). Most of MeCN was removed under reduced pressure. The remaining solvent was removed by lyophilization to give compound **35** (10.40 mg) as a white powder.

Scheme 52: Synthetic route for compound 30



Procedure for synthesis of **D29**

To a mixture of Compound **D26** (50 mg, 0.088 mmol), 1-pentenylboronic acid (50 mg, 0.44 mmol), Na_2CO_3 (19 mg, 0.18 mmol) in H_2O (0.5 mL) and dioxane (2 mL) was added Pd(dppf)Cl_2 (13 mg, 0.018 mmol), the mixture was purged with N_2 for one time, then the mixture was stirred at 110 °C under microwave for 1 hour under N_2 atmosphere. Crude LCMS showed desired MS value. The mixture was poured into water (30 mL), extracted with DCM (30 mL x 3), the combined extracts was washed with brine (50 mL), dried over anhydrous Na_2SO_4 , filtered, the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by Combi flash to give 150 mg of compound **D29** as a yellow gum.

Procedure for synthesis of **D30**


To a solution of compound **D29** (120 mg, 0.215 mmol) in MeOH (10 mL) was added Pd/C (20 mg), the mixture was purged with H_2 for three times and stirred at 20°C under H_2 balloon (15 psi) for 3 hours. Crude LCMS showed the reaction was completed. The mixture was filtered, the filtrate was concentrated under reduced pressure to give 100 mg of compound **D30** as a yellow gum.

Procedure for synthesis of compound **30**

To a solution of compound **D30** (100 mg, 0.179 mmol) in DCM (3 mL) was added TFA (2

mL), the mixture was stirred at 20°C for 1 hour. Crude LCMS showed the reaction was completed. The mixture was concentrated under reduced pressure to give a residue, the pH value of the residue was adjusted to 8 with saturated aqueous NaHCO₃, extracted with DCM (30 mL x 3), dried over anhydrous Na₂SO₄, filtered, the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (0.05% HCl). Most of CH₃CN was removed by evaporation under reduced pressure, and the remaining solvent was removed by lyophilization to give 10.5 mg of compound **30** as a white powder. .

Scheme 53: General Synthetic route for compound 163



Procedure for synthesis of **D33**

To a solution of compound **D31** (1.00 g, 2.43 mmol) in anhydrous THF (10 mL) was added compound **D32** (1.28 g, 6.08 mmol) at 0°C, the mixture was stirred at 0°C for 2 hours. Crude LCMS showed the reaction was completed. The reaction was quenched with brine (100 mL), the mixture was extracted with EtOAc (100 mL x 2), the combined extracts were washed with brine (100 mL), dried over anhydrous Na₂SO₄, filtered, the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by combi flash to give 600 mg of compound **D33** as a yellow gum.

Procedure for synthesis of **D34**


To a solution of compound **D33** (550 mg, 1.25 mmol) in DCM (3 mL) was added BBr_3 (627 mg, 2.50 mmol) at 0°C , then the mixture was allowed to warm to 20°C and stirred at 20°C for 3 hours. Crude LCMS showed the reaction worked well. the reaction was quenched with saturated aqueous NH_4Cl (30 mL), the pH value of the mixture was adjusted to 8 with saturated aqueous NaHCO_3 , extracted with EtOAc (50 mL x 3), the combined extracts was washed with brine (100 mL), dried over anhydrous Na_2SO_4 , filtered, the filtrate was concentrated under reduced pressure to give 600 mg of the crude product, confirmed by HNMR. 100 mg was used to next step, but no reaction. Then the crude product was purified by Combi flash to give 360 mg of compound **D34** as a yellow gum.

Procedure for synthesis of **D36**

To a mixture of compound **D34** (310 mg, 0.729 mmol), compound **D35** (409 mg, 2.19 mmol) and PPh_3 (382 mg, 1.46 mmol) in anhydrous THF (2 mL) was added DEAD (254 mg, 1.46 mmol) at 0°C , then the mixture was allowed to warm to 20°C and stirred at 20°C for 17 hours. Crude LCMS showed the reaction worked well. The reaction was quenched with water (30 mL), extracted with EtOAc (30 mL x 3), the combined extracts was washed with brine (50 mL), dried over anhydrous Na_2SO_4 , filtered, the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by Combi flash to give 150 mg of compound **D36** as a yellow gum.

Procedure for synthesis of compound **163**

To a solution of compound **D36** (150 mg, 0.252 mmol) in DCM (3 mL) was added TFA (3 mL), the mixture was stirred at 20°C for 0.5 hour. Crude LCMS showed the reaction was completed. The mixture was concentrated under reduced pressure to give a residue. then the pH value of the mixture was adjusted to pH = 8 with saturated aqueous NaHCO_3 , then diluted with water (15 mL), extracted with DCM (30 mL x 3), the combined extracts was washed with brine (50 mL), dried over anhydrous Na_2SO_4 , filtered, the filtrate was concentrated under reduced pressure to give a residue. The residue was purified by prep-HPLC (0.05% HCl). Most of CH_3CN was removed by evaporation under reduced pressure, and the remaining solvent was removed by lyophilization to give 27.8 mg of compound **163** as a yellow gum.

Scheme 54: Synthetic route for compound 23**Procedure for synthesis of D37**

To a solution of compound **D31** (1.00 g, 2.43 mmol) in dioxane (10 mL) was added NaOH (800 mg, 20.0 mmol) and H_2O (10 mL), the mixture was stirred at 50°C for 16 hours to give a yellow solution. TLC showed the reaction was complete. The reaction solution was concentrated under reduced pressure to remove dioxane, then to the reaction mixture was added 6M HCl dropwise until the $\text{pH} = 5$. The mixture was extracted with DCM (20 mL x 2), dried over anhydrous Na_2SO_4 , filtered, concentrated under reduced pressure to give compound **D37** (952 mg) as a yellow solid.

Procedure for synthesis of D38

To a solution of compound **D37** (952 mg, 2.72 mmol) in POCl_3 (10 mL) was added N,N -diethylaniline (1.2 g, 8.16 mmol), the reaction mixture was stirred at 90°C for 2 hours to give a brown solution. LCMS showed the reaction was complete. The mixture was concentrated under reduced pressure to remove POCl_3 , then the residue was partitioned between DCM (20 mL) and saturated NaHCO_3 (20 mL), the aqueous phase was extracted with DCM (20 mL x 2), the combined organic phase was washed with brine (40 mL), dried over anhydrous Na_2SO_4 , filtered, concentrated under reduced pressure to give a brown oil. The crude product was purified by Combi Flash to give compound **D38** (828 mg) as a yellow oil.

Procedure for synthesis of D40


To a solution of compound **D38** (200 mg, 0.544 mmol) and compound **D39** (202 mg, 0.652 mmol) in dioxane (4 mL) was added K_2CO_3 (188 mg, 1.36 mmol) in H_2O (1 mL) and $Pd(dppf)Cl_2$ (20 mg, 0.272 mmol), the mixture was stirred under N_2 balloon at 90 °C for 16 hours to give a black solution. LCMS showed 43.8% the desired MS value. To the solution was added H_2O (10 mL), extracted with EtOAc (10 mL x 2), the combined organic phase was washed with brine (10 mL), dried over anhydrous Na_2SO_4 , filtered, concentrated under reduced pressure to give a brown oil, which was purified by Combi Flash to give compound **D40** (119 mg) as a yellow oil.

Procedure for synthesis of D41

To a suspension of compound **D40** (181 mg, 0.352 mmol) in MeOH (5 mL) was added Pd/C (50% wet, 10% Pd), the mixture was stirred under H_2 balloon (15 psi) at 25 °C for 16 hours to give a black suspension. LCMS showed the reaction was complete. The suspension was filtered through a pad of Celite, the combined filtrates were concentrated under reduced pressure to give compound **D41** (121 mg) as a yellow oil.

Procedure for synthesis of compound 23

To the solution of compound **D41** (121 mg, 0.234 mmol) in DCM (4 mL) was added TFA (1 mL), the reaction solution was stirred at 25°C for 2 hours to give a yellow solution. LCMS showed the reaction was complete. To the reaction solution was added aqueous saturated $NaHCO_3$ solution (10 mL), extracted with DCM (10 mL x 2), the combined organic phase was concentrated under reduced pressure to give a brown oil. The crude product was purified by prep-HPLC (0.05% HCl). To the eluent containing the desired product was added saturated $NaHCO_3$ until the pH = 7, extracted with DCM (20 mL x 3), the combined organic phase was concentrated under reduced pressure. The residual aqueous solution was lyophilized to give compound **23** (3.9 mg) as a white powder.


Scheme 55: Synthetic route for compound 165**Procedure for synthesis of D43**

To a solution of compound **D38** (120 mg, 0.326 mmol), compound **D42** (235 mg, crude, about 0.489 mmol), $\text{Pd(PPh}_3)_4$ (65 mg, 0.056 mmol) in dioxane (3 mL) and H_2O (750 μL) was added Na_2CO_3 (86 mg, 0.82 mmol). The reaction mixture was stirred at 110 °C for 1 hour under N_2 under microwave condition. TLC (PE/EtOAc = 5/1, SiO_2) showed the reaction was completed. The reaction mixture was diluted with DCM (10 mL) and water (10 mL), and then filtered. The filtrate was separated. The organic layer was dried over anhydrous Na_2SO_4 , filtered, concentrated under reduced pressure to give the crude product as a brown gum, which was purified by Combi flash to give compound **D43** (126 mg) as a colorless oil.. The impure product was used directly in the next step without further purification.

Procedure for synthesis of compound 165

To a solution of compound **D43** (133 mg, crude) in DCM (1.6 mL) was added TFA (400 μL). The reaction solution was stirred at 25 °C for 1 hour. LCMS showed the reaction was completed. The reaction solution was diluted with DCM (10 mL) and water (5 mL). To the mixture was added ammonia water (0.5 mL, 28%) until aqueous layer pH > 7. The organic layer was separated and washed with water (10 mL), then concentrated under reduced pressure to give the crude product as a brown oil, which was purified by prep-HPLC (0.05% HCl as additive). Most of MeCN was removed under reduced pressure; the remaining solvent was removed by lyophilization to give compound **165** (35.9 mg) as an off-white powder.

Scheme 56: Synthetic route for compound 171



Procedure for synthesis of D45

To compound **D38** (200 mg, 0.54 mmol) and K_2CO_3 (187 mg, 1.36 mmol) in dioxane (1 mL) and H_2O (0.5 mL) was added compound **D44** (176 mg, 0.979 mmol) and Pd(dppf)Cl_2 (39.7 mg, 0.54 mmol). The reaction mixture was stirred at 110 °C for 16 hours under N_2 atmosphere. LCMS showed 82.4% of desired MS value. The mixture was partitioned between EtOAc (100 mL) and H_2O (100 mL). The aqueous was extracted with EtOAc (100 mL). The combined organic extract was washed with water (50 mL x 2), dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure to give compound **D45** as a red powder.

Procedure for synthesis of D46

To a solution of compound **D45** (100 mg, 0.221 mmol) and compound **D5** (53 mg, 0.26 mmol) in anhydrous DMF (1 mL) was added HATU (104 mg, 0.276 mmol) and TEA (37 mg, 0.36 mmol) under N_2 atmosphere. The mixture was stirred at 25°C under N_2 atmosphere for 16 hours. LCMS showed 74.3% desired MS value. The mixture was partitioned between EtOAc (50 mL) and H_2O (50 mL). The aqueous was extracted with EtOAc (50 mL). The combined organic extract was washed with water (50 mL x 2), dried over anhydrous Na_2SO_4 , filtered and concentrated under reduced pressure to give a residue. The residue was purified by Combi flash to give compound **D46** (95.0 mg) as a yellow oil.

Procedure for synthesis of compound 171

To a mixture of compound **D46** (95 mg, 0.15 mmol) in CH_2Cl_2 (4 mL) was added TFA (1 mL) in one portion. The mixture was stirred at 25 °C for 1 hour to give a yellow solution. LCMS showed the reaction was complete and 98.7% desired MS value. To the reaction solution was added aqueous saturated NaHCO_3 solution to adjust pH = 7 ~ 8, extracted with DCM (10 mL x 2), the combined organic phase was concentrated under reduced pressure to give a yellow oil, which was purified by prep-HPLC (0.05% HCl). Most of MeCN was removed under reduced pressure. The remaining solvent was removed by lyophilization to compound **171** (41.8 mg) as a yellow powder.

References

- D. B. Bregman, R.G. Pestell and V. J. Kidd. Cell cycle regulation and RNA polymerase II. *Front Biosci.* **2000** Feb; 1(5): D244-57.
- D. Desai, H. C. Wessling, R. P. Fisher, and D. O. Morgan. Effects of phosphorylation by CAK on cyclin binding by CDC2 and CDK2. *Mol. Cell Biol.* **1995** Jan; 15(1): 345–350.
- S. Akhtar, M. Heidemann, J. R. Tietjen, D. W. Zhang, R. D. Chapman, D. Eick, and A. Z. Ansari. TFIIH Kinase Places Bivalent Marks on the Carboxy-Terminal Domain of RNA Polymerase II. *Mol. Cell.* **2009** May; 15;34(3):387-93.
- S. Larochelle, R. Amat, K. G. Cutter, M. Sansó, C. Zhang, J. J. Allen, K. M. Shokat, D. L. Bentley and R. P. Fisher. Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II. *Nat. Struct. Mol. Biol.* **2012** Nov; 19(11):1108-15.
- G. I. Shapiro. Cyclin-Dependent Kinase Pathways as Targets for Cancer Treatment. *J. Clin. Oncol.* **2006** Apr; 10;24(11):1770-83.
- G. Lolli and L. N. Johnson. CAK-Cyclin-dependent Activating Kinase: a key kinase in cell cycle control and a target for drugs? *Cell Cycle.* **2005** Apr; 4(4):572-7.
- T. I. Lee and R. A. Young. Transcriptional Regulation and its misregulation in Disease. *Cell.* **2013** Mar; 14;152(6):1237-51.
- S. Nekhai, M. Zhou, A. Fernandez, W. S. Lane, Ned J.C. Lamb, J. Brady, A. Kumar. *Biochem. J.* **2002** Jun; 15;364(Pt 3):649-57.
- Y. K. Kim, C. F. Bourgeois, R. Pearson, M. Tyagi, M. J. West, J. Wong, S. Y. Wu, C. M. Chiang, and J. Karn. Recruitment of TFIIH to the HIV LTR is a rate-limiting step in the emergence of HIV from latency. *EMBO. J.* **2006** Aug; 9; 25(15): 3596–3604.

A. J. Kapasi and D. H. Spector. Inhibition of the Cyclin-Dependent Kinases at the Beginning of Human Cytomegalovirus Infection Specifically Alters the Levels and Localization of the RNA Polymerase II Carboxyl-Terminal Domain Kinases cdk9 and cdk7 at the Viral Transcriptosome. *J. Virol.* **2008** Jan; 82(1): 394–407.

Eickhoff et al, Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors. PCT WO2013/128028A1.

Table 1. Enzymatic activity of CDKs (1, 2, 5 and 7) and selectivity of CDK7

#cpds	CDK1	CDK2	CDK5	CDK7	CDK1 /CDK7*	CDK2 /CDK7**	CDK5 /CDK7***
1	C	C	B	A	B	B	C
2	C	B	B	B	A	B	B
3	C	C	B	A	A	B	B
4	C	B	B	A	B	B	B
8	C	C	C	B	B	B	C
9	B	B	A	A	B	B	C
10	B	B	A	A	B	B	C
11	C	B	B	A	A	B	B
12	B	B	A	A	B	B	C
13	C	C	B	A	A	B	B
14	B	B	B	A	A	B	B
15	C	C	C	A	A	A	B
16	B	B	A	A	B	B	C
17	C	B	B	A	B	B	C
18	B	B	A	A	B	B	C
19	C	B	B	A	A	B	B
20	C	C	C	A	A	A	A
21	C	C	C	A	A	A	A
24	B	B	A	A	B	B	B
25	B	A	A	A	B	C	C
27	B	B	A	A	A	B	B
28	C	B	B	A	B	B	C
31	B	A	A	A	B	B	C
33	B	B	A	A	B	B	C
34	C	B	B	A	B	C	C
36	B	B	A	A	B	C	C
38	C	C	B	A	A	A	B
39	C	C	C	A	A	A	A
40	C	B	B	A	A	B	C
42	C	B	B	A	A	A	B

Activity range: A indicates $IC_{50} \leq 100$ nM, B indicates $100 < IC_{50} \leq 1,000$ nM, C indicates $IC_{50} > 1,000$ nM

* CDK1/CDK7: Selectivity of CDK7 inhibition over CDK1 inhibition [fold]

** CDK2/CDK7: Selectivity of CDK7 inhibition over CDK2 inhibition [fold]

*** CDK5/CDK7: Selectivity of CDK7 inhibition over CDK5 inhibition [fold]

Selectivity range: A indicates [fold] > 200 , B indicates $20 < [fold] \leq 200$, C indicates [fold] ≤ 20

Table 1 Continued

#cpds	CDK1	CDK2	CDK5	CDK7	CDK1 /CDK7*	CDK2 /CDK7**	CDK5 /CDK7***
43	C	C	C	A	A	A	A
44	B	B	A	A	B	B	B
46	C	C	C	A	A	A	A
47	B	B	A	A	B	B	C
48	C	C	B	A	A	A	B
51	C	C	C	A	B	B	B
52	C	B	B	A	C	C	C
54	C	B	B	A	B	B	C
55	B	B	B	A	B	B	C
56	C	C	B	A	B	B	C
57	C	C	B	A	A	A	B
61	C	B	B	A	B	B	C
62	B	B	A	A	B	B	C
63	B	B	B	A	B	B	B
64	C	C	B	A	A	A	B
65	C	C	B	A	B	B	C
66	C	C	B	A	A	A	A
67	C	B	B	A	B	C	C
69	B	A	A	A	B	B	C
70	C	B	B	A	A	B	B
71	C	C	B	A	B	B	B
72	B	B	B	A	A	B	B
73	C	C	B	A	A	A	B
74	C	C	B	A	B	B	B
75	C	C	B	A	A	B	B
76	C	C	B	A	A	B	B
77	B	B	B	A	A	B	B
78	B	B	A	A	A	B	B
79	C	C	C	A	A	A	A
80	B	B	A	A	A	B	B

Activity range: A indicates $IC_{50} \leq 100$ nM, B indicates $100 < IC_{50} \leq 1,000$ nM, C indicates $IC_{50} > 1,000$ nM

* CDK1/CDK7: Selectivity of CDK7 inhibition over CDK1 inhibition [fold]

** CDK2/CDK7: Selectivity of CDK7 inhibition over CDK2 inhibition [fold]

*** CDK5/CDK7: Selectivity of CDK7 inhibition over CDK5 inhibition [fold]

Selectivity range: A indicates [fold] > 200 , B indicates $20 < [fold] \leq 200$, C indicates [fold] ≤ 20

Table 1 Continued

#cpds	CDK1	CDK2	CDK5	CDK7	CDK1 /CDK7*	CDK2 /CDK7**	CDK5 /CDK7***
117	C	C	C	B	A	A	B
118	C	B	B	A	B	B	B
119	C	B	B	A	A	B	B
120	C	B	B	A	A	A	B
121	C	B	B	A	A	B	B
122	C	B	B	A	A	B	B
123	B	B	A	A	B	B	C
124	B	B	A	A	B	B	C
125	C	C	C	A	A	B	B
126	C	B	B	A	A	B	B
127	C	B	B	A	A	B	B
128	B	B	A	A	B	B	C
129	C	B	B	A	A	A	B
130	C	B	B	A	A	B	B
131	C	C	C	A	B	B	B
132	C	C	B	A	A	B	B
133	C	B	B	A	A	B	B
134	C	B	B	A	A	B	B
135	C	C	C	A	A	B	B
136	C	C	B	A	A	A	B
137	B	A	A	A	C	C	C
138	B	B	A	A	A	B	C
139	C	B	B	A	A	B	B
140	B	B	A	A	B	B	C
141	B	B	A	A	B	B	C
142	C	B	B	A	A	B	B
143	B	B	A	A	B	B	C
144	B	B	A	A	B	B	C
145	B	B	A	A	B	B	C
146	B	B	B	A	A	A	B

Activity range: A indicates $IC_{50} \leq 100$ nM, B indicates $100 < IC_{50} \leq 1,000$ nM, C indicates $IC_{50} > 1,000$ nM

* CDK1/CDK7: Selectivity of CDK7 inhibition over CDK1 inhibition [fold]

** CDK2/CDK7: Selectivity of CDK7 inhibition over CDK2 inhibition [fold]

*** CDK5/CDK7: Selectivity of CDK7 inhibition over CDK5 inhibition [fold]

Selectivity range: A indicates [fold] > 200 , B indicates $20 < [fold] \leq 200$, C indicates [fold] ≤ 20

Table 1 Continued

#cpds	CDK1	CDK2	CDK5	CDK7	CDK1 /CDK7*	CDK2 /CDK7**	CDK5 /CDK7***
147	C	C	B	A	A	B	B
148	C	B	A	A	A	A	B
149	B	A	A	A	B	B	C
150	C	C	B	A	A	A	B
151	B	B	B	A	A	B	B
152	C	B	A	A	A	B	B
153	C	C	B	A	A	A	B
154	C	B	A	A	A	A	B
155	B	B	A	A	A	B	B
156	C	B	B	A	A	B	B
157	C	B	B	A	A	A	B
158	B	B	A	A	B	B	B
159	C	B	B	A	A	B	B
160	C	B	B	A	A	B	B
161	B	B	B	A	A	B	B
163	C	B	B	A	A	B	B
164	C	C	C	A	B	B	B
165	C	C	B	A	A	B	B
167	C	C	B	A	A	B	B
168	C	B	B	A	A	B	B
169	C	C	C	A	A	B	B
170	C	C	B	A	A	B	B
171	C	C	C	A	A	A	A
172	C	B	B	A	A	B	B
173	C	C	B	A	A	B	B
174	C	C	B	A	A	A	B
175	C	C	C	A	A	B	B
176	B	B	B	A	B	B	B
177	B	B	A	A	A	B	C
178	C	B	A	A	A	B	C

Activity range: A indicates $IC_{50} \leq 100$ nM, B indicates $100 < IC_{50} \leq 1,000$ nM, C indicates $IC_{50} > 1,000$ nM

* CDK1/CDK7: Selectivity of CDK7 inhibition over CDK1 inhibition [fold]

** CDK2/CDK7: Selectivity of CDK7 inhibition over CDK2 inhibition [fold]

*** CDK5/CDK7: Selectivity of CDK7 inhibition over CDK5 inhibition [fold]

Selectivity range: A indicates [fold] > 200 , B indicates $20 < [fold] \leq 200$, C indicates [fold] ≤ 20

Table 1 Continued

#cpds	CDK1	CDK2	CDK5	CDK7	CDK1 /CDK7*	CDK2 /CDK7**	CDK5 /CDK7***
179	B	B	B	A	B	B	B
180	B	B	A	A	B	B	C
181	B	B	B	A	B	B	B
182	C	C	C	A	A	A	A
183	C	C	C	A	A	A	A
184	C	C	B	A	A	A	B
185	C	C	C	A	A	A	B
186	C	C	C	A	A	A	B
187	C	C	C	A	A	A	A
188	C	C	C	B	B	C	C
189	C	C	B	A	A	A	B
190	C	C	C	A	A	A	B
191	B	B	B	A	B	B	B
192	C	C	C	A	A	A	A
193	C	C	B	A	A	A	B
194	C	C	C	A	A	A	A
195	C	C	B	A	A	A	A
196	C	C	B	A	A	A	A
197	C	C	B	A	A	A	B
198	C	C	B	A	A	A	A
199	C	C	C	A	A	A	A
200	C	C	C	A	A	A	A
201	C	C	B	A	A	A	B
202	C	C	C	A	A	A	A
203	C	C	C	A	A	A	A
204	C	C	C	A	A	A	A
205	C	C	B	A	A	A	B
206	C	C	B	A	A	A	B
207	C	C	B	A	A	A	B
208	B	A	B	A	B	C	B
Activity range: A indicates $IC_{50} \leq 100$ nM, B indicates $100 < IC_{50} \leq 1,000$ nM, C indicates $IC_{50} > 1,000$ nM							
* CDK1/CDK7: Selectivity of CDK7 inhibition over CDK1 inhibition [fold]							
** CDK2/CDK7: Selectivity of CDK7 inhibition over CDK2 inhibition [fold]							
*** CDK5/CDK7: Selectivity of CDK7 inhibition over CDK5 inhibition [fold]							
Selectivity range: A indicates [fold] > 200 , B indicates $20 < [fold] \leq 200$, C indicates [fold] ≤ 20							

Table 1 Continued

#cpds	CDK1	CDK2	CDK5	CDK7	CDK1 /CDK7*	CDK2 /CDK7**	CDK5 /CDK7***
209	C	C	C	A	A	A	A
210	C	C	B	A	A	A	A
211	C	C	C	A	A	A	A
212	C	C	C	A	A	B	B
213	C	C	C	A	A	A	A
214	C	C	C	A	A	A	A
215	C	C	C	A	A	A	A
216	C	C	C	A	A	A	A
217	C	C	C	A	A	A	A
218	C	C	C	A	A	A	A
219	C	C	C	A	A	A	A
220	C	C	C	A	A	A	A
221	C	C	C	A	A	A	A
222	C	B	B	A	A	A	A
223	C	C	C	A	A	B	B
224	C	C	C	A	A	A	A
225	C	B	B	A	A	A	A
226	C	C	C	A	A	A	A
227	C	C	C	A	A	A	A
228	C	C	B	A	A	A	A
229	C	B	B	A	B	C	C
230	C	C	C	A	A	A	A
231	C	C	C	A	A	A	A
232	C	C	C	A	A	A	A
233	C	B	C	A	A	B	A
234	C	C	C	A	A	A	A
235	C	C	B	A	A	B	B
236	B	B	B	A	A	B	B
237	C	C	C	A	A	A	A
238	C	C	C	A	A	A	A
Activity range: A indicates $IC_{50} \leq 100$ nM, B indicates $100 < IC_{50} \leq 1,000$ nM, C indicates $IC_{50} > 1,000$ nM * CDK1/CDK7: Selectivity of CDK7 inhibition over CDK1 inhibition [fold] ** CDK2/CDK7: Selectivity of CDK7 inhibition over CDK2 inhibition [fold] *** CDK5/CDK7: Selectivity of CDK7 inhibition over CDK5 inhibition [fold] Selectivity range: A indicates [fold] > 200 , B indicates $20 < [fold] \leq 200$, C indicates [fold] ≤ 20							

Table 1 Continued

#cpds	CDK1	CDK2	CDK5	CDK7	CDK1 /CDK7*	CDK2 /CDK7**	CDK5 /CDK7***
239	C	C	C	A	A	A	A
240	C	C	C	A	A	A	A
241	C	C	C	A	A	A	B
242	C	B	B	A	A	B	B
243	C	C	C	A	A	A	A
244	C	C	C	A	A	A	A
245	C	C	C	A	A	A	A
246	C	C	C	A	A	A	A
247	C	C	C	A	A	A	A
248	C	C	C	A	A	A	A
249	C	C	C	A	A	A	A
250	C	C	C	A	A	A	B
251	C	C	C	A	A	A	A
252	C	C	C	A	A	A	A
253	C	C	C	B	B	B	B
254	C	C	B	A	A	B	B
255	C	C	B	A	A	A	B
256	C	C	C	A	A	A	A
257	C	B	B	A	A	B	B
258	C	C	C	A	A	A	A
259	C	C	C	A	A	A	A
260	C	C	C	B	B	B	B
261	C	C	C	A	A	A	A
262	C	C	C	B	B	B	B
263	C	C	C	B	B	B	B
264	C	C	C	B	B	B	B
265	C	C	C	A	A	A	A
266	C	C	C	A	A	A	A
267	C	C	C	B	B	B	B
268	C	C	C	A	A	A	A
Activity range: A indicates $IC_{50} \leq 100$ nM, B indicates $100 < IC_{50} \leq 1,000$ nM, C indicates $IC_{50} > 1,000$ nM							
* CDK1/CDK7: Selectivity of CDK7 inhibition over CDK1 inhibition [fold]							
** CDK2/CDK7: Selectivity of CDK7 inhibition over CDK2 inhibition [fold]							
*** CDK5/CDK7: Selectivity of CDK7 inhibition over CDK5 inhibition [fold]							
Selectivity range: A indicates [fold] > 200 , B indicates $20 < [fold] \leq 200$, C indicates [fold] ≤ 20							

Table 1 Continued

Table 3. H460 viability assay

#cpds	IC50	#cpds	IC50	#cpds	IC50	#cpds	IC50
1	A	46	B	97	A	139	A
2	A	47	A	98	A	140	B
3	B	48	A	99	A	141	B
4	B	49	B	100	A	142	B
5	B	50	A	101	B	143	B
6	A	51	B	102	A	144	A
7	C	52	B	103	A	145	A
8	C	53	A	104	A	146	A
9	A	54	A	105	B	147	A
10	A	55	B	106	A	148	A
11	A	56	A	107	A	149	A
12	A	57	B	108	A	150	A
13	A	59	B	109	A	151	A
14	A	60	A	110	A	152	A
16	A	61	A	112	A	153	A
17	B	62	A	113	A	154	A
18	A	63	A	116	A	155	A
20	A	64	A	118	A	156	A
21	A	65	B	119	A	157	A
22	A	66	A	120	A	160	A
23	A	67	B	121	A	161	A
24	A	68	A	122	A	163	A
25	A	69	A	123	A	165	A
27	A	70	B	124	A	167	A
29	B	71	B	126	A	170	A
31	A	72	A	127	A	171	A
33	A	73	A	128	A	172	B
34	B	74	B	129	A	173	B
38	A	75	B	130	A	174	A
39	B	76	A	132	B	175	B
40	A	77	A	133	A	176	A
41	A	78	A	134	B	177	A
42	A	79	B	135	B	178	A
43	A	80	A	136	B	179	A
44	A	90	B	137	A	180	A
45	A	96	A	138	A	181	A

Activity range: A indicates $IC_{50} \leq 1 \mu M$, B indicates $1 < IC_{50} \leq 10 \mu M$, C indicates $IC_{50} > 10 \mu M$

Table 4. MM.1S viability assay

#cpds	IC50	#cpds	IC50	#cpds	IC50	#cpds	IC50
13	A	79	B	163	A	186	B
14	A	90	C	171	A	187	B
20	B	102	A	174	A	188	B
21	A	104	A	175	B	189	A
38	A	105	A	176	A	192	B
39	B	108	A	177	A	193	A
42	A	134	B	178	A	194	A
43	B	143	A	180	A	195	A
46	B	150	A	181	A	196	B
48	A	153	A	182	A	197	A
66	A	154	A	183	A	198	A
72	A	160	A	184	A		
73	A	161	A	185	B		

Activity range: A indicates $IC_{50} \leq 1$ μ M, B indicates $1 < IC_{50} \leq 10$ μ M, C indicates $IC_{50} > 10$ μ M

Table 5 Continued








#cpds	IC50	#cpds	IC50	#cpds	IC50	#cpds	IC50
245	B	253	B	262	C	270	B
246	A	254	A	263	C	271	A
247	B	255	A	264	C	272	B
248	B	256	A	265	B	273	B
249	A	257	A	266	B	274	A
250	B	258	A	267	C	275	B
251	A	260	B	268	C	276	A
252	A	261	B	269	B		








Activity range: A indicates $IC_{50} \leq 1 \text{ uM}$, B indicates $1 < IC_{50} \leq 10 \text{ uM}$, C indicates $IC_{50} > 10 \text{ uM}$








Table 10. Comparative data of CDK7 selectivity profile in CDKs family








CDKs family	WO2013128028	compound 210 (uM)
	VIII-59 (uM)	
CDK1/CycA2	1.276	>10
CDK1/CycB1	2.131	>10
CDK1/CycE1	1.124	>10
CDK2/CycA2	0.407	3.606
CDK2/CycD1	1.7	>10
CDK2/CycE1	0.172	3.481
CDK3/CycC	3.976	>10
CDK3/CycE1	0.592	>10
CDK4/CycD1	7.746	>10
CDK4/CycD2	5.434	>10
CDK4/CycD3	>10	>10
CDK5/p25NCK	0.317	>10
CDK5/p35NCK	0.217	4.789
CDK6/CycD1	7.498	>10
CDK6/CycD2	>10	>10
CDK6/CycD3	>10	>10
CDK7/CycH/MAT1	0.003	0.015
CDK8/CycC	>10	>10
CDK9/CycK	2.573	>10
CDK9/CycT1	2.006	>10
CDK12 wt/CycK	2.812	>10
CDK12 R722C/CycK	N/A	>10
CDK13/CycK	7.415	>10
CDK16/CycY	0.054	3.96
CDK17/p35NCK	1.729	>10
CDK19/CycC	>10	>10
CDK20/CycH	8.786	>10
CDK20/CycT1	9.698	>10








Table 11. Summarized compounds 1-279 in terms of their structures and corresponding characteristics.








#cpds	Structure	Characterization Data
1		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.79 (1H, s), 7.68 (1H, d, $J = 2.0$ Hz), 7.64 (1H, s), 7.51-7.58 (1H, m), 7.32-7.43 (3H, m), 6.44-6.57 (2H, m), 5.38 (1H, s), 4.52 (2H, d, $J = 6.0$ Hz), 4.25-4.35 (2H, m), 3.03-3.14 (1H, m), 2.85-2.96 (3H, m), 1.85-1.95 (2H, m), 1.10-1.40 (8H, m); LCMS: 100%, MS (ESI): m/z 431.0 $[\text{M} + \text{H}]^+$
2		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.86 (1H, s), 7.73 (1H, d, $J = 2.0$ Hz), 7.55-7.65 (3H, m), 7.31-7.36 (3H, m), 6.50 (1H, s), 4.69 (2H, d, $J = 6.0$ Hz), 3.80-3.90 (4H, m), 2.94-3.05 (5H, m), 1.27 (6H, d, $J = 6.8$ Hz); LCMS: 98.0%, MS (ESI): m/z = 418.0 $[\text{M} + \text{H}]^+$
3		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.86 (1H, s), 7.73 (1H, d, $J = 2.0$ Hz), 7.60-7.65 (3H, m), 7.31-7.40 (3H, m), 6.50 (1H, s), 4.69 (2H, d, $J = 6.0$ Hz), 3.80-4.00 (4H, m), 2.97-3.04 (1H, m), 2.45-2.55 (4H, m), 2.38 (3H, s), 1.26 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z = 432.1 $[\text{M} + \text{H}]^+$
4		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.86 (1H, s), 7.73 (1H, d, $J = 2.4$ Hz), 7.61-7.68 (3H, m), 7.31-7.40 (3H, m), 6.50 (1H, s), 4.69 (2H, d, $J = 6.4$ Hz), 4.45-4.55 (2H, m), 3.92-4.00 (1H, m), 3.25-3.35 (2H, m), 2.99-3.05 (1H, m), 1.95-2.00 (2H, m), 1.50-1.55 (2H, m), 1.27 (6H, d, $J = 7.2$ Hz); LCMS: 100%, MS (ESI): m/z = 433.0 $[\text{M} + \text{H}]^+$
5		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.65 (1H, d, $J = 3.6$ Hz), 7.83 (1H, s), 7.68-7.75 (2H, m), 7.50-7.67 (2H, m), 7.30-7.42 (1H, m), 6.53 (1H, s), 4.89 (2H, s), 4.60-4.70 (2H, m), 2.95-3.09 (1H, m), 2.76-2.94 (3H, m), 1.80-1.87 (2H, m), 1.27 (8H, d, $J = 6.8$ Hz); LCMS: 97.8%, MS (ESI): m/z 433.1 $[\text{M} + \text{H}]^+$
6		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.62 (1H, s), 8.55 (1H, d, $J = 4.4$ Hz), 7.92 (1H, s), 7.80 (1H, d, $J = 2.0$ Hz), 7.62 (1H, s), 7.56 (1H, d, $J = 4.8$ Hz), 7.42 (1H, brs), 6.56 (1H, s), 4.78 (2H, d, $J = 6.0$ Hz), 4.65-4.75 (2H, m), 2.89-3.05 (4H, m), 1.85-1.95 (2H, m), 1.20-1.30 (8H, m); LCMS: 99.0%, MS (ESI): m/z 433.1 $[\text{M} + \text{H}]^+$
7		yellow powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.53 (1H, brs), 7.85-7.90 (2H, m), 7.74 (1H, s), 7.73 (1H, d, $J = 7.2$ Hz), 7.25-7.45 (3H, m), 6.53 (1H, s), 4.77 (2H, d, $J = 6.8$ Hz), 3.80-3.85 (2H, m), 3.45-3.55 (2H, m), 3.10-3.26 (1H, m), 2.55-2.60 (2H, m), 2.40-2.48 (2H, m), 2.36 (3H, s), 1.30 (6H, d, $J = 6.8$ Hz); LCMS: 94.7%, MS (ESI): m/z = 460.1 $[\text{M} + \text{H}]^+$








8		Racemic mixture; white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.07 (1H, brs), 7.92 (1H, s), 7.89 (1H, s), 7.75-7.80 (2H, m), 7.20-7.40 (3H, m), 6.53 (1H, s), 4.85 (2H, s), 4.50-4.60 (1H, m), 3.25-3.35 (2H, m), 3.15-3.20 (1H, s), 2.90-3.05 (2H, m), 2.25-2.30 (1H, m), 1.71-1.85 (1H, m), 1.32 (6H, d, $J = 6.4$ Hz); LCMS: 99.4%, MS (ESI): m/z 446.1 $[\text{M} + \text{H}]^+$
9		off-white solid; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.99 (1H, d, $J = 2.4$ Hz), 8.17 (1H, d, $J = 8.4$ Hz), 7.77 (2H, d, $J = 7.6$ Hz), 7.58 (1H, s), 7.37-7.51 (3H, m), 5.33 (2H, d, $J = 6.0$ Hz), 4.70-4.80 (2H, m), 2.88-3.05 (4H, m), 1.85-1.95 (2H, m), 1.21-1.38 (8H, m); LCMS: 100%, MS (ESI): m/z 417.5 $[\text{M} + \text{H}]^+$
10		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.98 (1H, s), 7.71 (1H, d, $J = 8.0$ Hz), 7.58 (1H, s), 7.34 (1H, d, $J = 6.8$ Hz), 7.10 (1H, t, $J = 7.6$ Hz), 6.43 (1H, brs), 5.13 (2H, d, $J = 5.2$ Hz), 4.70-4.80 (2H, m), 4.28 (3H, s), 2.91-3.08 (4H, m), 1.85-1.95 (2H, m), 1.26-1.40 (8H, m); LCMS: 100%, MS (ESI): m/z 420.1 $[\text{M} + \text{H}]^+$
11		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.97 (1H, d, $J = 8.0$ Hz), 7.62 (1H, s), 7.25-7.37 (2H, m), 7.04 (1H, t, $J = 7.6$ Hz), 6.69 (1H, brs), 4.75 (2H, d, $J = 6.4$ Hz), 4.60-4.72 (3H, m), 3.09-3.19 (2H, m), 2.91-3.09 (4H, m), 1.90-1.95 (2H, m), 1.41-1.45 (2H, m), 1.31-1.35 (2H, m), 1.29 (6H, d, $J = 6.4$ Hz), 0.83 (3H, t, $J = 7.6$ Hz); LCMS: 95.6%, MS (ESI): m/z 488.1 $[\text{M} + \text{Na}]^+$
12		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.85 (1H, s), 7.73 (1H, d, $J = 2.0$ Hz), 7.63-7.65 (1H, m), 7.61 (1H, s), 7.56 (1H, brs), 7.29-7.40 (3H, m), 6.50 (1H, s), 4.76-4.80 (2H, m), 4.68 (2H, d, $J = 6.4$ Hz), 2.91-3.09 (4H, m), 2.00-2.10 (2H, m), 1.90-1.95 (2H, m), 1.70-1.75 (2H, m), 1.60-1.70 (4H, m), 1.30-1.44 (2H, m); LCMS: 100%, MS (ESI): m/z 458.1 $[\text{M} + \text{H}]^+$
13		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 8.24 (1H, d, $J = 2.0$ Hz), 8.10-8.23 (4H, m), 7.87 (1H, s), 7.68 (1H, s), 7.45-7.55 (1H, m), 7.35-7.40 (1H, m), 7.25-7.35 (1H, m), 6.55-6.65 (1H, m), 4.75 (2H, d, $J = 5.6$ Hz), 4.55-4.65 (2H, m), 3.20-3.35 (1H, m), 2.85-3.00 (2H, m), 1.90-2.05 (2H, m), 1.35-1.50 (2H, m), 1.31 (9H, s); LCMS: 100%, MS (ESI): m/z 464.1 $[\text{M} + \text{H}]^+$
14		White powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.26 (1H, s), 8.17 (1H, s), 7.84 (1H, d, $J = 9.2$ Hz), 7.67-7.01 (2H, m), 7.63 (1H, s), 7.48-7.50 (3H, m), 7.39 (1H, t, $J = 6.0$ Hz), 6.43-6.44 (1H, m), 4.66-4.69 (4H, m), 3.06 (3H, d, $J = 4.8$ Hz), 2.86-3.04 (4H, m), 1.87-1.90 (2H, m), 1.25-1.34 (8H, m); LCMS: 100%, MS (ESI): m/z 539.1 $[\text{M} + \text{H}]^+$








15		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.66 (1H, d, $J = 4.0$ Hz), 7.72 (1H, d, $J = 6.8$ Hz), 7.65 (1H, brs), 7.63 (1H, s), 7.24-7.28 (1H, m), 6.07 (1H, brs), 5.01 (2H, d, $J = 4.0$ Hz), 4.68-4.70 (2H, m), 3.00 (3H, d, $J = 4.8$ Hz), 2.85-2.95 (3H, m), 1.84-1.88 (2H, m), 1.37 (9H, s), 1.21-1.32 (2H, m); LCMS: 96.2%, MS (ESI): m/z 438.1[M + H] $^+$
16		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 7.70-7.75 (2H, m), 7.52 (1H, s), 7.14-7.20 (2H, m), 6.37 (1H, brs), 5.02 (2H, d, $J = 5.2$ Hz), 4.65-4.75 (2H, m), 3.95 (3H, s), 2.83-3.02 (4H, m), 1.80-1.85 (2H, m), 1.20-1.31 (8H, m); LCMS: 100%, MS (ESI): m/z 420.1[M + H] $^+$
17		White powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.59 (1H, s), 7.32-7.46 (3H, m), 7.20-7.26 (1H, m), 6.84-7.09 (3H, m), 6.30 (1H, brs), 4.45-4.75 (4H, m), 3.37-3.49 (1H, m), 3.25-3.35 (2H, m), 2.96-3.07 (1H, m), 2.80-2.90 (2H, m), 2.15-2.25 (2H, m), 1.20-1.35 (8H, m); LCMS: 100%, MS (ESI): m/z 519.2[M + Na] $^+$
18		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 8.00 (1H, s), 7.88 (1H, s), 7.74 (1H, s), 7.45-7.50 (1H, m), 7.30-7.45 (3H, m), 6.51 (1H, s), 4.55 (2H, s), 4.35-4.50 (2H, m), 3.15-3.30 (1H, m), 2.70-2.85 (2H, m), 1.80-1.95 (2H, m), 1.15-1.35 (2H, m); LCMS: 100%, MS (ESI): m/z 469.9 [M + H] $^+$
19		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.54-7.65 (2H, m), 7.51 (1H, d, $J = 7.6$ Hz), 7.33-7.42 (2H, m), 7.24-7.26 (1H, m), 6.05 (1H, brs), 4.81 (2H, d, $J = 5.2$ Hz), 4.70-4.80 (2H, m), 3.01 (3H, d, $J = 4.8$ Hz), 2.84-3.00 (4H, m), 1.85-1.92 (2H, m), 1.25-1.39 (2H, m), 1.25 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 445.1[M + Na] $^+$
20		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 8.64 (1H, d, $J = 4.4$ Hz), 8.10-8.35 (4H, m), 7.67 (1H, s), 7.40-7.50 (1H, m), 7.25-7.40 (2H, m), 4.80 (2H, d, $J = 5.2$ Hz), 4.55-4.75 (2H, m), 3.20-3.40 (1H, m), 2.85-3.05 (2H, m), 2.78 (3H, d, $J = 4.4$ Hz), 1.90-2.05 (2H, m), 1.40-1.55 (2H, m), 1.31 (6H, s); LCMS: 100%, MS (ESI): m/z 477.1 [M + Na] $^+$
21		(<i>S</i>)-methyl; off-white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.79 (1H, s), 7.66 (1H, d, $J = 2.0$ Hz), 7.62 (1H, s), 7.56 (1H, d, $J = 7.2$ Hz), 7.27-7.42 (3H, m), 7.11 (1H, d, $J = 7.6$ Hz), 6.46 (1H, s), 5.37-5.50 (1H, m), 4.46-4.63 (2H, m), 2.95-3.05 (1H, m), 2.86-2.95 (1H, m), 2.74-2.86 (2H, m), 1.82-1.86 (2H, m), 1.50 (3H, d, $J = 6.8$ Hz), 1.13-1.35 (8H, m); LCMS: 100%, MS (ESI): m/z 446.1[M + H] $^+$







22		white powder; $^1\text{H-NMR}$ (DMSO- d_6 , 400 MHz): δ 9.12 (1H, brs), 8.00-8.20 (3H, m), 7.83 (1H, s), 7.62 (1H, d, J = 8.0 Hz), 7.29-7.42 (2H, m), 7.21 (1H, t, J = 6.8 Hz), 4.70 (2H, d, J = 6.0 Hz), 4.50-4.60 (2H, m), 3.17-3.27 (1H, m), 2.95-3.05 (1H, m), 2.80-2.90 (2H, m), 1.85-1.95 (2H, m), 1.28-1.43 (2H, m), 1.23 (6H, d, J = 6.8 Hz); LCMS: 99.0%, MS (ESI): m/z 444.0[M + H] $^+$
23		white powder; $^1\text{H-NMR}$ (CDCl $_3$, 400 MHz): δ 7.93-8.25 (1H, m), 7.88 (1H, s), 7.67-7.84 (3H, m), 7.28-7.42 (3H, m), 6.51 (1H, s), 4.76 (2H, s), 3.25-3.30 (2H, m), 3.12-3.23 (1H, m), 2.80-3.00 (4H, m), 1.89-2.15 (4H, m), 1.29 (6H, d, J = 6.8 Hz); LCMS: 99.1%, MS (ESI): m/z 417.1 [M + H] $^+$
24		white powder; $^1\text{H-NMR}$ (CDCl $_3$, 400 MHz): δ 8.79 (1H, t, J = 5.6 Hz), 8.16 (1H, d, J = 2.0 Hz), 7.95 (3H, brs), 7.81 (1H, s), 7.72 (1H, s), 7.51-7.58 (1H, m), 7.35-7.48 (3H, m), 6.56 (1H, s), 4.62 (2H, d, J = 5.6 Hz), 4.45-4.50 (2H, m), 3.20-3.30 (1H, m), 2.84 (2H, t, J = 12.4 Hz), 1.85-1.95 (2H, m), 1.20-1.40 (11H, m); LCMS: 100%, MS (ESI): m/z 446.2 [M + H] $^+$
25		(1 <i>R</i> , 4 <i>R</i>); white powder; $^1\text{H-NMR}$ (CDCl $_3$, 400 MHz): δ 7.98 (1H, brs), 7.88 (1H, s), 7.79 (1H, s), 7.77 (1H, d, J = 2.0 Hz), 7.73 (1H, d, J = 6.4 Hz), 7.29-7.45 (3H, m), 6.52 (1H, s), 4.76 (2H, d, J = 6.0 Hz), 3.14-3.26 (1H, m), 2.76-2.86 (1H, m), 2.60-2.72 (1H, m), 1.95-2.16 (4H, m), 1.73-1.86 (2H, m), 1.12-1.43 (8H, m); LCMS: 98.1%, MS (ESI): m/z 431.1[M + H] $^+$
26		(1 <i>S</i> , 4 <i>S</i>); white powder; $^1\text{H-NMR}$ (CDCl $_3$, 400 MHz): δ 7.98 (1H, brs), 7.88 (1H, s), 7.79 (1H, s), 7.77 (1H, d, J = 2.0 Hz), 7.73 (1H, d, J = 6.8 Hz), 7.28-7.41 (3H, m), 6.51 (1H, s), 4.76 (2H, s), 3.12-3.16 (1H, m), 3.03-3.13 (1H, s), 2.75-2.89 (1H, m), 2.18-2.34 (2H, m), 1.73-1.85 (4H, m), 1.56-1.68 (2H, m), 1.30 (6H, d, J = 7.2 Hz); LCMS: 100%, MS (ESI): m/z 431.1[M + H] $^+$
27		white powder; $^1\text{H-NMR}$ (CDCl $_3$, 400 MHz): δ 8.67 (1H, brs), 8.14 (1H, d, J = 2.0 Hz), 7.81 (1H, s), 7.71 (1H, s), 7.51-7.58 (1H, m), 7.36-7.46 (3H, m), 6.56 (1H, s), 4.59 (2H, s), 3.70-3.80 (2H, m), 3.40-3.50 (2H, m), 2.85-2.95 (1H, m), 1.25-1.30 (4H, m), 1.21 (6H, d, J = 7.2 Hz), 1.03 (3H, s); LCMS: 100%, MS (ESI): m/z 446.1 [M + H] $^+$
28		white powder; $^1\text{H-NMR}$ (CDCl $_3$, 400 MHz): δ 8.12 (1H, s), 7.68 (1H, d, J = 7.6 Hz), 7.56 (1H, s), 7.39 (1H, d, J = 8.4 Hz), 7.18-7.25 (2H, m), 7.10-7.20 (1H, m), 6.41 (1H, s), 4.93 (2H, d, J = 5.2 Hz), 4.80-4.85 (2H, m), 2.88-3.08 (4H, m), 1.90-1.95 (2H, m), 1.33-1.42 (2H, m), 1.29 (6H, d, J = 6.8 Hz); LCMS: 96.9%, MS (ESI): m/z 405.1[M + H] $^+$







29		yellow gum; $^1\text{H-NMR}$ (DMSO- d_6 , 400 MHz): δ 9.05 (1H, brs), 8.17 (1H, s), 7.95-8.15 (4H, m), 7.80 (1H, s), 7.50-7.60 (1H, m), 7.35-7.50 (4H, m), 6.56 (1H, s), 4.63 (2H, d, J = 5.6 Hz), 4.35-4.60 (2H, m), 3.10-3.35 (1H, m), 2.80-2.95 (2H, m), 1.85-2.00 (2H, m), 1.25-1.45 (2H, m); LCMS: 99.2%, MS (ESI): m/z 424.0 $[\text{M} + \text{H}]^+$
30		white powder; $^1\text{H-NMR}$ (DMSO- d_6 , 400 MHz): δ 8.81 (1H, brs), 8.17 (1H, d, J = 2.4 Hz), 7.70-8.00 (5H, m), 7.50-7.60 (1H, m), 7.35-7.50 (3H, m), 6.57 (1H, s), 4.61 (2H, d, J = 5.6 Hz), 4.40-4.55 (2H, m), 3.20-3.30 (1H, m), 2.75-2.90 (2H, m), 2.40-2.50 (2H, m), 1.80-1.95 (2H, m), 1.50-1.60 (2H, m), 1.20-1.45 (6H, m), 0.80-0.90 (3H, m); LCMS: 100%, MS (ESI): m/z 460.1 $[\text{M} + \text{H}]^+$
31		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 9.60 (1H, s), 8.59 (1H, d, J = 6.0 Hz), 7.80 (1H, d, J = 7.6 Hz), 7.60-7.73 (3H, m), 7.58 (1H, s), 6.60 (1H, s), 5.31 (2H, d, J = 6.0 Hz), 4.70-4.80 (2H, m), 2.88-3.07 (4H, m), 1.84-1.95 (2H, m), 1.23-1.39 (8H, m); LCMS: 95.0%, MS (ESI): m/z 417.2 $[\text{M} + \text{H}]^+$
32		Racemic mixture; white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.86 (1H, s), 7.73 (1H, d, J = 1.6 Hz), 7.54-7.69 (3H, m), 7.28-7.42 (3H, m), 6.50 (1H, s), 4.95-5.05 (1H, m), 4.64-4.78 (2H, m), 4.54-4.62 (1H, m), 3.09-3.20 (2H, m), 2.94-3.09 (3H, m), 2.78-2.88 (1H, m), 1.32 (3H, d, J = 6.8 Hz), 1.27 (6H, d, J = 6.4 Hz); LCMS: 100%, MS (ESI): m/z 432.1 $[\text{M} + \text{H}]^+$
33		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.61 (1H, s), 7.29-7.43 (2H, m), 7.20-7.25 (1H, m), 6.96 (1H, brs), 5.08 (2H, d, J = 6.0 Hz), 4.73-4.78 (2H, m), 2.85-3.09 (4H, m), 2.67 (3H, s), 1.84-1.89 (2H, m), 1.26-1.29 (8H, m); LCMS: 98.8%, MS (ESI): m/z 421.0 $[\text{M} + \text{H}]^+$
34		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.23 (1H, brs), 7.83-7.92 (2H, m), 7.78 (1H, s), 7.60 (1H, d, J = 6.8 Hz), 7.30-7.46 (3H, m), 6.52 (1H, s), 4.85-4.95 (2H, m), 4.67 (2H, s), 3.04-3.23 (3H, m), 2.01-2.15 (2H, m), 1.43-1.60 (2H, m); LCMS: 100%, MS (ESI): m/z 415.2 $[\text{M} + \text{H}]^+$
35		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 9.15 (1H, t, J = 5.6 Hz), 8.22 (1H, s), 8.18 (1H, d, J = 1.6 Hz), 7.80-7.90 (3H, m), 7.80 (1H, s), 7.51-7.59 (1H, m), 7.37-7.49 (3H, m), 6.56 (1H, s), 4.63-4.65 (3H, m), 4.40-4.55 (1H, m), 3.25-3.35 (1H, m), 2.85-3.05 (2H, m), 2.47 (3H, s), 1.90-2.00 (2H, m), 1.25-1.50 (2H, m); LCMS: 100%, MS (ESI): m/z 432.1 $[\text{M} + \text{H}]^+$







36		white powder; $^1\text{H-NMR}$ (DMSO- d_6 , 400 MHz): δ 9.01 (1H, brs), 8.17 (1H, d, $J = 2.0$ Hz), 7.94 (1H, s), 7.70-7.90 (4H, m), 7.53 (1H, d, $J = 8.0$ Hz), 7.35-7.50 (2H, m), 6.56 (1H, s), 4.62 (2H, d, $J = 6.0$ Hz), 4.40-4.60 (2H, m), 3.60-3.70 (1H, m), 2.80-2.90 (2H, m), 1.80-1.95 (2H, m), 1.40-1.55 (2H, m); LCMS: 89%, MS (ESI): m/z 516.1 $[\text{M} + \text{H}]^+$
37		white powder; $^1\text{H-NMR}$ (DMSO- d_6 , 400 MHz): δ 9.02 (1H, t, $J = 6.0$ Hz), 8.17 (1H, d, $J = 2.0$ Hz), 7.90-8.10 (4H, m), 7.80 (1H, s), 7.50-7.60 (1H, m), 7.30-7.50 (3H, m), 6.56 (1H, s), 4.62 (2H, d, $J = 6.0$ Hz), 4.35-4.50 (2H, m), 3.15-3.35 (1H, m), 2.80-2.95 (2H, m), 1.80-1.95 (2H, m), 1.25-1.45 (2H, m); LCMS: 100%, MS (ESI): m/z 408.0 $[\text{M} + \text{H}]^+$
38		white powder; $^1\text{H-NMR}$ (DMSO- d_6 , 400 MHz): δ 8.21 (1H, d, $J = 2.4$ Hz), 8.10 (1H, brs), 7.75-7.85 (4H, m), 7.73 (1H, s), 7.62-7.64 (1H, m), 7.46-7.56 (2H, m), 6.57 (1H, s), 4.68-4.78 (2H, m), 4.60-4.70 (2H, m), 3.29-3.33 (1H, m), 2.88-2.97 (3H, m), 1.86-1.99 (2H, m), 1.32-1.47 (2H, m), 1.23 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 466.0 $[\text{M} + \text{H}]^+$
39		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.78 (1H, s), 7.68 (1H, s), 7.59 (1H, s), 7.30-7.39 (1H, m), 7.12-7.19 (1H, m), 6.93-7.01 (2H, m), 6.44 (1H, s), 4.77 (2H, d, $J = 6.0$ Hz), 4.63-4.69 (2H, m), 3.93 (3H, s), 2.96-3.06 (1H, m), 2.82-2.94 (3H, m), 1.82-1.93 (2H, m), 1.20-1.38 (8H, m); LCMS: 98.7%, MS (ESI): m/z 462.1 $[\text{M} + \text{H}]^+$
40		white powder; $^1\text{H-NMR}$ (400 MHz, DMSO- d_6): δ 10.17 (1H, brs), 9.21 (1H, brs), 8.85-9.00 (2H, m), 8.22 (1H, s), 8.05 (1H, s), 7.83 (1H, s), 7.53-7.55 (1 H, m), 7.37-7.48 (3H, m), 6.59 (1H, s), 4.70 (2H, d, $J = 6.0$ Hz), 3.90-4.00 (1H, m), 3.10-3.25 (2H, m), 2.87-3.05 (3H, m), 1.75-1.90 (2H, m), 1.60-1.75 (2 H, m), 1.23 (6 H, d, $J = 6.4$ Hz); LCMS: 100%, MS (ESI): m/z 432.1 $[\text{M} + \text{H}]^+$
41		white powder; $^1\text{H-NMR}$ (DMSO- d_6 , 400 MHz): δ 9.17 (1H, t, $J = 6.0$ Hz), 8.21 (1H, s), 8.17 (1H, d, $J = 2.0$ Hz), 7.95-8.15 (3H, m), 7.80 (1H, s), 7.53-7.60 (1H, m), 7.35-7.50 (3H, m), 6.56 (1H, s), 4.35-4.70 (4H, m), 3.20-3.45 (1H, m), 2.80-2.95 (2H, m), 1.80-2.00 (2H, m), 1.25-1.50 (2H, m); LCMS: 95.9%, MS (ESI): m/z 458.1 $[\text{M} + \text{H}]^+$
42		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.87 (1H, s), 7.73 (1H, s), 7.59 (1H, s), 7.44 (1H, s), 7.30-7.39 (1H, m), 7.07-7.18 (2H, m), 6.51 (1H, s), 4.71-4.88 (4H, m), 2.86-3.05 (4H, m), 1.84-1.93 (2H, m), 1.23-1.37 (8H, m); LCMS: 98.9%, MS (ESI): m/z 450.1 $[\text{M} + \text{H}]^+$







43		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.81 (1H, s), 7.55-7.74 (3H, m), 7.27-7.37 (1H, m), 7.21-7.25 (1H, m), 7.12-7.19 (1H, m), 6.47 (1H, s), 4.71-4.84 (2H, m), 4.60 (2H, d, $J = 5.6$ Hz), 2.89-3.11 (4H, m), 2.55 (3H, s), 1.88-1.96 (2H, m), 1.20-1.44 (8H, m); LCMS: 91.7%, MS (ESI): m/z 446.1[M + H] $^+$
44		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.59 (1H, s), 7.48-7.55 (1H, m), 7.40-7.46 (1H, m), 7.29-7.39 (3H, m), 7.03-7.13 (2H, m), 6.45 (1H, s), 4.80 (2H, d, $J = 6.0$ Hz), 4.64-4.75 (2H, m), 2.98-3.07 (1H, m), 2.85-2.97 (3H, m), 1.81-1.92 (2H, m), 1.21-1.39 (8H, m); LCMS: 100%, MS (ESI): m/z 448.0[M + H] $^+$
45		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400MHz): δ 8.96 (1H, brs), 7.84 (1H, s), 7.68-7.80 (3H, m), 7.62 (1H, d, $J = 7.2$ Hz), 7.40-7.46 (1H, m), 7.25-7.36 (2H, m), 6.81 (1H, d, $J = 3.2$ Hz), 6.67 (1H, s), 4.83 (2H, d, $J = 5.6$ Hz), 4.28-4.48 (2 1.70-1.88 (2H, m), 1.23 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 432.1[M + H] $^+$
46		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400MHz): δ 8.23-8.30 (1H, m), 8.20 (1H, d, $J = 2.0$ Hz), 7.93 (1H, d, $J = 7.6$ Hz), 7.63-7.90 (7H, m), 6.57 (1H, s), 4.53-4.79 (4H, m), 3.27-3.35 (1H, m), 2.86-2.99 (3H, m), 1.87-1.99 (2H, m), 1.34-1.47 (2H, m), 1.23 (6H, d, $J = 7.2$ Hz); LCMS: 100%, MS (ESI): m/z 500.0[M + H] $^+$
47		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400MHz): δ 9.07 (1H, t, $J = 6.0$ Hz), 8.46 (1H, d, $J = 2.4$ Hz), 7.96 (1H, s), 7.60-7.87 (6H, m), 7.39-7.46 (1H, m), 7.32 (1H, d, $J = 7.2$ Hz), 6.54 (1H, s), 4.60-4.69 (4H, m), 3.20-3.31 (1H, m), 2.83-2.97 (3H, m), 1.80-1.93 (2H, m), 1.18-1.41 (8H, m); LCMS: 98.8%, MS (ESI): m/z 432.0[M + H] $^+$
48		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400MHz): δ 9.32 (1H, t, $J = 6.0$ Hz), 8.56 (1H, d, $J = 8.4$ Hz), 8.35 (1H, d, $J = 8.4$ Hz), 8.09 (1H, d, $J = 8.4$ Hz), 7.77-7.95 (6H, m), 7.67-7.75 (2H, m), 7.63 (1H, d, $J = 6.4$ Hz), 7.43-7.54 (2H, m), 4.76 (2H, d, $J = 6.4$ Hz), 4.55-4.67 (2H, m), 3.28 (1H, s), 2.83-2.98 (3H, m), 1.85-1.98 (2H, m), 1.30-1.45 (2H, m), 1.23 (6H, d, $J = 6.8$ Hz); LCMS: 99%, MS (ESI): m/z 493.1[M + H] $^+$
49		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 9.46-9.72 (2H, m), 8.64-8.85 (2H, m), 7.88 (3H, brs), 7.78 (1H, s), 7.25 (1H, d, $J = 6.8$ Hz), 7.05-7.14 (1H, m), 6.63-6.71 (1H, m), 6.54 (1H, t, $J = 7.2$ Hz), 4.65-4.75 (2H, m), 4.48 (2H, d, $J = 5.6$ Hz), 3.45-3.55 (2H, m), 3.24-3.38 (2H, m), 3.02-3.13 (2H, m), 2.87-2.99 (3H, m), 2.79 (3H, d, $J = 4.0$ Hz), 2.05-2.15 (2H, m), 1.90-1.97 (2H, m), 1.57-1.71 (2H, m), 1.31-1.43 (2H, m), 1.22 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 478.1 [M + H] $^+$







50		white powder; $^1\text{H-NMR}$ (CD_3OD , 400 MHz): δ 7.91 (2H, d, J = 7.2 Hz), 7.87 (1H, s), 7.80 (1H, s), 7.48-7.60 (4H, m), 7.35 (1H, t, J = 8.0 Hz), 7.21 (1H, d, J = 7.6 Hz), 4.71-4.81 (4H, m), 3.36-3.42 (1H, m), 3.04-3.10 (3H, m), 2.00-2.11 (2H, m), 1.50-1.59 (2H, m), 1.28 (6H, d, J = 7.2 Hz); LCMS: 100%, MS (ESI): m/z 485.1 [$\text{M} + \text{H}$] $^+$
51		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.62 (1H, s), 7.27-7.37 (3H, m), 7.05-7.14 (2H, m), 6.95-7.03 (3H, m), 6.88-6.94 (1H, m), 6.60 (1H, t, J = 5.6 Hz), 4.77-4.91 (2H, m), 4.67 (2H, d, J = 5.6 Hz), 3.20-3.32 (1H, m), 2.98-3.09 (1H, m), 2.81-2.97 (2H, m), 1.97-2.12 (2H, m), 1.52-1.63 (2H, m), 1.28 (6H, d, J = 6.8 Hz); LCMS: 98.3%, MS (ESI): m/z 458.0 [$\text{M} + \text{H}$] $^+$
52		Racemic mixture; white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.86 (1H, s), 7.70-7.80 (2H, m), 7.57-7.67 (2H, m), 7.30-7.43 (3H, m), 6.51 (1H, s), 4.71-4.83 (3H, m), 4.69 (2H, d, J = 6.0 Hz), 2.91-3.07 (3H, m), 1.85-1.94 (4H, m), 1.28-1.40 (2H, m), 0.96 (3H, t, J = 7.4 Hz); LCMS: 94.1%, MS (ESI): m/z 470.0 [$\text{M} + \text{Na}$] $^+$
53		off-white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 10.64 (1H, brs), 9.23 (1H, brs), 8.22 (3H, brs), 7.85 (1H, s), 7.17-7.41 (3H, m), 7.01-7.12 (1H, m), 4.65-4.89 (2H, m), 4.49-4.63 (2H, m), 3.37-3.47 (2H, m), 3.20-3.29 (1H, m), 3.01-3.18 (3H, m), 2.86-3.00 (3H, m), 2.58-2.78 (6H, m), 1.77-2.19 (6H, m), 1.34-1.50 (2H, m), 1.22 (6H, d, J = 6.8 Hz); LCMS: 100%, MS (ESI): m/z 492.1 [$\text{M} + \text{H}$] $^+$
54		yellow powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.58 (1H, s), 7.28-7.32 (1H, m), 7.19-7.24 (1H, m), 7.08-7.15 (1H, m), 7.04 (1H, d, J = 8.0 Hz), 6.92 (1H, t, J = 7.2 Hz), 4.70-4.85 (4H, m), 3.15-3.25 (4H, m), 2.86-3.07 (4H, m), 1.84-2.02 (6H, m), 1.26-1.36 (8H, m); LCMS: 100%, MS (ESI): m/z 435.1 [$\text{M} + \text{H}$] $^+$
55		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 9.17 (1H, brs), 8.15-8.25 (3H, m), 7.85 (1H, s), 7.32 (1H, d, J = 7.2 Hz), 7.09-7.21 (3H, m), 4.68 (2H, d, J = 6.0 Hz), 4.55-4.65 (2H, m), 3.22-3.32 (1H, m), 3.02-3.12 (1H, m), 2.93-3.03 (2H, m), 2.65-2.73 (2H, m), 1.89-1.99 (2H, m), 1.52-1.62 (2H, m), 1.38-1.48 (2H, m), 1.23 (6H, d, J = 6.8 Hz), 0.93 (3H, t, J = 6.8 Hz); LCMS: 100%, MS (ESI): m/z 408.1 [$\text{M} + \text{H}$] $^+$
56		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.59 (1H, s), 7.46 (1H, d, J = 7.2 Hz), 7.26-7.32 (2H, m), 7.20-7.24 (1H, m), 7.04-7.13 (2H, m), 6.90-7.00 (2H, m), 6.87 (1H, d, J = 8.4 Hz), 6.63-6.71 (1H, m), 4.79 (2H, d, J = 6.4 Hz), 4.70-4.78 (2H, m), 2.86-3.07 (4H, m), 1.85-1.90 (2H, m), 1.21-1.38 (8H, m); LCMS: 98.8%, MS (ESI): m/z 458.1 [$\text{M} + \text{H}$] $^+$

57		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.60 (1H, s), 7.41-7.48 (2H, m), 7.29-7.40 (4H, m), 7.21-7.25 (1H, m), 6.87-6.97 (2H, m), 6.67-6.76 (1H, m), 5.13 (2H, s), 4.68-4.82 (4H, m), 2.85-3.08 (4H, m), 1.82-1.92 (2H, m), 1.23-1.35 (8H, m); LCMS: 100%, MS (ESI): m/z 472.1 $[\text{M} + \text{H}]^+$
58		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.30 (1H, s), 7.83 (1H, d, $J = 7.6$ Hz), 7.71 (1H, d, $J = 6.4$ Hz), 7.60 (1H, s), 7.34-7.53 (5H, m), 7.28-7.32 (1H, m), 7.20-7.24 (1H, m), 4.70-4.75 (2H, m), 4.60 (2H, d, $J = 6.0$ Hz), 2.87-3.06 (4H, m), 1.83-1.92 (2H, m), 1.25-1.35 (8H, m); LCMS: 93.0%, MS (ESI): m/z 482.0 $[\text{M} + \text{H}]^+$
59		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 9.06 (1H, d, $J = 2.4$ Hz), 8.86 (1H, brs), 8.57 (1H, d, $J = 8.8$ Hz), 8.20 (1H, d, $J = 8.8$ Hz), 7.90-7.95 (2H, m), 7.80 (1H, d, $J = 7.2$ Hz), 7.71 (1H, s), 7.53 (1H, t, $J = 7.6$ Hz), 6.68 (1H, s), 5.28 (2H, brs), 4.31-4.44 (2H, m), 2.84-2.93 (1H, m), 2.71-2.83 (2H, m), 2.59-2.68 (1H, m), 1.40-1.60 (2H, m), 1.21 (6H, d, $J = 6.8$ Hz), 0.80-1.00 (2H, m); LCMS: 100%, MS (ESI): m/z 483.0 $[\text{M} + \text{H}]^+$
60		light pink powder; $^1\text{H-NMR}$ ($\text{DMSO-d}_6 + \text{D}_2\text{O}$, 400 MHz): δ 8.15 (1H, d, $J = 1.6$ Hz), 8.03 (1H, s), 7.79 (1H, d, $J = 1.6$ Hz), 7.51-7.58 (1H, m), 7.38-7.47 (3H, m), 6.54-6.59 (1H, m), 4.59-4.72 (2H, m), 4.36-4.58 (2H, m), 3.20-3.34 (1H, m), 3.10 (6H, s), 2.78-2.91 (2H, m), 1.80-1.97 (2H, m), 1.20-1.39 (2H, m); LCMS: 92.0%, MS (ESI-HRMS): m/z 433.2577 $[\text{M} + \text{H}]^+$
61		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 9.26 (1H, brs), 8.14-8.34 (3H, m), 7.87 (1H, s), 7.35 (1H, d, $J = 7.6$ Hz), 7.13-7.24 (4H, m), 6.85-6.98 (3H, m), 6.78 (1H, t, $J = 7.2$ Hz), 4.52-4.71 (4H, m), 3.21-3.35 (1H, m), 3.06-3.16 (1H, m), 2.91-3.04 (2H, m), 1.89-2.01 (2H, m), 1.37-1.52 (2H, m), 1.22 (6H, d, $J = 6.4$ Hz); LCMS: 100%, MS (ESI): m/z 457.1 $[\text{M} + \text{H}]^+$
62		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 8.97 (1H, t, $J = 6.0$ Hz), 8.25 (1H, d, $J = 1.6$ Hz), 7.73-7.84 (4H, m), 7.36 (1H, d, $J = 5.2$ Hz), 7.08 (1H, d, $J = 5.6$ Hz), 6.57 (1H, s), 4.64 (2H, d, $J = 6.0$ Hz), 4.36-4.45 (2H, m), 3.20-3.25 (1H, m), 2.87-2.94 (1H, m), 2.77 (2H, t, $J = 12.4$ Hz), 1.79-1.92 (2H, m), 1.14-1.42 (8H, m); LCMS: 100%, MS (ESI): m/z 438.0 $[\text{M} + \text{H}]^+$







63		white powder; $^1\text{H-NMR}$ (DMSO- d_6 , 400MHz): δ 8.96 (1H, brs), 7.99-8.21 (3H, m), 7.81 (1H, s), 7.33-7.40 (2H, m), 7.23-7.30 (1H, m), 7.19 (1H, d, J = 8.0 Hz), 7.12 (2H, t, J = 7.2 Hz), 6.67 (1H, t, J = 7.6 Hz), 6.52 (2H, d, J = 8.0 Hz), 4.43-4.56 (4H, m), 3.18-3.29 (4H, m), 2.95-3.08 (1H, m), 2.80-2.93 (2H, m), 1.83-1.95 (2H, m), 1.30-1.44 (2H, m), 1.23 (6H, d, J = 6.8 Hz); LCMS: 100%, MS (ESI): m/z 471.0[M + H] $^+$
64		yellow powder; $^1\text{H-NMR}$ (DMSO- d_6 , 400MHz): δ 8.89 (1H, brs), 7.75-7.85 (4H, m), 7.24-7.36 (4H, m), 4.50-4.61 (4H, m), 3.07 (3H, s), 2.79-2.94 (4H, m), 1.81-1.88 (2H, m), 1.63 (3H, s), 1.29-1.38 (2H, m), 1.21 (6H, d, J = 6.8 Hz); LCMS: 100%, MS (ESI): m/z 437.1[M + H] $^+$
65		white powder; $^1\text{H-NMR}$ (DMSO- d_6 , 400MHz): δ 9.02 (1H, brs), 7.99 (1H, d, J = 2.0 Hz), 7.72-7.90 (4H, m), 7.70 (1H, s), 7.42 (1H, s), 7.37 (1H, d, J = 8.0 Hz), 7.31 (1H, d, J = 8.0 Hz), 6.49 (1H, s), 4.55-4.67 (4H, m), 3.23-3.30 (1H, m), 2.85-2.94 (3H, m), 2.16 (3H, s), 1.82-1.93 (2H, m), 1.19-1.39 (8H, m); LCMS: 100%, MS (ESI): m/z 446.1[M + H] $^+$
66		white powder; $^1\text{H-NMR}$ (CDCl $_3$, 400MHz): δ 7.56 (1H, s), 7.34 (1H, d, J = 6.8 Hz), 7.33 (1H, d, J = 6.8 Hz), 7.20-7.30 (1H, m), 6.92 (1H, t, J = 7.2 Hz), 6.85 (1H, d, J = 7.2 Hz), 6.57-6.65 (1H, m), 4.68-4.87 (4H, m), 4.52-4.57 (1H, m), 2.95-3.09 (4H, m), 2.69-2.83 (4H, m), 2.40 (3H, s), 2.18-2.30 (2H, m), 1.95-2.09 (4H, m), 1.38-1.50 (2H, m), 1.26 (6H, d, J = 6.8 Hz); LCMS: 100%, MS (ESI): m/z 479.1[M + H] $^+$
67		white powder; $^1\text{H-NMR}$ (CD $_3$ OD, 400 MHz): δ 9.09 (1H, t, J = 6.0 Hz), 8.12 (1H, d, J = 2.4 Hz), 7.74-7.84 (4H, m), 7.66 (1H, s), 7.61 (1H, d, J = 8.4 Hz), 7.49 (1H, d, J = 8.4 Hz), 6.53 (1H, s), 4.55-4.66 (4H, m), 3.24-3.28 (1H, m), 2.85-2.94 (3H, m), 1.82-1.92 (2H, m), 1.18-1.42 (8H, m); LCMS: 97.6%, MS (ESI): m/z 466.1[M + H] $^+$
68		white powder; $^1\text{H-NMR}$ (DMSO- d_6 , 400 MHz): δ 8.95 (1H, t, J = 6.0 Hz), 7.70-7.80 (3H, m), 7.65-7.75 (1H, m), 7.41-7.62 (5H, m), 7.10-7.20 (1H, m), 7.01-7.05 (1H, m), 7.12 (1H, d, J = 3.2 Hz), 4.25-4.50 (4H, m), 3.10-3.25 (1H, m), 2.87-2.95 (1H, m), 2.55-2.65 (2H, m), 1.65-1.85 (4H, m), 1.24 (6H, d, J = 6.8 Hz); LCMS: 100%, MS (ESI): m/z 481.0 [M + H] $^+$







69		light blue solid; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.61 (1H, s), 7.30 (1H, d, $J = 7.6$ Hz), 7.13 (1H, d, $J = 6.8$ Hz), 7.05 (1H, t, $J = 7.6$ Hz), 6.50 (1H, t, $J = 5.6$ Hz), 4.78 (2H, d, $J = 6.8$ Hz), 4.65-4.73 (2H, m), 3.43 (3H, s), 3.00-3.10 (1H, m), 2.82-2.97 (5H, m), 2.57-2.63 (2H, m), 1.83-1.96 (2H, m), 1.22-1.36 (8H, m); LCMS: 100%, MS (ESI): m/z 449.1[M + H] $^+$
70		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 10.24 (1H, brs), 10.14 (1H, brs), 8.87 (1H, brs), 8.06 (1H, s), 7.77-7.84 (2H, m), 7.72 (1H, s), 7.65 (1H, d, $J = 8.4$ Hz), 7.56 (1H, d, $J = 7.6$ Hz), 7.41 (1H, t, $J = 7.6$ Hz), 7.28 (1H, t, $J = 8.0$ Hz), 7.12 (1H, d, $J = 7.6$ Hz), 4.59 (2H, s), 4.44-4.55 (2H, m), 2.83-2.97 (3H, m), 2.70-2.78 (1H, m), 2.34 (2H, t, $J = 7.2$ Hz), 2.22 (2H, t, $J = 7.2$ Hz), 2.12 (6H, s), 1.65-1.76 (4H, m), 1.22 (6H, d, $J = 6.8$ Hz), 1.03-1.15 (2H, m); LCMS: 100%, MS (ESI): m/z 613.2[M + H] $^+$
71		off-white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 8.53 (1H, brs), 8.22 (1H, d, $J = 8.4$ Hz), 7.79 (1H, d, $J = 8.4$ Hz), 7.71 (1H, s), 7.62 (1H, d, $J = 6.8$ Hz), 7.51 (1H, d, $J = 8.8$ Hz), 7.41 (1H, t, $J = 8.0$ Hz), 5.19 (2H, s), 4.34-4.44 (2H, m), 2.86-2.94 (1H, m), 2.75-2.85 (2H, m), 2.64-2.74 (1H, m), 2.27-2.36 (1H, m), 1.54-1.66 (2H, m), 1.17-1.23 (8H, m), 1.06-1.15 (2H, m), 0.95-1.06 (2H, m); LCMS: 100%, MS (ESI): m/z 457.1[M + H] $^+$
72		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.21 (1H, s), 7.87 (1H, d, $J = 7.6$ Hz), 7.67-7.75 (2H, m), 7.60-7.67 (2H, m), 7.41-7.49 (3H, m), 7.34-7.40 (1H, m), 7.11-7.21 (1H, m), 4.63-4.79 (4H, m), 2.87-3.06 (4H, m), 1.88 (2H, d, $J = 10.0$ Hz), 1.26-1.35 (8H, m); LCMS: 100%, MS (ESI): m/z 482.1 [M + H] $^+$
73		off-white solid; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 8.55-8.59 (2H, m), 8.39 (1H, d, $J = 8.8$ Hz), 7.88 (1H, d, $J = 8.4$ Hz), 7.80-7.85 (2H, m), 7.69-7.75 (4H, m), 7.51-7.56 (2H, m), 7.45-7.50 (2H, m), 5.87 (1H, s), 4.64 (2H, d, $J = 6.4$ Hz), 4.38-4.13 (2H, m), 3.26-3.28 (1H, m), 2.86-2.99 (3H, m), 1.86-1.89 (2H, m), 1.39-1.42 (2H, m), 1.25 (6H, d, $J = 6.8$ Hz); LCMS: 100.0%, MS (ESI): m/z 492.1[M + H] $^+$
74		light brown powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 Hz): δ 8.36 (1H, d, $J = 8.8$ Hz), 7.90 (1H, d, $J = 8.0$ Hz), 7.56-7.63 (2H, m), 7.51-7.56 (1H, m), 7.38-7.47 (2H, m), 7.29-7.38 (1H, m), 7.15-7.25 (3H, m), 4.54 (2H, s), 4.24-4.40 (2H, m), 2.80-2.89 (1H, m), 2.70-2.80 (2H, m), 2.61-2.70 (1H, m), 1.48-1.66 (2H, m), 1.18 (6H, d, $J = 7.2$ Hz), 0.90-1.04 (2H, m); LCMS: 99.2%, MS (ESI): m/z 531.1[M + Na] $^+$







75		white powder; $^1\text{H-NMR}$ (DMSO- d_6 , 400 MHz): δ 8.83 (1H, brs), 8.37 (1H, d, $J = 2.4$ Hz), 7.87 (1H, s), 7.73 (1H, s), 7.67 (1H, s), 7.58 (1H, dd, $J = 8.0, 2.0$ Hz), 7.27 (1H, d, $J = 8.0$ Hz), 6.49 (1H, d, $J = 1.6$ Hz), 4.65 (2H, s), 4.43-4.46 (2H, m), 2.85-2.95 (3H, m), 2.74-2.76 (1H, m), 2.39 (3H, s), 1.63-1.66 (2H, m), 1.23 (6H, d, $J = 6.8$ Hz), 1.05-1.07 (2H, m); LCMS: 99.5%, MS (ESI): m/z 446.1[M + H] $^+$
76		white powder; $^1\text{H-NMR}$ (DMSO- d_6 , 400 MHz): δ 7.73 (1H, s), 7.39 (1H, d, $J = 7.6$ Hz), 7.28-7.35 (2H, m), 7.18-7.24 (1H, m), 7.17 (1H, d, $J = 7.6$ Hz), 6.94 (1H, t, $J = 8.0$ Hz), 6.67 (1H, t, $J = 7.4$ Hz), 6.09 (1H, d, $J = 7.8$ Hz), 4.64 (2H, s), 4.31-4.43 (2H, m), 3.79 (2H, t, $J = 8.0$ Hz), 3.11 (2H, t, $J = 8.0$ Hz), 2.87-2.95 (1H, m), 2.79-2.87 (2H, m), 2.67-2.76 (1H, m), 1.56-1.69 (2H, m), 1.23 (6H, d, $J = 7.2$ Hz), 0.94-1.11 (2H, m); LCMS: 97.8%, MS (ESI): m/z 483.0[M + H] $^+$
77		white powder; $^1\text{H-NMR}$ (DMSO- d_6 , 400 MHz): δ 9.59 (1H, s), 8.84 (1H, t, $J = 6.4$ Hz), 8.38 (1H, d, $J = 8.8$ Hz), 8.19-8.29 (1H, m), 7.94-8.06 (2H, m), 7.65-7.76 (2H, m), 7.64 (1H, s), 7.40-7.52 (2H, m), 4.92 (2H, d, $J = 6.4$ Hz), 4.81-4.91 (2H, m), 2.92-3.08 (4H, m), 1.86-2.04 (2H, m), 1.34-1.46 (2H, m), 1.28 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 494.0[M + H] $^+$
78		white powder; $^1\text{H-NMR}$ (CDCl $_3$, 400 MHz): δ 9.47 (1H, s), 8.26-8.28 (1H, m), 8.05 (2H, d, $J = 8.4$ Hz), 7.87-7.90 (2H, m), 7.73-7.75 (1H, m), 7.58-7.66 (4H, m), 7.39-7.41 (2H, m), 4.75-4.82 (4H, m), 2.93-3.05 (4H, m), 1.85-1.92 (2H, m), 1.28-1.38 (8H, m); LCMS: 99.4%, MS (ESI): m/z 493.1[M + H] $^+$
79		white powder; $^1\text{H-NMR}$ (CDCl $_3$, 400 MHz): δ 8.64 (1H, d, $J = 5.6$ Hz), 7.84 (1H, d, $J = 8.0$ Hz), 7.73 (1H, d, $J = 8.4$ Hz), 7.62-7.66 (3H, m), 7.54 (1H, s), 7.40-7.49 (4H, m), 7.15 (1H, m), 4.84-4.91 (1H, m), 4.63-4.66 (2H, m), 4.22-4.27 (1H, m), 2.96-3.03 (1H, m), 2.83-2.92 (3H, m), 2.78-2.92 (3H, m), 1.84-1.87 (2H, m), 1.26-1.28 (8H, m); LCMS: 100.0%, MS (ESI): m/z 493.1[M + H] $^+$
80		yellow powder; $^1\text{H-NMR}$ (CDCl $_3$, 400 MHz): δ 9.19 (1H, brs), 8.63 (1H, t, $J = 6.6$ Hz), 8.52 (1H, d, $J = 8.0$ Hz), 8.19 (1H, d, $J = 8.0$ Hz), 7.82-7.89 (2H, m), 7.69-7.75 (3H, m), 7.47-7.53 (2H, m), 4.78-4.86 (4H, m), 2.92-3.09 (4H, m), 1.92-1.97 (2H, m), 1.27-1.42 (8H, m); LCMS: 100.0%, MS (ESI): m/z 494.1[M + H] $^+$







81		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400MHz): δ 8.83 (1H, d, $J = 8.0$ Hz), 7.75-7.87 (2H, m), 7.58-7.68 (3H, m), 7.55 (1H, s), 7.39-7.52 (2H, m), 7.20-7.35 (2H, m), 7.04-7.14 (1H, m), 4.87-4.95 (1H, m), 4.50-4.62 (2H, m), 4.38-4.45 (1H, m), 2.93-3.02 (1H, m), 2.87 (1H, s), 2.68-2.80 (2H, m), 1.18-1.29 (8H, m); LCMS: 100%, MS (ESI): m/z 509.0[M + H] $^+$
82		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 10.14 (1H, brs), 7.57 (1H, s), 7.46 (1H, dd, $J = 7.6, 1.6$ Hz), 7.17-7.31 (3H, m), 7.13 (1H, brs), 7.05-7.11 (1H, m), 6.93 (1H, d, $J = 7.6$ Hz), 6.60-6.71 (2H, m), 4.77 (2H, d, $J = 6.0$ Hz), 4.69-4.76 (2H, m), 2.97-3.05 (1H, m), 2.86-2.97 (3H, m), 2.45-2.51 (2H, m), 2.42 (2H, t, $J = 6.0$ Hz), 2.24 (6H, s), 1.79-1.90 (4H, m), 1.22-1.35 (8H, m); LCMS: 100%, MS (ESI): m/z 608.3[M + Na] $^+$
83		off-white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.61 (1H, s), 7.23 (1H, t, $J = 7.8$ Hz), 6.94 (1H, s), 6.85-6.87 (2H, m), 6.55 (1H, t, $J = 5.6$ Hz), 4.74-4.78 (2H, m), 4.68 (2H, d, $J = 5.6$ Hz), 3.21 (4H, t, $J = 5.0$ Hz), 2.92-3.07 (4H, m), 2.57 (4H, t, $J = 5.0$ Hz), 3.35 (3H, s), 1.87-1.89 (2H, m), 1.26-1.35 (8H, m); LCMS: 97.4%, MS (ESI): m/z 464.1[M + H] $^+$
84		off-white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 9.97 (1H, brs), 8.85 (1H, brs), 7.70 (1H, s), 7.28-7.39 (3H, m), 7.21-7.28 (1H, m), 7.17 (1H, d, $J = 7.6$ Hz), 7.07 (1H, s), 6.88 (1H, dd, $J = 8.0, 2.0$ Hz), 6.63 (1H, dd, $J = 8.0, 2.0$ Hz), 4.54 (2H, s), 4.39-4.60 (2H, m), 2.81-2.95 (3H, m), 2.69-2.79 (1H, m), 2.28 (2H, t, $J = 7.4$ Hz), 2.19 (2H, t, $J = 7.0$ Hz), 2.09 (6H, s), 1.60-1.72 (4H, m), 1.22 (6H, d, $J = 6.8$ Hz), 0.95-1.14 (2H, m); LCMS: 98.5%, MS (ESI): m/z 608.3[M + Na] $^+$
85		yellow solid; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.61 (1H, s), 7.23-7.25 (1H, m), 6.84-6.96 (3H, m), 6.56-6.59 (1H, m), 4.75-4.79 (2H, m), 4.68-4.70 (2H, m), 3.77 (2H, t, $J = 7.8$ Hz), 3.64 (2H, t, $J = 7.2$ Hz), 3.02-3.05 (1H, m), 2.92-2.99 (3H, m), 2.48-2.58 (4H, m), 2.40 (6H, s), 1.89-1.97 (4H, m), 1.26-1.37 (8H, m); LCMS: 96.6%, MS (ESI): m/z 563.3[M + H] $^+$
86		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 9.91 (1H, brs), 8.84 (1H, brs), 7.70 (1H, s), 7.29-7.38 (3H, m), 7.22-7.29 (1H, m), 7.14-7.20 (1H, m), 7.07 (1H, s), 6.85-6.92 (1H, m), 6.61-6.66 (1H, m), 4.54 (2H, s), 4.38-4.49 (2H, m), 2.81-2.94 (3H, m), 2.66-2.79 (1H, m), 2.27 (2H, q, $J = 7.6$ Hz), 1.59-1.73 (2H, m), 1.22 (6H, d, $J = 6.8$ Hz), 0.99-1.10 (5H, m); LCMS: 100%, MS (ESI): m/z 529.3[M + H] $^+$







87		white solid; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.24 (1H, s), 7.93 (1H, d, $J = 8.4$ Hz), 7.62-7.65 (3H, m), 7.49-7.53 (1H, m), 7.34-7.41 (4H, m), 7.18-7.22 (1H, m), 7.68 (1H, t, $J = 4.4$ Hz), 4.82 (2H, d, $J = 5.2$ Hz), 4.53-4.57 (2H, m), 3.01-3.08 (1H, m), 2.89-2.95 (1H, m), 2.58-2.66 (2H, m), 1.82-1.95 (2H, m), 1.21-1.35 (8H, m); LCMS: 100.0%, MS (ESI): m/z 485.2[M + H] $^+$
88		off-white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.58 (1H, s), 7.48 (1H, dd, $J = 7.6, 1.2$ Hz), 7.29-7.32 (1H, m), 7.10-7.32 (3H, m), 7.02-7.25 (2H, m), 6.95 (1H, d, $J = 8.0$ Hz), 6.52-6.79 (2H, m), 4.61-4.92 (4H, m), 2.82-3.12 (4H, m), 2.37 (2H, q, $J = 7.6$ Hz), 1.81-1.95 (2H, m), 1.27-1.46 (8H, m), 1.13 (3H, t, $J = 7.6$ Hz); LCMS: 97%, MS (ESI): m/z 584.4[M + H] $^+$
89		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 10.13 (1H, brs), 8.49 (1H, s), 8.20 (1H, d, $J = 7.6$ Hz), 7.76 (1H, d, $J = 7.6$ Hz), 7.70 (1H, s), 7.57 (1H, s), 7.31-7.39 (3H, m), 7.22-7.30 (2H, m), 7.13-7.16 (1H, m), 6.81-6.84 (1H, m), 4.75 (2H, s), 4.48-4.51 (2H, m), 2.95-3.02 (1H, m), 2.71-2.77 (1H, m), 2.59-2.66 (2H, m), 2.39-2.48 (4H, m), 2.26 (6H, s), 1.82-1.85 (4H, m), 1.69-1.73 (2H, m), 1.25 (6H, d, $J = 6.4$ Hz), 1.03-1.22 (2H, m); LCMS: 96.5%, MS (ESI): m/z 613.3[M + H] $^+$
90		white solid; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 10.03 (1H, brs), 8.55 (1H, d, $J = 4.0$ Hz), 8.09 (1H, d, $J = 4.4$ Hz), 7.71 (1H, d, $J = 4.0$ Hz), 7.57-7.59 (1H, m), 7.35-7.53 (7H, m), 6.98 (1H, brs), 4.77-4.79 (1H, m), 4.56-4.58 (2H, m), 4.24-4.27 (1H, m), 2.84-3.05 (4H, m), 2.66-2.67 (2H, m), 2.52-2.54 (2H, m), 2.32 (6H, s), 1.99-2.01 (2H, m), 1.80-1.83 (2H, m), 1.27-1.28 (8H, m); LCMS: 100%, MS (ESI): m/z 621.4[M + H] $^+$
91		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 9.86 (1H, brs), 7.59 (1H, s), 7.43-7.50 (3H, m), 7.21-7.23 (1H, m), 7.02-7.07 (1H, m), 6.93 (2H, d, $J = 8.4$ Hz), 6.80-6.83 (2H, m), 4.73-4.81 (4H, m), 2.90-3.04 (4H, m), 2.43-2.51 (4H, m), 2.31 (6H, s), 1.75-1.90 (4H, m), 1.27-1.29 (8H, m); LCMS: 100%, MS (ESI): m/z 586.4[M + H] $^+$
92		white powder $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 10.41 (1H, brs), 8.44-8.50 (2H, m), 7.73 (1H, d, $J = 5.6$ Hz), 7.66 (1H, s), 7.44-7.56 (4H, m), 7.42 (1H, t, $J = 6.8$ Hz), 7.32 (1H, d, $J = 6.8$ Hz), 4.22-4.44 (4H, m), 2.67-2.91 (4H, m), 2.42 (2H, t, $J = 7.2$ Hz), 2.25 (2H, t, $J = 7.2$ Hz), 2.13 (6H, s), 1.63-1.78 (4H, m), 1.20 (6H, d, $J = 7.2$ Hz), 1.04-1.07 (2H, m); LCMS: 100%, MS (ESI): m/z 621.4[M + H] $^+$







93		white powder; $^1\text{H-NMR}$ (DMSO- d_6 , 400 MHz): δ 9.89 (1H, brs), 7.68-7.71 (2H, m), 7.25-7.30 (1H, m), 7.22 (1H, dd, J = 10.8, 9.20 Hz), 7.15 (1H, d, J = 8.0 Hz), 7.05 (1H, s), 6.85 (1H, dd, J = 8.40, 2.0 Hz), 6.65-6.73 (1H, m), 4.49-4.54 (4H, m), 2.87-2.94 (4H, m), 2.38 (2H, t, J = 7.2 Hz), 2.18-2.22 (2H, t, J = 7.2 Hz), 2.10 (6H, s), 1.70-1.80 (2H, m), 1.64-1.68 (2H, m), 1.21-1.23 (8H, m); LCMS: 93.9%, MS (ESI): m/z 626.4[M + Na] $^+$
94		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.59 (1H, brs), 8.11 (1H, s), 7.61 (1H, s), 7.29-7.30 (2H, m), 7.13 (1H, d, J = 7.6 Hz), 7.06 (1H, t, J = 3.6 Hz), 6.85-6.95 (1H, m), 6.64-6.67 (2H, m), 4.69-4.73 (4H, m), 2.94-3.03 (1H, m), 2.89-2.92 (3H, m), 2.50 (2H, t, J = 6.8 Hz), 2.41 (2H, t, J = 6.8 Hz), 2.27 (6H, s), 1.98-2.01 (2H, m), 1.86-1.91 (4H, m), 1.29-1.33 (8H, m); LCMS: 100.0%, MS (ESI): m/z 620.3[M + H] $^+$
95		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 10.62 (1H, brs), 8.46 (1H, d, J = 8.8 Hz), 8.14 (1H, d, J = 9.2 Hz), 7.63 - 7.74 (3H, m), 7.56 (1H, s), 7.35 (1H, t, J = 7.2 Hz), 5.17 (2H, d, J = 6.0 Hz), 4.75-85 (2H, m), 2.86 - 3.06 (4H, m), 2.62 (2H, t, J = 7.2 Hz), 2.49 (2H, t, J = 6.4 Hz), 2.35 (6H, s), 1.85 - 2.04 (4H, m), 1.24 - 1.32 (10H, m); LCMS: 93.5%, MS (ESI): m/z 567.4[M + Na] $^+$
96		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.86-7.92 (2H, m), 7.68 (1H, d, J = 7.6 Hz), 7.62 (1H, s), 7.43-7.49 (3H, m), 7.33-7.41 (3H, m), 4.72-4.75 (4H, m), 3.71 (3H, s), 2.90-3.05 (4H, m), 1.87-1.91 (2H, m), 1.27-1.36 (8H, m); LCMS: 97.4%, MS (ESI): m/z 496.3[M + H] $^+$
97		white powder; $^1\text{H-NMR}$ (DMSO- d_6 , 400 MHz): δ 8.90 (1H, brs), 8.18 (1H, dd, J = 7.6, 1.2 Hz), 7.88-7.95 (1H, m), 7.82-7.88 (1H, m), 7.72 (1H, s), 7.78 (1H, d, J = 7.6 Hz), 7.55-7.62 (1H, m), 7.41-7.55 (3H, m), 5.21 (2H, s), 4.15-4.45 (2H, m), 2.85-3.00 (1H, m), 2.70-2.85 (2H, m), 2.60-2.70 (1H, m), 1.45-1.60 (2H, m), 1.21 (6H, d, J = 6.8 Hz), 0.85-1.00 (2H, m); LCMS: 97.4%, MS (ESI): m/z 483.3 [M+H] $^+$
98		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 9.95 (1H, brs), 8.88 (1H, brs), 7.91 (1H, brs), 7.58-7.65 (3H, m), 7.36-7.39 (2H, m), 7.24-2.28 (2H, m), 4.95 (2H, d, J = 5.2 Hz), 4.82-4.85 (2H, m), 2.96-3.02 (4H, m), 1.91-1.94 (2H, m), 1.34-1.40 (2H, m), 1.24 (6H, d, J = 7.2 Hz); LCMS: 100.0%, MS (ESI): m/z 482.3[M+H] $^+$







99		white powder; $^1\text{H-NMR}$ (DMSO- d_6 , 400 MHz): δ 8.24 (1H, d, J = 2.4 Hz), 8.00-8.05 (2H, m), 7.76 (1H, s), 7.51-7.52 (1H, m), 7.50-7.51 (1H, m), 7.44-7.48 (4H, m), 7.36-7.44 (1H, m), 7.08 (1H, d, J = 2.4 Hz), 4.70 (2H, s), 4.35-4.45 (2H, m), 2.84-2.92 (3H, m), 2.71-2.75 (1H, m), 1.66-1.69 (2H, m), 1.22 (6H, d, J = 7.2 Hz), 1.05-1.07 (2H, m); LCMS: 97.6%, MS (ESI): m/z 508.3[M + H] $^+$
100		white powder; $^1\text{H-NMR}$ (DMSO- d_6 , 400 MHz): δ 8.73 (1H, s), 8.07 (1H, s), 7.70-7.71 (2H, m), 7.58-7.61 (2H, m), 7.44-7.52 (3H, m), 4.58 (2H, s), 4.24-4.57 (2H, m), 2.87-2.90 (1H, m), 2.70-2.80 (3H, m), 1.60-1.65 (2H, m), 1.21 (6H, d, J = 6.8 Hz), 0.97-1.02 (2H, m); LCMS: 100%, MS (ESI): m/z 560.1[M + H] $^+$
101		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.25 (1H, brs), 7.89-7.95 (2H, m), 7.64-7.68 (6H, m), 7.45-7.49 (5H, m), 7.34-7.44 (1H, m), 4.74-4.77 (2H, m), 4.69 (2H, d, J = 6.0 Hz), 2.91-3.03 (4H, m), 1.90-2.00 (2H, m), 1.39-1.41 (2H, m), 1.27 (6H, d, J = 6.8 Hz); LCMS: 95.1%, MS (ESI): m/z 580.3[M + Na] $^+$
102		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.56 (1H, brs), 7.65 (1H, d, J = 8.0 Hz), 7.60 (1H, s), 7.49-7.56 (2H, m), 7.33-7.42 (3H, m), 7.18-7.24 (1H, m), 7.11-7.17 (1H, m), 6.50 - 6.70 (2H, m), 4.86 (2H, d, J = 3.6 Hz), 4.55-4.69 (2H, m), 2.96-3.08 (1H, m), 2.79-2.92 (3H, m), 1.77-1.83 (2H, m), 1.19-1.31 (8H, m); LCMS: 100%, MS (ESI): m/z 481.3[M + H] $^+$
103		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.15 (1H, s), 7.80 (1H, d, J = 8.8 Hz), 7.70-7.75 (2H, m), 7.63 (1H, s), 7.49-7.51 (1H, m), 7.42-7.45 (3H, m), 7.27-7.32 (1H, m), 4.66-4.75 (4H, m), 2.92-3.04 (4H, m), 1.89-1.92 (2H, m), 1.28-1.34 (8H, m); LCMS: 100.0%, MS (ESI): m/z 516.2[M + H] $^+$
104		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.29 (1H, s), 6.20 (1H, s), 7.85 (1H, d, J = 8.8 Hz), 7.72-7.73 (1H, m), 7.64 (1H, s), 7.42-7.51 (4H, m), 7.34 (1H, d, J = 8.8 Hz), 4.68-4.75 (4H, m), 2.91-3.06 (4H, m), 1.89-1.92 (2H, m), 1.28-1.38 (8H, m); LCMS: 100.0%, MS (ESI): m/z 550.3[M + H] $^+$








105		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.10 (1H, brs), 7.86 (1H, d, $J = 10$ Hz), 7.69-7.71 (1H, m), 7.62 (1H, s), 7.57 (1H, t, $J = 6.60$ Hz), 7.42-7.45 (3H, m), 7.30-7.35 (2H, m), 7.15-7.20 (2H, m), 7.06-7.15 (3H, m), 4.69-4.76 (4H, m), 2.91-3.05 (4H, m), 1.88-1.91 (2H, m), 1.32-1.35 (2H, m), 1.28 (6H, d, $J = 6.4$ Hz); LCMS: 100%, MS (ESI): m/z 574.3[M + H] ⁺
106		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.12 (1H, s), 7.79 (1H, d, $J = 8.8$ Hz), 7.65-7.71 (2H, m), 7.64 (1H, s), 7.42-7.47 (4H, m), 7.23 (1H, d, $J = 8.8$ Hz), 4.74-4.77 (2H, m), 4.68 (2H, d, $J = 6.4$ Hz), 2.90-3.04 (4H, m), 2.70 (2H, t, $J = 7.8$ Hz), 1.89-1.91 (2H, m), 1.68-1.75 (2H, m), 1.33-1.37 (2H, m), 1.29 (6H, d, $J = 6.4$ Hz), 1.0 (3H, t, $J = 7.4$ Hz); LCMS: 100.0%, MS (ESI): m/z 524.3[M + H] ⁺
107		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.87 (1H, s), 7.73 (1H, d, $J = 8.8$ Hz), 7.67 (1H, dd, $J = 7.2, 2.0$ Hz), 7.56 (1H, s), 7.45-7.56 (2H, m), 7.35 (1H, dd, $J = 7.2, 2.0$ Hz), 6.92 (1H, dd, $J = 8.8, 2.4$ Hz), 6.56 (1H, d, $J = 2.0$ Hz), 6.38 (1H, brs), 4.50-4.67 (4H, m), 4.41-4.45 (1H, m), 2.94-3.06 (1H, m), 2.80-2.92 (3H, m), 1.78-1.89 (2H, m), 1.20-1.31 (14H, m); LCMS: 100 %, MS (ESI): m/z 540.3 [M+ H] ⁺
108		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.16 (1H, s), 7.84 (1H, dd, $J = 9.6, 4.8$ Hz), 7.68-7.70 (1H, m), 7.62 (1H, brs), 7.54-7.57 (1H, m), 7.44-7.50 (3H, m), 7.27-7.30 (1H, m), 7.14-7.20 (1H, m), 4.66-4.77 (4H, m), 2.91-3.05 (4H, m), 1.86-1.99 (2H, m), 1.31-1.37 (2H, m), 1.28 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 500.2[M + H] ⁺
109		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.66 (1H, t, $J = 6.2$ Hz), 7.58-7.60 (2H, m), 7.39 (1H, s), 7.28-7.36 (3H, m), 4.78-4.81 (2H, m), 4.73 (2H, d, $J = 6.4$ Hz), 2.94-3.05 (4H, m), 2.82 (2H, t, $J = 6.2$ Hz), 2.61 (2H, t, $J = 6.2$ Hz), 1.85-1.95 (4H, m), 1.77-1.82 (2H, m), 1.31-1.41 (2H, m), 1.27 (6H, d, $J = 6.8$ Hz); LCMS: 100.0%, MS (ESI): m/z 486.4[M + H] ⁺
110		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.92 (1H, t, $J = 6.2$ Hz), 8.16 (1H, d, $J = 6.4$ Hz), 7.76-7.79 (2H, m), 7.60-7.62 (3H, m), 7.31-7.33 (2H, m), 7.24-7.26 (1H, m), 6.82-6.87 (1H, m), 4.85-4.91 (4H, m), 2.98-3.08 (4H, m), 2.00-2.03 (2H, m), 1.47-1.52 (2H, m), 1.27 (6H, d, $J = 6.8$ Hz); LCMS: 100.0%, MS (ESI): m/z 482.3[M + H] ⁺







111		white powder; $^1\text{H-NMR}$ (DMSO- d_6 , 400 MHz): δ 8.49 (1H, brs), 7.59-7.68 (2H, m), 7.48-7.57 (2H, m), 7.30-7.43 (3H, m), 7.11-7.24 (2H, m), 6.55-6.64 (2H, m), 5.26 (1H, d, $J = 7.6$ Hz), 4.85 (2H, d, $J = 5.6$ Hz), 4.50-4.60 (2H, m), 3.90-4.04 (1H, m), 2.86-3.08 (3H, m), 1.97 (3H, s), 1.88 (2H, d, $J = 11.2$ Hz), 1.20-1.31 (8H, d, $J = 6.84$ Hz); LCMS: 95.8%, MS (ESI): m/z 545.1[M + Na] $^+$
112		white powder; $^1\text{H-NMR}$ (CDCl $_3$, 400 MHz): δ 8.71 (1H, brs), 7.60 (1H, s), 7.50-7.54 (2H, m), 7.37-7.39 (2H, m), 7.09-7.10 (2H, m), 6.78-6.83 (1H, m), 6.68 (1H, d, $J = 2.0$ Hz), 6.55-6.58 (1H, m), 4.86 (2H, d, $J = 4.8$ Hz), 4.55-4.62 (2H, m), 3.00-3.03 (1H, m), 2.82-2.88 (3H, m), 1.78-1.81 (2H, m), 1.22-1.30 (8H, m); LCMS: 100%, MS (ESI): m/z 499.4[M + H] $^+$
113		white powder; $^1\text{H-NMR}$ (CDCl $_3$, 400 MHz): δ 8.92 (1H, brs), 7.58 (1H, s), 7.48-7.53 (2H, m), 7.35-7.38 (3H, m), 6.99-7.05 (1H, m), 6.87-6.92 (1H, m), 6.60-6.63 (2H, m), 4.83 (2H, d, $J = 5.2$ Hz), 4.60-4.65 (2H, m), 2.96-3.03 (2H, m), 2.81-2.87 (2H, m), 1.85-1.90 (2H, m), 1.33-1.41 (2H, m), 1.26 (6H, d, $J = 6.8$ Hz); LCMS: 97.0%, MS (ESI): m/z 499.2[M + H] $^+$
114		white powder; $^1\text{H-NMR}$ (CDCl $_3$, 400 MHz): δ 7.66-7.69 (2H, m), 7.57-7.59 (1H, m), 7.52-7.54 (1H, m), 7.38-7.44 (3H, m), 7.24-7.25 (1H, m), 7.16-7.20 (1H, m), 6.89-6.91 (1H, m), 6.66 (1H, s), 4.85 (2H, d, $J = 6.0$ Hz), 4.76-4.81 (1H, m), 3.94-4.05 (3H, m), 3.44-3.51 (2H, m), 3.01-3.08 (1H, m), 2.00-2.06 (2H, m), 1.45-1.55 (2H, m), 1.30 (6H, d, $J = 6.8$ Hz); LCMS: 100.0%, MS (ESI): m/z 482.3[M + H] $^+$
115		white powder; $^1\text{H-NMR}$ (DMSO- d_6 , 400 MHz): δ 11.53 (1H, brs), 7.76 (1H, s), 7.66 (1H, d, $J = 8.0$ Hz), 7.56-7.60 (2H, m), 7.48-7.51 (1H, m), 7.32-7.39 (2H, m), 7.30 (1H, t, $J = 6.8$ Hz), 7.21 (1H, t, $J = 7.2$ Hz), 7.13 (1H, t, $J = 7.2$ Hz), 6.59 (1H, d, $J = 1.6$ Hz), 5.08-5.12 (1H, m), 4.85 (2H, d, $J = 6.8$ Hz), 3.03-3.10 (1H, m), 2.76-2.80 (2H, m), 2.34-2.40 (2H, m), 2.33 (3H, s), 2.17-2.21 (2H, m), 1.96-2.03 (2H, m), 1.31 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 518.3[M + Na] $^+$
116		white powder; $^1\text{H-NMR}$ (DMSO- d_6 , 400 MHz): δ 8.48 (1H, brs), 7.78 (1H, s), 7.45-7.65 (3H, m), 7.33-7.43 (3H, m), 7.15-7.25 (2H, m), 6.45-6.60 (2H, m), 4.83 (2H, s), 4.55-4.65 (2H, m), 2.96-3.10 (1H, m), 2.75-2.90 (3H, m), 2.19 (3H, s), 1.70-1.85 (2H, m), 1.29 (6H, d, $J = 6.8$ Hz), 1.10-1.25 (2H, m); LCMS: 100%, MS (ESI): m/z 538.4 [M + H] $^+$

117		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.55 (1H, brs), 7.63 (1H, d, $J = 9.6$ Hz), 7.62 (1H, s), 7.52-7.54 (2H, m), 7.36-7.40 (3H, m), 7.22 (1H, t, $J = 7.6$ Hz), 7.15 (1H, t, $J = 7.6$ Hz), 6.63-6.65 (2H, m), 5.33-5.42 (2H, m), 4.88 (2H, d, $J = 6.0$ Hz), 4.70-4.74 (2H, m), 3.04-3.06 (1H, m), 2.80-2.87 (2H, m), 2.32-2.36 (1H, m), 1.83-1.86 (2H, m), 1.59-1.66 (2H, m), 1.27-1.31 (8H, m); LCMS: 100.0%, MS (ESI): m/z 531.3[M + Na] $^+$
118		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.52 (1H, brs), 7.59-7.66 (4H, m), 7.38-7.42 (2H, m), 7.29-7.31 (1H, m), 7.20 (1H, t, $J = 7.8$ Hz), 7.13 (1H, t, $J = 7.4$ Hz), 6.82 (1H, s), 6.75 (1H, t, $J = 5.8$ Hz), 4.73-4.79 (4H, m), 3.02-3.08 (1H, m), 2.87-2.98 (3H, m), 1.84-1.87 (2H, m), 1.23-1.32 (8H, m); LCMS: 99.3%, MS (ESI): m/z 481.3[M + H] $^+$
119		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.68 (1H, brs), 7.61-7.63 (1H, m), 7.55-7.57 (2H, m), 7.39-7.43 (3H, m), 7.21-7.26 (3H, m), 6.58 (1H, brs), 4.73 (2H, d, $J = 4.8$ Hz), 4.56-4.60 (2H, m), 2.97-3.00 (2H, m), 2.76-2.82 (2H, m), 1.84-1.86 (2H, m), 1.25-1.44 (8H, m); LCMS: 100%, MS (ESI): m/z 515.2[M + H] $^+$
120		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.36 (1H, s), 8.21 (1H, s), 7.92 (1H, d, $J = 8.8$ Hz), 7.71-7.73 (1H, m), 7.62 (1H, s), 7.45-7.53 (4H, m), 7.30-7.40 (1H, m), 4.68-4.76 (4H, m), 2.91-3.04 (4H, m), 1.92-1.95 (2H, m), 1.35-1.39 (2H, m), 1.28 (6H, d, $J = 6.8$ Hz); LCMS: 95.5%, MS (ESI): m/z 507.2[M + H] $^+$
121		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 9.19 (1H, brs), 8.58 (1H, d, $J = 2.0$ Hz), 8.10 (1H, dd, $J = 8.8$ Hz, 2.4 Hz), 7.60 (1H, s), 7.52-7.58 (2H, m), 7.43-7.46 (2H, m), 7.31 (1H, d, $J = 8.8$ Hz), 6.76 (1H, d, $J = 0.8$ Hz), 6.55 (1H, t, $J = 5.2$ Hz), 4.82 (2H, d, $J = 5.2$ Hz), 4.55-4.58 (2H, m), 2.98-3.03 (1H, m), 2.81-2.91 (3H, m), 1.78-1.82 (2H, m), 1.29 (6H, d, $J = 6.8$ Hz), 1.21-1.26 (2H, m); LCMS: 99.2%, MS (ESI): m/z 526.3[M + H] $^+$
122		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.94 (1H, t, $J = 6.0$ Hz), 7.59 (1H, s), 7.51 (1H, d, $J = 6.4$ Hz), 7.46 (1H, d, $J = 6.8$ Hz), 7.18-7.25 (2H, m), 6.95 (1H, s), 4.82-4.87 (4H, m), 4.01 (2H, t, $J = 5.6$ Hz), 2.96-3.04 (6H, m), 1.94-2.04 (6H, m), 1.35-1.45 (2H, m), 1.26 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 486.3[M + H] $^+$







123		Pink powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.15 (1H, s), 7.59 (1H, d, $J = 8.0$ Hz), 7.52-7.54 (2H, m), 7.47-7.48 (1H, m), 7.27-7.31 (3H, m), 7.10-7.20 (1H, m), 6.61 (1H, brs), 4.65-4.70 (2H, m), 4.56-4.59 (2H, m), 2.95-3.01 (2H, m), 2.75-2.81 (2H, m), 1.83-1.85 (2H, m), 1.20-1.32 (8H, m); LCMS: 97.6%, MS (ESI): m/z 482.2 $[\text{M} + \text{H}]^+$
124		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 9.06 (1H, brs), 8.65-8.75 (1H, m), 8.33 (1H, s), 7.75 (1H, d, $J = 8.0$ Hz), 7.71 (1H, s), 7.46-7.52 (2H, m), 7.30-7.37 (2H, m), 7.06 (1H, td, $J = 7.6, 2.8$ Hz), 4.93 (2H, s), 4.42-4.45 (2H, m), 2.82-2.91 (4H, m), 1.69-1.72 (2H, m), 1.21 (6H, d, $J = 6.8$ Hz), 1.12-1.14 (2 H, m); LCMS: 98.6%, MS (ESI): m/z 522.2 $[\text{M} + \text{Na}]^+$
125		Racemic mixture; white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 8.91 (1 H, t, $J = 5.6$ Hz), 7.75 (1H, s), 7.58 (1H, d, $J = 7.6$ Hz), 7.52-7.56 (1H, m), 7.44-7.51 (2H, m), 7.30-7.37 (2H, m), 7.09-7.15 (1H, m), 7.00-7.05 (1H, m), 6.59 (1H, s), 4.78-4.89 (2H, m), 4.00-4.30 (2H, m), 3.35-3.45 (2H, m), 2.80-2.95 (1H, m), 2.30-2.35 (1H, m), 1.70-1.80 (1H, m), 1.40-1.50 (1H, m), 1.21 (6H, d, $J = 7.2$ Hz), 1.05-1.15 (2H, m); LCMS: 100 %, MS (ESI): $m/z = 481.2$ $[\text{M} + \text{H}]^+$
126		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.84 (1H, brs), 8.66 (1H, t, $J = 6.4$ Hz), 8.37 (1H, d, $J = 8.0$ Hz), 8.25 (1H, s), 7.71-7.73 (1H, m), 7.67 (1H, s), 7.45-7.47 (4H, m), 7.19 (1H, t, $J = 8.0$ Hz), 7.82-7.86 (2H, m), 4.58 (2H, d, $J = 6.4$ Hz), 2.94-3.07 (4H, m), 2.69 (2H, t, $J = 7.4$ Hz), 2.34-2.37 (2H, m), 1.93-1.97 (4H, m), 1.35-1.41 (2H, m), 8.66 (6H, d, $J = 7.2$ Hz); LCMS: 100.0%, MS (ESI): m/z 610.4 $[\text{M} + \text{H}]^+$
127		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.86 (1H, s), 8.38 (1H, s), 7.98-8.01 (1H, m), 7.88 (1H, d, $J = 8.8$ Hz), 7.72-7.74 (1H, m), 7.64 (1H, s), 7.44-7.48 (4H, m), 4.69-4.75 (4H, m), 2.89-3.06 (4H, m), 2.70 (3H, s), 1.85-1.91 (2H, m), 1.28-1.35 (8H, m); LCMS: 100%, MS (ESI): m/z 524.3 $[\text{M} + \text{H}]^+$
128		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.57 (1H, s), 7.38 (2H, d, $J = 7.6$ Hz), 7.25-7.30 (5H, m), 7.21 (1H, d, $J = 8.0$ Hz), 7.01 (1H, t, $J = 7.2$ Hz), 6.75-6.82 (1H, m), 4.87 (2H, d, $J = 5.2$ Hz), 4.70-4.80 (1H, m), 4.62 (4H, s), 2.87-3.06 (4H, m), 1.85-1.94 (2H, m), 1.23-1.38 (8H, m); LCMS: 99.7%, MS (ESI): $m/z = 483.3$ $[\text{M} + \text{H}]^+$

129		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.84 (1H, brs), 7.62-7.65 (2H, m), 7.51-7.53 (2H, m), 7.35-7.38 (3H, m), 7.21 (1H, t, $J = 7.4$ Hz), 7.14 (1H, t, $J = 7.4$ Hz), 6.61-6.64 (2H, m), 4.86 (2H, d, $J = 6.4$ Hz), 3.99-4.03 (2H, m), 3.49-3.54 (2H, m), 3.40 (2H, s), 2.99-3.05 (1H, m), 2.19-2.24 (2H, m), 1.43-1.45 (2H, m), 1.29 (6H, d, $J = 6.8$ Hz); LCMS: 98.3%, MS (ESI): m/z 511.2[M + H] $^+$
130		Racemic mixture; white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 9.17 (1H, brs), 7.61-7.63 (2H, m), 7.49-7.52 (2H, m), 7.34-7.39 (3H, m), 7.20 (1H, t, $J = 7.2$ Hz), 7.12 (1H, t, $J = 7.2$ Hz), 6.69 (1H, brs), 6.56 (1H, s), 4.88 (2H, s), 4.33-4.36 (2H, m), 3.82-3.85 (2H, m), 3.05-3.50 (2H, m), 2.88-3.03 (1H, m), 2.80-2.84 (3H, m), 2.58-2.64 (1H, m), 1.27 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 497.2[M + H] $^+$
131		(3R); white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 10.45 (1H, brs), 7.65 (1H, d, $J = 7.2$ Hz), 7.62 (1H, s), 7.46-7.53 (2H, m), 7.40 (1H, d, $J = 7.6$ Hz), 7.29-7.35 (2H, m), 7.20 (1H, t, $J = 7.6$ Hz), 7.12 (1H, t, $J = 7.6$ Hz), 6.89 (1H, brs), 6.53 (1H, s), 4.75-5.01 (2H, m), 4.20-4.35 (2H, m), 2.83-3.06 (2H, m), 2.45-2.65 (2H, m), 1.58-1.70 (2H, m), 1.24-1.29 (8H, m); LCMS: 100%, MS (ESI): m/z 481.3[M + H] $^+$
132		White powder; $^1\text{H NMR}$ (CDCl_3 , 400 MHz): δ 7.54-7.59 (2H, m), 7.47-7.52 (2H, m), 7.32-7.38 (2H, m), 7.27-7.29 (1H, m), 4.80-4.84 (2H, m), 4.69-4.72 (2H, m), 3.50 (2H, s), 3.15-3.21 (3H, m), 2.93-3.02 (3H, m), 2.76 (2H, t, $J = 7.0$ Hz), 2.02-2.07 (2H, m), 1.24-1.28 (8H, m); LCMS: 100%, MS (ESI): m/z 500.2[M + H] $^+$
133		White powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.57-7.63 (2H, m), 7.51 (1H, t, $J = 6.4$ Hz), 7.40 (1H, s), 7.30-7.40 (2H, m), 7.27-7.30 (1H, m), 4.75-4.83 (4H, m), 4.71 (2H, d, $J = 6.4$ Hz), 4.02 (2H, t, $J = 5.2$ Hz), 2.92-3.06 (6H, m), 1.93-2.00 (2H, m), 1.31-1.44 (2 H, m), 1.27 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 488.2[M + H] $^+$
134		White powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.15 (1H, s), 7.63-7.65 (1H, m), 7.61 (1H, s), 7.39-7.42 (3H, m), 7.31-7.34 (1H, m), 5.95-6.03 (1H, m), 4.68-4.82 (4H, m), 3.65 (2H, t, $J = 7.8$ Hz), 2.93-3.10 (6H, m), 1.93-1.99 (2H, m), 1.32-1.42 (2H, m), 1.27 (6H, d, $J = 6.8$ Hz); LCMS: 98.2%, MS (ESI): m/z 523.3[M + Na] $^+$







135		White powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.57 (1H, s), 7.23-7.28 (1H, m), 7.16-7.22 (1H, m), 6.93 (1H, d, $J = 7.6$ Hz), 6.75-6.84 (2H, m), 4.73-4.81 (4H, m), 3.28-3.36 (2H, m), 3.19-3.26 (2H, m), 2.86-3.08 (4H, m), 2.23-2.33 (2H, m), 1.84-1.94 (2H, m), 1.51-1.64 (4H, m), 1.39-1.46 (2H, m), 1.23-1.38 (10H, m); LCMS: 100 %, MS (ESI): $m/z = 489.3$ $[\text{M} + \text{H}]^+$
136		White powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.10 (1H, s), 7.63 (1H, d, $J = 8.0$ Hz), 7.59 (1H, s), 7.51 (1H, s), 7.46 (1H, dd, $J = 8.0, 1.2$ Hz), 7.29-7.35 (1H, m), 7.27 (1H, d, $J = 1.6$ Hz), 7.15-7.20 (1H, m), 6.41-6.51 (1H, m), 4.81 (2H, d, $J = 5.2$ Hz), 4.38-4.42 (2H, m), 2.95-3.05 (1H, m), 2.80-2.90 (1H, m), 2.60-2.70 (2H, m), 1.68-1.75 (2H, m), 1.27 (6H, d, $J = 7.2$ Hz), 1.10-1.22 (2H, m); LCMS: 100%, MS (ESI): m/z 516.2 $[\text{M} + \text{H}]^+$
137		White powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.96 (1H, s), 7.59-7.61 (2H, m), 7.50-7.52 (1H, m), 7.46-7.48 (1H, m), 7.32-7.41 (3H, m), 7.28-7.30 (1H, m), 6.39 (1H, t, $J = 5.6$ Hz), 4.63 (2H, d, $J = 5.2$ Hz), 4.53-4.56 (2H, m), 2.98-3.05 (2H, m), 2.72-2.78 (2H, m), 1.82-1.84 (2H, m), 1.18-1.29 (8H, m); LCMS: 100%, MS (ESI): m/z 482.3 $[\text{M} + \text{H}]^+$
138		Yellow powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.58 (1H, s), 7.48-7.51 (1H, m), 7.33-7.35 (2H, m), 7.24-7.26 (1H, m), 6.91-6.98 (2H, m), 6.70 (1H, s), 6.37 (1H, t, $J = 5.2$ Hz), 4.66-4.69 (4H, m), 2.98-3.03 (1H, m), 2.89-2.95 (3H, m), 1.85-1.89 (2H, m), 1.55 (6H, s), 1.24-1.34 (8H, m); LCMS: 100%, MS (ESI): m/z 541.3 $[\text{M} + \text{H}]^+$
139		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 9.43 (1H, s), 8.25-8.26 (2H, m), 7.73 (1H, d, $J = 6.4$ Hz), 7.63 (1H, s), 7.57-7.59 (1H, m), 7.48-7.53 (3H, m), 7.32 (1H, t, $J = 6.2$ Hz), 4.68-4.73 (4H, m), 2.0-3.04 (4H, m), 1.90-1.93 (2H, m), 1.28-1.37 (8H, m); LCMS: 97.6%, MS (ESI): m/z 483.1 $[\text{M} + \text{H}]^+$
140		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 8.81 (1H, brs), 7.72 (1H, s), 7.38-7.46 (1H, m), 7.25-7.32 (2H, m), 7.18-7.24 (1H, m), 6.96-7.01 (1H, m), 6.86-6.94 (2H, m), 4.59 (2H, s), 4.18-4.32 (2H, m), 2.84-2.96 (1H, m), 2.65-2.81 (3H, m), 1.60-1.72 (2H, m), 1.21 (6H, d, $J = 7.2$ Hz), 0.94-1.09 (2H, m); LCMS: 99.1%, MS (ESI): m/z 498.1 $[\text{M} + \text{H}]^+$
141		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 8.79 (1H, brs), 7.71 (1H, brs), 7.37-7.51 (3H, m), 7.27-7.31 (3H, m), 7.08 (1H, d, $J = 7.6$ Hz), 4.61 (2H, s), 4.20-4.25 (2H, m), 2.82-2.95 (1H, m), 2.63-2.79 (3H, m), 1.97-2.10 (1H, m), 1.55-1.65 (2H, m), 1.21 (2H, d, $J = 7.2$ Hz), 0.86-1.15 (6H, m); LCMS: 100%, MS (ESI): m/z 565.2 $[\text{M} + \text{H}]^+$







142		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.82-7.91 (2H, m), 7.51-7.61 (3H, m), 7.17 (1H, t, $J = 7.6$ Hz) 6.72 (1H, d, $J = 8.4$ Hz), 5.13 (2H, d, $J = 6.0$ Hz), 4.93 (2H, brs), 4.75-4.82 (2H, m), 2.86-3.06 (4H, m), 1.85-1.92 (2H, m), 1.29-1.38 (2H, m), 1.26 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 432.2 $[\text{M} + \text{H}]^+$
143		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 11.10 (1H, brs), 9.62 (1H, brs), 8.91 (1H, brs), 7.71 (1H, s), 7.62 (1H, d, $J = 7.6$ Hz), 7.50-7.57 (2H, m), 7.31-7.42 (3H, m), 6.98 (1H, t, $J = 8.0$ Hz), 6.62 (1H, s), 4.85 (2H, s), 4.10-4.28 (2H, m), 2.85-2.91 (1H, m), 2.58-2.78 (3H, m), 2.43-2.47 (2H, m), 2.26 (2H, t, $J = 7.2$ Hz), 2.12 (6H, s), 1.72-1.80 (2H, m), 1.42-1.52 (2H, m), 1.20 (6H, d, $J = 7.2$ Hz), 0.81-0.98 (2H, m); LCMS: 100%, MS (ESI): m/z 609.2 $[\text{M} + \text{H}]^+$
144		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 11.30 (1H, brs), 10.08 (1H, brs), 8.90 (1H, brs), 7.72 (1H, s), 7.65 (1H, d, $J = 7.6$ Hz), 7.49-7.61 (2H, m), 7.30-7.42 (3H, m), 6.98 (1H, t, $J = 8.0$ Hz), 6.62 (1H, s), 4.88 (2H, s), 4.10-4.65 (2H, m), 2.85-2.96 (1H, m), 2.65-2.77 (3H, m), 1.91-2.01 (1H, m), 1.49-1.61 (2H, m), 1.21 (6H, d, $J = 6.8$ Hz), 0.91-1.01 (2H, m), 0.81-0.90 (4H, m); LCMS: 96.9%, MS (ESI): m/z 564.1 $[\text{M} + \text{H}]^+$
145		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 11.17 (1H, brs), 9.68 (1H, s), 8.89 (1H, brs), 7.73 (1H, s), 7.67 (1H, d, $J = 7.6$ Hz), 7.49-7.60 (2H, m), 7.31-7.43 (3H, m), 6.99 (1H, t, $J = 7.6$ Hz), 6.62 (1H, s), 4.87 (2H, s), 4.10-4.30 (2H, m), 2.85-2.92 (1H, m), 2.64-2.81 (3H, m), 2.32 (2H, d, $J = 7.2$ Hz), 2.09-2.20 (1H, m), 1.50-1.62 (2H, m), 1.21 (6H, d, $J = 7.2$ Hz), 0.95-1.02 (8H, m); LCMS: 97.7%, MS (ESI): m/z 580.1 $[\text{M} + \text{H}]^+$
146		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 8.95 (1H, s), 8.45 (1H, s), 8.05 (1H, s), 7.81-7.88 (1H, m), 7.70-7.77 (2H, m), 7.58-7.66 (2H, m), 7.46-7.55 (2H, m), 7.35 (1H, s), 4.61 (2H, s), 4.18-4.39 (2H, m), 2.85-2.95 (1H, m), 2.70-2.82 (3H, m), 1.60-1.70 (2H, m), 1.21 (6H, d, $J = 6.4$ Hz), 0.93-1.10 (2H, m); LCMS: 98.7%, MS (ESI): m/z 525.1 $[\text{M} + \text{H}]^+$
147		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 8.83 (1H, s), 8.03 (1H, s), 7.69-7.79 (2H, m), 7.59-7.67 (2H, m), 7.44-7.56 (3H, m), 4.61 (2H, s), 4.15-4.32 (2H, m), 3.45-3.57 (4H, m), 2.83-2.93 (1H, m), 2.66-2.79 (3H, m), 1.81-1.92 (4H, m), 1.55-1.66 (2H, m), 1.20 (6H, d, $J = 6.8$ Hz) 0.91-1.05 (2H, m); LCMS: 100%, MS (ESI): m/z 579.3 $[\text{M} + \text{H}]^+$

148		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.56-7.65 (2H, m), 7.43-7.56 (2H, m), 7.26-7.39 (3H, m), 4.56-4.85 (6H, m), 3.82-3.95 (2H, m), 2.85-3.05 (6H, m), 1.85-1.95 (2H, m), 1.23-1.40 (8H, m), 1.13-1.23 (6H, m); LCMS: 100%, MS (ESI): m/z 579.2 $[\text{M} + \text{Na}]^+$
149		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400MHz): δ 10.30 (1H, brs), 7.53-7.62 (3H, m), 7.42 (1H, d, $J = 7.6$ Hz), 7.31-7.40 (2H, m), 6.98-7.05 (1H, m), 6.69 (1H, d, $J = 7.2$ Hz), 6.65 (1 H, brs), 6.58-6.62 (2H, m), 4.89 (2H, d, $J = 5.2$ Hz), 4.62-4.70 (2H, m), 2.98-3.03 (1H, m), 3.02 (6H, s), 2.81-2.90 (3H, m), 1.75-1.82 (2H, m), 1.29 (8H, d, $J = 6.8$ Hz); LCMS: 97.1%, MS (ESI): m/z 567.3 $[\text{M} + \text{H}]^+$
150		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 8.71 (1H, brs), 7.97 (1H, d, $J = 5.2$ Hz), 7.79 (1H, s), 7.70 (1H, s), 7.44-7.51 (1H, m), 7.28-7.39 (4H, m), 4.56-4.68 (2H, m), 4.26-4.38 (2H, m), 3.88-4.00 (1H, m), 2.75-2.93 (5H, m), 2.68-2.75 (1H, m), 1.90-2.02 (2H, m), 1.84 (3H, s), 1.62-1.78 (4H, m), 1.17-1.24 (9H, m); LCMS: 100%, MS (ESI): m/z 565.2 $[\text{M} + \text{Na}]^+$
151		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.12 (1H, s), 7.99 (1H, s), 7.94 (1H, s), 7.57-7.68 (4H, m), 7.35-7.47 (5H, m), 6.40 (1H, brs), 4.68-4.82 (4H, m), 2.89-3.08 (7H, m), 1.88-1.93 (2H, m), 1.29-1.38 (2H, m), 1.26 (6H, d, $J = 7.2$ Hz); LCMS: 98.5%, MS (ESI): m/z 565.2 $[\text{M} + \text{H}]^+$
152		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.22 (1H, s), 8.15 (1H, s), 7.75 (1H, s), 7.57-7.69 (4H, m), 7.30-7.44 (5H, m), 7.20-7.25 (1H, m), 7.12-7.19 (1H, m), 4.60-4.82 (4H, m), 2.85-3.06 (4H, m), 1.80-1.99 (2H, m), 1.20-1.40 (8H, m); LCMS: 99.5%, MS (ESI): m/z 551.1 $[\text{M} + \text{H}]^+$
153		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 9.34 (1H, s), 8.88-8.92 (2H, m), 8.65 (1H, s), 8.31-8.37 (1H, m), 8.24-8.29 (1H, m), 7.82 (1H, d, $J = 6.8$ Hz), 7.66-7.75 (2H, m), 7.48-7.58 (2H, m), 4.84 (2H, s), 4.29-4.33 (2H, m), 2.73-2.93 (7H, m), 1.62-1.67 (2H, m), 1.21 (6H, d, $J = 6.8$ Hz), 0.98-1.11 (2H, m); LCMS: 100%, MS (ESI): m/z 551.3 $[\text{M} + \text{H}]^+$
154		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.04 (1H, s), 7.96 (1H, s), 7.63 (1H, t, $J = 4.4$ Hz), 7.59 (1H, s), 7.36-7.43 (3H, m), 7.29-7.35 (1H, m), 4.75-4.85 (2H, m), 4.69 (2H, d, $J = 4.8$ Hz), 3.70-3.80 (4H, m), 3.09-3.23 (1H, m), 2.95-3.01 (3H, m), 2.40-2.50 (4H, m), 2.33 (3H, s), 1.95-2.10 (2H, m), 1.40-1.55 (2H, m), 1.25 (6H, d, $J = 6.8$ Hz); LCMS: 98.8%, MS (ESI): m/z 558.4 $[\text{M} + \text{H}]^+$








155		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.17 (1H, s), 8.06 (1H, s), 7.64-7.69 (1H, m), 7.59 (1H, s), 7.37-7.41 (2H, m), 7.28-7.35 (2H, m), 5.76 (1H, d, $J = 8.4$ Hz), 4.72-4.82 (2H, m), 4.67 (2H, d, $J = 6.8$ Hz), 4.13-4.26 (1H, m), 3.98-4.05 (2H, m), 3.49-3.58 (2H, m), 2.93-3.05 (4H, m), 1.98-2.05 (2H, m), 1.87-1.94 (2H, m), 1.25-1.34 (10H, m); LCMS: 99.1%, MS (ESI): m/z 559.3 $[\text{M} + \text{H}]^+$
156		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 8.65 (1H, brs), 7.71-7.75 (2H, m), 7.64 (1H, s), 7.51 (1H, d, $J = 7.2$ Hz), 7.31-7.44 (3H, m), 4.65 (2H, s), 4.35-4.41 (2H, m), 3.69-3.76 (4H, m), 2.92-2.97 (4H, m), 2.76-2.90 (4H, m), 1.65-1.76 (2H, m), 1.19-1.25 (8H, m); LCMS: 100%, MS (ESI): m/z 517.3 $[\text{M} + \text{H}]^+$
157		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.55 (1H, d, $J = 7.6$ Hz), 8.33 (1H, s), 7.63 (1H, d, $J = 7.6$ Hz), 7.60 (1H, s), 7.44-7.51 (1H, m), 7.39-7.43 (2H, m), 7.34 (1H, d, $J = 13.2$ Hz), 7.26-7.30 (1H, m), 6.98 (1H, dd, $J = 12.8, 4.8$ Hz), 4.66-4.75 (2H, m), 4.63 (2H, d, $J = 5.6$ Hz), 3.21-3.43 (1H, m), 3.05 (3 H, d, $J = 4.4$ Hz), 2.86-2.99 (3H, m), 2.08-2.18 (2H, m), 1.48-1.63 (2H, m), 1.25 (6H, d, $J = 7.2$ Hz); LCMS: 96.8%, MS (ESI): m/z 557.3 $[\text{M} + \text{H}]^+$
158		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.16 (1H, s), 7.82 (1H, d, $J = 9.6$ Hz), 7.65-7.72 (2H, m), 7.61 (1H, s), 7.39-7.49 (4H, m), 7.18 (1H, dd, $J = 8.8, 2.0$ Hz), 4.61-4.74 (4H, m), 3.03 (3H, s), 2.86-3.02 (4H, m), 1.82-1.89 (2H, m), 1.20-1.35 (8H, m); LCMS: 98.3%, MS (ESI): m/z 575.3 $[\text{M} + \text{H}]^+$
159		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 8.90 (1H, brs), 8.44 (1H, s), 7.75 (1H, s), 7.52-7.61 (3H, m), 7.44-7.49 (2H, m), 6.93-7.00 (2H, m), 4.60 (2H, s), 4.35-4.41 (2H, m), 2.95-3.05 (1H, m), 2.85-2.95 (1H, m), 2.72-2.80 (2H, m), 1.74-1.83 (2H, m), 1.05-1.25 (8H, m); LCMS: 98.3%, MS (ESI): m/z 498.2 $[\text{M} + \text{H}]^+$
160		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.99 (1H, s), 7.54-7.61 (2H, m), 7.49 (1H, s), 7.41-7.47 (2H, m), 7.34-7.40 (2H, m), 7.11 (1H, d, $J = 5.2$ Hz), 6.64 (1H, q, $J = 4.4$ Hz), 4.50-4.68 (4H, m), 3.10-3.21 (1H, m), 2.90-3.00 (3H, m), 2.92-2.96 (1H, m), 2.77-2.83 (2H, m), 2.47 (3H, s), 1.94-2.05 (2H, m), 1.31-1.45 (2H, m), 1.25 (6H, d, $J = 7.2$ Hz); LCMS: 100%, MS (ESI): m/z 553.3 $[\text{M} + \text{H}]^+$







161		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.12 (1H, s), 7.99 (1H, s), 7.81 (1H, d, $J = 9.2$ Hz), 7.63-7.70 (3H, m), 7.45-7.55 (3H, m), 7.43-7.47 (1H, m), 6.52 (1H, brs), 4.63-4.90 (4H, m), 2.85-3.10 (5H, m), 1.90-1.94 (2H, m), 1.25-1.28 (2H, m), 1.27 (6H, d, $J = 6.8$ Hz), 0.85-1.90 (2H, m), 0.65-0.70 (2H, m); LCMS: 98.7%, MS (ESI): m/z 565.3 $[\text{M} + \text{H}]^+$.
162		off-white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.20-8.30 (1H, m), 7.88 (1H, s), 7.70-7.76 (2H, m), 7.38 (1H, d, $J = 8.0$ Hz), 7.28 (1H, d, $J = 6.0$ Hz), 7.20-7.30 (2H, m), 7.14 (2H, d, $J = 9.2$ Hz), 6.61 (2H, d, $J = 8.8$ Hz), 6.5 (1H, s), 4.56 (2H, d, $J = 6.4$ Hz), 3.30-3.40 (4H, m), 3.05-3.15 (1H, m), 2.00-2.15 (4H, m), 1.24 (6H, d, $J = 6.8$ Hz); LCMS: 100 %, MS (ESI): m/z 495.1 $[\text{M} + \text{H}]^+$
163		Racemic mixture; yellow gum; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 9.59 (1H, brs), 9.38 (1H, brs), 9.22 (1H, t, $J = 6.0$ Hz), 8.24 (6H, d, $J = 2.0$ Hz), 8.10 (1H, s), 7.85-7.95 (2H, m), 7.80 (1H, m), 7.57 (2H, d, $J = 2.4$ Hz), 7.35-7.50 (4H, m), 7.05-7.20 (1H, m), 6.62 (1H, s), 5.21 (1H, m), 4.82 (2H, d, $J = 5.6$ Hz), 3.45-3.55 (1H, m), 3.25-3.45 (3H, m), 3.10-3.25 (1H, m), 2.15-2.30 (1H, m), 1.34 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 495.2 $[\text{M} + \text{H}]^+$.
164		Racemic mixture; colorless gum; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 9.20-9.75 (3H, brs), 8.88 (1H, brs), 8.18 (1H, s), 7.89 (1H, s), 7.84 (1H, s), 7.30-7.60 (6H, m), 7.10-7.25 (1H, m), 6.50-6.70 (2H, m), 4.95-5.10 (1H, m), 4.73 (2H, d, $J = 6.0$ Hz), 3.40-3.55 (1H, m), 3.15-3.40 (3H, m), 2.95-3.10 (1H, m), 2.05-2.25 (2H, m), 1.30 (6H, d, $J = 6.4$ Hz); LCMS: 100%, MS (ESI): m/z 532.1 $[\text{M} + \text{Na}]^+$
165		off-white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400MHz): δ 9.13-9.25 (2H, m), 9.93-9.06 (1H, m), 8.25 (1H, d, $J = 2.0$ Hz), 8.14 (1H, s), 8.04-8.12 (2H, m), 7.87 (1H, s), 7.55-7.63 (1H, m), 7.43-7.51 (2H, m), 7.37-7.43 (2H, m), 7.35 (1H, d, $J = 7.7$ Hz), 6.61 (1H, s), 4.83 (2H, d, $J = 6.0$ Hz), 3.35-3.40 (2H, m), 3.15-3.20 (1H, m), 2.97-3.09 (2H, m), 2.89-2.97 (1H, m), 1.84-2.00 (4H, m), 1.34 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 493.2 $[\text{M} + \text{H}]^+$
166		Racemic mixture; white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 9.45 (1H, brs), 8.84 (1H, brs), 8.19 (1H, s), 7.89 (1H, s), 7.75-7.84 (2H, m), 7.35-7.55 (6H, m), 7.29 (1H, d, $J = 8.4$ Hz), 6.59 (1H, s), 5.00-5.10 (1H, m), 4.73 (2H, d, $J = 6.0$ Hz), 3.20-3.40 (4H, m), 2.95-3.10 (1H, m), 2.100-2.25 (2H, m), 1.30 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 544.1 $[\text{M} + \text{H}]^+$







167		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.17 (1H, s), 8.00-8.15 (2H, m), 7.90 (1H, s), 7.84 (1H, s), 7.80-7.82 (1H, m), 7.78 (1H, d, $J = 1.6$ Hz), 7.30-7.45 (4H, m), 7.07 (1H, d, $J = 8.4$ Hz), 6.53 (1H, s), 4.89 (2H, d, $J = 6.4$ Hz), 3.23-3.35 (5H, m), 3.10-3.15 (4H, m), 1.37 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 494.1 $[\text{M} + \text{H}]^+$
168		off-white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 9.21 (1H, t, $J = 6.0$ Hz), 8.55-8.65 (1H, m), 8.25-8.35 (1H, m), 8.26 (1H, d, $J = 2.0$ Hz), 8.21 (2H, d, $J = 8.4$ Hz), 8.08 (1H, s), 7.87 (1H, s), 7.55-7.60 (1H, m), 7.45-7.49 (1H, m), 7.38-7.43 (2H, m), 7.33 (2H, d, $J = 8.4$ Hz), 6.62 (1H, s), 4.83 (2H, d, $J = 6.0$ Hz), 3.14-3.18 (1H, m), 2.86-3.10 (4H, m), 1.95-2.00 (2H, m), 1.75-1.88 (2H, m), 1.34 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 493.1 $[\text{M} + \text{H}]^+$
169		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400MHz): δ 10.47 (1H, brs), 9.21-9.22 (1H, m), 8.71-8.72 (1H, m), 8.49-8.50 (1H, m), 8.27 (1H, s), 8.21 (1H, s), 8.02 (1H, s), 7.77-7.95 (3H, m), 7.50-7.56 (1H, m), 7.43-7.47 (3H, m), 6.60 (1H, s), 4.75 (2H, d, $J = 4.8$ Hz), 3.39-3.45 (2H, m), 3.14-3.18 (1H, m) 3.00-3.03 (2H, m), 2.90-2.92 (1H, m), 1.95-2.01 (2H, m), 1.72-1.85 (2H, m), 1.30 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 531.1 $[\text{M} + \text{Na}]^+$
170		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 9.81 (1H, brs), 9.16 (1H, brs), 8.44 (1H, s), 8.30-8.40 (1H, m), 8.10-8.25 (1H, m), 7.83-7.91 (2H, m), 7.69-7.78 (2H, m), 7.51 (1H, d, $J = 8.4$ Hz), 7.30-7.42 (3H, m), 6.52 (1H, s), 4.88 (2H, d, $J = 6.4$ Hz), 3.55-3.65 (2H, m), 3.24-3.42 (2H, m) 3.10-3.20 (2H, m), 2.15-2.30 (4H, m), 1.36 (6H, d, $J = 6.8$ Hz); LCMS: 99.4%, MS (ESI): m/z 527.1 $[\text{M} + \text{H}]^+$
171		yellow powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 9.30 (1H, t, $J = 6.0$ Hz), 8.25-8.45 (4H, m), 8.16-8.25 (2H, m), 8.11 (1H, s), 7.85 (1H, s), 7.51-7.63 (2H, m), 7.35-7.51 (4H, m), 6.60 (1H, s), 4.80 (2H, d, $J = 6.0$ Hz), 4.45-4.55 (1H, m), 3.55-3.65 (1H, m), 3.25-3.35 (1H, m), 3.15-3.25 (2H, m), 2.90-3.00 (1H, m), 2.00-2.10 (1H, m), 1.85-1.95 (1H, m), 1.45-1.63 (2 H, m), 1.34 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 536.1 $[\text{M} + \text{H}]^+$
172		yellow powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 9.31 (1H, t, $J = 6.0$ Hz), 8.24-8.35 (3H, m), 8.16-8.26 (2H, m), 8.11 (1H, s), 7.88 (1H, s), 7.58-7.66 (1H, m), 7.29-7.55 (5H, m), 6.63 (1H, s), 4.84 (2H, d, $J = 6.0$ Hz), 4.43-4.53 (1H, m), 3.58-3.68 (1H, m), 3.25-3.34 (1H, m), 3.08-3.23 (2H, m), 2.84-2.94 (1H, m), 1.85-2.05 (2H, m), 1.46-1.56 (2H, m), 1.35 (6H, d, $J = 6.8$ Hz); LCMS: 97.7%, MS (ESI): m/z 558.1 $[\text{M} + \text{Na}]^+$








173		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.10-8.23 (3H, m), 7.89 (1H, d, $J = 1.2$ Hz), 7.86 (1H, s), 7.78 (1H, d, $J = 1.6$ Hz), 7.72 (1H, d, $J = 7.6$ Hz), 7.51 (1H, d, $J = 7.6$ Hz), 7.29-7.43 (3H, m), 6.53 (1H, s), 4.91-4.98 (1H, m), 4.83-4.91 (2H, m), 3.42-3.58 (2H, m), 3.20-3.35 (3H, m), 2.16-2.38 (4H, m), 1.37 (6H, d, $J = 6.4$ Hz); LCMS: 96.6%, MS (ESI): m/z 543.0[M + H] $^+$
174		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 12.09 (1H, brs), 9.93 (1H, brs), 9.66 (1H, brs), 9.09 (1H, brs), 8.18 (1H, d, $J = 2.0$ Hz), 7.83 (2H, s), 7.50-7.62 (1H, m), 7.35-7.48 (3H, m), 6.58 (1H, s), 4.63 (4H, d, $J = 6.0$ Hz), 3.59-3.75 (2H, m), 3.42-3.59 (5H, m), 3.26-3.42 (2H, m), 2.95-3.11 (1H, m), 2.71-2.90 (2H, m), 2.04-2.20 (2H, m), 1.44-1.66 (2H, m), 1.21 (6H, d, $J = 7.2$ Hz); LCMS: 100%, MS (ESI): m/z 501.1[M + H] $^+$
175		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 9.30 (1H, brs), 7.64-7.66 (2H, m), 7.52-7.58 (2H, m), 7.43-7.47 (1H, m), 7.32-7.39 (2H, m), 7.19-7.26 (1H, m), 7.13-7.16 (1H, m), 6.82-6.86 (1H, m), 6.5 (1H, d, $J = 4.8$ Hz), 5.99 (1H, brs), 4.92 (2H, d, $J = 6.0$ Hz), 4.20 (2H, s), 3.86-3.91 (2H, m), 3.32-3.37 (2H, m), 2.97-3.04 (1H, m), 1.28 (6H, d, $J = 7.2$ Hz); LCMS: 100.0%, MS (ESI): m/z 481.3[M + H] $^+$
176		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400 MHz): δ 8.89 (1H, brs), 8.32 (1H, s), 7.85 (1H, d, $J = 7.6$ Hz), 7.70-7.75 (2H, m), 7.55-7.60 (2H, m), 7.45-7.51 (2H, m), 4.59 (2H, s), 4.43-4.49 (1H, m), 4.27-4.30 (4H, m), 3.60-3.63 (1H, m), 3.45-3.51 (1H, m), 2.82-2.91 (2H, m), 2.74-2.80 (2H, m), 1.60-1.68 (2H, m), 1.10-1.22 (8H, m); LCMS: 98.8%, MS (ESI): m/z 581.3[M + H] $^+$
177		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.87 (1H, brs), 7.74 (1H, d, $J = 2.4$ Hz), 7.62-7.67 (2H, m), 7.38-7.46 (2H, m), 7.29-7.38 (2H, m), 7.09 (1H, d, $J = 2.4$ Hz), 4.75-4.85 (2H, m), 4.54 (2H, d, $J = 6.0$ Hz), 4.06-4.33 (3H, m), 3.90-4.05 (2H, m), 3.42-3.57 (2H, m), 3.25-3.30 (1H, m), 2.91-3.10 (3H, m), 2.10-2.15 (2H, m), 1.80-1.15 (2H, m), 1.55-1.76 (4H, m), 1.27 (6H, d, $J = 7.2$ Hz); LCMS: 98.1%, MS (ESI): $m/z = 581.3$ [M + Na] $^+$
178		white powder; $^1\text{H-NMR}$ (DMSO-d_6 , 400MHz): δ 13.00 (1H, brs), 9.76 (1H, t, $J = 6.0$ Hz), 7.72 (1H, s), 7.69 (1 H, d, $J = 7.6$ Hz), 7.60 (2H, d, $J = 8.4$ Hz), 7.42-7.47 (1H, m), 7.36-7.41 (1H, m), 4.64-4.82 (4H, m), 4.00-4.13 (1H, m), 3.81-3.93 (2H, m), 2.87-3.02 (3H, m), 2.56 (3H, s), 1.95-2.02 (2H, m), 1.75-1.82 (2H, m), 1.53-1.65 (2H, m), 1.37-1.48 (2H, m), 1.21 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 573.3[M + H] $^+$







179		white powder; ¹ H-NMR (DMSO-d ₆ , 400 MHz): δ 8.71 (1H, brs), 7.74 (1H, s), 7.70 (1H, s), 7.61 (1H, s), 7.49-7.52 (1H, m), 7.31-7.48 (3H, m), 4.65(2H, s), 4.45-4.51 (2H, m), 3.01-3.10 (1H, m), 2.60-2.90 (7H, m), 2.30-2.50 (4H, m), 2.22 (3H, s), 1.75-1.85 (2H, m), 1.10-1.30 (8H, m); LCMS: 98.3%, MS (ESI): m/z 530.3[M + H] ⁺
180		white powder; ¹ H-NMR (CD ₃ OD, 400 MHz): δ 7.67 (1H, s), 7.60-7.63 (3H, m), 7.40-7.42 (3H, m), 4.78-4.85 (2H, m), 4.71 (2H, s), 3.25-3.35 (1H, m), 3.05-3.20 (8H, m), 2.90-3.10 (3H, m), 1.95-2.05 (2H, m), 1.45-1.55 (2H, m), 1.27 (3H, d, J = 7.2 Hz); LCMS: 100%, MS (ESI): m/z 516.3[M + H] ⁺
181		white powder; ¹ H-NMR (CDCl ₃ , 400 MHz): δ 8.68 (1H, brs), 7.64 (1H, d, J = 2.4 Hz), 7.50-7.59 (2H, m), 7.26-7.37 (2H, m), 7.21-7.25 (1H, m), 6.33 (1H, d, J = 2.4 Hz), 4.79 (2H, s), 4.70-4.80 (2H, m), 4.55 (2H, d, J = 6.0 Hz), 2.80-2.99 (4H, m), 1.81-1.85 (2H, m), 1.17-1.26 (8H, m); LCMS: 100%, MS (ESI): m/z 462.1[M + H] ⁺
182		white powder; ¹ H-NMR (CDCl ₃ , 400 MHz): δ 8.85 (1H, s), 7.60-7.66 (2H, m), 7.43-7.50 (2H, m), 7.30-7.35 (2H, m), 7.17-7.23 (1H, m), 7.10-7.16 (1H, m), 6.67 (1H, brs), 6.63 (1H, d, J = 1.2 Hz), 4.97 (2H, d, J = 5.2 Hz), 4.43-4.49 (2H, m), 2.97-3.08 (1H, m), 2.75-2.80 (1H, m), 2.72-2.75 (2H, m), 1.59-1.64 (2H, m), 1.28-1.30 (6H, m), 1.10-1.19 (2H, m); LCMS: 96.5%, MS (ESI): m/z 515.2[M + H] ⁺
183		(S)-methyl; white powder; ¹ H-NMR (CDCl ₃ , 400 MHz): δ 8.16 (1H, s), 7.82 (1H, dd, J = 8.8, 0.8 Hz), 7.70 (1H, d, J = 8.4 Hz), 7.60-7.65 (2H, m), 7.45-7.51 (1H, m), 7.39-7.43 (2H, m), 7.32-7.39 (1H, m), 7.10-7.18 (2H, m), 5.35-5.45 (1H, m), 4.36-4.54 (2H, m), 2.95-3.07 (1H, m), 2.66-2.88 (3H, m), 1.68-1.85 (2H, m), 1.50 (3H, d, J = 7.2 Hz), 1.27 (6H, d, J = 6.8 Hz), 1.05-1.22 (2H, m); LCMS: 100%, MS (ESI): m/z 496.2[M + H] ⁺
184		white powder; ¹ H-NMR (DMSO-d ₆ , 400 MHz): δ 11.37 (1H, brs), 7.70 (1H, s), 7.52 (1H, d, J = 7.6 Hz), 7.38 (1H, d, J = 8.4 Hz), 7.31-7.36 (2H, m), 7.26-7.28 (1H, m), 7.08 (1H, t, J = 7.2, 8.8 Hz), 7.00 (1H, t, J = 7.2 Hz), 6.52 (1H, s), 4.78 (2H, s), 4.39-4.42 (2H, m), 2.82-2.94 (3H, m), 2.67-2.77 (1H, m), 2.36 (3H, s), 1.64-1.67 (2H, m), 1.21-1.23 (6H, d, J = 7.2 Hz), 1.01-1.11 (2H, m); LCMS: 98.1%, MS (ESI): m/z 495.3[M + H] ⁺







185		white powder; $^1\text{H-NMR}$ (CD_3OD , 400 MHz) δ : 7.60 (1H, s), 7.56 (1H, d, $J = 7.6$ Hz), 7.39 (1H, d, $J = 8.0$ Hz), 7.23 (1H, t, $J = 8.0$ Hz), 7.13 (1H, t, $J = 7.6$ Hz), 7.01-7.07 (2H, m), 6.90 (1H, d, $J = 8.0$ Hz), 6.49 (1H, s), 5.07 (2H, s), 4.20-4.33 (2H, m), 2.90-3.03 (1H, m), 2.63-2.75 (1H, m), 2.41-2.55 (2H, m), 1.45-1.55 (2H, m), 1.24 (6H, d, $J = 6.8$ Hz), 0.95-1.10 (2H, m); LCMS: 100%, MS (ESI): m/z 497.3 $[\text{M} + \text{H}]^+$
186		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.67 (1H, s), 7.58-7.66 (2H, m), 7.31-7.39 (2H, m), 7.16-7.22 (1H, m), 7.09-7.15 (2H, m), 6.95 (1H, d, $J = 7.6$ Hz), 6.87 (1H, t, $J = 6.0$ Hz), 6.63 (1H, d, $J = 1.2$ Hz), 4.97 (2H, d, $J = 5.6$ Hz), 4.30-4.45 (2H, m), 3.96 (3H, s), 2.95-3.08 (1H, m), 2.71-2.82 (1H, m), 2.58-2.69 (2H, m), 1.53-1.63 (2H, m), 1.28 (6H, d, $J = 6.8$ Hz), 1.01-1.16 (2H, m); LCMS: 100%, MS (ESI): m/z 511.3 $[\text{M} + \text{H}]^+$
187		(<i>S</i>)-methyl; white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.85 (1H, brs), 7.60-7.67 (2H, m), 7.57 (1H, d, $J = 7.6$ Hz), 7.43-7.49 (1H, m), 7.29-7.40 (3H, m), 7.11-7.25 (2H, m), 6.58-6.65 (2H, m), 5.70-5.80 (1H, m), 4.24-4.29 (2H, m), 2.94-3.08 (1H, m), 2.75-2.85 (1H, m), 2.60-2.74 (2H, m), 1.53-1.67 (5H, m), 1.19-1.30 (8H, m); LCMS: 100%, MS (ESI): m/z 495.3 $[\text{M} + \text{H}]^+$
188		(<i>R</i>)-methyl; white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.85 (1H, brs), 7.60-7.67 (2H, m), 7.57 (1H, d, $J = 7.6$ Hz), 7.43-7.49 (1H, m), 7.29-7.40 (3H, m), 7.11-7.25 (2H, m), 6.58-6.65 (2H, m), 5.70-5.80 (1H, m), 4.24-4.29 (2H, m), 2.94-3.08 (1H, m), 2.75-2.85 (1H, m), 2.60-2.74 (2H, m), 1.53-1.67 (5H, m), 1.19-1.30 (8H, m); LCMS: 100%, MS (ESI): m/z 495.3 $[\text{M} + \text{H}]^+$
189		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.04 (1H, s), 7.61 (1H, s), 7.50-7.55 (1H, m), 7.35-7.40 (1H, m), 6.87-6.96 (2H, m), 4.86 (2H, d, $J = 5.6$ Hz), 4.65-4.70 (2H, m), 3.55-3.59 (2H, m), 3.32-3.38 (1H, m), 2.96-3.04 (1H, m), 2.985-2.95 (2H, m), 2.81 (2H, t, $J = 6.8$ Hz), 2.10-2.20 (2H, m), 1.55-1.65 (2H, m), 1.26 (6H, d, $J = 7.06$ Hz); LCMS: 94.97%, MS (ESI): m/z 535.3 $[\text{M} + \text{H}]^+$
190		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.50 (1H, brs), 7.60-7.65 (2H, m), 7.41 (1H, d, $J = 7.6$ Hz), 7.32-7.37 (2H, m), 7.16-7.23 (2H, m), 7.09-7.16 (1H, m), 6.52-6.60 (2H, m), 4.82 (2H, d, $J = 4.8$ Hz), 4.58-4.68 (2H, m), 2.97-3.08 (1H, m), 2.8-2.93 (3H, m), 2.37 (3H, s), 1.77-1.87 (2H, m), 1.24-1.32 (8H, m); LCMS: 100%, MS (ESI): m/z 495.3 $[\text{M} + \text{H}]^+$
191		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.44 (1H, brs), 7.58-7.68 (2H, m), 7.42 (1H, d, $J = 7.6$ Hz), 7.31-7.38 (2H, m), 7.10-7.24 (3H, m), 6.60 (1H, d, $J = 1.2$ Hz), 6.45-6.54 (1H, m), 4.82 (2H, d, $J = 5.6$ Hz), 4.60-4.65 (2H, m), 2.97-3.08 (1H, m), 2.81-2.94 (3H, m), 2.39 (3H, s), 1.80-1.85 (2H, m), 1.23-1.33 (8H, m); LCMS: 100%, MS (ESI): m/z 495.3 $[\text{M} + \text{H}]^+$

192		(<i>S</i>)-methyl; white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.61 (1H, s), 7.50-7.56 (2H, m), 7.27-7.37 (3H, m), 7.12-7.20 (2H, m), 5.44-5.54 (1H, m), 4.52-4.64 (2H, m), 2.80-3.06 (12H, m), 1.80-1.90 (2H, m), 1.48 (3H, d, $J = 7.2$ Hz), 1.26-1.33 (8H, m); LCMS: 99.4%, MS (ESI): m/z 530.4 $[\text{M} + \text{H}]^+$
193		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.59 (1H, s), 7.56 (1H, s), 7.42 (1H, dd, $J = 8.0, 1.2$ Hz), 7.27-7.30 (1H, m), 7.20-7.26 (2H, m), 7.17 (1H, s), 4.87 (2H, d, $J = 6.0$ Hz), 4.72-4.77 (2H, m), 2.90-3.09 (12H, m), 1.85-1.88 (2H, m), 1.27 (8H, d, $J = 7.2$ Hz); LCMS: 100%, MS (ESI): m/z 550.3 $[\text{M} + \text{H}]^+$
194		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.71 (1H, t, $J = 5.6$ Hz), 8.55 (1H, d, $J = 8.4$ Hz), 8.28 (1H, d, $J = 8.0$ Hz), 7.87 (1H, d, $J = 8.4$ Hz), 7.76 (1H, t, $J = 7.6$ Hz), 7.71 (1H, s), 7.64 (1H, d, $J = 8.4$ Hz), 7.58 (1H, d, $J = 7.6$ Hz), 7.44-7.54 (2H, m), 7.37 (1H, t, $J = 7.2$ Hz), 4.93 (2H, d, $J = 6.0$ Hz), 4.65-4.80 (2H, m), 3.00-3.13 (1H, m), 2.83-2.95 (3H, m), 1.83-1.89 (2H, m), 1.24-1.35 (8H, m); LCMS: 100%, MS (ESI): m/z 527.3 $[\text{M} + \text{H}]^+$
195		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.14-8.20 (1H, m), 7.56 (1H, s), 7.50 (1H, d, $J = 2.4$ Hz), 7.45 (1H, dd, $J = 7.6, 1.2$ Hz), 7.39 (1H, dd, $J = 8.0, 1.2$ Hz), 7.27-7.30 (1H, m), 6.46 (1H, d, $J = 2.4$ Hz), 5.02 (2H, d, $J = 6.0$ Hz), 4.82-4.91 (2H, m), 4.25-4.37 (1H, m), 3.20-3.29 (2H, m), 2.89-3.05 (4H, m), 2.70-2.82 (2H, m), 2.16-2.24 (2H, m), 2.04-2.13 (2H, m), 1.91-1.96 (2H, m), 1.35-1.41 (2H, m), 1.28 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 549.3 $[\text{M} + \text{H}]^+$
196		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.71 (1H, d, $J = 2.8$ Hz), 7.68 (1H, s), 7.50-7.59 (2H, m), 7.39 (1H, t, $J = 8.0$ Hz), 7.29 (1H, dd, $J = 8.0, 1.2$ Hz), 7.15 (1H, d, $J = 8.4$ Hz), 7.07 (1H, d, $J = 2.4$ Hz), 4.70-4.85 (4H, m), 3.98-4.14 (1H, m), 2.89-3.13 (6H, m), 2.63-2.75 (2H, m), 1.83-1.94 (4H, m), 1.27-1.44 (10H, m); LCMS: 96.8%, MS (ESI): m/z 614.3 $[\text{M} + \text{Na}]^+$
197		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.38 (1H, t, $J = 6.0$ Hz), 8.05 (1H, d, $J = 4.4$ Hz), 7.75 (1H, d, $J = 2.0$ Hz), 7.62 (1H, s), 7.54 (1H, d, $J = 8.0$ Hz), 7.37 (1H, t, $J = 8.0$ Hz), 7.27 (1H, s), 7.10 (1H, d, $J = 2.0$ Hz), 4.70-4.91 (4H, m), 2.85-3.10 (7H, m), 1.89-1.95 (2H, m), 1.26-1.42 (8H, m); LCMS: 98.0%, MS (ESI): m/z 523.2 $[\text{M} + \text{H}]^+$







198		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.69 (1H, d, J = 2.20 Hz), 7.58 (1H, s), 7.50-7.56 (1H, m), 7.39 (1H, t, J = 7.95 Hz), 7.29 (1H, d, J = 6.85 Hz), 6.93 (1H, d, J = 2.4 Hz), 6.81 (1H, t, J = 5.6 Hz), 4.76 (2H, d, J = 5.6 Hz), 4.70-4.75 (2H, m), 3.90-3.95 (2H, m), 3.70-3.75 (2H, m), 2.86-3.07 (6H, m), 2.72-2.75 (2H, m), 1.88-1.90 (2H, m), 1.28 (8H, d, J = 6.8 Hz); LCMS: 100%, MS (ESI): m/z 578.3 $[\text{M}+\text{H}]^+$
199		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.93 (1H, t, J = 6.4 Hz), 7.62-7.71 (2H, m), 7.45-7.52 (1H, m), 7.32 (1H, t, J = 8.0 Hz), 7.20-7.25 (1H, m), 6.39 (1H, d, J = 2.0 Hz), 5.35 (1H, d, J = 8.4 Hz), 4.77-4.95 (4H, m), 3.97-4.16 (1H, m), 2.93-3.15 (3H, m), 1.93-2.04 (5H, m), 1.66 (6H, s), 1.31-1.44 (2H, m), 1.26 (6H, d, J = 7.2 Hz); LCMS: 100%, MS (ESI): m/z 566.2 $[\text{M}+\text{H}]^+$
200		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.70 (1H, s), 7.60 (1H, s), 7.55 (1H, d, J = 8.0 Hz), 7.40 (1H, t, J = 8.0 Hz), 7.25-7.29 (1H, m), 6.97 (1H, s), 6.79 (1H, brt, J = 5.2 Hz), 4.64-4.77 (4H, m), 3.95-4.05 (2H, m), 3.72-3.78 (4H, m), 3.50-3.75 (2H, m), 2.84-3.08 (4H, m), 1.93-2.05 (2H, m), 1.25-1.35 (8H, m); LCMS: 100%, MS (ESI): m/z 579.3 $[\text{M}+\text{H}]^+$
201		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.72 (1H, d, J = 2.45 Hz), 7.68 (1H, s), 7.51-7.61 (2H, m), 7.40 (1H, t, J = 8.07 Hz), 7.26-7.29 (1H, m), 7.18 (1H, d, J = 8.07 Hz), 7.09 (1H, d, J = 2.8 Hz), 4.69-4.83 (4H, m), 4.15-4.19 (1H, m), 3.92-3.97 (2H, m), 3.40-3.50 (2H, m), 2.88-3.08 (4H, m), 1.76-1.98 (4H, m), 1.49-1.57 (4H, m), 1.33-1.45 (2H, m), 1.27-1.31 (6H, d, J = 6.8 Hz); LCMS: 100%, MS (ESI): m/z 615.3 $[\text{M}+\text{Na}]^+$
202		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400MHz): δ 7.79 (1H, t, J = 6.0 Hz), 7.55 (1H, d, J = 2.8 Hz), 7.51 (1H, s), 7.40 (1H, d, J = 8.0 Hz), 7.25-7.30 (1H, m), 7.17 (1H, d, J = 7.2 Hz), 5.93 (1H, d, J = 2.8 Hz), 4.89 (2H, d, J = 6.0 Hz), 4.75-4.85 (2H, m), 3.80 (4H, t, J = 4.8 Hz), 3.34 (4H, t, J = 4.8 Hz), 2.88-3.05 (4H, m), 1.85-1.95 (2H, m), 1.31-1.40 (2H, m), 1.28 (6H, d, J = 6.8 Hz); LCMS: 100%, MS (ESI): m/z 551.2 $[\text{M}+\text{H}]^+$
203		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400MHz): δ 7.59 (1H, s), 7.57 (1H, s), 7.43 (1H, d, J = 8.0 Hz), 7.30 (1H, t, J = 8.0 Hz), 7.22-7.25 (1H, m), 7.14-7.19 (2H, m), 4.88 (2H, d, J = 6.4 Hz), 4.71-4.83 (2H, m), 3.78-3.90 (4H, m), 2.84-3.08 (8H, m), 1.85-1.98 (2H, m), 1.31-1.41 (2H, m), 1.28 (6H, d, J = 6.8 Hz); LCMS: 100%, MS (ESI): m/z 551.2 $[\text{M}+\text{H}]^+$

204		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.58 (1H, s), 7.56 (1H, s), 7.38-7.42 (1H, m), 7.28-7.32 (1H, m), 7.19-7.25 (2H, m), 7.14 (1H, s), 4.87 (2H, d, $J = 6.0$ Hz), 4.70-4.80 (2H, m), 3.28-3.35 (2H, m), 2.87-3.06 (4H, m), 2.49-2.59 (2H, m), 1.90-2.00 (2H, m), 1.68-1.72 (2H, m), 1.24-1.43 (11H, m), 0.98 (3H, d, $J = 7.2$ Hz); LCMS: 100%, MS (ESI): m/z 563.3 $[\text{M} + \text{H}]^+$
205		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.64 (1H, d, $J = 2.4$ Hz), 7.62 (1H, s), 7.56-7.62 (1H, m), 7.38-7.43 (1H, m), 7.34-7.37 (1H, m), 6.94 (1H, d, $J = 2.4$ Hz), 6.73-6.76 (1H, m), 4.77-4.94 (2H, m), 4.42-4.71 (4H, m), 4.33-4.39 (1H, m), 3.98 (1H, dd, $J = 12.0, 3.6$ Hz), 3.67 (1H, dd, $J = 12.0, 4.4$ Hz), 2.83-3.09 (4H, m), 1.84-1.88 (2H, m), 1.27-1.33 (8H, m); LCMS: 91.5%, MS (ESI): m/z 565.2 $[\text{M} + \text{H}]^+$
206		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.58 (1H, s), 7.30 (1H, t, $J = 5.2$ Hz), 7.17-7.26 (2H, m), 7.10 (1H, d, $J = 7.2$ Hz), 5.01 (2H, d, $J = 5.6$ Hz), 4.76-4.91 (2H, m), 3.84-3.97 (4H, m), 2.89-3.07 (8H, m), 1.86-1.97 (2H, m), 1.25-1.40 (8H, m); LCMS: 100%, MS (ESI): m/z 485.2 $[\text{M} + \text{H}]^+$
207		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.47 (1H, brs), 7.62-7.65 (2H, m), 7.43-7.52 (1H, m), 7.29-7.33 (1H, m), 7.18-7.24 (1H, m), 6.41 (1H, s), 4.78-4.85 (6H, m), 3.20-3.30 (1H, m), 2.90-3.06 (3H, m), 2.00-2.05 (2H, m), 1.48-1.54 (2H, m), 1.19-1.34 (6H, m); LCMS: 97.4%, MS (ESI): m/z 518.1 $[\text{M} + \text{Na}]^+$
208		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.44 (1H, d, $J = 8.8$ Hz), 8.25 (1H, d, $J = 8.0$ Hz), 7.98 (1H, s), 7.85 (1H, d, $J = 7.2$ Hz), 7.76 (1H, t, $J = 6.4$ Hz), 7.35-7.70 (7H, m), 4.95-5.34 (2H, m), 4.44-4.64 (2H, m), 3.19-3.78 (6H, m), 2.95-3.13 (1H, m), 1.78-1.91 (4H, m), 1.24-1.29 (6H, m); LCMS: 97.1%, MS (ESI): m/z 522.3 $[\text{M} + \text{H}]^+$
209		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 9.26 (1H, brs), 8.62 (1H, d, $J = 8.4$ Hz), 8.30 (1H, d, $J = 8.4$ Hz), 7.88 (1H, d, $J = 8.0$ Hz), 7.80 (1H, t, $J = 7.6$ Hz), 7.68-7.75 (2H, m), 7.56-7.67 (3H, m), 7.40-7.45 (2H, m), 5.11 (1H, brs), 4.72 (2H, s), 3.40-3.45 (4H, m), 3.00-3.05 (1H, m), 2.85-2.90 (2H, m), 1.97-2.05 (3H, m), 1.53-1.69 (2H, m), 1.29 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 507.3 $[\text{M} + \text{H}]^+$
210		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.86 (1H, t, $J = 6.0$ Hz), 7.61-7.69 (2H, m), 7.48 (1H, d, $J = 8.0$ Hz), 7.32 (1H, t, $J = 8.0$ Hz), 7.22 (1H, d, $J = 8.0$ Hz), 6.39 (1H, d, $J = 2.5$ Hz), 4.73-4.95 (4H, m), 2.89-3.06 (4H, m), 1.85-1.95 (2H, m), 1.65 (6H, s), 1.29-1.38 (2H, m), 1.26 (6H, d, $J = 7.0$ Hz); LCMS: 94.9%, MS (ESI): m/z 524.1 $[\text{M} + \text{H}]^+$

211		(3R); white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.64-7.72 (1H, m), 7.47-7.52 (1H, m), 7.34-7.44 (2H, m), 7.27 (1H, d, $J = 1.0$ Hz), 6.78 (0.7H, t, $J = 6.0$ Hz) 6.56 (0.3H, t, $J = 5.5$ Hz), 5.28-5.39 (1H, m) 5.09-5.25 (1H, m), 4.46-4.79 (4H, m), 3.68-4.02 (2H, m), 3.20-3.27 (1H, m), 3.05-3.13 (1H, m), 2.78-3.02 (5H, m) 2.35-2.52 (2H, m), 2.01-2.10 (2H, m), 1.75-1.91 (1H, m) 1.53-1.66 (1H, m), 1.30 (6H, d, $J = 6.5$ Hz), 1.17-1.23 (3H, m); LCMS: 100%, MS (ESI): m/z 577.2[M + H] $^+$
212		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 9.28 (1H, brs), 8.56 (1H, d, $J = 8.4$ Hz), 8.25 (1H, d, $J = 8.4$ Hz), 7.82 (1H, d, $J = 7.6$ Hz), 7.63-7.77 (3H, m), 7.51-7.63 (3H, m), 7.38-7.42 (2H, m), 5.20 (1H, brs), 4.65 (2H, d, $J = 5.6$ Hz), 3.22-3.53 (6H, m), 2.88-3.01 (1H, m), 1.88-2.00 (4H, m), 1.21 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 523.2[M + H] $^+$
213		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.51 (1H, d, $J = 8.5$ Hz), 8.22- 8.31 (2H, m), 7.87 (1H, d, $J = 7.5$ Hz), 7.73-7.81 (2H, m), 7.68 (1H, d, $J = 9.0$ Hz), 7.54-7.64 (3H, m), 7.38-7.49 (2H, m), 5.51 (1H, s), 4.56 (2H, d, $J = 7.0$ Hz), 4.25 (2H, d, $J = 8.5$ Hz), 3.34-3.43 (2H, m), 3.07-3.17 (1H, m), 2.76-2.88 (2H, m), 1.93-2.01 (3H, m), 1.55-1.70 (2H, m), 1.33 (7 H, d, $J = 7.0$ Hz); LCMS: 100%, MS (ESI): m/z 529.2[M + Na] $^+$
214		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.56 (1H, s), 7.28-7.35 (2H, m), 7.08 (1H, dd, $J = 6.4, 2.4$ Hz), 6.07-6.14 (1H, m), 6.05 (1H, s), 4.65-4.75 (2H, m), 4.56-4.61 (4H, m), 3.58 (3H, s), 3.09-3.23 (1H, m), 2.84-3.06 (3H, m), 2.5 (3H, s), 1.96-2.04 (2H, m), 1.43-1.57(2H, m), 1.27 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 490.2[M + H] $^+$
215		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 9.78 (1H, brs), 8.66 (1H, d, $J = 8.8$ Hz), 8.32 (1H, d, $J = 8.0$ Hz), 7.89 (1H, d, $J = 8.4$ Hz), 7.85 (1H, s), 7.80 (1H, t, $J = 7.6$ Hz), 7.65-7.75 (2H, m), 7.57-7.67 (2H, m), 7.42-7.49 (2H, m), 4.78 (2H, d, $J = 5.6$ Hz), 4.31 (2H, d, $J = 7.2$ Hz), 3.35-3.40 (2H, m), 3.08-3.16(1H, m), 2.80-2.90 (2H, m), 2.18-2.24 (1H, m), 2.10-2.20 (2H, m), 1.53-1.67 (2H, m), 1.32 (6H, d, $J = 7.2$ Hz); LCMS: 100%, MS (ESI): m/z 530.3[M + H] $^+$
216		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 9.08 (1H, brt, $J = 6.4$ Hz), 8.62 (1H, d, $J = 8.8$ Hz), 8.27 (1H, d, $J = 8.8$ Hz), 7.86 (1H, d, $J = 8.4$ Hz), 7.76-7.83 (1H, m), 7.67-7.73 (2H, m), 7.62-7.66 (1H, m), 7.55-7.61 (2H, m), 7.36-7.44 (2H, m), 4.90-5.02 (2H, m), 4.72 (2H, d, $J = 6.4$ Hz), 2.99-3.08 (1H, m), 2.85-2.96 (2H, m), 2.75 (2H, d, $J = 6.8$ Hz), 1.69-1.93 (3H, m), 1.23-1.30 (8H, m); LCMS: 100%, MS (ESI): m/z 507.2[M + H] $^+$







217		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.75-8.89 (1H, m), 7.57-7.68 (2H, m), 7.60-7.65 (1H, m), 7.26-7.33 (1H, m), 7.18-7.23 (1H, m), 6.38 (1H, d, $J = 2.8$ Hz), 4.88-5.01 (2H, m), 4.82 (2H, d, $J = 6.0$ Hz), 2.96-3.01 (1H, m), 2.82-2.92 (2H, m), 2.7 (2H, d, $J = 6.4$ Hz), 1.78-1.86 (2H, m), 1.60-1.77 (7H, m), 1.22-1.29 (8H, m); LCMS: 94.8 %, MS (ESI): m/z 538.4 $[\text{M} + \text{H}]^+$
218		Mixture of 2 trans-isomers; white powder; $^1\text{H-NMR}$ (CD_3OD , 400 MHz): δ 9.03 (1H, d, $J = 8.4$ Hz), 8.29 (1H, d, $J = 8.0$ Hz), 8.21-8.26 (1H, m), 8.11-8.19 (2H, m), 7.93-8.02 (1H, m), 7.77-7.85 (2H, m), 7.61-7.77 (3H, m), 4.97-5.08 (2H, m), 4.56-4.63 (1H, m), 4.38-4.47 (1H, m), 3.75-3.86 (1H, m), 3.35-3.46 (2H, m), 2.93-3.05 (2H, m), 2.77-2.87 (1H, m), 1.95-2.16 (2H, m), 1.64-1.78 (1H, m), 1.27 (6 H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 546.2 $[\text{M} + \text{Na}]^+$
219		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 9.10 (1 H, brt, $J = 6.0$ Hz), 8.62 (1H, d, $J = 8.4$ Hz), 8.27 (1H, d, $J = 8.8$ Hz), 7.87 (1H, d, $J = 8.4$ Hz), 7.80 (1H, t, $J = 8.0$ Hz), 7.67-7.72 (2H, m), 7.62-7.66 (1H, m), 7.55-7.62 (2H, m), 7.35-7.44 (2H, m), 4.73 (2H, d, $J = 6.4$ Hz), 4.57-4.68 (2H, m), 3.37-3.51 (2H, m), 2.98-3.10 (1H, m), 2.78 (2H, s), 1.66-1.79 (2H, m), 1.52-1.65 (2H, m), 1.28 (6H, d, $J = 7.2$ Hz); LCMS: 100%, MS (ESI): m/z 523.1 $[\text{M} + \text{H}]^+$
220		Racemic mixture; white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 9.16 (1H, d, $J = 8.8$ Hz), 7.60-7.70 (2H, m), 7.47-7.52 (2H, m), 7.32-7.42 (2H, m), 7.24-7.25 (2H, m), 6.33-6.41 (1H, m), 5.43-5.55 (1H, m), 4.86-4.93 (1H, m), 4.71-4.83 (3H, m), 2.86-2.98 (4H, m), 1.89-1.98 (2H, m), 1.23-1.26 (8H, m), 1.19 (3H, d, $J = 7.09$ Hz); LCMS: 100%, MS (ESI): m/z 476.2 $[\text{M} + \text{H}]^+$
221		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.95-9.10 (1H, m), 7.68 (1H, d, $J = 2.4$ Hz), 7.63 (1H, s), 7.56-7.61 (1H, m), 7.32-7.38 (2H, m), 7.26-7.31 (1H, m), 6.38 (1H, d, $J = 2.8$ Hz), 4.86-4.96 (2H, m), 4.57-4.64 (2H, m), 2.95-3.04 (1H, m), 2.83-2.93 (2H, m), 2.65 (2H, d, $J = 6.4$ Hz), 1.78-1.87(2H, m), 1.57-1.70 (7H, m), 1.20-1.29 (8H, m); LCMS: 97.5%, MS (ESI): m/z 526.2 $[\text{M} + \text{Na}]^+$
222		Mixture of 2 trans-isomers; white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 9.04 (1H, d, $J = 8.80$ Hz), 8.29 (2H, t, $J = 8.0$ Hz), 8.09-8.22 (2 H, m), 7.94-8.04 (1H, m), 7.65-7.82 (5H, m), 5.07-5.15 (2H, m), 3.67-3.80 (2H, m), 3.54-3.61 (1H, m), 3.34-3.45 (2H, m), 2.86-3.00 (2H, m), 2.73-2.78 (1H, m), 2.03-2.08 (1H, m), 1.86-1.92 (1H, m), 1.51-1.67 (1H, m), 1.26 (6H, d, $J = 7.2$ Hz); LCMS: 99.6%, MS (ESI): m/z 523.2 $[\text{M} + \text{H}]^+$







223		Mixture of 2 trans-isomers; white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 9.25-9.38 (1H, m), 7.66-7.67 (2H, m), 7.58-7.59 (1H, d, J = 4.0 Hz), 7.35-7.37 (2H, m), 7.27-7.28 (1H, m), 6.36-6.40 (1H, m), 5.16-5.23 (1H, m), 4.52-3.63 (2H, m), 4.15-4.22 (1H, m), 3.50-3.55 (1H, m), 3.38-3.40 (2H, m), 3.29-3.32 (1H, m), 2.96-3.05 (1H, m), 2.73-2.77 (1H, m), 2.63-2.66 (1H, m), 1.67-1.75 (2H, m), 1.66-1.67 (6H, m), 1.20-1.24 (6H, d, J = 4.8 Hz); LCMS: 100%, MS (ESI): m/z 520.2 $[\text{M}+\text{H}]^+$
224		white powder; $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 9.07-9.18 (1H, m), 7.68 (1H, d, J = 2.0 Hz), 7.66 (1H, s), 7.54-7.61 (1H, m), 7.33-7.43 (2H, m), 7.28-7.32 (1H, m), 6.39 (1H, d, J = 2.5 Hz), 5.03 (1H, brs), 4.55-4.65 (2H, m), 3.36-3.43 (2H, m), 3.30-3.35 (2H, m), 2.95-3.02 (1H, m), 2.71-2.80 (2H, m), 1.83-1.95 (3H, m), 1.68 (6H, s), 1.43-1.56 (2H, m), 1.24 (6H, d, J = 7.0 Hz); LCMS: 100%, MS (ESI): m/z 504.2 $[\text{M} + \text{H}]^+$
225		(3 <i>R</i> , 4 <i>R</i>); white powder; $^1\text{H-NMR}$ (CD_3OD , 400 MHz): δ 8.30-8.39 (2H, m), 7.94 (1H, d, J =8.0 Hz), 7.70-7.83 (2H, m), 7.58-7.69 (4H, m), 7.45-7.51 (2H, m), 4.55-4.75 (2H, m), 3.75-4.06 (1H, m), 3.35-3.40 (1H, m), 3.08-3.19 (2H, m), 2.90-3.06 (2H, m), 2.52-2.69 (1H, m), 2.38-2.50 (1H, m), 1.68-1.80 (1 H, m), 1.36-1.60 (2H, m), 1.20-1.31 (6H, m); LCMS: 100%, MS (ESI): m/z 522.3 $[\text{M}+\text{H}]^+$
226		(3 <i>S</i> , 4 <i>S</i>); white powder; $^1\text{H-NMR}$ (CD_3OD , 400 MHz): δ 8.30-8.39 (2H, m), 7.94 (1H, d, J =8.0 Hz), 7.70-7.83 (2H, m), 7.58-7.69 (4H, m), 7.45-7.51 (2H, m), 4.55-4.75 (2H, m), 3.75-4.06 (1H, m), 3.35-3.40 (1H, m), 3.08-3.19 (2H, m), 2.90-3.06 (2H, m), 2.52-2.69 (1H, m), 2.38-2.50 (1H, m), 1.68-1.80 (1 H, m), 1.36-1.60 (2H, m), 1.20-1.31 (6H, m); LCMS: 100%, MS (ESI): m/z 522.3 $[\text{M}+\text{H}]^+$
227		white powder; $^1\text{H NMR}$ (500 MHz, CDCl_3): δ 9.55-9.71 (1H, m), 7.77 (1H, s), 7.70 (1H, d, J = 2.5 Hz), 7.67 (1H, dd, J = 7.5, 1.5 Hz), 7.34-7.43 (2H, m), 7.27-7.31 (1H, m), 6.39 (1H, d, J = 2.5 Hz), 4.63-4.72 (2H, m), 4.26 (2H, d, J = 7.0 Hz), 3.17-3.26 (2H, m), 3.00-3.12 (1H, m), 2.68-2.77 (2H, m), 2.04-2.13 (1H, m), 1.92-1.985 (2H, m), 1.68 (6H, s), 1.35-1.048 (2H, m), 1.27 (6H, d, J = 6.5 Hz); LCMS: 100%, MS (ESI): m/z 527.2 $[\text{M} + \text{Na}]^+$
228		white powder; $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 9.00-9.05 (1H, m), 7.68 (1H, d, J = 2.0 Hz), 7.63 (1H, s), 7.59 (1H, d, J = 7.2 Hz), 7.31-7.4 (2H, m), 7.27-7.3 (1H, m), 6.39 (1H, d, J = 2.4 Hz), 4.53-4.65 (4H, m), 3.35-3.49 (2H, m), 2.93-3.05 (1H, m), 2.65 (2H, s), 1.69 (6H, s), 1.6-1.65 (2H, m), 1.49-1.56 (2H, m), 1.25 (6H, d, J = 6.8 Hz); LCMS: 100%, MS (ESI): m/z 520.2 $[\text{M} + \text{H}]^+$






229		white powder; ^1H NMR (400 MHz, CDCl_3): δ 9.31-9.48 (1H, m), 7.65-7.75 (2H, m), 7.59-7.65 (1H, m), 7.33-7.43 (2H, m), 7.27-7.30 (1H, m), 6.39 (1H, s), 5.37-5.37 (1H, m), 4.60 (2H, s), 3.41-3.59 (2H, m), 3.10-3.22 (2H, m), 2.95-3.06 (3H, m), 1.6-1.81 (10H, m), 1.19-1.24 (6H, d, $J = 7.2$ Hz); LCMS: 100%, MS (ESI): m/z 520.2 $[\text{M} + \text{H}]^+$
230		white powder; ^1H NMR (400 MHz, CDCl_3): δ 9.15-9.26 (1H, m), 7.64-7.69 (2H, m), 7.25-7.29 (2H, m), 7.10-7.17 (1H, m), 6.37 (1H, d, $J = 2.8$ Hz), 4.75-4.85 (2H, m), 4.60 (2H, d, $J = 5.6$ Hz), 2.89-3.06 (4H, m), 2.65 (3H, s), 1.86-1.94 (2H, m), 1.67 (6H, s), 1.30-1.40 (2H, m), 1.27 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 504.3 $[\text{M} + \text{H}]^+$
231		White powder; ^1H NMR (CDCl_3): δ 7.54-7.58 (1H, m), 7.28-7.33 (2H, m), 7.09-7.14 (1H, m), 6.03-6.11 (2H, m), 4.65-4.79 (2H, m), 4.48-4.63 (2H, m), 3.61 (3H, s), 2.86-3.07 (4H, m), 2.50 (3H, s), 1.89-1.98 (2H, m), 1.37-1.49 (8H, m), 1.26 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 518.3 $[\text{M} + \text{H}]^+$
232		white powder; ^1H NMR (400 MHz, CDCl_3): δ 9.15-9.35 (1H, m), 7.64-7.66 (2H, m), 7.23-7.30 (2H, m), 7.12-7.15 (1H, m), 6.36 (1H, d, $J = 2.4$ Hz), 4.98 (1H, brs), 4.58 (2H, d, $J = 4.4$ Hz), 3.36 (2H, t, $J = 6.4$ Hz), 3.12-3.13 (2H, m), 2.96-3.03 (1H, m), 2.56-2.64 (m, 5H), 1.77-1.80 (m, 3H), 1.66 (6H, s), 1.20-1.30 (8H, m); LCMS: 100%, MS (ESI): m/z 518.3 $[\text{M} + \text{H}]^+$
233		(3 <i>R</i> , 4 <i>R</i>); white powder; ^1H NMR (400 MHz, CDCl_3): δ 9.20-9.33 (1H, m), 7.68 (1H, d, $J = 2.4$ Hz), 7.66 (1H, s), 7.58-7.63 (1H, m), 7.32-7.42 (2H, m), 7.28-7.32 (1H, m), 6.39 (1H, d, $J = 2.4$ Hz), 5.36 (1H, brs), 4.53-4.65 (2H, m), 4.16-4.32 (1H, m), 3.34-3.45 (1H, m), 3.23-3.28 (1H, m), 3.10-3.18 (1H, m), 2.92-3.07 (2H, m), 2.61-2.68 (1H, m), 2.53-2.58 (1H, m), 1.68 (6H, d, $J = 2.4$ Hz), 1.50-1.65 (3H, m), 1.20-1.27 (6H, m); LCMS: 100%, MS (ESI): m/z 520.3 $[\text{M} + \text{H}]^+$
234		Racemic mixture; white powder; ^1H NMR (CDCl_3 , 400 MHz): δ 9.20-9.31 (1H, m), 8.60 (1H, $J = 8.4$ Hz, d), 8.23 (1H, $J = 8.4$ Hz, d), 7.80 (1H, $J = 8.0$ Hz, d), 7.70-7.76 (1H, m), 7.62-7.68 (2H, m), 7.49-7.62 (3H, m), 7.32-7.41 (2H, m), 4.98-5.12 (1H, m), 4.55-4.74 (2H, m), 3.86-4.02 (1H, m), 3.45-3.60 (1H, m), 3.20-3.37 (1H, m), 2.91-3.08 (1H, m), 2.54-2.75 (2H, m), 1.40-1.65 (2H, m), 1.15-1.31 (6H, m); LCMS: 95.9%, MS (ESI): m/z 497.2 $[\text{M} + \text{H}]^+$







235		white solid; ^1H NMR (CDCl_3 , 400 MHz): δ 7.57 (1H, m), 7.12-7.16 (1H, m), 7.05-7.07 (2H, m), 6.04 (1H, t, $J = 4\text{ Hz}$), 4.79-4.83 (2H, m), 4.74-4.75 (2H, d, $J = 5.2\text{ Hz}$), 2.94-3.06 (4H, m), 2.41 (1H, s), 1.91-1.94 (2H, m), 1.34-1.41 (2H, m), 1.29-1.31 (6H, d, $J = 6.8\text{ Hz}$); LCMS: 100.0%, MS (ESI): m/z 394.2 $[\text{M} + \text{H}]^+$
236		white powder; ^1H NMR (400 MHz, CDCl_3): δ 9.05 (1 H, t, $J = 6.4\text{ Hz}$), 7.68 (1H, d, $J = 2.4\text{ Hz}$), 7.64 (1H, s), 7.59 (1H, dd, $J = 7.2\text{ Hz}$, 1.6 Hz), 7.27-7.41 (3H, m), 6.39 (1H, d, $J = 2.4\text{ Hz}$), 4.77-4.87 (2H, m), 4.61 (2H, d, $J = 6.4\text{ Hz}$), 2.91-3.07 (4H, m), 1.90-1.98 (2H, m), 1.68 (6H, s), 1.31-1.44 (2H, m), 1.25 (6H, d, $J = 6.8\text{ Hz}$); LCMS: 100%, MS (ESI): m/z 590.3 $[\text{M} + \text{H}]^+$
237		(3R); white powder; ^1H -NMR (CDCl_3 , 400 MHz): δ 9.66-9.78 (1H, m), 8.59 (1H, d, $J = 8.0\text{ Hz}$), 8.24 (1H, d, $J = 8.0\text{ Hz}$), 7.70-7.85 (3H, m), 7.62-7.68 (2H, m), 7.50-7.59 (2H, m), 7.35-7.40 (2H, m), 4.71 (2H, d, $J = 4.8\text{ Hz}$), 4.40-4.50 (1H, m), 4.15-4.25 (1H, m), 3.15-3.26 (1H, m), 2.98-3.10 (1H, m), 1.45-1.68 (1H, m), 1.20-1.26 (6H, m), 1.00 (3H, t, $J = 7.2\text{ Hz}$); LCMS: 98.1%, MS (ESI): m/z 482.2 $[\text{M} + \text{H}]^+$
238		white powder; ^1H NMR (400 MHz, CDCl_3): δ 8.81 (1H, t, $J = 6.0\text{ Hz}$), 7.57-7.71 (2H, m), 7.45 (1H, d, $J = 8.0\text{ Hz}$), 7.29 (1H, t, $J = 8.0\text{ Hz}$), 7.20 (1H, d, $J = 7.6\text{ Hz}$), 6.39 (1H, d, $J = 2.0\text{ Hz}$), 4.83 (2H, d, $J = 6.0\text{ Hz}$), 4.55-4.65 (2H, m), 3.34-3.46 (2H, m), 2.93-3.05 (1H, m), 2.67 (2H, s), 1.58-1.68 (8H, m), 1.45-1.55 (2H, m), 1.25 (6H, d, $J = 7.2\text{ Hz}$); LCMS: 100%, MS (ESI): m/z 554.2 $[\text{M} + \text{H}]^+$
239		white powder; ^1H NMR (400 MHz, CDCl_3): δ ppm 7.55 (1H, s), 7.34 (1H, d, $J = 8.0\text{ Hz}$), 7.28 (1H, d, $J = 8.0\text{ Hz}$), 7.19 (1H, t, $J = 8.0\text{ Hz}$), 6.79 (1H, t, $J = 5.6\text{ Hz}$), 5.27 (2H, d, $J = 5.6\text{ Hz}$), 4.71-4.85 (2H, m), 2.94-3.05 (4H, m), 1.91-1.93 (2H, m), 1.68 (6H, s), 1.31-1.44 (2H, m), 1.27 (6H, d, $J = 6.8\text{ Hz}$); LCMS: 100%, MS (ESI): m/z 458.2 $[\text{M} + \text{H}]^+$
240		Racemic mixture; white powder; ^1H NMR (400 MHz, CDCl_3): δ 9.25-9.30 (1H, m), 8.61 (1 H, d, $J = 8.4\text{ Hz}$), 8.26 (1H, d, $J = 8.4\text{ Hz}$), 7.86 (1H, d, $J = 8.4\text{ Hz}$), 7.78 (1 H, t, $J = 7.6\text{ Hz}$), 7.53-7.73 (5H, m), 7.36-7.45 (2H, m), 5.44 (1H, brs), 4.68 (2H, s), 3.95-4.10 (1H, m), 3.54-3.65 (1H, m), 3.40-3.52 (1H, m), 3.08-3.24 (1H, m), 2.93-3.07 (3H, m), 1.65-1.81 (2H, m), 1.26 (6H, d, $J = 6.8\text{ Hz}$); LCMS: 100%, MS (ESI): m/z 497.2 $[\text{M} + \text{H}]^+$






241		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.32-8.40 (1H, m), 7.73 (1H, t, $J = 8.0$ Hz), 7.56 (1H, s), 7.39-7.43 (1H, m), 7.35-7.38 (1H, m), 7.27-7.31 (1H, m), 7.23-7.27 (1H, m), 4.82 (2H, d, $J = 6.0$ Hz), 4.7-4.78 (2H, m), 2.80-2.99 (4H, m), 1.80-1.85 (2H, m), 1.59 (6 H, s), 1.18-1.23 (8H, m); LCMS: 100%, MS (ESI): m/z 535.2 $[\text{M}+\text{H}]^+$
242		white powder; $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.58-7.70 (3H, m), 7.37 (1H, t, $J = 8.0$ Hz), 6.85-6.94 (1H, m), 5.07 (2H, d, $J = 6.0$ Hz), 4.79-4.82 (2H, m), 2.89-3.05 (4H, m), 1.87-1.89 (2H, m), 1.25 - 1.33 (10H, m); LCMS: 95.5%, MS (ESI): m/z 425.1 $[\text{M} + \text{H}]^+$
243		white powder; $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 8.86 (1H, t, $J = 6.0$ Hz), 8.55 (1H, d, $J = 8.8$ Hz), 8.26 (1H, d, $J = 8.8$ Hz), 7.98 (1H, d, $J = 1.6$ Hz), 7.91 (1H, dd, $J = 8.8, 2.0$ Hz), 7.66-7.69 (2H, m), 7.63-7.66 (1H, m), 7.58-7.62 (1H, m), 7.37-7.44 (2H, m), 4.74 (2H, d, $J = 6.0$ Hz), 4.53-4.56 (2H, m), 3.32-3.38 (2H, m), 3.0-3.07 (1H, m), 2.67 (2H, s), 1.71 (6H, s), 1.60-1.63 (3H, m), 1.50-1.52 (3H, m), 1.29 (6 H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 581.2 $[\text{M} + \text{H}]^+$
244		white powder; $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.55-7.64 (2H, m), 7.31-7.40 (2H, m), 7.19-7.25 (1H, m), 6.14 (1H, s), 5.04 (2H, d, $J = 6.4$ Hz), 4.76-4.86 (2H, m), 4.12(3H, s), 2.85-3.07(4H, m), 1.83-1.95 (2H, m), 1.6 (6H, s), 1.30-1.40 (2H, m), 1.26 (6H, d, $J = 7.2$ Hz); LCMS: 98.0%, MS (ESI): m/z 538.2 $[\text{M} + \text{H}]^+$
245		(3R); white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 9.28-9.46 (1H, m), 8.65 (1H, d, $J = 8.4$ Hz), 8.33 (1H, d, $J = 8.8$ Hz), 7.91 (1H, d, $J = 8.0$ Hz), 7.83 (1H, t, $J = 8.0$ Hz), 7.72-7.78 (2H, m), 7.59-7.70 (3H, m), 7.42-7.52 (2H, m), 5.08-5.17 (1H, m), 4.74 (2H, d, $J = 5.6$ Hz), 3.75-3.86 (1H, m), 3.51-3.72 (2H, m), 3.03-3.14 (1H, m), 2.84 (2H, d, $J = 5.6$ Hz), 1.32 (6H, d, $J = 6.8$ Hz); LCMS:100%, MS (ESI): m/z 497.3 $[\text{M}+\text{H}]^+$
246		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.86 (1H, d, $J = 6.4$ Hz), 7.66-7.68 (2H, m), 7.48 (1H, d, $J = 7.2$ Hz), 7.32 (1H, t, $J = 8.0$ Hz), 7.23 (1H, d, $J = 7.2$ Hz), 6.41-6.42 (1H, d, $J = 2.4$ Hz), 4.85 (2H, d, $J = 6.4$ Hz), 3.98-4.00 (2H, m), 3.38-3.42 (1H, m), 2.97-3.06 (1H, m), 2.86 (1H, s), 2.37-2.42 (1H, m), 1.98-2.07 (2H, m), 1.68-1.76 (2H, m), 1.67 (6H, s), 1.36-1.39 (3H, s), 1.27 (6H, d, $J = 6.8$ Hz); LCMS: 97.0%, MS (ESI): m/z 538.2 $[\text{M}+\text{H}]^+$






247		(4 <i>S</i>); white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 9.32-9.55 (1H, m), 8.65 (1H, d, $J = 8.8$ Hz), 8.33 (1H, d, $J = 8.8$ Hz), 7.91 (1H, d, $J = 8.0$ Hz), 7.83 (1H, t, $J = 8.0$ Hz), 7.72-7.78 (2H, m), 7.59-7.70 (3H, m), 7.42-7.52 (2H, m), 5.11-5.20 (1H, m), 4.66-4.80 (2H, m), 3.97-4.11 (1H, m), 3.55-3.69 (1H, m), 3.28-3.42 (1H, m), 3.03-3.14 (1H, m), 2.65-2.80 (2H, m), 1.25-1.34 (8H, m); LCMS: 100%, MS (ESI): m/z 497.2 $[\text{M}+\text{H}]^+$
248		(3 <i>S</i>); white powder; $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 9.23-9.49 (1H, m), 8.52-8.61 (1H, m), 8.12-8.23 (1H, m), 7.69-7.84 (2H, m), 7.45-7.67 (5H, m), 7.28-7.4 (2H, m), 4.47-4.71 (2H, m), 4.12-4.33 (1H, m), 3.58-3.77 (2H, m), 3.09-3.30 (3H, m), 2.87-3.00 (2H, m), 1.19 (6H, d, $J = 5.6$ Hz); LCMS: 100%, MS (ESI): m/z 483.2 $[\text{M} + \text{H}]^+$
249		white powder; $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 7.77-7.84 (2H, m), 7.58 (1H, s), 7.47-7.54 (2H, m), 7.30 (1H, d, $J = 8.0$ Hz), 5.12 (2H, d, $J = 6.0$ Hz), 4.75-4.86 (2H, m), 2.85-3.11 (4H, m), 1.84-1.92 (2H, m), 1.71 (6H, s), 1.29-1.34 (2H, m), 1.27 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 541.2 $[\text{M} + \text{H}]^+$
250		(3 <i>S</i>); white powder; $^1\text{H NMR}$ (400 MHz, CDCl_3): δ ppm 7.81 (1H, brt, $J = 5.6$ Hz), 7.56 (1H, s), 7.11-7.17 (1H, m), 7.05-7.09 (1H, m), 7.02-7.05 (1H, m), 5.08-5.20 (1H, m), 4.81-4.90 (3H, m), 3.32-3.36 (1H, m), 3.20-3.26 (1H, m), 2.89-3.09 (6H, m), 2.30-2.38 (4H, m), 1.92-2.09 (4H, m), 1.36-1.48 (2H, m), 1.20-1.30 (12H, m); LCMS: 98%, MS (ESI): m/z 527.10 $[\text{M} + \text{H}]^+$
251		(4 <i>R</i>); white powder; $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 9.19-9.47 (1H, m), 8.58-8.67 (1H, m), 8.25-8.33 (1H, m), 7.85-7.91 (1H, m), 7.76-7.84 (1H, m), 7.57-7.74 (5H, m), 7.39-7.46 (2H, m), 5.04-5.31 (1H, m), 4.64-4.76 (2H, m), 3.91-4.08 (1H, m), 3.55-3.76 (1H, m), 3.26-3.43 (1H, m), 2.93-3.15 (2H, m), 2.68-2.87 (1H, m), 1.47-1.74 (2H, m), 1.24-1.30 (6H, m); LCMS: 100%, MS (ESI): m/z 497.2 $[\text{M} + \text{H}]^+$
252		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.81-8.87 (1H, m), 7.57-7.61 (2H, m), 7.42 (1H, d, $J = 8.0$ Hz), 7.26 (1H, d, $J = 8.0$ Hz), 7.13-7.18 (1H, m), 6.33 (1H, d, $J = 2.4$ Hz), 4.78 (2H, d, $J = 6.0$ Hz), 4.60-4.68 (2H, m), 3.19-3.28 (2H, m), 2.89-2.98 (1H, m), 2.74 (2H, d, $J = 20.4$ Hz), 1.82-1.91 (2H, m), 1.57-1.63 (6H, m), 1.19 (6H, d, $J = 7.2$ Hz); LCMS: 100%, MS (ESI): m/z 556.2 $[\text{M}+\text{H}]^+$

253		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 9.16-9.62 (1H, m), 7.57-7.62 (1H, m), 7.48-7.54 (1H, m), 7.50 (1H, d, $J = 8.0$ Hz), 7.19-7.24 (1H, m), 7.07-7.13 (1H, m), 6.33-6.38 (1H, m), 6.22-6.28 (1H, m), 4.75-4.90 (4H, m), 2.76-3.01 (4H, m), 1.75-1.98 (6H, m), 1.15-1.26 (8H, m), 0.91-1.02 (3H, m), 0.69-0.77 (3H, m); LCMS: 100%, MS (ESI): m/z 552.2 $[\text{M}+\text{H}]^+$
254		(3R); white powder; $^1\text{H NMR}$ (400 MHz, CDCl_3): δ ppm 7.85 (1H, brt, $J = 5.2$ Hz), 7.55 (1H, s), 7.12-7.16 (1H, m), 7.04-7.08 (2H, m), 5.15 (1H, dd, $J = 14.8, 6.40$ Hz), 4.83-4.89 (3H, m), 3.36 (1H, dd, $J = 9.6, 4.8$ Hz), 3.20-3.29 (1H, m), 3.05-3.09 (1H, m), 2.91-3.04 (5H, m), 2.36 (1H, m), 1.96-2.14 (3H, m), 1.91 (2H, m), 1.29-1.40 (2H, m), 1.16-1.25 (12H, m); LCMS: 96.5%, MS (ESI): m/z 527.2 $[\text{M} + \text{H}]^+$
255		white powder; $^1\text{H NMR}$ (400 MHz, CDCl_3): δ 8.21 (1H, d, $J = 8.8$ Hz), 7.89 (1H, t, $J = 5.6$ Hz), 7.77 (2H, t, $J = 8.4$ Hz), 7.59 (1H, s), 7.56 (1H, d, $J = 8.4$ Hz), 7.49 (1H, t, $J = 7.6$ Hz), 5.38 (2H, d, $J = 6.0$ Hz), 4.72-4.82 (2H, m), 2.86-3.10 (4H, m), 1.84-1.92 (2H, m), 1.69 (6H, s), 1.30-1.37 (1H, m), 1.28 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 475.2 $[\text{M} + \text{H}]^+$
256		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 8.31 (1H, t, $J = 6.0$ Hz), 7.56 (1H, s), 7.34-7.40 (2H, m), 7.23 (1H, t, $J = 8.0$ Hz), 7.12 (1H, d, $J = 7.2$ Hz), 4.81 (2H, d, $J = 6.0$ Hz), 4.70-4.78 (2H, m), 4.44 (1H, brs), 2.79-2.98 (4H, m), 2.15 (3H, s), 1.75-1.84 (2H, m), 1.58 (6H, s), 1.22-1.29 (2H, m), 1.19 (6H, d, $J = 6.4$ Hz); LCMS: 100%, MS (ESI): m/z 538.2 $[\text{M}+\text{H}]^+$
257		yellow powder; $^1\text{H NMR}$ (CDCl_3 , 400 MHz): δ 7.60 (1H, s), 7.33-7.35 (2H, m), 7.18-7.23 (1H, m), 6.59 (1H, t, $J = 4.0$ Hz), 5.08 (2H, d, $J = 5.6$ Hz), 4.82-4.85 (2H, m), 2.95-3.04 (4H, m), 1.89-1.92 (2H, m), 1.34-1.37 (2H, m), 1.28 (6H, d, $J = 6.8$ Hz); LCMS: 100.0%, MS (ESI): m/z 434.1 $[\text{M} + \text{H}]^+$
258		white powder; $^1\text{H-NMR}$ (CDCl_3 , 400 MHz): δ 7.51 (1H, s), 7.46 (1H, d, $J = 6.8$ Hz), 7.28 (1H, t, $J = 7.6$ Hz), 7.12 (1H, d, $J = 6.4$ Hz), 6.19-6.26 (1H, m), 6.04-6.08 (1H, m), 4.72 (2H, br s), 4.55-4.60 (2H, m), 3.52 (3H, s), 2.79-2.97 (4H, m), 1.71-1.99 (2H, m), 1.44 (6H, s), 1.24-1.27 (2H, m), 1.20 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 538.3 $[\text{M}+\text{H}]^+$

259		white powder; ^1H NMR (CDCl_3 , 400 MHz): δ 8.16 (1H, d, $J=6.0$ Hz), 7.59 (1H, s), 7.10-7.30 (3H, m), 6.20 (1H, s), 4.75-4.85 (4H, m), 4.15 (3H, s), 2.85-3.05 (4H, m), 2.60 (3H, s), 1.65-1.90 (2H, m), 1.64 (3H, s), 1.25-1.35 (2H, m), 1.26 (6H, d, $J = 6.8$ Hz); LCMS: 98.70%, MS (ESI): m/z 518.3 $[\text{M} + \text{H}]^+$
260		(2S); white powder; ^1H -NMR (CDCl_3 , 400 MHz): δ 9.25 (1H, br s), 8.62 (1H, d, $J = 8.0$ Hz), 8.31 (1H, d, $J = 8.8$ Hz), 7.88 (1H, d, $J = 8.4$ Hz), 7.78-7.83 (1H, m), 7.70-7.75 (2H, m), 7.63-7.68 (2H, m), 7.58-7.62 (1H, m), 7.38-7.50 (2H, m), 4.93-5.14 (2H, m), 4.74 (2H, d, $J = 6.4$ Hz), 3.60-3.64 (1H, m), 3.33-3.44 (1H, m), 2.96-3.09 (1H, m), 2.84-2.90 (1H, m), 2.05-2.21 (1H, m), 1.61-1.89 (7H, m), 1.24-1.29 (6H, m); LCMS: 96.9%, MS (ESI): m/z 522.3 $[\text{M} + \text{H}]^+$
261		(3R, 4R); white powder; ^1H -NMR (CDCl_3 , 400 MHz): δ 9.35-9.37 (1H, m), 8.63 (1H, d, $J = 7.6$ Hz), 8.31 (1H, d, $J = 8.4$ Hz), 7.88 (1H, d, $J = 8.0$ Hz), 7.76-7.85 (1H, m), 7.73-7.74 (1H, m), 7.57-7.69 (3H, m), 7.43-7.48 (2H, m), 5.16-5.18 (1H, m), 4.66-4.73 (2H, m), 4.24-4.27 (1H, m), 3.57-3.64 (2H, m), 3.24-3.27 (1H, m), 2.98-3.15 (3H, m), 2.55-2.61 (2H, m), 1.98-2.19 (2H, m), 1.48-1.51 (1H, m), 1.25-1.31 (6H, m), 1.15-1.18 (3H, m); LCMS: 98.9%, MS (ESI): m/z 551.2 $[\text{M} + \text{H}]^+$
262		(2S); white powder; ^1H -NMR (CDCl_3 , 400 MHz): δ 8.91 (1H, br t, $J = 6.0$ Hz), 8.56 (1H, d, $J = 8.4$ Hz), 8.30 (1H, d, $J = 8.4$ Hz), 7.88 (1H, d, $J=8.0$ Hz), 7.77 (1H, t, $J = 7.2$ Hz), 7.72 (1H, s), 7.66 (1H, d, $J = 8.4$ Hz), 7.57-7.62 (1H, m), 7.48-7.53 (2H, m), 7.39 (1H, t, $J = 8.0$ Hz), 5.64 (1H, br s), 4.81-5.09 (4H, m), 3.57-3.63 (1H, m), 3.32-3.38 (1H, m), 2.96-3.08 (1H, m), 2.68-2.76 (1H, m), 2.08-2.14 (1H, m), 1.74-1.85 (1H, m), 1.63-1.70 (4H, m), 1.40-1.52 (2H, m), 1.27-1.32 (6H, m); LCMS: 98.1%, MS (ESI): m/z 556.2 $[\text{M} + \text{H}]^+$
263		(2S); white powder; ^1H -NMR (CDCl_3 , 400 MHz): δ 9.11-9.23 (1H, m), 8.64 (1H, d, $J = 8.0$ Hz), 8.33 (1H, d, $J = 8.4$ Hz), 7.91 (1H, d, $J = 8.0$ Hz), 7.83 (1H, t, $J = 7.6$ Hz), 7.70-7.76 (2H, m), 7.60-7.69 (3H, m), 7.42-7.50 (2H, m), 4.97-5.05 (1H, m), 4.72-4.89 (3H, m), 4.47 (1H, brs), 3.98-4.13 (1H, m), 3.70-3.84 (1H, m), 3.15 - 3.25 (1H, m), 2.98-3.08 (1H, m), 1.63-1.84 (5H, m), 1.27-1.34 (6H, m); LCMS: 100%, MS (ESI): m/z 508.2 $[\text{M} + \text{H}]^+$


264		(2S); white powder; ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ 8.97-9.03 (1H, m), 8.59 (1H, d, $J = 8.4$ Hz), 8.45 (1H, d, $J = 8.0$ Hz), 8.09 (1H, d, $J = 8.0$ Hz), 7.90 (1H, d, $J = 8.4$ Hz), 7.80-7.87 (2H, m), 7.65-7.71 (3H, m), 7.53-7.59 (1H, m), 4.88-4.98 (2H, m), 4.74-4.84 (1H, m), 4.61-4.69 (2H, m), 3.65 (1H, m), 3.47 (1H, m), 2.94 (1H, m), 2.79-2.89 (1H, m), 1.91 (1H, m), 1.49-1.69 (3H, m), 1.21-1.29 (8H, m); LCMS: 100%, MS (ESI): m/z 542.2 $[\text{M} + \text{H}]^+$
265		(1S, 4S); white powder; ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ ppm 8.86-9.27 (1H, m), 8.56 (1H, d, $J = 8.4$ Hz), 8.35 (1H, d, $J = 8.4$ Hz), 8.08 (1H, d, $J = 8.0$ Hz), 7.81-7.93 (2H, m), 7.56-7.79 (4H, m), 7.46-7.53 (2H, m), 6.58-6.90 (1H, m), 4.75 (2H, d, $J = 6.4$ Hz), 4.33 (1H, brs), 3.66-3.74 (2H, m), 2.85-2.96 (1H, m), 1.32-1.81 (8H, m), 1.23 (6H, d, $J = 5.6$ Hz); LCMS: 100%, MS (ESI): m/z 508.2 $[\text{M} + \text{H}]^+$
266		(1R, 4R); white powder; ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ ppm 8.87-9.28 (1H, m), 8.56 (1H, d, $J = 8.4$ Hz), 8.30-8.45 (1H, m), 8.08 (1H, d, $J = 8.0$ Hz), 7.82-7.95 (2H, m), 7.64-7.79 (3H, m), 7.56-7.62 (1H, m), 7.40-7.55 (2H, m), 6.58-6.95 (1H, m), 4.74 (2H, d, $J = 6.4$ Hz), 4.53 (1H, brs), 3.55-3.75 (1H, m), 3.35-3.41 (2H, m), 2.82-2.98 (1H, m), 1.73-2.02 (4H, m), 1.15-1.35 (10H, m); LCMS: 100%, MS (ESI): m/z 508.2 $[\text{M} + \text{H}]^+$
267		white solid; ^1H NMR (400 MHz, CDCl_3): δ ppm 9.20 (1H, br s), 8.63 (1H, d, $J = 8.4$ Hz), 8.30 (1H, d, $J = 8.4$ Hz), 7.88 (1H, d, $J = 8.0$ Hz), 7.80 (1H, m), 7.70-7.74 (2H, m), 7.57-7.69 (3H, m), 7.38-7.48 (2H, m), 4.96-5.03 (1H, m), 4.74 (2H, d, $J = 6.4$ Hz), 3.95-4.05 (2H, m), 3.40-3.45 (4H, m), 3.01-3.10 (1H, m), 1.87-1.98 (1H, m), 1.70-1.79 (2H, m), 1.36-1.45 (2H, m), 1.29 (6H, d, $J = 7.2$ Hz); LCMS: 100%, MS (ESI): m/z 508.2 $[\text{M} + \text{H}]^+$
268		white powder; ^1H NMR (400 MHz, CDCl_3): δ ppm 9.17 (1H, br t, $J = 6.4$ Hz), 8.62 (1H, d, $J = 8.4$ Hz), 8.29 (1H, d, $J = 8.4$ Hz), 7.88 (1H, d, $J = 8.0$ Hz), 7.78-7.83 (1H, m), 7.69-7.74 (2H, m), 7.56-7.66 (3H, m), 7.43 (2H, m), 4.75 (2H, d, $J = 6.4$ Hz), 3.87-3.92 (4H, m), 3.78-3.83 (4H, m), 3.05 (1H, m), 1.30 (6H, d, $J = 7.2$ Hz); LCMS: 100%, MS (ESI): m/z 480.2 $[\text{M} + \text{H}]^+$
269		white powder; ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ ppm 9.50 (1H, br t, $J = 6.4$ Hz), 8.56 (1H, d, $J = 8.4$ Hz), 8.32 (1H, d, $J = 8.0$ Hz), 8.08 (1H, d, $J = 7.6$ Hz), 7.97 (1H, s), 7.88-7.92 (1H, m), 7.81-7.87 (1H, m), 7.64-7.74 (2H, m), 7.53-7.59 (1H, m), 7.45-7.53 (2H, m), 4.89-4.95 (1H, m), 4.74-4.83 (2H, m), 4.57-4.60 (0.2H, m), 4.47-4.51 (0.8H, m), 3.55-3.65 (1H, m), 2.90-3.03 (1H, m), 1.78-1.93 (2H, m), 1.51-1.71 (5H, m), 1.18-1.32 (7H, m); LCMS: 99.7%, MS (ESI): m/z 509.2 $[\text{M} + \text{H}]^+$

270		white powder; ^1H NMR (400 MHz, $\text{DMSO}-d_6$): δ ppm 8.86-9.49 (1H, m), 8.57 (1H, d, $J = 8.8$ Hz), 8.35 (1H, br d, $J = 8.4$ Hz), 8.09 (1H, d, $J = 8.0$ Hz), 7.83-7.96 (2H, m), 7.65-7.83 (3H, m), 7.57-7.64 (1H, m), 7.46-7.54 (2H, m), 6.57-7.10 (1H, m), 4.72-4.81 (2H, m), 4.20-4.63 (1H, m), 3.65-3.80 (1H, m), 3.24-3.30 (1H, m), 2.83-2.98 (1H, m), 1.79-2.02 (2H, m), 1.41-1.75 (5H, m), 1.18-1.31 (9H, br s); LCMS: 96.8%, MS (ESI): m/z 508.2 $[\text{M}+\text{H}]^+$
271		(2S); white powder; ^1H NMR (400 MHz, CDCl_3): δ 9.20-9.27 (1H, m), 8.62 (1H, d, $J = 8.8$ Hz), 8.29 (1H, d, $J = 8.4$ Hz), 7.88 (1H, d, $J = 7.6$ Hz), 7.78-7.83 (1H, m), 7.68-7.75 (2H, m), 7.57-7.66 (3H, m), 7.39-7.48 (2H, m), 4.74 (2H, d, $J = 6.4$ Hz), 4.51-4.60 (2H, m), 3.86-3.94 (1H, m), 3.73-3.82 (1H, m), 3.50-3.57 (1H, m), 3.28-3.43 (2H, m), 3.14-3.21 (1H, m), 2.96-3.08 (2H, m), 1.29 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 509.2 $[\text{M} + \text{H}]^+$
272		(1S, 4S); white powder; ^1H -NMR (CDCl_3 , 400 MHz): δ 9.67 (1H, br t, $J = 6.4$ Hz), 8.66 (1H, d, $J = 8.4$ Hz), 8.32 (1H, d, $J = 8.4$ Hz), 7.89 (1H, d, $J = 8.4$ Hz), 7.83 (1H, s), 7.77-7.82 (1H, m), 7.70-7.75 (2H, m), 7.57-7.66 (2H, m), 7.41-7.49 (2H, m), 5.18 (1H, br t, $J = 6.8$ Hz), 4.79 (2H, d, $J = 6.4$ Hz), 3.88 (1H, br s), 3.03-3.19 (1H, m), 2.09 - 2.21 (2H, m), 1.74-1.97 (6H, m) 1.34-1.40 (1H, d, $J = 4.4$ Hz), 1.32 (6 H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 509.2 $[\text{M}+\text{H}]^+$
273		(1R, 4R); white powder; ^1H NMR (400 MHz, CDCl_3) δ 9.71 (1H, br t, $J = 6.4$ Hz), 8.66 (1H, d, $J = 8.4$ Hz), 8.31 (1H, d, $J = 8.8$ Hz), 7.89 (1H, d, $J = 8.4$ Hz), 7.84 (1H, s), 7.80 (1H, td, $J = 7.2$, 1.6 Hz), 7.69-7.75 (2H, m), 7.58-7.66 (2H, m), 7.44 (2H, m), 5.05-5.15 (1H, m), 4.79 (2H, d, $J = 6.4$ Hz), 3.74-3.85 (1H, m), 3.06-3.19 (1H, m), 2.23-2.31 (2H, m), 2.08-2.13 (2H, m), 1.63-1.76 (2H, m), 1.50-1.56 (2H, m), 1.42-1.49 (1H, m), 1.32 (6H, d, $J = 7.2$ Hz); LCMS: 100%, MS (ESI): m/z 509.2 $[\text{M} + \text{H}]^+$
274		Racemic mixture; white solid; ^1H -NMR (CDCl_3 , 400 MHz): δ 7.63-7.70 (2H, m), 7.43-7.59 (3H, m), 7.33-7.40 (2H, m), 7.21 (1H, t, $J = 8.0$ Hz), 7.14 (1H, t, $J = 8.0$ Hz), 6.96 (1H, brs), 6.62 (1H, s), 5.18-5.21 (1H, m), 4.84 (2H, s), 3.84 (1H, d, $J = 11.6$ Hz), 3.45-3.70 (3H, m), 3.23-3.37 (1H, m), 2.97-3.07 (1H, m), 2.75-2.95 (3H, m), 2.61 (1H, s), 1.28 (6H, d, $J = 6.8$ Hz); LCMS: 100%, MS (ESI): m/z 497.3 $[\text{M} + \text{H}]^+$

275		White solid; ^1H NMR (CDCl_3 , 400 MHz): δ 8.44 (1H, d, J = 4.4 Hz), 7.87 (1H, s), 7.75 (1H, d, J = 2.0 Hz), 7.65-7.70 (2H, m), 7.64 (1H, s), 7.50-7.55 (1H, m), 7.29-7.43 (3H, m), 7.15-7.25 (1H, m), 6.51 (1H, s), 5.01 (2H, s), 4.74 (2H, d, J = 6.0 Hz), 4.25 (2H, t, J = 6.0 Hz), 3.13 (2H, t, J = 5.6 Hz), 3.00-3.10 (1H, m), 1.29 (6H, d, J = 6.4 Hz); LCMS: 100%, MS (ESI): m/z 466.1 $[\text{M} + \text{H}]^+$
276		white powder; ^1H NMR (400 MHz, CDCl_3): δ 8.85 (1H, br s), 8.19 (2H, br s), 7.68 (1H, s), 7.60 (1H, d, J = 2.40 Hz), 7.43 (1H, d, J = 8.00 Hz), 7.27 (1H, t, J = 8.00 Hz), 7.10-7.18 (4H, m), 7.04 (1H, d, J = 8.00 Hz), 6.60 (1H, br s), 6.34 (1H, d, J = 2.38 Hz), 4.82 (2H, d, J = 6.40 Hz), 4.61 (1H, s), 3.02-3.13 (1H, m), 6.80 Hz), 1.59 (6H, s), 1.27 (6H, d, J = 6.80 Hz); HPLC: 96.1% MS (ESI): m/z 556.2 $[\text{M} + \text{H}]^+$
277		yellow powder; ^1H NMR (400 MHz, CDCl_3): δ 8.58-8.97 (2H, m), 7.69 (1H, s), 7.59 (1H, d, J = 2.4 Hz), 7.41-7.45 (1H, m), 7.28 (1H, t, J = 8.0 Hz), 7.16-7.19 (1H, m), 6.68 (1H, t, J = 2.8 Hz), 6.34 (1H, d, J = 2.4 Hz), 5.77 (1H, t, J = 2.8 Hz), 4.70-4.92 (3H, m), 3.03-3.12 (1H, m), 1.60 (6H, s), 1.25 (6H, d, J = 7.2 Hz); HPLC: 99.4% MS (ESI): m/z 506.1 $[\text{M} + \text{H}]^+$
278		Yellow solid; ^1H -NMR (CD_3OD , 400 MHz): δ 8.47-8.53 (1H, m), 8.36 (1H, d, J = 6.4 Hz), 7.95-8.04 (1H, m), 7.47-7.81 (7H, m), 5.02-5.11 (1H, m), 4.63-4.72 (1H, m), 3.62-3.74 (1H, m), 3.27-3.61 (4H, m), 3.21-3.25 (1H, m), 2.64-3.03 (12H, m), 2.08-2.17 (2H, m), 1.97-2.04 (1H, m), 1.75-1.88 (1H, m), 1.49-1.62 (1H, m), 1.23 (6H, d, J = 6.4 Hz); LCMS: 97.9%, MS (ESI): 651.3 m/z $[\text{M} + \text{H}]^+$
279		White powder; ^1H NMR (CD_3OD , 400 MHz): δ 8.63 (1H, d, J = 6.0 Hz), 8.46-8.49 (1H, m), 8.21 (1H, d, J = 8.4 Hz), 8.01-8.05 (1H, m), 7.82-7.98 (2H, m), 7.69-7.81 (3H, m), 7.59-7.67 (2H, m), 5.02-5.11 (1H, m), 4.70-4.79 (1H, m), 3.73-3.79 (1H, m), 3.56-3.62 (1H, m), 3.33-3.51 (3H, m), 2.79-3.02 (3H, m), 1.83-2.07 (2H, m), 1.51-1.68 (1H, m), 1.29 (6H, d, J = 7.2 Hz); LCMS: 100%, MS (ESI): 523.2 m/z $[\text{M} + \text{H}]^+$

Claims

1. A compound having the general formula I



Formula I

wherein

X is, independently at each occurrence, selected from CH and N;

L^1 is either absent or independently, at each occurrence, selected from the group consisting of -NH-, -NH(CH₂)-, -NH(C=O)-, -NHSO₂-, -O-, -O(CH₂)-, -(C=O)-, -(C=O)NH- and -(C=O)(CH₂)-;

Q is, independently at each occurrence, selected from the group consisting of C3-C8 cycloalkyl, aryl, heteroaryl, heterocyclyl, and C1-C6 alkyl, wherein C1-C6 alkyl is substituted with one or two of -OR⁵, -N(R⁵)R⁵, aryl, heteroaryl and heterocyclyl,

C3-C8 cycloalkyl can be substituted with one or two of R³ and R⁴ and -(C=O)R⁵,

heterocyclyl can be substituted with one or two of R³ and R⁴ and -(C=O)R⁵,

aryl or heteroaryl substituted with one or two of C1-C6 alkyl, -OR⁵, -N(R⁵)R⁵, -(C=O)R⁵, halogen, heteroaryl and heterocyclyl;

R¹ is hydrogen;


R² is, at each occurrence, independently selected from the group consisting of halogen, C1-C6 alkyl, C3-C10 cycloalkyl, -CN, -(C=O)CH₃, -NR⁹R¹² and C1-C3 haloalkyl;

R³ is independently, at each occurrence, selected from the group consisting of hydrogen, -OR⁵, halogen, -N(R⁵)R⁵, -NR⁹R¹², -NH(C=O)R⁵, -(C=O)NH₂, aryl, heteroaryl, heterocyclyl, C1-C6


alkyl and C1-C6 alkyl substituted with -OH or -NH₂;

R⁴ is, independently, at each occurrence, selected from the group consisting of hydrogen, halogen, -OR⁵, -N(R⁵)R⁵, (=O), aryl, heteroaryl, heterocyclyl, C1-C6 alkyl and C1-C6 alkyl substituted with -OH or -NH₂;

R⁵ is, at each occurrence, independently selected from the group consisting of hydrogen, C1-C6 alkyl, C3-C8 cycloalkyl, C1-C3 haloalkyl, heteroaryl, heterocyclyl, heteroaryl substituted with one or two of halogen, -OR¹¹, -N(R¹¹)R¹¹, C1-C6 alkyl and C1-C6 alkyl substituted with -OH or -NH₂, heterocyclyl substituted with one or two of halogen, -OR¹¹, -N(R¹¹)R¹¹, C1-C6 alkyl and C1-C6 alkyl substituted with -OH or -NH₂;




R⁶ is, at each occurrence, independently selected from the group consisting of hydrogen, and any structure of the following group **B**;



Group B

R^7 is, at each occurrence, independently selected from the group consisting of hydrogen, C1-C6 alkyl, and any structure of the following group C;



Group C

R^8 and R^{10} are, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C3 haloalkyl, $-NH_2$, $-OH$, $-OR^5$, $-CN$, $-(C=O)R^5$, $-(C=O)OR^5$, $-(C=O)NH_2$, $-(C=O)NHR^{21}$, $-CH_2(C=O)NHR^{21}$, $-NH(C=O)R^{13}$, $-NHS(=O)_2R^5$, $-S(=O)_2NH_2$, $-S(=O)_2NHR^{21}$, and C1-C6 alkyl substituted with $-OH$, $-OR^5$ or $-NHR^9$;

R^9 is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C3 haloalkyl, $-OR^5$, $-CN$, C3-C10 cycloalkyl, C3-C10 heterocyclyl and C1-C6 alkyl substituted with $-OH$ or $-OR^5$;

R^{11} is, at each occurrence, independently selected from the group consisting of hydrogen, C1-C6 alkyl and C3-C10 cycloalkyl;

R^{12} is, at each occurrence, absent or independently selected from the group consisting of C1-C6 alkyl, C1-C6 alkyl substituted with $-OR^5$ or $-N(R^5)R^5$, C6-C10 aryl, phenyl, benzyl, C3-C9 heteroaryl, C3-C6 heterocyclyl, benzyl substituted with one to four halogens or C1-C3 alkyls, C3-C9 heteroaryl substituted with one to four halogens or C1-C3 alkyls, C3-C6 heterocyclyl substituted with C1-C3 alkyl, and C6-C10 aryl substituted with one to four halogens and/or one to four $-NH(C=O)R^{13}$;

R^{13} is, at each occurrence, independently selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkyl substituted with $-CN$, $-OH$, $-OR^5$, $-NH_2$, $-NHR^5$ or $-N(R^5)R^5$ and C3-C10 cycloalkyl;

R^{14} and R^{15} are, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C6 alkyl substituted with $-OH$ or $-NH_2$, C3-C10 cycloalkyl, $-(C=O)R^5$, $-(C=O)NHR^{21}$, $-C(R^9)(R^{11})OR^{21}$, $-NH(C=O)R^{21}$, $-NR^9R^{21}$, $-OR^{21}$, $-OC(R^9)(R^{11})(R^{21})$, C3-C10 heterocyclyl, C3-C10 heterocyclyl substituted with R^4 , C3-C10 heteroaryl substituted with one to four halogens or C1-C3 alkyl, C6-C10 aryl, e.g. phenyl and aryl substituted with $-(C=O)R^5$, $-(C=O)OR^5$, $-(C=O)NH_2$, $-(C=O)NHR^{21}$, $-CH_2(C=O)NHR^{21}$, $-NH(C=O)R^{13}$, $-NHS(=O)_2R^5$, $-S(=O)_2NH_2$ or $-S(=O)_2NHR^{21}$;

R^{16} is, at each occurrence, independently selected from the group consisting of hydrogen, C1-C6 alkyl, $-(C=O)R^{13}$ and C1-C6 alkyl substituted with $-OR^5$;

R^{17} , R^{18} , R^{19} and R^{20} are, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C3 haloalkyl, C6-C10 aryl, e.g. phenyl, $-CN$, $-CHCF_3NR^9R^{11}$, $-OH$, $-OR^{21}$, $-NO_2$, $-(C=O)R^5$, $-(C=O)OR^5$, $-(C=O)NH_2$, $-(C=O)NHR^{21}$, $-$


$\text{NH}(\text{C}=\text{O})\text{R}^{13}$, $-\text{NHR}^5$, $-\text{NHS}(\text{=O})_2\text{R}^5$, $-\text{S}(\text{=O})_2\text{NH}_2$, $-\text{S}(\text{=O})_2\text{NHR}^{21}$ and C1-C6 alkyl substituted with $-\text{CN}$, $-\text{OH}$, $-\text{OR}^5$, $-(\text{C}=\text{O})\text{NHR}^5$, $-\text{NH}_2$, $-\text{NH}(\text{C}=\text{O})\text{R}^5$, $-\text{NHR}^5$ or $-\text{N}(\text{R}^5)\text{R}^5$;


R^{21} is, at each occurrence, independently selected from the group consisting of C1-C6 alkyl, C3-C10 cycloalkyl, C3-C10 heterocyclyl, C1-C3 haloalkyl, aryl, phenyl, benzyl, C1-C6 alkyl substituted with $-\text{CN}$, $-\text{OH}$, $-\text{OR}^5$, $-\text{NH}_2$, $-\text{NHR}^5$ or $-\text{N}(\text{R}^5)\text{R}^5$, aryl substituted with halogen or C1-C3 haloalkyl, C3-C10 heteroaryl substituted with one to four halogens or C1-C3 alkyl and C3-C10 heterocyclyl substituted with R^4 ;

R^{22} and R^{23} are, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C3 haloalkyl, $-\text{OH}$, $-\text{OR}^5$, $-\text{CN}$ and C1-C6 alkyl substituted with $-\text{OH}$, $-\text{OR}^5$ or $-\text{NHR}^9$;

R^{24} and R^{25} are, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C3 haloalkyl, $-\text{NH}_2$, $-\text{OH}$, $-\text{OR}^5$, $-\text{CN}$, $-(\text{C}=\text{O})\text{R}^5$, $-(\text{C}=\text{O})\text{OR}^5$, $-(\text{C}=\text{O})\text{NH}_2$, $-(\text{C}=\text{O})\text{NHR}^{21}$, $-\text{CH}_2(\text{C}=\text{O})\text{NHR}^{21}$, $-\text{NH}(\text{C}=\text{O})\text{R}^{13}$, $-\text{NHS}(\text{=O})_2\text{R}^5$, $-\text{S}(\text{=O})_2\text{NH}_2$ or $-\text{S}(\text{=O})_2\text{NHR}^{21}$ and C1-C6 alkyl substituted with $-\text{OH}$, $-\text{OR}^5$ or $-\text{NHR}^9$;

with the proviso that one of R^6 and R^7 is not H;



with the proviso that when R^6 is , then one of R^{14} and R^{15} is not H, and if R^{14} is H, then R^{15} is not Cl;

wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is absent, Q is heterocycyl substituted with R^3 and R^4 , R^3 is $\text{N}(\text{R}^5)\text{R}^5$, R^4 is H, R^5 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q is heterocycyl substituted with R^3 and R^4 , R^3 is CH_3 , R^4 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is $-(\text{C}=\text{O})-$, Q is heterocycyl substituted with R^3 and R^4 , R^4 is H, X is N, Z is phenyl, R^6 is 1H-pyrazole, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^3 is not H;

wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is $-(\text{C}=\text{O})-$, Q is heterocycyl substituted with R^3 and R^4 , R^3 is $\text{N}(\text{R}^5)\text{R}^5$, R^4 is H, R^5 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole,

wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q is heterocycyl substituted with R^3 and R^4 , R^3 is H, R^4 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q is C3-C8 cycloalkyl substituted with R^3 and R^4 , R^3 is $\text{N}(\text{R}^5)\text{R}^5$, R^4 is H, R^5 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is NH, Q is heterocycyl substituted with R^3 and R^4 , R^3 is H, R^4 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is NH, Q is C3-C8 cycloalkyl substituted with R^3 and R^4 , R^3 is $\text{N}(\text{R}^5)\text{R}^5$, R^4 is H, R^5 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q is heterocycyl substituted with R^3 and R^4 , R^3 is H, R^4 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is F, then R^6 is not 1H-pyrazole;


wherein, if R^1 is CH_3 , R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q is heterocycyl substituted with R^3 and R^4 , R^3 is H, R^4 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q is heterocycyl substituted with R^3 and R^4 , R^3 is CH_3 , R^4 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

or an enantiomer, stereoisomeric form, mixture of enantiomers, diastereomer, mixture of diastereomers, racemate of the above mentioned compounds, or a pharmaceutically acceptable salt thereof.

2. The compound according to claim 1,


wherein R^1 is hydrogen and the compound has the general formula II



Formula II

wherein X, Q, L^1 , R^2 and Z are as defined in claim 1.

3. The compound according to any of claims 1, having the general formula III



Formula III

wherein X, L¹, R¹, R² and Z are as defined in claim 1, and

Q¹ is either absent or independently, at each occurrence, selected from the group consisting of aryl, heteroaryl, heterocyclyl, aryl substituted with one or two of C1-C6 alkyl, -OR⁵, -N(R⁵)R⁵, and halogen; heteroaryl substituted with one or two of C1-C6 alkyl, -OR⁵, -N(R⁵)R⁵ and halogen; and heterocyclyl substituted with one or two of R²⁹ and R³⁰;

R²⁹ is either absent or independently, at each occurrence, selected from the group consisting of hydrogen, -OR⁵, halogen, -N(R⁵)R⁵, -NR⁹R¹², -NH(C=O)R⁵, -(C=O)NH₂, aryl, heteroaryl, heterocyclyl, C1-C6 alkyl and C1-C6 alkyl substituted with -OH or -NH₂;

R³⁰ is, independently, at each occurrence, selected from the group consisting of hydrogen, halogen, -OR⁵, -N(R⁵)R⁵, (=O), aryl, heteroaryl, heterocyclyl, C1-C6 alkyl and C1-C6 alkyl substituted with -OH or -NH₂;

wherein R⁵, R⁹ and R¹² are as defined in claim 1;

L² is either absent or independently, at each occurrence, selected from the group consisting of -O-, -NH-, -(C=O)- and -(C=O)NH-;

Y¹ is, independently at each occurrence, selected from CH, C(OH) and N;

Y² is, independently at each occurrence, selected from CH, CR³⁰, O and N;

m is, independently at each occurrence, selected from 0, 1 and 2;

n is, independently at each occurrence, selected from 0 and 1;

wherein, if R¹ is H, R² is CH(CH₃)₂, L¹ is absent, Q¹ is absent, L² is absent, Y¹ is N, Y² is CH, m is 1, n is 1, R²⁹ is N(R⁵)R⁵, R³⁰ is H, R⁵ is H, X is N, Z is phenyl, R⁷ is H, R⁸ is H, R⁹ is H and R¹⁰ is H, then R⁶ is not 1H-pyrazole;

wherein, if R¹ is H, R² is CH(CH₃)₂, L¹ is O, Q¹ is absent, L² is absent, Y¹ is CH, Y² is N, m is 1, n is 1, R²⁹ is CH₃, R³⁰ is H, X is N, Z is phenyl, R⁷ is H, R⁸ is H, R⁹ is H and R¹⁰ is H, then R⁶ is not 1H-pyrazole;

wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is $-(\text{C}=\text{O})-$, Q^1 is absent, L^2 is absent, Y^1 is N, Y^2 is N, m is 1, n is 1, R^{30} is H, X is N, Z is phenyl, R^6 is 1H-pyrazole, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^{29} is not H;

wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is $-(\text{C}=\text{O})-$, Q^1 is absent, L^2 is absent, Y^1 is N, Y^2 is CH, m is 1, n is 1, R^{29} is $\text{N}(\text{R}^5)\text{R}^5$, R^{30} is H, R^5 is H, R^{30} is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 1, n is 1, R^{29} is H, R^{30} is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 1, n is 0, R^{29} is H, R^{30} is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is CH, m is 1, n is 1, R^{29} is $\text{N}(\text{R}^5)\text{R}^5$, R^{30} is H, R^5 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is NH, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 1, n is 0, R^{29} is H, R^{30} is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is absent, Q^1 is absent, L^2 is absent, Y^1 is N, Y^2 is CH, m is 1, n is 0, R^{29} is $\text{N}(\text{R}^5)\text{R}^5$, R^{30} is H, R^5 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is NH, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is CH, m is 1, n is 1, R^{29} is $\text{N}(\text{R}^5)\text{R}^5$, R^{30} is H, R^5 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

04 Sep 2023

2019250507

wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is absent, Q^1 is absent, L^2 is absent, Y^1 is N, Y^2 is CH, m is 2, n is 0, R^{29} is $\text{N}(\text{R}^5)\text{R}^5$, R^{30} is H, R^5 is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;


wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 2, n is 0, R^{29} is H, R^{30} is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is F, then R^6 is not 1H-pyrazole;

wherein, if R^1 is H, R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 1, n is 1, R^{29} is CH_3 , R^{30} is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

wherein, if R^1 is CH_3 , R^2 is $\text{CH}(\text{CH}_3)_2$, L^1 is O, Q^1 is absent, L^2 is absent, Y^1 is CH, Y^2 is N, m is 2, n is 0, R^{29} is H, R^{30} is H, X is N, Z is phenyl, R^7 is H, R^8 is H, R^9 is H and R^{10} is H, then R^6 is not 1H-pyrazole;

or an enantiomer, stereoisomeric form, mixture of enantiomers, diastereomer, mixture of diastereomers, racemate of the above mentioned compounds, or a pharmaceutically acceptable salt thereof.


4. The compound according to any of claims 1 - 3, having the general formula IV



Formula IV

wherein X, L¹ and R² are as defined in claim 1;


wherein m, n, Y¹, Y², L², R²⁹, R³⁰ and Q¹ are as defined in claim 3;



wherein Z¹ is

wherein R⁶, R⁷, R⁸, R⁹ and R¹⁰ are as defined in claim 1.

5. A compound having the general formula V




Formula V

wherein X, L¹, R², R⁶, R²² and R²³ are as defined in claim 1;

wherein X¹ is CR²⁴ or N, and X² is CR²⁵ or N, wherein R²⁴ and R²⁵ are as defined in claim 1;

wherein m, n, Y¹, Y², L², R²⁹, R³⁰ and Q¹ are as defined in claim 3.

6. A compound having the general formula VI



Formula VI

wherein X, L¹ and R² are as defined in claim 1;


wherein m, n, Y¹, Y², L², R²⁹, R³⁰ and Q¹ are as defined in claim 3;

X³ is, independently at each occurrence, selected from CR¹⁰ and N;

R²⁶, R²⁷ and R²⁸ are, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C1-C6 alkyl, C1-C3 haloalkyl, -OR⁵, -CN and C1-C6 alkyl substituted with -OH, -OR⁵ or -NHR⁹;

R⁵, R⁹ and R¹⁰ are as defined in claim 1;


R⁷ is any structure of the following group E;



Group E

wherein R^8 and $R^{14} - R^{20}$ are as defined in claim 1.

7. The compound according to any of claims 1 – 5, having the general formula VII




.Formula VII

wherein X , L^1 , R^2 , R^6 , R^{22} , R^{23} , R^{24} and R^{25} are as defined in claim 1;

m, n, Y¹, Y², L², R²⁹, R³⁰ and Q¹ are as defined in claim 3.


8. The compound according to any of claims 1 and 2, having the general formula VIII



Formula VIII

wherein Q, X, L¹, R², R⁶ and R¹⁰ are as defined in claim 1.

9. The compound according to any of claims 1 – 5, having the general formula IX




Formula IX

wherein X is N;

L¹, R², R⁶, R²², R²³, R²⁴ and R²⁵ are as defined in claim 1, and X³ is as defined in claim 6;

wherein Q² is any structure of the following group F;










Group F








R^{31} and R^{32} are either absent or independently, at each occurrence, selected from the group consisting of hydrogen, $-OR^5$, halogen, $-N(R^5)R^5$, $-NR^9R^{12}$, $-NH(C=O)R^5$, $-(C=O)NH_2$, aryl, heteroaryl, heterocyclyl, C1-C6 alkyl and C1-C6 alkyl substituted with $-OH$ or $-NH_2$;







wherein R^5 , R^9 and R^{12} are as defined in claim 1.







10. The compound according to any of the foregoing claims, having a structure selected from structures 14, 17, 47, 48, 58, 65, 67, 68, 72, 73, 75-81, 90, 92, 96-161, 175-182, 184-186, 189-191, 193-205, 207-219, 221-234, 236-238, 240, 241, 243-256, 258-274 and 276– 279:.







#cpds	Structure
14	
17	







47	
48	
58	
65	
67	
68	
72	







73	
75	
76	
77	
78	
79	
80	







81	
90	
92	
96	
97	
98	







99	
100	
101	
102	
103	
104	








105	
106	
107	
108	
109	
110	








111	 <chem>CC(C)c1nn(CCNc2ccccc2c3c[nH]c4ccccc43)n(CCNc5ccc(NC(C)=O)cc5)n1</chem>
112	 <chem>CC(C)c1nn(CCNc2ccc(N)cc2)n(CCNc3c[nH]c4cc(F)ccc43)n1</chem>
113	 <chem>CC(C)c1nn(CCNc2ccc(N)cc2)n(CCNc3c[nH]c4cc(F)ccc43)n1</chem>
114	 <chem>CC(C)c1nn(CCNc2ccccc2c3c[nH]c4ccccc43)n(CCNc5ccccc5C6OCCOCC6)n1</chem>
115	 <chem>CC(C)c1nn(CCNc2ccccc2c3c[nH]c4ccccc43)n(CCNc5ccc(OC6CCN(C)CC6)cc5)n1</chem>
116	 <chem>CC(C)c1nn(CCNc2ccc(N)cc2)n(CCNc3ccc(NC(=O)c4c[nH]c5ccccc45)cc3)n1</chem>








117	
118	
119	
120	
121	
122	

123	
124	
125	
126	
127	
128	








129	
130	
131	
132	
133	
134	








135	
136	
137	
138	
139	
140	
141	

142	
143	
144	
145	
146	
147	
148	








149	
150	
151	
152	
153	
154	
155	








156	
157	
158	
159	
160	
161	
175	








176	
177	
178	
179	
180	
181	
182	







184	
185	
186	
189	
190	
191	
193	







194	
195	
196	
197	
198	
199	
200	







201	
202	
203	
204	
205	
207	
208	







209	
210	
211	
212	
213	
214	
215	






216	
217	
218	
219	
221	
222	
223	







224	
225	
226	
227	
228	
229	







230	
231	
232	
233	
234	
236	






237	
238	
240	
241	
243	
244	






245	
246	
247	
248	
249	
250	

251	
252	
253	
254	
255	

256	
258	
259	
260	
261	
262	

263	
264	
265	
266	
267	
268	

269	
270	
271	
272	
273	

274	
276	
277	
278	
279	

11. A pharmaceutical composition comprising a compound according to any of claims 1 – 10 as an active ingredient, together with at least one pharmaceutically acceptable carrier, excipient and/or diluent.

12. A compound according to claim 1 – 10 when used as pharmaceutically active agent,

wherein said pharmaceutically active agent preferably has an inhibitory activity on cyclin-dependent kinase 7 (CDK7).

13. A compound according to any one of claims 1 to 10 when used in a method of prevention and/or treatment of a disease which is associated with inhibition of apoptosis, abnormal transcriptional activity and/or cell cycle arrest by aberrant activity and/or overexpression of one or several cyclin-dependent kinases (CDKs), in particular cyclin-dependent kinase 7 (CDK7), wherein the disease is selected from proliferative diseases, infectious diseases, including opportunistic diseases, immunological diseases, autoimmune diseases, and inflammatory diseases.

14. The compound when used according to claim 13, wherein the proliferative disease is a cancer, preferably a cancer selected from the group comprising or consisting of: adenocarcinoma, choroidal melanoma, acute leukemia, acoustic neurinoma, ampullary carcinoma, anal carcinoma, astrocytoma, basal cell carcinoma, pancreatic cancer, Desmoid tumor, bladder cancer, bronchial carcinoma, estrogen dependent and independent breast cancer, Burkitt's lymphoma, corpus cancer, Carcinoma unknown primary tumor (CUP-syndrome), colorectal cancer, small intestine cancer, small intestinal tumors, ovarian cancer, endometrial carcinoma, ependymoma, epithelial cancer types, Ewing's tumors, gastrointestinal tumors, gastric cancer, gallbladder cancer, gall bladder carcinomas, uterine cancer, cervical cancer, cervix, glioblastomas, gynecologic tumors, ear, nose and throat tumors, hematologic tumor, hairy cell leukemia, urethral cancer, skin cancer, skin testis cancer, brain tumors (gliomas), brain metastases, testicle cancer, hypophysis tumor, carcinoids, Kaposi's sarcoma, laryngeal cancer, germ cell tumor, bone cancer, colorectal carcinoma, head and neck tumors (tumors of the ear, nose and throat area), colon carcinoma, craniopharyngiomas, oral cancer (cancer in the mouth area and on lips), cancer of the central nervous system, liver cancer, liver metastases, leukemia, eyelid tumor, lung cancer, lymphomas, stomach cancer, malignant melanoma, malignant neoplasia, malignant tumors gastrointestinal tract, breast carcinoma, rectal cancer, medulloblastomas, melanoma, meningiomas, Hodgkin's / Non-Hodgkin's lymphoma, mycosis

fungoides, nasal cancer, neurinoma, neuroblastoma, kidney cancer, renal cell carcinomas, oligodendroglioma, esophageal carcinoma, osteolytic carcinomas and osteoplastic carcinomas, osteosarcomas, ovarian carcinoma, pancreatic carcinoma, penile cancer, plasmacytoma, prostate cancer, pharyngeal cancer, rectal carcinoma, retinoblastoma, vaginal cancer, thyroid carcinoma, esophageal cancer, T-cell lymphoma, thymoma, tube carcinoma, eye tumors, urethral cancer, urologic tumors, urothelial carcinoma, vulva cancer, wart appearance, soft tissue tumors, soft tissue sarcoma, Nephroblastoma, cervical carcinoma, tongue cancer, invasive ductal carcinoma, invasive lobular carcinoma, ductal carcinoma in situ, lobular carcinoma in situ, small-cell lung carcinoma, non-small-cell lung carcinoma, bronchial adenoma, pleuropulmonary blastoma, mesothelioma, brain stem glioma, hypothalamic glioma, cerebellar astrocytoma, cerebral astrocytoma, neuroectodermal tumor, pineal tumors, sarcoma of the uterus, salivary gland cancers, anal gland adenocarcinomas, mast cell tumors, pelvis tumor, ureter tumor, hereditary papillary renal cancers, sporadic papillary renal cancers, intraocular melanoma, hepatocellular carcinoma, cholangiocarcinoma, mixed hepatocellular cholangiocarcinoma, squamous cell carcinoma, malignant melanoma, Merkel cell skin cancer, non-melanoma skin cancer, hypopharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer, oral cavity cancer, squamous cell cancer, oral melanoma, AIDS-related lymphoma, cutaneous T-cell lymphoma, lymphoma of the central nervous system, malignant fibrous histiocytoma, lymph sarcoma, rhabdomyosarcoma, malignant histiocytosis, fibroblastic sarcoma, hemangiosarcoma, hemangiopericytoma, leiomyosarcoma (LMS), canine mammary carcinoma, and feline mammary carcinoma.

15. The compound when used according to claim 13, wherein the infectious disease including opportunistic diseases is selected from the group comprising or consisting of AIDS, Adenovirus Infection, Alveolar Hydatid Disease (AHD), Amoebiasis, Angiostrongyliasis, Anisakiasis, Anthrax, Babesiosis, Balantidiasis, Baylisascaris Infection, Bilharzia (Schistosomiasis), Blastocystis hominis Infection, Lyme Borreliosis, Botulism, Brainerd Diarrhea, Brucellosis, Bovine Spongiform Encephalopathy (BSE), Candidiasis, Capillariasis, Chronic Fatigue Syndrome (CFS), Chagas Disease, Chickenpox, Chlamydia pneumoniae Infection, Cholera, Chronic Fatigue Syndrome, Creutzfeldt-Jakob Disease (CJD), Clonorchiasis, Cutaneous Larva migrans (CLM), Coccidioidomycosis, Conjunctivitis, Coxsackievirus A16 (Cox A16), Cryptococcal disease, Cryptosporidiosis, West Nile fever,

Cyclosporiasis, Neurocysticercosis, Cytomegalovirus Infection, Dengue Fever, Dipylidium caninum Infection, Ebola Hemorrhagic Fever (EHF), Alveolar Echinococcosis (AE), Encephalitis, Entamoeba coli Infection, Entamoeba dispar Infection, Entamoeba hartmanni Infection, Entamoeba polecki Infection, Pinworm Infection, Enterovirus Infection (Polio / Non-Polio), Epstein Barr Virus Infection, Escherichia coli Infection, Foodborne Infection, Aphthae epizooticae, Fungal Dermatitis, Fungal Infections, Gastroenteritis, Group A streptococcal Disease, Group B streptococcal Disease, Hansen's Disease (Leprosy), Hantavirus Pulmonary Syndrome, Head Lice Infestation (Pediculosis), Helicobacter pylori Infection, Hematologic Disease, Hendra Virus Infection, Hepatitis (HCV, HBV), Herpes Zoster (Shingles), HIV Infection, Human Ehrlichiosis, Human Parainfluenza Virus Infection, Influenza, Isosporiasis, Lassa Fever, Leishmaniasis, Visceral leishmaniasis (VL), Malaria, Marburg Hemorrhagic Fever, Measles, Meningitis, Mycobacterium avium Complex (MAC) Infection, Naegleria Infection, Nosocomial Infections, Nonpathogenic Intestinal Amebae Infection, Onchocerciasis, Opisthorchiasis, Papilloma virus Infection, Parvovirus Infection, Plague, Pneumocystis Pneumonia (PCP), Polyomavirus Infection, Q Fever, Rabies, Respiratory Syncytial Virus (RSV) Infection, Rheumatic Fever, Rift Valley Fever, Rotavirus Infection, Roundworms Infection, Salmonellosis, Scabies, Shigellosis, Shingles, Sleeping Sickness, Smallpox, Streptococcal Infection, Tapeworm Infection, Tetanus, Toxic Shock Syndrome, Tuberculosis, duodenum, Vibrio parahaemolyticus Infection, Vibrio septicemia, Viral Hemorrhagic Fever, Warts, Waterborne infectious Diseases, Varicella-Zoster Virus infection, Pertussis and Yellow Fever.

16. The compound when used according to claim 13, wherein the immunological disease and/or autoimmune disease is selected from the group comprising or consisting of: asthma, diabetes, rheumatic diseases, AIDS, rejection of transplanted organs and tissues, rhinitis, chronic obstructive pulmonary diseases, osteoporosis, ulcerative colitis, sinusitis, lupus erythematosus, recurrent infections, atopic dermatitis / eczema and occupational allergies, food allergies, drug allergies, severe anaphylactic reactions, anaphylaxis, manifestations of allergic diseases, primary immunodeficiencies, antibody deficiency states, cell mediated immunodeficiencies, severe combined immunodeficiency, DiGeorge syndrome, Hyper IgE syndrome (HIES), Wiskott-Aldrich syndrome (WAS), ataxia-telangiectasia, immune mediated cancers, white cell

defects, autoimmune diseases, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), immune-mediated or Type 1 Diabetes Mellitus, immune mediated glomerulonephritis, scleroderma, pernicious anemia, alopecia, pemphigus, pemphigus vulgaris, myasthenia gravis, inflammatory bowel diseases, Crohn's disease, psoriasis, autoimmune thyroid diseases, Hashimoto's disease, dermatomyositis, Goodpasture syndrome (GPS), myasthenia gravis (MG), Sympathetic ophthalmia, Phakogene Uveitis , chronic aggressive hepatitis, primary biliary cirrhosis, autoimmune hemolytic anemia , and Werlhof's disease .

17. The compound when used according to claim 13, wherein the inflammatory disease is caused, induced, initiated and/or enhanced by bacteria, viruses, prions, parasites, fungi, and/or caused by irritative, traumatic, metabolic, allergic, autoimmune, or idiopathic agents.


18. The compound when used according to claim 13 or 17, wherein the inflammatory disease is selected from the group comprising or consisting of inflammatory diseases of the central nervous system (CNS), inflammatory rheumatic diseases, inflammatory diseases of blood vessels, inflammatory diseases of the middle ear, inflammatory bowel diseases, inflammatory diseases of the skin, inflammatory disease uveitis, and inflammatory diseases of the larynx.

19. The compound when used according to any of claims 13, 17 or 18, wherein the inflammatory disease is selected from inflammatory diseases of the central nervous system (CNS), inflammatory rheumatic diseases, inflammatory diseases of blood vessels, inflammatory diseases of the middle ear, inflammatory bowel diseases, inflammatory diseases of the skin, inflammatory disease uveitis, inflammatory diseases of the larynx, wherein preferably said inflammatory diseases are selected from the group comprising abscessation, acanthamoeba infection, acne vulgaris, actinomycosis, acute inflammatory dermatoses, acute laryngeal infections of adults, acute multifocal placoid pigment epitheliopathy, acute (thermal) injury, acute retinal necrosis, acute suppurative otitis media, algal disorders, allergic contact dermatitis, amyloidosis angioedema, ankylosing spondylitis, aspergillosis, atopic dermatitis, pseudorabies, autoantibodies in vasculitis, bacterial disorders, bacterial laryngitis, bacterial

meningitis, Behçet's disease (BD), birdshot choroidopathy, Gilchrist's disease, Borna disease, brucellosis, bullous myringitis, bursitis, candidiasis, canine distemper encephalomyelitis, canine distemper encephalomyelitis in immature animals, canine hemorrhagic fever, canine herpes virus encephalomyelitis, cholesteatoma, chronic granulomatous diseases (CGD), chronic inflammatory dermatoses, chronic relapsing encephalomyelitis, chronic suppurative otitis media, Ocular Cicatricial pemphigoid (OCP), common upper respiratory infection, granuloma, Crohn's disease, cryptococcal disease, dermatomyositis, diphtheria, discoid lupus erythematosus (DLE), drug-induced vasculitis, drug or hypersensitivity reaction, encephalitozoonosis, eosinophilic meningoencephalitis, Erythema multiforme (EM), feline leukemia virus, feline immunodeficiency virus, feline infectious peritonitis, feline Polioencephalitis, feline spongiform encephalopathy, fibromyalgia, Fuchs Heterochromic Uveitis, gastroesophageal (laryngopharyngeal) reflux disease, giant cell arteritis, glanders, glaucomatocyclitic crisis, gonorrhea granular myringitis, Granulomatous meningoencephalitis (GME), herpes simplex, histoplasmosis, idiopathic diseases, idiopathic inflammatory disorders, immune and idiopathic disorders, infections of the immunocompromised host, infectious canine hepatitis, inhalation laryngitis, interstitial nephritis, irritant contact dermatitis, juvenile rheumatoid arthritis, Kawasaki's disease, La Crosse virus encephalitis, laryngeal abscess, laryngotracheobronchitis, leishmaniasis, lens-induced uveitis, leprosy, leptospirosis, leukemia, lichen planus, lupus, lymphoma, meningitis, meningoencephalitis in greyhounds, miscellaneous meningitis / meningoencephalitis, microscopic polyangiitis, multifocal choroiditis, multifocal distemper encephalomyelitis in mature animals, multiple sclerosis, Muscle Tension Dysphonia (MTD), mycotic (fungal) diseases, mycotic diseases of the CNS, necrotizing encephalitis, neosporosis, old dog encephalitis, onchocerciasis, parasitic encephalomyelitis, parasitic infections, Pars planitis, parvovirus encephalitis, pediatric laryngitis, pollution and inhalant allergy, polymyositis, post-vaccinal canine distemper encephalitis, prion protein induced diseases, protothecosis, protozoal encephalitis-encephalomyelitis, psoriasis, psoriatic arthritis, pug dog encephalitis, radiation injury, radiation laryngitis, radionecrosis, relapsing polychondritis, Reiter's syndrome, retinitis pigmentosa, retinoblastoma, rheumatoid arthritis, Rickettsial disorders, rocky mountain spotted fever, salmon poisoning disease (SPD), Sarcocystosis, sarcoidosis, schistosomiasis, scleroderma, Rhinoscleroma, serpiginous choroiditis, shaker dog disease, Sjogren's syndrome, spasmodic

croup, spirochetal (syphilis) diseases, spongiotic dermatitis, sporotrichosis, steroid responsive meningitis-arteritis, Stevens-Johnson syndrome (SJS, EM major), epiglottitis, sympathetic ophthalmia, Syngamosis, syphilis, systemic vasculitis in sarcoidosis, Takayasu's arteritis, tendinitis (tendonitis), Thromboangiitis obliterans (Buerger Disease), tick-borne encephalitis in dogs, toxic epidermal necrolysis (TEN), toxocariasis, toxoplasmosis, trauma, traumatic laryngitis, trichinosis, trypanosomiasis, tuberculosis, tularemia, ulcerative colitis, urticaria (hives), vasculitis, vasculitis and malignancy, vasculitis and rheumatoid arthritis, vasculitis in the idiopathic inflammatory myopathies, vasculitis of the central nervous system, vasculitis secondary to bacterial, fungal, and parasitic infection, viral disorders, viral laryngitis, vitiligo, vocal abuse, vocal-cord hemorrhage, Vogt-Koyanagi- Harada syndrome (VKH), Wegener's granulomatosis, and Whipple's disease.

Figure 1



A one-way ANOVA was performed to compare tumor volume among vehicle group and treatment groups, * indicates $p<0.5$, ** indicates $p<0.01$, *** indicates $p<0.001$.